Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

WIPO - WORLD PATENTS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATIONS PUBLISHED IN 2012



Publication No.: WO2012001009A1  Published: 05/Jan/2012

Title: POLYMERIC SYSTEM FOR DELIVERING A PRESERVATIVE-FREE PROSTAGLANDIN-BASED NONVISCOUS SOLUTION

Applicant/Assignee: LABORATOIRES THEA

Application No.: WO2011EP60848 (PCT/EP2011/60848)   Filing Date: 28/Jun/2011

Abstract:

The present invention relates to an ophthalmic solution which comprises: - at least one prostaglandin

- a solubilizing agent

- a carbomer gelling agent

- a carbomer-polymerization-inhibiting agent

- a co-gelling/co-solubilizing agent.

Priority: US20100359699P Applic. Date: 2010-06-29; FR20100055236 Applic. Date: 2010-06-29

Inventor: MERCIER FABRICE [FR]


Publication No.: WO2012001076A1  Published: 05/Jan/2012

Title: USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: WO2011EP60953 (PCT/EP2011/60953)   Filing Date: 29/Jun/2011

Abstract:

The present invention relates to a novel use of a compound of the formula (I) or of one of its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, or hydrates, in the preparation of a medicament intended to prevent and/or treat rosacea.

Priority: FR20100055245 Applic. Date: 2010-06-29

Inventor: AUBERT JEROME [FR]


Publication No.: WO2012001083A2  Published: 05/Jan/2012

Title: NOVEL EPRINOMECTIN INJECTABLE COMPOSITIONS

Applicant/Assignee: CEVA SANTE ANIMALE SA

Application No.: WO2011EP60969 (PCT/EP2011/60969)   Filing Date: 29/Jun/2011

Abstract:

An improved injectable parasiticide composition for treating infections caused by ectoparasites and endoparasites, wherein the formulation comprises a solvent system comprising polyethylene glycol and optionally other excipients and a pharmaceutically acceptable solvent or mixture of solvents and co-solvents, said novel formulation being capable of improving the bioavailability and residence time of the parasiticide in the treated non human mammals. Preferred compositions according to the invention comprise parasiticides which are macrocyclic lactones having poor liphophilic properties, such as for example eprinomectin.

Priority: US20100359663P Applic. Date: 2010-06-29

Inventor: CILLIERS HANNELIE [ZA]


Publication No.: WO2012001093A2  Published: 05/Jan/2012

Title: LIQUID FORMULATIONS OF RUPATADINE FUMARATE

Applicant/Assignee: J. URIACH Y COMPANIA, S.A

Application No.: WO2011EP60994 (PCT/EP2011/60994)   Filing Date: 30/Jun/2011

Abstract:

The present invention provides cyclodextrin-free aqueous liquid formulations of rupatadine fumarate, useful for the treatment of allergic rhinitis and urticaria. Said formulations comprise rupatadine fumarate, one or more cosolvents and one or more pH regulating agents wherein the composition has a pH between 4 and 6.5.

Priority: US20100364992P Applic. Date: 2010-07-16; EP20100382184 Applic. Date: 2010-06-30

Inventor: SURIOL FERRER MONTSERRAT [ES]; MORLESIN CAPDEVILA SILVIA [ES]


Publication No.: WO2012001403A1  Published: 05/Jan/2012

Title: TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING FLURBIPROFEN

Applicant/Assignee: EDKO PAZARLAMA TANITIM TICARET LIMITED SIRKETI, GOLDING, LOUISE

Application No.: WO2011GB51220 (PCT/GB2011/51220)   Filing Date: 28/Jun/2011

Abstract:

The invention provides topical pharmaceutical compositions comprising flurbiprofen, or a pharmaceutically acceptable derivative thereof, in combination with a solubilising system which comprises at least one glycol ether and at least one glycol ester. These are suitable for treating any condition associated with pain, inflammation and/or stiffness, for example sub-dermal pain in the joints or soft tissue.

Priority: GB20100010954 Applic. Date: 2010-06-29

Inventor: EMBIL KORAL [TR]; FIGUEROA RAY [US]


Publication No.: WO2012001411A2  Published: 05/Jan/2012

Title: FORMULATIONS AND DELIVERY

Applicant/Assignee: LONDONPHARMA LTD, ROSS, ELIZABETH ANITA

Application No.: WO2011GB51230 (PCT/GB2011/51230)   Filing Date: 29/Jun/2011

Abstract:

The invention provides pharmaceutical compositions for the sublingual delivery of opioids. The invention also provides delivery devices adapted for sublingual delivery of such compositions.

Priority: GB20100011028 Applic. Date: 2010-06-30

Inventor: SAMS MARTIN JAMES [GB]; HIGH JULIET VICTORIA [GB]; JAMIESON PAUL ANDREW [GB]; ROSS CALVIN JOHN


Publication No.: WO2012001469A1  Published: 05/Jan/2012

Title: DESMOPRESSIN FOR REDUCING NOCTURNAL VOIDS

Applicant/Assignee: FERRING INTERNATIONAL CENTER S.A

Application No.: WO2011IB01010 (PCT/IB2011/01010)   Filing Date: 22/Mar/2011

Abstract:

The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.

Priority: US2010-732161 Applic. Date: 2010-03-25

Inventor: NORGAARD JENS PETER [DK]; KLEIN BJARKE MIRNER [DK]


Publication No.: WO2012001494A2  Published: 05/Jan/2012

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING PARACETAMOL AND PROCESS FOR PREPARING THE SAME

Applicant/Assignee: TROIKAA PHARMACEUTICALS LIMITED

Application No.: WO2011IB01519 (PCT/IB2011/01519)   Filing Date: 29/Jun/2011

Abstract:

Disclosed herein are injectable compositions containing high concentration of paracetamol or its pharmaceutically acceptable salts wherein the concentration of paracetamol or its pharmaceutically acceptable salt is >150mg/ml in a judiciously tailored solvent system comprising glycofurol, ethanol, water or a solvent system comprising glycofurol, ethanol, polyethylene glycol, water. The viscosity of the said injectables is <28 cps. Further disclosed is the process for preparing the said injectables.

The injectables can be administered by intramuscular route, intravenous route or as intravenous infusion after diluting in one of the routinely used intravenous fluids, infusion solutions of antibacterial, antifungal and amoebicidal drugs and along with anxiolytics (Midazolam injection ) or narcotic analgesics (Fentanyl Citrate injection etc) as they remain stable, clear and transparent atleast for 6 hours after dilution.

Priority: IN2010MU00630 Applic. Date: 2010-09-09; IN2009MU03023 Applic. Date: 2010-06-30

Inventor: PATEL KETAN R [IN]; PATEL MILAN R [IN]; SHAH PRAKASHCHANDRA J [IN]


Publication No.: WO2012001679A1  Published: 05/Jan/2012

Title: INJECTABLE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF JOINTS

Applicant/Assignee:

Application No.: WO2011IL00495 (PCT/IL2011/00495)   Filing Date: 15/Jun/2011

Abstract:

The present invention relates to an injectable pharmaceutical formulation for the alleviation or reduction of joint irritation or for the reduction of worsening of existing joint inflammation, formulated for intra-articular injection comprising an active polyol ingredient, which polyol active ingredient is xylitol. Use of the intra-articular injectable formulations for the treatment of joint diseases or conditions including arthritis is described.

Priority: IL20100206739 Applic. Date: 2010-06-30

Inventor: SEGAL DAVID [IL]


Publication No.: WO2012002547A1  Published: 05/Jan/2012

Title: BOSENTAN SOLID DISPERSION

Applicant/Assignee: FUJI CHEMICAL INDUSTRY CO., LTD

Application No.: WO2011JP65230 (PCT/JP2011/65230)   Filing Date: 01/Jul/2011

Abstract:

Provided is a bosentan-containing pharmaceutical composition which has good bosentan solubility in water regardless of pH and maintains that solubility even in long-term storage. A solid dispersion is formed from (A) bosentan and (B) a matrix component selected from cellulose polymers, synthetic homopolymers, and synthetic copolymers, wherein the (A) and (B) mass ratio (A:B) is between 1:0.05 and 1:10, the soluble concentration in water at 37 C is between 50 and 500 [mu]g/mL, and the soluble concentration in potassium dihydrogenphosphate-sodium hydroxide aqueous solution having a pH of 6.8 at 37 C is 0.6 to 10 mg/mL.

Priority: JP20100154120 Applic. Date: 2010-07-06; JP20100152120 Applic. Date: 2010-07-02

Inventor: OSHIO NAOTOU [JP]; HIRAI YOUSUKE [JP]; SAKAI HITOSHI [JP]; TANAKA NOBUKAZU [JP]; SANADA KUNIO [JP]


Publication No.: WO2012002918A1  Published: 05/Jan/2012

Title: FORMULATION FOR OSTEOPOROSIS

Applicant/Assignee:

Application No.: WO2011TR00150 (PCT/TR2011/00150)   Filing Date: 02/Jun/2011

Abstract:

The present invention relates to pharmaceutical formulations with high bioavailability comprising calcium, genistein and vitamin D in order to be used in the prophylaxis and treatment of osteoporosis and related diseases.

Priority: TR20100004464 Applic. Date: 2010-06-03

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2012003045A2  Published: 05/Jan/2012

Title: PROCESS FOR THE PREPARATION OF POLY(ALKYLENE OXIDE) DERIVATIVES FOR MODIFICATION OF BIOLOGICALLY ACTIVE MOLECULES AND MATERIALS

Applicant/Assignee: HORIAN AMERICA, CORP

Application No.: WO2011US35733 (PCT/US2011/35733)   Filing Date: 09/May/2011

Abstract:

A a method for producing activated linear polymers and activatable branched polymers thereof, is carried out by a) reacting a linear nonpeptidic activatable polymer, chemically blocked at one end, with an azole ring activating group that provides a leaving group to produce an intermediate polymer of the general formula poly-Im

b) reacting said poly-Im with an alkylating agent to form an imidazolium salt of the general formula poly-Im+(alkyl)X-"

and c) reacting said poly-Im+(alkyl)X- with a linker molecule bearing at least two nucleophilic moieties to produce an activatable branched polymer derivative thereof. In some embodiments "poly" is a polymer selected from the group consisting of poly(alkylene oxides), poly(oxyethylated polyols), poly(olefinic alcohols), and polymers of alkylene oxide and propylene oxide

in some embodiments "Im+" is an imidazolium ion

and in some embodiments "X-" is an anionic counterion selected from the group consisting of halides, nitrates, sulfonates, chlorates, citrates, succinates, tartrates, lactates, sulfates, phosphates, acetates, triflates, and borates.

Priority: US20100360729P Applic. Date: 2010-07-01

Inventor: VAILLARD SANTIAGO EDUARDO [AR]; GONZALEZ MARIANELA [AR]; GRAU RICARDO JOSE ANTONIO [AR]


Publication No.: WO2012003141A1  Published: 05/Jan/2012

Title: COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES

Applicant/Assignee: ALCON RESEARCH, LTD

Application No.: WO2011US41784 (PCT/US2011/41784)   Filing Date: 24/Jun/2011

Abstract:

The use of certain urea compounds, for the treatment of retinal disorders associated with pathologic ocular angiogenesis and/or neovascularization is disclosed.

Priority: US20100361003P Applic. Date: 2010-07-02

Inventor: MAY JESSE A [US]; BINGAMAN DAVID P [US]; ROMANO CARMELO [US]


Publication No.: WO2012003349A2  Published: 05/Jan/2012

Title: DISSOLVABLE FIBROUS WEB STRUCTURE ARTICLE COMPRISING ACTIVE AGENTS

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: WO2011US42640 (PCT/US2011/42640)   Filing Date: 30/Jun/2011

Abstract:

The personal care compositions of the present invention are in the form of an Article comprising a dissolvable fibrous web structure. The fibers of the dissolvable fibrous web structure comprise a surfactant

a water soluble polymeric structurant

and a plasticizer. Additionally the ratio of the water soluble water soluble polymeric structurant to the active agent in the fiber is 3.5 or less.

Priority: US20100360982P Applic. Date: 2010-07-02

Inventor: GLENN ROBERT WAYNE JR [US]; CHHABRA RAJEEV [US]; ALLEN JR WILLIAM MAXWELL [US]; BRENNAN JONATHAN PAUL [US]


Publication No.: WO2012003960A1  Published: 12/Jan/2012

Title: TOPICAL APPLICATION OF ERYTHROPOIETIN FOR THE TREATMENT OF EYE DISORDERS AND INJURIES

Applicant/Assignee:

Application No.: WO2011EP03328 (PCT/EP2011/03328)   Filing Date: 05/Jul/2011

Abstract:

The invention relates to the use of erythropoietin (EPO), in particular EPO in a pharmaceutical preparation, for the treatment of traumatized or diseased eyes, in particular the case of endothelial dysfunction or dystrophies of the eye, preferably in connection with mechanical or pathological injuries of the cornea and conditions related thereto, as well as injuries following eye surgery.

Priority: EP20100006960 Applic. Date: 2010-07-06

Inventor: BADER AUGUSTINUS [DE]


Publication No.: WO2012003968A1  Published: 12/Jan/2012

Title: NOVEL GASTRO- RETENTIVE DOSAGE FORMS COMPRISING A GABA ANALOG AND AN OPIOID

Applicant/Assignee: GRUENENTHAL GMBH

Application No.: WO2011EP03343 (PCT/EP2011/03343)   Filing Date: 06/Jul/2011

Abstract:

The present invention provides a gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. The present invention further provides a method of treating a disorder by administering to a patient in need thereof, a gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. The said opioid is either in slow release form or in immediate release form.

Priority: US20100399045P Applic. Date: 2010-07-06

Inventor: SESHA RAMESH [US]


Publication No.: WO2012003987A1  Published: 12/Jan/2012

Title: ORAL DOSAGE FORM OF DEFERASIROX

Applicant/Assignee: RATIOPHARM GMBH

Application No.: WO2011EP03387 (PCT/EP2011/03387)   Filing Date: 07/Jul/2011

Abstract:

The invention relates to an oral dosage form containing deferasirox, binder, disintegrant and optionally wicking agent, wherein the introduction of the dosage form into water leads to a suspension wherein the suspended particles have an average particle size (D50) of 20 [mu]m to 120 [mu]m, and also to a method of producing it.

Priority: EP20100007059 Applic. Date: 2010-07-08

Inventor: PAETZ JANA [DE]; RIMKUS KATRIN [DE]


Publication No.: WO2012004231A1  Published: 12/Jan/2012

Title: DOSAGE FORM

Applicant/Assignee: JAGOTEC AG

Application No.: WO2011EP61257 (PCT/EP2011/61257)   Filing Date: 04/Jul/2011

Abstract:

?n elongate dosage form of generally cylindrical shape having two opposing ends, the dosage form being buoyant in. gastric fluid, wherein the dosage form is weight biased such that. one end is heavier than the ether end. The dosage form is adapted to float on gastric fluid with its long axis substantially perpendicular to the surface of the: fluid with its heavier end pointing: generally

downwards and into the fluid.

Priority: GB20100018917 Applic. Date: 2010-11-09; GB20100011271 Applic. Date: 2010-07-05

Inventor: GRENIER PASCAL [FR]; NHAMIAS ALAIN [FR]; VERGNAULT GUY [FR]


Publication No.: WO2012004291A1  Published: 12/Jan/2012

Title: IMPROVED METHOD FOR STEM CELL DIFFERENTIATION IN VIVO BY DELIVERY OF MORPHOGENES WITH MESOPOROUS SILICA AND CORRESPONDING PHARMACEUTICAL ACTIVE INGREDIENTS.

Applicant/Assignee: NANOLOGICA AB

Application No.: WO2011EP61377 (PCT/EP2011/61377)   Filing Date: 06/Jul/2011

Abstract:

A pharmaceutical active ingredient for cell differentiation to alleviate cell and cell-related deficiencies in mammals comprising porous silica containing a releasable agent capable of contributing to a cell environment conducive for stem cell differentiation in co-implanted stem cells and /or in endogenous stem cells.

Priority: US20100361741P Applic. Date: 2010-07-06

Inventor: GARCIA-BENNETT ALFONSO E [SE]; KOZLOVA ELENA NICKOLAEVNA [SE]


Publication No.: WO2012004308A1  Published: 12/Jan/2012

Title: STABLE AQUEOUS FORMULATIONS COMPRISING POORLY WATER SOLUBLE ACTIVE INGREDIENTS

Applicant/Assignee: KRKA, D.D., NOVO MESTO

Application No.: WO2011EP61419 (PCT/EP2011/61419)   Filing Date: 06/Jul/2011

Abstract:

The present invention relates to a formulation comprising one or more active ingredients of poor water solubility for medical or non-medical use in the rearing of animals. The inventive formulation is suitable for administration to the animals via their drinking water. It exhibits superior stability. Said formulation comprises an active ingredient, a thickener combination and water, wherein the thickener combination comprises at least one thickener selected from the following groups A, B, C and D: (A) cellulose derivatives, such as methyl cellulose, sodium carboxy methyl cellulose, (B) non-cellulosic polysaccharide thickeners such as xanthan gums, Arabic gum, (C) cross-linked polyacrylic acid polymers, (D) hydrocolloidal hydrated silicates.

Priority: EP20100168532 Applic. Date: 2010-07-06

Inventor: LESKOVAR DENISE [SI]; VRECER FRANC [SI]; KRAMAR ANDREJKA [SI]; KOLENC IVANKA [SI]; GOBEC IVAN [SI]; PRINC HELENA [SI]


Publication No.: WO2012006081A1  Published: 12/Jan/2012

Title: ORAL FORMULATION OF KINASE INHIBITORS

Applicant/Assignee: PONIARD PHARMACEUTICALS, INC

Application No.: WO2011US42162 (PCT/US2011/42162)   Filing Date: 28/Jun/2011

Abstract:

The invention is directed to formulations of bioactive compounds of limited water solubility, inhibitors of focal adhesion kinase (FAK) of the 2,4-diaminopyridine class, adapted for oral administration to patients. The formulations are self-emulsifying in the gastrointestinal tract of the patients, providing enhanced absorption and bioavailability of the bioactive compounds as dispersions or emulsions in an oil base. For example, esters of PEG-ylated glycerol can be used as the oil, in conjunction with surfactants such as lecithin and TEPG succinate and solubilizers such as PEG 400 to provide useful oral formulations for administration to patients having a malcondition wherein inhibition of FAK is medically indicated, such as cancer or arthritis.

Priority: US20100359694P Applic. Date: 2010-06-29

Inventor: CHEN ANDREW XIAN [US]; TSAI YALI J [US]


Publication No.: WO2012006959A1  Published: 19/Jan/2012

Title: CONTROLLED RELEASE PREPARATION

Applicant/Assignee:

Application No.: WO2011CN77167 (PCT/CN2011/77167)   Filing Date: 14/Jul/2011

Abstract:

Disclosed are a controlled release preparation with improved performance and a method for preparing the controlled release preparation. The controlled release preparation comprises: a core containing drugs and a controlled release coating coated on the core. The controlled release coating contains a plasticizer, a polymer that is insoluble in water and gastrointestinal digestive juice, and particles of a porogen which are embedded in the polymer and coated by a polymer coating soluble in gastric juice and/or intestinal juice but insoluble in water. The reproducibility of drug release of the controlled release preparation is improved, the release time lag is reduced, and the bioavailability is improved. Therefore, targeted and controlled release of drugs in gastrointestinal track is achieved.

Priority: CN20101227254 Applic. Date: 2010-07-16

Inventor: ZHONG SHUGUANG [CN]


Publication No.: WO2012006961A1  Published: 19/Jan/2012

Title: CONTROLLED RELEASE FORMULATION

Applicant/Assignee:

Application No.: WO2011CN77179 (PCT/CN2011/77179)   Filing Date: 15/Jul/2011

Abstract:

A controlled release formulation, particularly a controlled release formulation with zero-order release, comprising: (1) a core containing at least one drug

(2) a controlled release coating membrane coated outside of the core. The controlled release coating membrane comprises at least one polymer insoluble in water and gastrointestinal digestive fluid and a cyclodextrin derivative, wherein the cyclodextrin derivative is a water-soluble cyclodextrin derivative with an average substitution value (or DS) of no less than 5 of the hydroxyl group on each glucose unit, and disperses in the controlled release coating membrane in single molecular form and/or in micellar form. The drug release from the controlled release formulation is relatively less affected in vivo and in vitro and is relatively faster with a relatively smaller time lag. The bioavailability of the drug is higher, the stability of the drug release is increased, and the mechanical strength of the controlled release coating membrane of the formulation is also increased.

Priority: CN20101228791 Applic. Date: 2010-07-16

Inventor: ZHONG SHUGUANG [CN]


Publication No.: WO2012007130A1  Published: 19/Jan/2012

Title: TREATMENT OF LUNG INFECTIONS BY ADMINISTRATION OF TOBRAMYCIN BY AEROLISATION

Applicant/Assignee: XELLIA PHARMACEUTICALS APS

Application No.: WO2011EP03405 (PCT/EP2011/03405)   Filing Date: 08/Jul/2011

Abstract:

The present invention regards a novel administration form and a novel administration regime useful in the treatment and prevention of a bacterial lung infection in patient in need thereof, in particular by providing a composition useful for aerosolization of a highly concentrated solution of aminoglycosides such as Tobramycin.

Priority: NO20100001576 Applic. Date: 2010-11-08; US20100363330P Applic. Date: 2010-07-12

Inventor: NORLING THOMAS [DK]


Publication No.: WO2012007159A2  Published: 19/Jan/2012

Title: NOVEL GASTRO-RETENTIVE DOSAGE FORMS

Applicant/Assignee: GRUENENTHAL GMBH

Application No.: WO2011EP03496 (PCT/EP2011/03496)   Filing Date: 13/Jul/2011

Abstract:

The present invention provides a gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one opioid, at least one form of acetaminophen, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. The present invention further provides a method of treating pain by administering to a patient in need thereof, a gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one opioid, at least one form of acetaminophen, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. The acetaminophen is either in slow release form or in immediate release form or as combination of both. The present invention further provides a gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one opioid, at least one form of acetaminophen, an opioid antagonist and at least one pharmaceutically acceptable excipient, wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration.

Priority: US20100399589P Applic. Date: 2010-07-14

Inventor: SESHA RAMESH [US]


Publication No.: WO2012007352A1  Published: 19/Jan/2012

Title: AQUEOUS COMPOSITION COMPRISING BROMHEXINE

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: WO2011EP61527 (PCT/EP2011/61527)   Filing Date: 07/Jul/2011

Abstract:

The present invention relates to aqueous compositions comprising bromhexine, the composition containing an amount of sugar alcohols of less than 10 g based on 100 ml of the composition, and to the use thereof for secretolytic therapy in acute and chronic bronchopulmonary disorders.

Priority: EP20100169236 Applic. Date: 2010-07-12

Inventor: SCHEURING UWE [DE]; PLOHMANN BERND [DE]; ZAMPONI ANNETTE [DE]


Publication No.: WO2012007512A1  Published: 19/Jan/2012

Title: NEW FORMULATIONS OF 14 - EPI -ANALOGUES OF VITAMIN D

Applicant/Assignee: HYBRIGENICS SA

Application No.: WO2011EP61973 (PCT/EP2011/61973)   Filing Date: 13/Jul/2011

Abstract:

The present invention provides formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.

Priority: EP20100305783 Applic. Date: 2010-07-15; US2010-836974 Applic. Date: 2010-07-15

Inventor: DELANSORNE REMI [FR]


Publication No.: WO2012007517A1  Published: 19/Jan/2012

Title: FORMULATIONS OF 14 - EPI -ANALOGUES OF VITAMIN D

Applicant/Assignee: HYBRIGENICS SA

Application No.: WO2011EP61984 (PCT/EP2011/61984)   Filing Date: 13/Jul/2011

Abstract:

The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.

Priority: EP20100305783 Applic. Date: 2010-07-15; US2010-836974 Applic. Date: 2010-07-15

Inventor: DELANSORNE REMI [FR]


Publication No.: WO2012007538A1  Published: 19/Jan/2012

Title: FERRIMANNITOL-OVALBUMIN TABLET COMPOSITION

Applicant/Assignee: TEDEC MEIJI FARMA S.A

Application No.: WO2011EP62022 (PCT/EP2011/62022)   Filing Date: 14/Jul/2011

Abstract:

The invention refers to an oral pharmaceutical tableted dosage form which comprises a mixture of: a) granules comprising ferrimannitol-ovalbumin (FMOA) and at least an intragranular pharmaceutical acceptable excipient including a binder

and b) extragranular pharmaceutical excipients including a filler and a binder

which may be obtained by wet-granulation and compression.

Priority: EP20100382196 Applic. Date: 2010-07-15

Inventor: TORRES-SUAREZ ANA ISABEL [ES]; GIL ALEGRE MARIA ESTHER [ES]; TAVARES DA SILVA FERNANDES DANIEL FILIPE [ES]


Publication No.: WO2012007570A2  Published: 19/Jan/2012

Title: NEW FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D

Applicant/Assignee: HYBRIGENICS SA

Application No.: WO2011EP62127 (PCT/EP2011/62127)   Filing Date: 15/Jul/2011

Abstract:

The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.

Priority: US2010-836974 Applic. Date: 2010-07-15; EP20100305783 Applic. Date: 2010-07-15

Inventor: DELANSORNE REMI [FR]


Publication No.: WO2012007906A2  Published: 19/Jan/2012

Title: EUDERMIC COMPOSITIONS

Applicant/Assignee: POLITECNICO DI TORINO

Application No.: WO2011IB53112 (PCT/IB2011/53112)   Filing Date: 12/Jul/2011

Abstract:

Eudermic composition comprising at least one eudermically active principle, at least one vehicle for said active principle, and porous silica particles, wherein the active principle is contained in at least one pore of at least a first portion of such silica particles and in the vehicle.

Priority: IT2010TO00612 Applic. Date: 2010-07-14

Inventor: ONIDA BARBARA [IT]; MORTERA RENATO SILVIO [IT]


Publication No.: WO2012010022A1  Published: 26/Jan/2012

Title: NEW USE OF HESPERETIN

Applicant/Assignee: NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD

Application No.: WO2011CN75765 (PCT/CN2011/75765)   Filing Date: 15/Jun/2011

Abstract:

The present invention discloses a use of hesperetin or a plant extract containing hesperetin in manufacture of products for improving and/or promoting cutaneous microcirculation, or eliminating and/or relieving diseases or conditions related to poor cutaneous microcirculation. The present invention also discloses a composition comprising an effective amount of hesperetin or plant extract containing hesperetin, as well as a method for improving and/or promoting cutaneous microcirculation, or eliminating and/or relieving diseases or conditions related to poor cutaneous microcirculation by using hesperetin. The cutaneous microcirculation in the present invention is preferably cutaneous microcirculation of ocular region.

Priority: CN20101231389 Applic. Date: 2010-07-20

Inventor: HU LIU [CN]; LAN HONGYING [CN]


Publication No.: WO2012010159A1  Published: 26/Jan/2012

Title: BIODEGRADABLE NANO-, MESO-, AND MICRO-POLYMER PARTICLES FOR MAINTAINING A LOW SURFACE TENSION IN THE LUNG AND FOR PROTECTING THE PULMONARY SURFACTANT

Applicant/Assignee: JUSTUS-LIEBIG-UNIVERSITAET GIESSEN

Application No.: WO2011DE01471 (PCT/DE2011/01471)   Filing Date: 18/Jul/2011

Abstract:

The invention relates to biocompatible nano-, meso-, and micro-polymer particles which can bind pathogenic proteins that penetrate into the lining layer of the lung. Known pathogenic proteins in the pulmonary lining layer are negatively charged. Said proteins damage the pulmonary surfactant system, which is essential for maintaining a low surface tension in the lung and thus for functional breathing. Polymer particles according to the invention have a diameter between 20 nm and 10 pm, are water-insoluble, and have a positive surface charge and a low surface hydrophobicity. The isoelectric point of the particles is greater than 5, so that the particles are present in the lining layer of the lung as positively charged particles, and also greater than the isoelectric point of the pathogenic proteins to be bound. The polymer particles according to the invention can be produced by means of precipitation or emulsion methods for example. The polymer particles according to the invention can be used for maintaining a low surface tension in the lung and for protecting the pulmonary surfactant.

Priority: EP20100169915 Applic. Date: 2010-07-16

Inventor: BECK-BROICHSITTER MORITZ [DE]; SCHMEHL THOMAS [DE]; GESSLER TOBIAS [DE]


Publication No.: WO2012010478A1  Published: 26/Jan/2012

Title: COMBINATION OF SILOXANE AND ACTIVE INGREDIENT FOR TREATING DENTAL DISORDER

Applicant/Assignee: BAYER INNOVATION GMBH

Application No.: WO2011EP61953 (PCT/EP2011/61953)   Filing Date: 13/Jul/2011

Abstract:

The invention relates to a pharmaceutical composition comprising a siloxane according to general formula (I) wherein R means -C1-C6-alkyl

R1 and R2 each mean independently of one another -C1-C6-alkyl, or together form a (2n)-membered ring

and n is an integer of from 2 to 8

for use in combination with a pharmacologically active ingredient in the prophylaxis or treatment of a dental disorder.

Priority: EP20100007536 Applic. Date: 2010-07-21

Inventor: SCHULZ HANS H [DE]


Publication No.: WO2012010854A1  Published: 26/Jan/2012

Title: INHALATION FORMULATIONS COMPRISING CARMOTEROL IN COMBINATION WITH A CORTICOSTEROID

Applicant/Assignee: CIPLA LIMITED, CURTIS, PHILIP, ANTHONY

Application No.: WO2011GB01114 (PCT/GB2011/01114)   Filing Date: 25/Jul/2011

Abstract:

A pharmaceutical composition comprising carmoterol in combination with a corticosteroid selected from fluticasone, ciclesonide or mometasone, and, optionally, one or more pharmaceutically acceptable excipients.

Priority: IN2011MU00069 Applic. Date: 2011-01-10; IN2010MU02346 Applic. Date: 2010-08-20; IN2010MU02219 Applic. Date: 2010-08-04; IN2010MU02105 Applic. Date: 2010-07-23

Inventor: MALHOTRA GEENA [IN]; PURANDARE SHRINIVAS MADHUKAR [IN]; LULLA AMAR [IN]


Publication No.: WO2012011133A1  Published: 26/Jan/2012

Title: CLAY AND METHOD FOR ITS PRODUCTION

Applicant/Assignee:

Application No.: WO2010IT00322 (PCT/IT2010/00322)   Filing Date: 21/Jul/2010

Abstract:

Clay obtained from an ore comprising from 50% to 60% of a clay fraction and from 40% to 50% of a non-clay fraction, in which said clay fraction comprises two or more minerals selected from the group consisting of illite, saponite, chlorite, kaolinite, goethite, and lizardite, while the non-clay fraction comprises calcite and quartz

uses of such a clay, and method for the production thereof.

Priority: WO2010IT00322 Applic. Date: 2010-07-21

Inventor: BATTAGLINO CLAUDIA [IT]


Publication No.: WO2012012162A2  Published: 26/Jan/2012

Title: CORE-SHEATH IMPLANT DEVICE HAVING AN INNER CORE LOBE

Applicant/Assignee: SURMODICS PHARMACEUTICALS, INC

Application No.: WO2011US42314 (PCT/US2011/42314)   Filing Date: 29/Jun/2011

Abstract:

The core-sheath implant device allows for a bioactive agent release profile that can be tailored to a particular therapy. The device features one or more lobes extending from an inner core at least partially through the outer sheath. Depending on the particular design of such an implant device, a variety of release profiles can be achieved.

Priority: US20100360140P Applic. Date: 2010-06-30

Inventor: HUDSON MICHAEL E [US]


Publication No.: WO2012012184A2  Published: 26/Jan/2012

Title: OPHTHALMIC DEVICES CONTAINING CHEMOKINE ANTAGONISTS

Applicant/Assignee: JOHNSON & JOHNSON VISION CARE, INC

Application No.: WO2011US42404 (PCT/US2011/42404)   Filing Date: 29/Jun/2011

Abstract:

Ionic ophthalmic devices, methods of treating chemoattractant cytokine receptor 2 (CCR2) mediated inflammatory conditions, and methods of making such devices are disclosed herein.

Priority: US20100359963P Applic. Date: 2010-06-30

Inventor: CHAOUK HASSAN [US]


Publication No.: WO2012012264A1  Published: 26/Jan/2012

Title: METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALLERGY

Applicant/Assignee: ALCON RESEARCH, LTD

Application No.: WO2011US44036 (PCT/US2011/44036)   Filing Date: 14/Jul/2011

Abstract:

The present invention relates to compositions comprising an antagonist of the histamine H1 receptor and a compatible antagonist of the histamine H4 receptor. The antagonist compounds are selected to prevent the H4 receptor antagonist from interfering with the H1 receptor antagonist's suppression of acute phase allergic responses in a patient. The present invention also relates to compositions comprising a mast cell stabilizer and a compatible antagonist of the histamine H4 receptor.

Priority: US20100365549P Applic. Date: 2010-07-19

Inventor: BEAUREGARD CLAY [US]; KLIMKO PETER G [US]; YANNI JOHN M [US]; GAMACHE DANIEL A [US]


Publication No.: WO2012012370A1  Published: 26/Jan/2012

Title: VITAMIN C AND CHROMIUM-FREE VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING AN NFKB-MEDIATED CONDITION OR DISEASE

Applicant/Assignee: SUMMA HEALTH SYSTEM

Application No.: WO2011US44443 (PCT/US2011/44443)   Filing Date: 19/Jul/2011

Abstract:

Provided herein is a pharmaceutical composition comprising vitamin C and chromium-free vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Also provided herein is a chromium-free pharmaceutical composition comprising vitamin C and vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Further provided herein is a method of treating, preventing, or managing an NFKB-mediated condition, disorder, or disease, comprising administering to the subject a therapeutically effective amount of vitamin C and chromium-free vitamin K.

Priority: US20100365715P Applic. Date: 2010-07-19

Inventor: JAMISON JAMES M [US]; MILLER THOMAS M [US]; NEAL DEBORAH R [US]; KOVACIK MARK WILLIAM [US]; ASKEW MICHAEL JOHN [US]; MOSTARDI RICHARD ALBERT [US]; MCGUIRE KAREN M [US]


Publication No.: WO2012012417A1  Published: 26/Jan/2012

Title: TRANSDERMAL ADHESIVE COMPOSITIONS, DEVICES, AND METHODS

Applicant/Assignee: 3M INNOVATIVE PROPERTIES COMPANY

Application No.: WO2011US44522 (PCT/US2011/44522)   Filing Date: 19/Jul/2011

Abstract:

A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers

and at least one pharmaceutically active compound which is susceptible to oxidative degradation

wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided.

Priority: US20100366358P Applic. Date: 2010-07-21

Inventor: DIZIO JAMES P [US]; JOHNSON ELIZABETH E [US]; WU ZHENG ZHI [US]; PRESZLER PRINCE AMY [US]


Publication No.: WO2012012476A1  Published: 26/Jan/2012

Title: PHARMACEUTICAL COMPOSITION WITH ENHANCED SOLUBILITY CHARACTERISTICS

Applicant/Assignee: ALCON RESEARCH, LTD

Application No.: WO2011US44596 (PCT/US2011/44596)   Filing Date: 20/Jul/2011

Abstract:

There are disclosed pharmaceutical compositions, particularly ophthalmic compositions, that contain relatively high concentrations of solubility enhancing polymer (e.g., polyether polymer, polyvinyl polymer or a combination thereof) for providing enhanced solubility of one or more therapeutic agents. In a preferred embodiment, the composition is a multi-dose topical aqueous ophthalmic composition that contains relatively high concentrations of solubility enhancing polymer (e.g., polyether polymer, polyvinyl polymer or a combination thereof) for providing enhanced solubility of one or more therapeutic agents.

Priority: US20100366328P Applic. Date: 2010-07-21

Inventor: CHOWHAN MASOOD A [US]; GHOSH MALAY [US]; HAN WESLEY WEHSIN [US]; LIN WAY-YU [US]; NGUYEN VINCENT [US]


Publication No.: WO2012012541A2  Published: 26/Jan/2012

Title: SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US44694 (PCT/US2011/44694)   Filing Date: 20/Jul/2011

Abstract:

The present invention provides an ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein said complex is associated with a biocompatible polymer. Said biocompatible polymer comprises a polymeric matrix configured to release said complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.

Priority: US20100366500P Applic. Date: 2010-07-21

Inventor: RIVERS HONGWEN M [US]; SPADA LON T [US]; LUU MICHELLE [US]


Publication No.: WO2012012546A2  Published: 26/Jan/2012

Title: METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US44701 (PCT/US2011/44701)   Filing Date: 20/Jul/2011

Abstract:

The present invention provides an intraocular implant comprising siRNA combined with a excipient effective to retard the initial release of the siRNA from an implant, wherein said siRNA and excipient is associated with a biocompatible polymer (e.g., a polymeric matrix), configured to release said siRNA into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.

Priority: US20100366504P Applic. Date: 2010-07-21

Inventor: RIVERS HONGWEN M [US]; SPADA LON T [US]; LUU MICHELLE [US]


Publication No.: WO2012013088A1  Published: 02/Feb/2012

Title: DRONEDARONE SOLID DISPERSION AND PREPARATION METHOD THEREOF

Applicant/Assignee: JIANGSU HENGRUI MEDICINE CO., LTD

Application No.: WO2011CN74989 (PCT/CN2011/74989)   Filing Date: 31/May/2011

Abstract:

A dronedarone solid dispersion and preparation method thereof are disclosed. Said solid dispersion is composed of active ingredient dronedarone or its pharmaceutically acceptable salts and carrier materials, wherein the carrier material is selected from polyvidone, copovidone and hydroxypropyl cellulose, or a mixture thereof.

Priority: CN20101251305 Applic. Date: 2010-07-30

Inventor: SUN PIAOYANG [CN]; PAN KAI [CN]; WU YUXIA [CN]


Publication No.: WO2012013229A1  Published: 02/Feb/2012

Title: THERAPEUTIC AGENT, COMPOSITION INCLUDING SAID AGENT, IMPLANTABLE DEVICE AND PROCESS FOR THE TREATMENT OF CERVICAL CANCER AND/OR FOR THE PREVENTION OF THE FORMATION OF NEOPLASMS IN CORRESPONDENCE OF THE CERVIX IN A HUMAN FEMALE GENITAL SYSTEM.

Applicant/Assignee: FONDAZIONE IRCCS

Application No.: WO2010EP60975 (PCT/EP2010/60975)   Filing Date: 28/Jul/2010

Abstract:

A medical composition including a chemotherapeutic medication or a targeted therapy medication is used in a human female patient for the treatment of a disease selected in the group comprising cervical cancer, cervical intraepithelial neoplasia (CIN), human papillomavirus (HPV) infection of the female genital system

the chemotherapeutic agent or targeted therapy medication is locally delivered directly to cervix of a female genital system by an implanted medical device including a stem to be implanted in the cervix. The stem has a drug carrying layer including the medical composition. A process for the treatment of the above diseases is also disclosed.

Priority: WO2010EP60975 Applic. Date: 2010-07-28

Inventor: RASPAGLIESI FRANCESCO [IT]


Publication No.: WO2012013472A1  Published: 02/Feb/2012

Title: MODULAR MICRONEEDLE TRANSPORT DEVICE

Applicant/Assignee: ROBERT BOSCH GMBH

Application No.: WO2011EP61547 (PCT/EP2011/61547)   Filing Date: 07/Jul/2011

Abstract:

The invention relates to a modular microneedle transport device (1

1') comprising a first module (20

20') that includes a fluid reservoir (23

23') for receiving a transport fluid (F), a microneedle unit (22), and a micropump unit (24) for pumping the transport fluid (F) from the fluid reservoir (23

23') into the microneedle unit (22) and/or vice versa

and further comprising a second module (10

10') comprising an actuator unit (10a) and a battery-powered control unit (10b)

wherein the second module (10

10') can be mounted in a recess (50) of the first module (20

20')

and wherein the micropump unit (24) can be mechanically actuated by the actuator unit (10a) by means of a pressure actuation surface (UP) provided in the recess (50) when the second module (10

10') is mounted.

Priority: DE201010038733 Applic. Date: 2010-07-30

Inventor: VAN TEEFFELEN KATHRIN [DE]


Publication No.: WO2012013551A1  Published: 02/Feb/2012

Title: FORMULATIONS CONTAINING EXTRACTS OF ECHINACEA ANGUSTIFOLIA AND ZINGIBER OFFICINALE WHICH ARE USEFUL IN REDUCING INFLAMMATION AND PERIPHERAL PAIN

Applicant/Assignee: INDENA S.P.A

Application No.: WO2011EP62421 (PCT/EP2011/62421)   Filing Date: 20/Jul/2011

Abstract:

Disclosed is a combination of lipophilic extracts of Zingiber officinale and Echinacea angustifolia for the treatment of itching, peripheral pain, superficial and deep inflammatory and painful states, pain associated with muscle spasms, herpes pain, and radiodermatitis caused by oncological radiotherapy, with or without fungal or bacterial infections.

Priority: IT2010MI01373 Applic. Date: 2010-07-26

Inventor: BOMBARDELLI EZIO [IT]; MORAZZONI PAOLO [IT]


Publication No.: WO2012013742A2  Published: 02/Feb/2012

Title: STABILIZATION OF FSH

Applicant/Assignee: FERRING B.V

Application No.: WO2011EP62986 (PCT/EP2011/62986)   Filing Date: 28/Jul/2011

Abstract:

The present invention, pertains in general to the field of stabilization of FSH formulations, in particular liquid FSH formulations. The stabilization is achieved by the addition of salts comprising pharmaceutically acceptable alkali metal cations, in preferred embodiments by the addition of pharmaceutically acceptable salts, i.e. sodium salts or potassium salts.

Priority: EP20100171428 Applic. Date: 2010-07-30

Inventor: SJOEGREN HELEN ULRIKA [SE]; BAGGER HEIDI LOUISE [DK]


Publication No.: WO2012013782A2  Published: 02/Feb/2012

Title: COMPOSITIONS FOR CONTROLLING HEARTWORM INFESTATION

Applicant/Assignee: CEVA SANTE ANIMALE

Application No.: WO2011EP63102 (PCT/EP2011/63102)   Filing Date: 29/Jul/2011

Abstract:

The present invention relates to ivermectin formulations for administration to pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse of conventional formulations. Preferred formulations are collars, collar strips, or medallions, attachments for collars, ear tags, bands which are affixed to limbs or parts of the body, adhesive strips and films, and peel-off films, or spot-on or pour-on forms which are administered at least twice a year up to around once a year.

Priority: US20100369434P Applic. Date: 2010-07-30

Inventor: FORGET PATRICK [FR]; KALTSATOS VASSILIOS [FR]; WARIN STEPHAN [FR]


Publication No.: WO2012013791A1  Published: 02/Feb/2012

Title: COMPOSITIONS FOR TREATING HEARTWORM INFESTATION

Applicant/Assignee: CEVA SANTE ANIMALE

Application No.: WO2011EP63129 (PCT/EP2011/63129)   Filing Date: 29/Jul/2011

Abstract:

The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse events of conventional formulations. Preferred formulations are implants and are administered at least twice a year, once a year, or at least once in 18 months, up to 24 months.

Priority: US20100369472P Applic. Date: 2010-07-30

Inventor: FORGET PATRICK [FR]; KALTSATOS VASSILIOS [FR]; WARIN STEPHAN [FR]


Publication No.: WO2012013792A1  Published: 02/Feb/2012

Title: A TRANSMUCOSAL COMPOSITION CONTAINING ANTHOCYANINS FOR ALLEVIATING A VISUAL DISCOMFORT

Applicant/Assignee: VISIOTACT PHARMA

Application No.: WO2011EP63130 (PCT/EP2011/63130)   Filing Date: 29/Jul/2011

Abstract:

The present invention relates to a composition comprising a natural extract containing anthocyanins and an agent for enhancing vigilance, and to a method for alleviating visual discomfort related to or caused by oxidative stress comprising administering via transmucosal route the composition of the invention, said composition being in a form adapted to transmucosal administration, said form preferably being a chewing gum, an orodispersible/orodisintegrating tablet or film or a buccal spray.

Priority: EP20100305843 Applic. Date: 2010-07-29

Inventor: LEPELLETIER YVES [FR]; HADJ-SLIMANE REDA [FR]


Publication No.: WO2012013928A1  Published: 02/Feb/2012

Title: COMPOSITIONS

Applicant/Assignee: NORGINE BV

Application No.: WO2011GB01122 (PCT/GB2011/01122)   Filing Date: 26/Jul/2011

Abstract:

The present invention concerns solid compressed oral pharmaceutical compositions comprising a mixture of at least two sulphate salts selected from the group consisting of sodium, potassium and magnesium for use, in particular, in cleansing the colon or treating faecal impaction, constipation, faecal retention, intestinal gas and cramping, or flatulence in a mammal. Methods of producing such compositions are also disclosed.

Priority: GB20110009121 Applic. Date: 2011-05-27; GB20100012588 Applic. Date: 2010-07-27

Inventor: COCKETT ALASDAIR [GB]; PAY PAUL [GB]; NASH GUY CAMERON [GB]


Publication No.: WO2012013994A2  Published: 02/Feb/2012

Title: PH-DEPENDENT GRADUAL RELEASE PHARMACEUTICAL COMPOSITION

Applicant/Assignee:

Application No.: WO2011HU00047 (PCT/HU2011/00047)   Filing Date: 12/May/2011

Abstract:

The invention concerns a pH-dependent gradual sustained release composition for increasing the pH in the upper part of the small intestines. Particles of the composition are provided with a multilayer polymer coating of specific structure which ensures the gradual release of the active agent in the range of pH 4.5 to 5.5. A process for preparing said composition is also claimed.

Priority: HU20100000407 Applic. Date: 2010-07-30

Inventor: HAJNAL PETER [HU]; SZEGO PETER [HU]; ANTAL ISTVAN NANDOR [HU]; DREDAN JUDIT [HU]; KLEBOVICH IMRE [HU]; LENGYEL MILENA BEA [HU]


Publication No.: WO2012014011A1  Published: 02/Feb/2012

Title: COMPOSITIONS COMPRISING POLYMERS PREPARED FROM 2-HYDROXYALKYL ACIDS

Applicant/Assignee: UNIVERSITE DE GENEVE

Application No.: WO2010IB53383 (PCT/IB2010/53383)   Filing Date: 26/Jul/2010

Abstract:

Described herein are compositions comprising polymers prepared by melt polycondensation of 2-hydroxyalkyl acids. Methods of making and using the compositions are also disclosed.

Priority: WO2010IB53383 Applic. Date: 2010-07-26

Inventor: MOELLER MICHAEL [CH]; ASMUS LUTZ [CH]; GURNY ROBERT [CH]


Publication No.: WO2012014238A1  Published: 02/Feb/2012

Title: COMPOSITION FOR THE TREATMENT AND PREVENTION OF HERPES SIMPLEX LABIALIS

Applicant/Assignee: PASQUALI S.R.L

Application No.: WO2011IT00179 (PCT/IT2011/00179)   Filing Date: 27/May/2011

Abstract:

Composition for the treatment and prevention of herpes simplex labialis comprising, in combination, the following substances: Mimosa tenuiflora bark extract, Aqua, sodium carboxymethyl betaglucan, Echinacea angustifolia root extract and Glycyrrhetinic acid.

Priority: IT2010FI00159 Applic. Date: 2010-07-27

Inventor: PASQUALI COSTANTINO [IT]


Publication No.: WO2012015487A1  Published: 02/Feb/2012

Title: COMBINATION OF DAPSONE WITH ADAPALENE

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US22428 (PCT/US2011/22428)   Filing Date: 25/Jan/2011

Abstract:

A composition suitable for topical application that contains at least two active ingredients, one of these being dapsone and one selected from the group consisting of adapalene, tazarotene and treinion for the effective treatment of acne and other dermatological conditions.

Priority: US2010-846079 Applic. Date: 2010-07-29

Inventor: AHLUWALIA GURPREET [US]; WARNER KEVIN S [US]; CHEN HAIGANG [US]; YANG MEIDONG [US]


Publication No.: WO2012015910A2  Published: 02/Feb/2012

Title: USE OF ADNF POLYPEPTIDES FOR TREATING NEURODEGENERATIVE DISEASES

Applicant/Assignee: ALLON THERAPEUTICS INC

Application No.: WO2011US45522 (PCT/US2011/45522)   Filing Date: 27/Jul/2011

Abstract:

This invention relates to the use of ADNF polypeptides in the treatment of neurodegenerative diseases based upon the identification of certain therapeutically effective pharmacokinetic parameters, dosing levels and formulations. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.

Priority: US20100368489P Applic. Date: 2010-07-28

Inventor: STEWART ALISTAIR JAMES [CA]; MORIMOTO BRUCE HISASHI [US]


Publication No.: WO2012015996A2  Published: 02/Feb/2012

Title: PRESERVATIVE FREE BIMATOPROST SOLUTIONS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US45652 (PCT/US2011/45652)   Filing Date: 28/Jul/2011

Abstract:

The present invention is directed to preservative-free solutions of bimatoprost for lowering intra-ocular pressure and treatment of glaucoma.

Priority: US20100368688P Applic. Date: 2010-07-29

Inventor: LIKITLERSUANG SUKHON [US]; PARASHAR AJAY P [US]; PUJARA CHETAN P [US]; KELLY WILLIAM F [US]


Publication No.: WO2012015998A2  Published: 02/Feb/2012

Title: PRESERVATIVE FREE BIMATOPROST AND TIMOLOL SOLUTIONS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US45654 (PCT/US2011/45654)   Filing Date: 28/Jul/2011

Abstract:

The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma.

Priority: US20100368685P Applic. Date: 2010-07-29

Inventor: LIKITLERSUANG SUKHON [US]; PARASHAR AJAY P [US]; PUJARA CHETAN P [US]; KELLY WILLIAM F [US]


Publication No.: WO2012016000A2  Published: 02/Feb/2012

Title: PRESERVATIVE FREE BRIMONIDINE AND TIMOLOL SOLUTIONS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US45656 (PCT/US2011/45656)   Filing Date: 28/Jul/2011

Abstract:

The present invention is directed to preservative-free solutions of brimonidine and timolol for lowering intra-ocular pressure and treatment of glaucoma.

Priority: US20100368681P Applic. Date: 2010-07-29

Inventor: LIKITLERSUANG SUKHON [US]; KELLY WILLIAM F [US]; PARASHAR AJAY P [US]; PUJARA CHETAN P [US]


Publication No.: WO2012016109A2  Published: 02/Feb/2012

Title: COMPOUNDS AND METHODS FOR SKIN REPAIR

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US45833 (PCT/US2011/45833)   Filing Date: 29/Jul/2011

Abstract:

The disclosure provides compositions and methods for treating a skin blemish. The compositions comprise a therapeutically effective amount of a compound useful for treating skin blemishes such as wounds, scars and wrinkles.

Priority: US20100419115P Applic. Date: 2010-12-02; US20100369232P Applic. Date: 2010-07-30

Inventor: JIANG GUANG L [US]; BURK ROBERT M [US]; IM WHA BIN [US]; BEDDINGFIELD FREDERICK C [US]; WHEELER LARRY A [US]; WHITCUP SCOTT M [US]


Publication No.: WO2012016683A2  Published: 09/Feb/2012

Title: ORAL DOSAGE FORM OF PREGABALIN

Applicant/Assignee: RATIOPHARM GMBH

Application No.: WO2011EP03873 (PCT/EP2011/03873)   Filing Date: 02/Aug/2011

Abstract:

The invention relates to oral dosage forms of pregabalin, preferably for modified release, and to processes for producing it.

Priority: EP20100008104 Applic. Date: 2010-08-03

Inventor: MEERGANS DOMINIQUE [DE]; PAETZ JANA [DE]


Publication No.: WO2012016690A1  Published: 09/Feb/2012

Title: USE OF GLYCERYL TRINITRATE FOR TREATING HEMATOMAS

Applicant/Assignee: G. POHL-BOSKAMP GMBH & CO. KG

Application No.: WO2011EP03888 (PCT/EP2011/03888)   Filing Date: 03/Aug/2011

Abstract:

Use of glyceryl trinitrate (GTN) for treating hematomas.

Priority: DE201010033182 Applic. Date: 2010-08-03

Inventor: BOSKAMP MARIANNE [DE]


Publication No.: WO2012016691A1  Published: 09/Feb/2012

Title: USE OF GLYCERYL TRINITRATE FOR TREATING TRAUMATIC EDEMA

Applicant/Assignee: G. POHL-BOSKAMP GMBH & CO. KG

Application No.: WO2011EP03890 (PCT/EP2011/03890)   Filing Date: 03/Aug/2011

Abstract:

Use of glyceryl trinitrate (GTN) for treating traumatic edemas.

Priority: DE201010033182 Applic. Date: 2010-08-03

Inventor: BOSKAMP MARIANNE [DE]


Publication No.: WO2012016708A1  Published: 09/Feb/2012

Title: ORAL DOSAGE FORM COMPRISING DIMEBOLIN AND DONEPEZIL

Applicant/Assignee: RATIOPHARM GMBH

Application No.: WO2011EP03925 (PCT/EP2011/03925)   Filing Date: 04/Aug/2011

Abstract:

The invention relates to oral dosage forms comprising dimebolin and donepezil and to processes for producing them.

Priority: DE201010033567 Applic. Date: 2010-08-06

Inventor: STEFAN RALPH [DE]; BRUECK SANDRA [DE]; STUMM DANIELA [DE]


Publication No.: WO2012016845A2  Published: 09/Feb/2012

Title: PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: WO2011EP62527 (PCT/EP2011/62527)   Filing Date: 21/Jul/2011

Abstract:

The invention relates to a pharmaceutical formulation to be administered by pressurized metered dose inhalers (pMDIs), comprising a compound of general formula (I). The invention also relates to the process for the preparation and to a pressurized metered dose inhaler filled with said pharmaceutical formulation.

Priority: EP20100171734 Applic. Date: 2010-08-03

Inventor: BONELLI SAURO [IT]; LOSI ELENA [IT]; ZAMBELLI ENRICO [IT]


Publication No.: WO2012016889A2  Published: 09/Feb/2012

Title: DRY POWDER FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: WO2011EP62872 (PCT/EP2011/62872)   Filing Date: 27/Jul/2011

Abstract:

The invention relates to a pharmaceutical formulation in the form of inhalable dry powder comprising particles of a phosphodiesterase-4 inhibitor as active ingredient. The invention also relates to the process for the preparation thereof, and to its use in the prevention and/or treatment of a respiratory disease such as asthma and COPD.

Priority: EP20100171748 Applic. Date: 2010-08-03

Inventor: COCCONI DANIELA [IT]; SCHIARETTI FRANCESCA [IT]; BILZI ROBERTO [IT]


Publication No.: WO2012017077A1  Published: 09/Feb/2012

Title: COMBINATION OF COMPOUNDS FOR TREATING OR PREVENTING SKIN DISEASES

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: WO2011EP63528 (PCT/EP2011/63528)   Filing Date: 05/Aug/2011

Abstract:

The invention relates to a combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea. It is the combination of a compound selected from azelaic acid and salts thereof with a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family. The invention also relates to a product in the form of a kit containing: (a) a first composition comprising a compound selected from azelaic acid and salts thereof, and (b) a second composition different from the first one and comprising a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family, as a combination product for application thereof as a medicament for treating and/or preventing skin diseases and in particular rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay.

Priority: US20100344499P Applic. Date: 2010-08-06

Inventor: CHAPPUIS JEAN-PAUL [FR]; AT EMMANUELLE [FR]


Publication No.: WO2012017363A1  Published: 09/Feb/2012

Title: EFFERVESCENT SOLID GALENIC FORMS FOR ANIMALS

Applicant/Assignee: VETALIS SARL

Application No.: WO2011IB53376 (PCT/IB2011/53376)   Filing Date: 28/Jul/2011

Abstract:

The present invention relates to effervescent solid galenic forms, in particular stones, intended for the collective treatment of animals by means of the drinking water thereof. The effervescent solid galenic form according to the invention is based on an effervescent couple which releases carbon dioxide when it is brought into contact with water, comprising at least one active substance or at least one active ingredient, a compression adjuvant, and at least one substance with a lubricating effect.

Priority: FR20100003225 Applic. Date: 2010-08-02

Inventor: CHERY LAURENT [FR]; WAJDA-DUBOS JEAN-PIERRE [FR]


Publication No.: WO2012017368A1  Published: 09/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, BECLOMETHASONE DIPROPIONATE AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53396 (PCT/IB2011/53396)   Filing Date: 01/Aug/2011

Abstract:

The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises Chitosan, Beclomethasone Dipropionate and Fusidic acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Beclomethasone Dipropionate in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00246 Applic. Date: 2010-08-02

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012017369A1  Published: 09/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING BIOPOLYMER, BETAMETHASONE DIPROPIONATE, CLOTRIMAZOLE AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53397 (PCT/IB2011/53397)   Filing Date: 01/Aug/2011

Abstract:

The present invention discloses a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The active ingredients, namely Chitosan, Betamethasone Dipropionate, Clotrimazole and Fusidic Acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Betamethasone Dipropionate and Clotrimazole in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water. The cream produced by the process of the present invention further optionally contains an ingredient selected from a group comprising, a buffering agent, an anti oxidant, a chelating agent, and a humectant, or any combination thereof.

Priority: IN2010MU00250 Applic. Date: 2010-08-02

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012017370A1  Published: 09/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, BETAMETHASONE DIPROPIONATE, TERBINAFINE HYDROCHLORIDE AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53399 (PCT/IB2011/53399)   Filing Date: 01/Aug/2011

Abstract:

The present invention discloses a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The active ingredients, namely Chitosan, Betamethasone Dipropionate, Terbinafine Hydrochloride and Fusidic Acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Betamethasone Dipropionate & Terbinafine Hydrochloride in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00251 Applic. Date: 2010-08-02

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012017371A1  Published: 09/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, CLOBETASOLE PROPIONATE, TERBINAFINE HYDROCHLORIDE AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53400 (PCT/IB2011/53400)   Filing Date: 01/Aug/2011

Abstract:

The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises Chitosan. Clobetasol Propionate, Terbinafine Hydrochloride and Fusidic acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Clobetasol Propionate and Terbinafine Hydrochloride in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00252 Applic. Date: 2010-08-02

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; GHOSH KAUSIK [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012017372A1  Published: 09/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING, BIOPOLYMER, CLOBETASOL PROPIONATE, MICONAZOLE NITRATE AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53401 (PCT/IB2011/53401)   Filing Date: 01/Aug/2011

Abstract:

The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises Chitosan. Clobetasol Propionate, Miconazole Nitrate and Fusidic acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Clobetasol Propionate and Miconazole Nitrate in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00253 Applic. Date: 2010-08-02

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012017381A1  Published: 09/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING, BIOPOLYMER, BECLOMETHASONE DIPROPIONATE, CLOTRIMAZOLE AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53426 (PCT/IB2011/53426)   Filing Date: 02/Aug/2011

Abstract:

The present invention discloses a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The active ingredients, namely Chitosan, Betamethasone Dipropionate, Clotrimazole and Fusidic Acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Betamethasone Dipropionate and Clotrimazole in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00247 Applic. Date: 2010-08-02

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012017382A1  Published: 09/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING BIOPOLYMER, BECLOMETHASONE DIPROPIONATE, MICONAZOLE NITRATE AND A PROCESS MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53427 (PCT/IB2011/53427)   Filing Date: 02/Aug/2011

Abstract:

The present invention discloses a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The active ingredients, namely Chitosan, Betamethasone Dipropionate, Miconazole Nitrate and Fusidic Acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen- free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Betamethasone Dipropionate and Miconazole Nitrate in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00248 Applic. Date: 2010-08-02

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012017383A1  Published: 09/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING BIOPOLYMER, BECLOMETHASONE DIPROPIONATE, TERBINAFINE HYDROCHLORIDE AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53428 (PCT/IB2011/53428)   Filing Date: 02/Aug/2011

Abstract:

The present invention discloses a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The active ingredients, namely Chitosan, Betamethasone Dipropionate, Terbinafine Hydrochloride and Fusidic Acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Betamethasone Dipropionate and Terbinafine Hydrochloride in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00249 Applic. Date: 2010-08-02

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012017406A1  Published: 09/Feb/2012

Title: EXOGENOUS PULMONARY SURFACTANT PREPARATION COMPRISING A PHOSPHOLIPID AND AN ADJUVANS

Applicant/Assignee: INDIAN INSTITUTE OF TECHNOLOGY (IIT), BOMBAY

Application No.: WO2011IB53471 (PCT/IB2011/53471)   Filing Date: 04/Aug/2011

Abstract:

The present invention describes exogenous surfactant preparations and surface- active drug delivery systems that can be used for the treatment of lung surfactant dysfunction in respiratory distress syndrome (RDS) and respiratory tract infections such as tuberculosis. The surface-active drug delivery systems relate to a drug loaded exogenous pulmonary surfactant vesicle. The vesicle can be a liposome. The vesicles achieve low surface tensions on film compression in the presence of mycobacterial lipids and address the surfactant dysfunction associated with RDS and respiratory tract infections such as tuberculosis. The invention provides for pulmonary surfactant replacement and can be administered as an aerosol or intratracheal instillation for RDS and respiratory tract infections such as tuberculosis, and can include drugs.

Priority: US20100371004P Applic. Date: 2010-08-05

Inventor: BANERJEE RINTI [IN]; CHIMOTE GEETANJALI CHANDRASHEKHAR [IN]


Publication No.: WO2012017471A1  Published: 09/Feb/2012

Title: NATURAL MEDICINAL COMPOUND

Applicant/Assignee: LOMBARDATRADING S.R.L

Application No.: WO2011IT00288 (PCT/IT2011/00288)   Filing Date: 03/Aug/2011

Abstract:

This invention refers to the sector of drugs intended for both human and animal use, and it particularly concerns a natural medicinal compound that contains a tannin-based vegetal active ingredient combined with carriers and with a synergic effect, wherein said vegetal active ingredient is natural chestnut extract (Castanea sativa), with tannin as the highest constituent substance, and said natural chestnut extract is contained in the compound in a weight rate between 5% and 80%.

Priority: IT2010CR00025 Applic. Date: 2010-08-05

Inventor: GRAZIANI RODOLFO [IT]; MERCORELLA GIOVANNI [IT]; ROSSI PIERENRICO [IT]; BIGNETTI GUIDO [IT]; PIGNACCA MICHELE [IT]


Publication No.: WO2012018069A1  Published: 09/Feb/2012

Title: PREPARATION FOR TREATMENT OF SPINAL CORD INJURY

Applicant/Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD, KEIO UNIVERSITY

Application No.: WO2011JP67838 (PCT/JP2011/67838)   Filing Date: 04/Aug/2011

Abstract:

A sustained release preparation containing a semaphorin 3A inhibitor as an active ingredient, which is a solid preparation that comprises the semaphorin 3A inhibitor and a carrier comprising a silicone containing a pharmaceutically acceptable poorly water-soluble solid substance.

Priority: JP20100177255 Applic. Date: 2010-08-06

Inventor: MAEDA MIHO [JP]; KISHINO AKIYOSHI [JP]; SANO AKIHIKO [JP]; OKANO HIDEYUKI [JP]; NAKAMURA MASAYA [JP]; ZHANG LIANG [JP]


Publication No.: WO2012018715A1  Published: 09/Feb/2012

Title: COLLAGEN-BASED IMPLANTS FOR SUSTAINED DELIVERY OF DRUGS

Applicant/Assignee:

Application No.: WO2011US46098 (PCT/US2011/46098)   Filing Date: 01/Aug/2011

Abstract:

The disclosure provides collagen-based constructs for use in drug delivery.

Priority: US20100369996P Applic. Date: 2010-08-02

Inventor: DEVORE DALE P [US]; DEWOOLFSON BRUCE H [US]; LAZAR ELIOT [US]


Publication No.: WO2012018829A1  Published: 09/Feb/2012

Title: COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: WO2011US46285 (PCT/US2011/46285)   Filing Date: 02/Aug/2011

Abstract:

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating hepatitis C using such combinations. To achieve maximal efficacy and to potentially eradicate the virus, it will be critical to utilize combination therapies, especially those targeting distinct HCV viral targets. In vitro replicon-based combination studies have shown that additive to synergistic effects can be achieved with various combinations of HCV inhibitors.

Priority: US20100371399P Applic. Date: 2010-08-06

Inventor: GAO MIN [US]; GARDINER DAVID F [US]; LEMM JULIE A [US]; MCPHEE FIONA [US]; VOSS STACEY A [US]


Publication No.: WO2012019009A1  Published: 09/Feb/2012

Title: CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN

Applicant/Assignee: FLEXION THERAPEUTICS

Application No.: WO2011US46601 (PCT/US2011/46601)   Filing Date: 04/Aug/2011

Abstract:

Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous Cortisol production.

Priority: US20100370666P Applic. Date: 2010-08-04

Inventor: BODICK NEIL [US]; BLANKS ROBERT C [US]; KUMAR ANJALI [US]; CLAYMAN MICHAEL D [US]; MORAN MARK [US]


Publication No.: WO2012019049A1  Published: 09/Feb/2012

Title: DEVICES, SYSTEMS, AND METHODS FOR EXCAVATING CANCER CELLS

Applicant/Assignee: GEORGIA TECH RESEARCH CORPORATION

Application No.: WO2011US46653 (PCT/US2011/46653)   Filing Date: 04/Aug/2011

Abstract:

Methods, devices, and systems are provided for guiding tumor movement, particularly in vivo for treatment of patients. The method may include implanting into a tissue site where tumor cells are present a device having one or more surface structures or substrates, such as aligned nanofibers, which provide physical guidance cues for directing the migration of the tumor cells from the first tissue location to a selected second location, for tumor cell extraction or death. The devices and systems may include a cytotoxic agent for contacting tumor cells migrated via the substrate. All or a portion of the at least one substrate may include one or more biochemical cues, such as a coating of laminin or another protein, which may be provided in a concentration gradient to facilitate uni -directional tumor cell migration.

Priority: US20100370630P Applic. Date: 2010-08-04

Inventor: BELLAMKONDA RAVI V [US]; JAIN ANJANA [US]


Publication No.: WO2012020219A2  Published: 16/Feb/2012

Title: FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS

Applicant/Assignee: NOVACTA BIOSYSTEMS LIMITED

Application No.: WO2011GB01191 (PCT/GB2011/01191)   Filing Date: 09/Aug/2011

Abstract:

Described is a A liquid colloidal pharmaceutical formulation of a type B lantibiotic for infusion or direct injection comprising a type B lantibiotic or a salt thereof, an isotonic aqueous solution comprising a sugar alcohol such as glycerol and/or a saccharide and optionally a buffer, wherein said final formulation for infusion or direct injection is clear of visual particulates.

Priority: GB20100013513 Applic. Date: 2010-08-11

Inventor: APPLEYARD ANTONY NICHOLAS [GB]; WADMAN SJOERD NICOLAAS [GB]


Publication No.: WO2012020279A1  Published: 16/Feb/2012

Title: PRODUCT FOR THE UPPER GASTRIC SPHERE

Applicant/Assignee: COMPAGNIE GERVAIS DANONE, DANONE ARGENTINA S.A

Application No.: WO2010IB02436 (PCT/IB2010/02436)   Filing Date: 13/Aug/2010

Abstract:

The invention concerns a product for the upper gastric sphere of humans. The product can address acidity in upper gastric sphere of humans. The product of the invention is typically to be administered orally, typically as food or food supplement. The product comprises a base product and several agents that provide benefits to the upper gastric sphere.

Priority: WO2010IB02436 Applic. Date: 2010-08-13

Inventor: WEILL RICARDO JULIAN [AR]; VALENTINI CELINE [FR]


Publication No.: WO2012020412A2  Published: 16/Feb/2012

Title: FIBRIN BASED SCAFFOLD, PREPARATION AND USE THEREOF

Applicant/Assignee: OMRIX BIOPHARMACEUTICALS LTD,

Application No.: WO2011IL00653 (PCT/IL2011/00653)   Filing Date: 10/Aug/2011

Abstract:

The invention relates to a fibrin-based scaffold suitable for supporting a population of cells comprising mesenchymal stem cells (MSC) and/or umbilical tissue derived cells (UTC) at the site of administration for a prolonged period of time. The scaffold is capable of supporting at least 1 x 106 cells/ml scaffold. The invention also relates to the preparation of the scaffold and to its use. Preparation of the scaffold is carried out with a fibrinogen component comprising fibrinogen having a final concentration of higher than 17.5 mg/ml scaffold. The scaffold and the embedded MSC and/or UTC can be used for increasing vascularization and/or wound healing at the site of administration.

Priority: IL20100207586 Applic. Date: 2010-08-12; US20100372929P Applic. Date: 2010-08-12

Inventor: ATLAS ROEE [IL]; NUR ISRAEL [IL]; MEIDLER ROBERTO [IL]; BAR LILIANA [IL]; BUENSUCESO CHARITO [US]; KIHM ANTHONY J [US]; DHANARAJ SRIDEVI [US]


Publication No.: WO2012021108A1  Published: 16/Feb/2012

Title: A BIODEGRADABLE OCULAR IMPLANT

Applicant/Assignee: NANYANG TECHNOLOGICAL UNIVERSITY, SINGAPORE HEALTH SERVICES PTE LTD

Application No.: WO2011SG00282 (PCT/SG2011/00282)   Filing Date: 12/Aug/2011

Abstract:

The present invention relates to a biodegradable ocular implant for sustained drug delivery, comprising a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed.

Priority: US20100372959P Applic. Date: 2010-08-12

Inventor: VENKATRAMAN SUBRAMANIAN [SG]; BOEY YIN CHIANG FREDDY [SG]; WONG TINA [SG]


Publication No.: WO2012021860A1  Published: 16/Feb/2012

Title: COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE

Applicant/Assignee: REVALESIO CORPORATION

Application No.: WO2011US47673 (PCT/US2011/47673)   Filing Date: 12/Aug/2011

Abstract:

Provided are methods for treating cardiovascular diseases and related conditions and symptoms (e.g., cardiac arrhythmia, vascular disease, myocardial infarction, congestive heart failure, myocarditis, atherosclerosis, and restenosis), comprising administering to a subject in need thereof a therapeutically effective amount of an electrokinetically altered aqueous fluid as described herein. In particular aspects, the electrokinetically altered aqueous fluids comprise an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures predominantly having an average diameter of less than about 100 nanometers and sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity. Provided are routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions, along with use of the electrokinetically altered aqueous fluids in surgical contexts, including but not limited to cardiovascular related surgeries. Additionally provided are methods for measuring biological activity of electrokinetically altered fluids.

Priority: US201161485071P Applic. Date: 2011-05-11; US20100373494P Applic. Date: 2010-08-13

Inventor: WATSON RICHARD L [US]; WOOD ANTHONY B [US]; ARCHAMBEAU GREGORY J [US]


Publication No.: WO2012022223A1  Published: 23/Feb/2012

Title: COMPOSITION COMPRISING LIGUSTROFLAVONE, RHOIFOLIN AND HYPERIN, AND USE THEREOF IN THE PREPARATION OF A MEDICAMENT

Applicant/Assignee: JIANGXI SHANXIANG PHARMACEUTICAL CO., LTD, JIANGXI QINGFENG PHARMACEUTICAL RESEARCH CO., LTD

Application No.: WO2011CN78016 (PCT/CN2011/78016)   Filing Date: 04/Aug/2011

Abstract:

Disclosed is a composition comprising ligustroflavone, rhoifolin and hyperin, which is prepared from 40% to 80% by weight of ligustroflavone, 5% to 45% by weight of rhoifolin and 1% to 40% by weight of hyperin. The composition can be used as a neuraminidase inhibitor for preventing and treating influenza, and can be formulated into pharmaceutically acceptable dosage forms.

Priority: CN20101253775 Applic. Date: 2010-08-16

Inventor: TANG CHUNSHAN [CN]; XIE NING [CN]; YANG XIAOLING [CN]; LV WUQING [CN]; LI ZHIYONG [CN]; YE JINGYING [CN]; LIU DIFA [CN]; CHENG FAN [CN]


Publication No.: WO2012022775A1  Published: 23/Feb/2012

Title: CONCENTRATE FOR MEDICAL SOLUTIONS, PRODUCTION THEREOF AND USE THEREOF IN DIALYSIS

Applicant/Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

Application No.: WO2011EP64180 (PCT/EP2011/64180)   Filing Date: 17/Aug/2011

Abstract:

The invention relates to a new dry concentrate for the production of medical solutions, more particularly dialysis solutions, which comprise electrolyte and buffer components and an osmotic agent, said concentrate comprising magnesium carbonate rather than magnesium chloride. The use of magnesium carbonate as the electrolyte avoids the formation of slurries. The use of anhydrous glucose as an osmotic agent, and optionally spatial separation of this osmotic agent from the other components, also avoids the occurrence of "caking" in the concentrate. The occurrence of "caking" is also improved by charging the sodium hydrogencarbonate buffer component together with sodium chloride and in isolation from all other components. This concentrate is particularly suitable for use in multichamber pouch systems. The concentrate is notable for good dissolution capacity and improved storage stability.

Priority: DE201010039489 Applic. Date: 2010-08-18

Inventor: SCHWEITZER THOMAS [DE]; FICHERT THOMAS [DE]; MATHIS PASCAL [DE]


Publication No.: WO2012022837A1  Published: 23/Feb/2012

Title: TRANSDERMAL COMPOSITIONS

Applicant/Assignee: HELSINGIN YLIOPISTO

Application No.: WO2011FI50717 (PCT/FI2011/50717)   Filing Date: 16/Aug/2011

Abstract:

The invention relates to a pharmaceutical composition for human and/or veterinary use for transdermal delivery, comprising at least one active drug substance selected from zwitterionic drug substances, non-steroidal anti-inflammatory drug substances, steroids and combinations thereof, together with alkali metal alcoholate of terpenoid as solubilizing agent and penetration enhancer for the active drug substance.

Priority: FI20100005855 Applic. Date: 2010-08-16; FI20100005854 Applic. Date: 2010-08-16

Inventor: TAHVANAINEN MARIA [FI]; HIRVONEN JOUNI [FI]


Publication No.: WO2012023024A2  Published: 23/Feb/2012

Title: CONTROLLED RELEASE FORMULATIONS OF DRONEDARONE

Applicant/Assignee: LUPIN LIMITED

Application No.: WO2011IB01882 (PCT/IB2011/01882)   Filing Date: 13/Aug/2011

Abstract:

The present invention relates to controlled release formulation of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of controlled release formulations of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day.

Priority: IN2010KO00924 Applic. Date: 2010-08-17

Inventor: DESHMUKH ASHISH ASHOKRAO [IN]; BHUTADA PRAVIN MEGHRAJJI [IN]; CHANDRAN SAJEEV [IN]; KULKARNI SHIRISHKUMAR [IN]


Publication No.: WO2012023077A1  Published: 23/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, A CORTICOSTEROID - CLOBETASOL PROPIONATE, AND AN ANTIFUNGAL AGENT - OXICONAZOLE NITRATE, AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53402 (PCT/IB2011/53402)   Filing Date: 01/Aug/2011

Abstract:

The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises Chitosan. Clobetasol Propionate, Oxiconazole Nitrate and Fusidic acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Clobetasol Propionate and Oxiconazole Nitrate in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00440 Applic. Date: 2010-08-17

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; GHOSH KAUSIK [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012023078A1  Published: 23/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, A CORTICOSTEROID - DEXAMETHASONE ACETATE, AND AN ANTIFUNGAL AGENT - OXICONAZOLE NITRATE, AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53403 (PCT/IB2011/53403)   Filing Date: 01/Aug/2011

Abstract:

The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises Chitosan. Dexamethasone Acetate, Oxiconazole Nitrate and Fusidic acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Dexamethasone Acetate & Oxiconazole Nitrate in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00441 Applic. Date: 2010-08-17

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; GHOSH KAUSIK [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012023080A1  Published: 23/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, A CORTICOSTEROID - FLUTICASONE PROPIONATE, AND AN ANTIFUNGAL AGENT -TERBINAFINE HYDROCHLORIDE AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53405 (PCT/IB2011/53405)   Filing Date: 01/Aug/2011

Abstract:

The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises Chitosan. Fluticasone Propionate, Terbinafine Hydrochloride and Fusidic acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Fluticasone Propionate & Terbinafine Hydrochloride in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00443 Applic. Date: 2010-08-17

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012023081A1  Published: 23/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, A CORTICOSTEROID - HYDROCORTISONE ACETATE, AND AN ANTIFUNGAL AGENT - OXICONAZOLE NITRATE, AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53406 (PCT/IB2011/53406)   Filing Date: 01/Aug/2011

Abstract:

The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises Chitosan. Hydrocortisone acetate, Oxiconazole Nitrate and Fusidic acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Hydrocortisone acetate and Oxiconazole Nitrate in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00444 Applic. Date: 2010-08-17

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; GHOSH KAUSIK [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012023082A1  Published: 23/Feb/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, A CORTICOSTEROID - HYDROCORTISONE ACETATE, AND AN ANTIFUNGAL AGENT - TERBINAFINE HYDROCHLORIDE, AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB53407 (PCT/IB2011/53407)   Filing Date: 01/Aug/2011

Abstract:

The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises Chitosan. Hydrocortisone acetate, Terbinafine Hydrochloride and Fusidic acid. The invention also discloses a process to make the medicinal cream containing Fusidic Acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic Acid under oxygen-free environment created using inert gas, preferably nitrogen, and Chitosan. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic Acid. The cream produced by the process of the present invention contains Fusidic Acid as the API that has been formed in situ from Sodium Fusidate, Hydrocortisone acetate and Terbinafine Hydrochloride in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water.

Priority: IN2010MU00445 Applic. Date: 2010-08-17

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012023873A1  Published: 23/Feb/2012

Title: COMBINATION OF VITAMINS AND MINERALS

Applicant/Assignee: S.C. BIOFARM S.A

Application No.: WO2011RO00012 (PCT/RO2011/00012)   Filing Date: 31/Mar/2011

Abstract:

The invention relates to a nutritional supplement composition presented as chewable tablets and to the method by which it is obtained. The nutritional supplement, according to the invention, contains a mixture of vitamins A, C, B1, B2, B6, D2, H, PP, calcium in the form of gluconate and pantotenat, folic acid, lutein, Echinacea, soy lecithin mixed with a fatty base such as hydrogenated vegetable oil and excipients such as powdered milk, powdered sugar, flavoring agents. The method, according to the invention, consists of successively incorporating the powdered components into a portion of melted fatty base during continuous homogenization, followed by the passage of the mixture through a rolling device, producing an homogenous paste which is then mixed with the remaining melted fatty base and homogenized for 25... 30 minutes at a temperature of 35... 37 DEG C

the mixture is then placed in a tablet molding device.

Priority: RO20100000299 Applic. Date: 2010-04-01

Inventor: SOROCEANU PAULA [RO]


Publication No.: WO2012023955A1  Published: 23/Feb/2012

Title: PHOSPHOLIPID DEPOT

Applicant/Assignee: DR. REDDY'S LABORATORIES, LTD

Application No.: WO2010US61015 (PCT/US2010/61015)   Filing Date: 17/Dec/2010

Abstract:

The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about (4) wt % relative to the total weight of the depot and the depot has a pH of between about (3) and about (6), method of making and administering same.

Priority: US20100375502P Applic. Date: 2010-08-20

Inventor: CHEN HAILIANG [US]; CHEN ANDREW XIAN [US]; SURAKANTI DUSHYANTH [US]; OKUMU FRANKLIN [US]


Publication No.: WO2012024196A2  Published: 23/Feb/2012

Title: A NOVEL METHOD FOR CREATING, SUSPENDING AND STABILIZING ELECTRONICALLY MODIFIED REACTION INTERMIDEATES

Applicant/Assignee:

Application No.: WO2011US47701 (PCT/US2011/47701)   Filing Date: 14/Aug/2011

Abstract:

A bio compatible free radical suspension comprising of oxygen and electronically modified reaction intermediates, where a fluorocarbon is used as an inert medium for stabilization of reaction intermediates. A stabilized bio compatible electronically modified derivative suspension is produced by the subjecting a fluorocarbon to certain stressors, such as oxidizing agents, reactive intermediates, physiological gases, benzo-?-pyrone derivatives, ultrasonic-cavitation, electric fields, magnetic fields, UV radiation, active metal catalyst, surfactant reactants, buffers, electrolytes, glucose, glucose derivatives, for the purpose of inducing a cascading immune response.

Priority: US20100373836P Applic. Date: 2010-08-15

Inventor: MARKOU DEMETRIOS [US]


Publication No.: WO2012024287A1  Published: 23/Feb/2012

Title: METHOD OF STABILIZING AND STERILIZING PEPTIDES OR PROTEINS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US47904 (PCT/US2011/47904)   Filing Date: 16/Aug/2011

Abstract:

The present invention provides a method for sterilizing a protein-containing bioerodible implant. The sterilization is accomplished using ss-radiation, or high energy electrons. Following sterilization the implant can be used in a variety of methods for the sustained release of a therapeutic protein to treat a disease or condition in a human or non-human subject. The sterilization process is compatible with proteins containing one or more disulfide bonds or easily oxidized methionine residues.

Priority: US20100374529P Applic. Date: 2010-08-17

Inventor: LYONS ROBERT T [US]; TROGDEN JOHN T [US]


Publication No.: WO2012024298A1  Published: 23/Feb/2012

Title: OPHTHALMIC FORMULATIONS OF SQUALAMINE

Applicant/Assignee: OHR PHARMACEUTICAL, INC

Application No.: WO2011US47920 (PCT/US2011/47920)   Filing Date: 16/Aug/2011

Abstract:

The invention relates to ophthalmic formulations of squalamine or its pharmaceutically acceptable salts for the treatment of conditions of the eye such as, for example, wet age-related macular degeneration (wet AMD), choroidal neovascularization, retinopathy, dry age-related macular degeneration (dry AMD), polypoidal choroidal vasculopathy, neovascularization following ocular surgery, macular edema, retinal venous occlusion, subchoroidal neovascularization, retinal epithelial detachment, pterygum or foveal geographic atrophy of the retinal pigment epithelium.

Priority: US20100374524P Applic. Date: 2010-08-17

Inventor: TARAPOREWALA IRACH B [US]; BACKENROTH SAMUEL I [US]


Publication No.: WO2012024405A2  Published: 23/Feb/2012

Title: CURCUMIN COMPOSITIONS AND USES THEREOF

Applicant/Assignee: THE OHIO STATE UNIVERSITY

Application No.: WO2011US48090 (PCT/US2011/48090)   Filing Date: 17/Aug/2011

Abstract:

A composition and method of increasing the bioavailability of curcumin is provided. A synergistic combination of excipient polymers provides increased bioavailability thereby increasing the plasma concentration of curcumin and its metabolite curcumin O-glucuronide. The curcumin pharmaceutical compositions are suitable for modifying DNA methylation and treating diseases such as cancer.

Priority: US20100374480P Applic. Date: 2010-08-17

Inventor: LIU ZHONGFA [US]; CHIU MING HEUNG [US]; CHAN KENNETH K [US]; HAVARD PATTY [US]; CHEN WEI [US]


Publication No.: WO2012024784A1  Published: 01/Mar/2012

Title: CELL-PROTECTIVE PEPTIDES AND USES THEREOF

Applicant/Assignee: UNIVERSITY OF TORONTO

Application No.: WO2011CA00969 (PCT/CA2011/00969)   Filing Date: 26/Aug/2011

Abstract:

A peptide comprising the amino acid sequence, X1X2RX3DX4X5 X6 X7 is provided, as well as a biomaterial comprising the peptide for use to treat conditions resulting from cell death or apoptosis.

Priority: US20100377666P Applic. Date: 2010-08-27

Inventor: RADISIC MILICA [CA]; DALLABRIDA SUSAN M [US]; RUPNICK MARIA ANN [US]


Publication No.: WO2012025496A1  Published: 01/Mar/2012

Title: HUMIDIFIED PARTICLES COMPRISING A THERAPEUTICALLY ACTIVE SUBSTANCE

Applicant/Assignee: NYCOMED GMBH

Application No.: WO2011EP64399 (PCT/EP2011/64399)   Filing Date: 22/Aug/2011

Abstract:

The invention relates to aerosolized and humidified particles comprising a therapeutically active substance which can be obtained by suspending dry inhalable particles in a carrier gas, adding water vapor and causing condensation of water on the particles. The invention further relates to methods to generate these particles, and apparatus useful to carry out such methods.

Priority: EP20100173759 Applic. Date: 2010-08-23

Inventor: RAHMEL DANIELA [DE]; TAUT FRIEDEMANN [DE]; DE MUYNCK CHRISTIAN [DE]; RAST MARKUS [DE]; IWATSCHENKO PETER [DE]; POHLMANN GERHARD [DE]; KOCH WOLFGANG [DE]; WINDT HORST [DE]


Publication No.: WO2012025677A1  Published: 01/Mar/2012

Title: INHALABLE GASEOUS DRUG CONTAINING KRYPTON FOR TREATING NEURO-INTOXICATION

Applicant/Assignee: L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE

Application No.: WO2011FR51849 (PCT/FR2011/51849)   Filing Date: 01/Aug/2011

Abstract:

The invention relates to a gaseous composition containing krypton gas for use as an inhalable drug for preventing or treating neuro-intoxication in humans, in which the krypton gas is the active principle and the proportion by volume of krypton is between 15 and 80%.

Priority: FR20100056715 Applic. Date: 2010-08-24

Inventor: LEMAIRE MARC [FR]


Publication No.: WO2012025921A1  Published: 01/Mar/2012

Title: COMPOSITIONS FOR GASTRIC DELIVERY OF ACTIVE AGENTS

Applicant/Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWUNIVERSITY OF JERUSALEM LTD

Application No.: WO2011IL00672 (PCT/IL2011/00672)   Filing Date: 18/Aug/2011

Abstract:

The present invention relates to compositions, including pharmaceutical compositions for oral administration, comprising: at least one therapeutically active agent

at least one surface active agent

at least one ester of poly-carboxylic acid and/or at least one ester of an aromatic carboxylic acid

and a non-aqueous medium, for use in the gastric absorption of said at least one therapeutically active agent of the composition and methods of oral administration of at least one therapeutically active agent utilizing compositions of the invention.

Priority: US20100376060P Applic. Date: 2010-08-23

Inventor: BEN-SASSON SHMUEL [IL]


Publication No.: WO2012026903A1  Published: 01/Mar/2012

Title: SYNERGISTIC COMPOSITIONS COMPRISING MEMANTINE AND GINGKO - BILOBA EXTRACT

Applicant/Assignee:

Application No.: WO2011TR00191 (PCT/TR2011/00191)   Filing Date: 19/Aug/2011

Abstract:

The present invention relates to formulations comprising memantine or any pharmaceutically acceptable derivative thereof and ginkgo biloba extract

and use of this type of formulations in the treatment of Alzheimer's disease.

Priority: TR20100007111 Applic. Date: 2010-08-25

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2012026904A1  Published: 01/Mar/2012

Title: A SINGLE UNIT DOSAGE FORM ON THE BASIS OF A COMBINATION COMPRISING DONEPEZIL AND GINKGO BILOBA EXTRACT

Applicant/Assignee:

Application No.: WO2011TR00192 (PCT/TR2011/00192)   Filing Date: 19/Aug/2011

Abstract:

The present invention relates to single unit dosage forms comprising donepezil or any pharmaceutically acceptable derivative thereof and ginkgo biloba extract

and use of this type of dosage forms in the treatment of Alzheimer's disease.

Priority: TR20100007109 Applic. Date: 2010-08-25

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2012027455A1  Published: 01/Mar/2012

Title: GLUTATHIONE-LANTHIONINE COMPOUNDS AND METHODS RELATED THERETO

Applicant/Assignee: THE UNIVERSITY OF TOLEDO, OKLAHOMA MEDICAL RESEARCH FOUNDATION

Application No.: WO2011US48940 (PCT/US2011/48940)   Filing Date: 24/Aug/2011

Abstract:

The present invention concerns glutathione -lanthionine compounds, the process of preparing such compounds, and their use. The invention also concerns methods of using the compounds and derivatives and combinations of these compounds in the treatment and/or prevention diseases, including diseases affecting the central nervous system.

Priority: US20100376566P Applic. Date: 2010-08-24

Inventor: HENSLEY KENNETH [US]


Publication No.: WO2012027566A2  Published: 01/Mar/2012

Title: NOVEL MEDICAL DEVICE COATINGS

Applicant/Assignee: TYRX, INC

Application No.: WO2011US49140 (PCT/US2011/49140)   Filing Date: 25/Aug/2011

Abstract:

The present invention relates to coatings comprising polyethylene glycol and at least one polyphenolic polymer. In particular, the polyphenolic polymer could be selected from the group consisting of tyrosine-derived polyarylates, linear polyesteramides, dihydroxybenzoate polymers, and resorcinol-derived polymers. The coating of the present invention may also include a drug, such as an antibiotic. The coatings of the present invention are suitable for use as coatings for medical devices, such as orthopedic pins or stents.

Priority: US20100376790P Applic. Date: 2010-08-25

Inventor: PULAPURA SATISH [US]; GE QING [US]


Publication No.: WO2012027882A1  Published: 08/Mar/2012

Title: PHARMACEUTICAL COMPOSITION FOR TREATING INSOMNIA AND PREPARATION METHOD THEREOF

Applicant/Assignee: HEBEI YILING MEDICINE RESEARCH INSTITUTE CO., LTD

Application No.: WO2010CN76472 (PCT/CN2010/76472)   Filing Date: 30/Aug/2010

Abstract:

A pharmaceutical composition for treating insomnia and preparation method thereof, said pharmaceutical composition comprises Radix Polygoni Multiflori and/or extracts thereof, Semen Ziziphi Spinosae and/or extracts thereof, Fructus Mori and/or extracts thereof, Ganoderma and/or extracts thereof, Bulbus Lilii and/or extracts thereof, Rhizoma Anemarrhenae and/or extracts thereof, Radix Salviae Miltiorrhizae and/or extracts thereof, Flos Chrysanthemi and/or extracts thereof, Poria and/or extracts thereof, and Flos Albiziae and/or extracts thereof. The pharmaceutical composition is used to treating insomnia and the symptoms of amnesia, dizziness, lassitude, and ache and weak at waist and knees et cetra.

Priority: WO2010CN76472 Applic. Date: 2010-08-30

Inventor: WU YILING [CN]


Publication No.: WO2012028276A2  Published: 08/Mar/2012

Title: DEVICE FOR METERING AN ACID-CONTAINING COMPOSITION

Applicant/Assignee: SANDERSTROTHMANN GMBH

Application No.: WO2011EP04273 (PCT/EP2011/04273)   Filing Date: 26/Aug/2011

Abstract:

The invention relates to a device for metering an acid-containing composition, in particular a composition for treating corns, comprising a housing made of plastic and a receiving space in which a composition comprising salicylic acid, ethanol, propylene glycol, a co-emulsifier and a thickening agent is received, wherein the composition contains 4-10% of salicylic acid, 1-6% of ethanol, 40-60% of propylene glycol, 2-5% of the co-emulsifier and 0.5-3% of thickening agent.

Priority: DE201020012043U Applic. Date: 2010-08-31

Inventor: SANDER MICHAEL [DE]


Publication No.: WO2012028315A1  Published: 08/Mar/2012

Title: A STABILIZER FOR THE PREPARATION OF A DRY POLIO INJECTABLE VACCINE COMPOSITION

Applicant/Assignee: SANOFI PASTEUR SA

Application No.: WO2011EP04394 (PCT/EP2011/04394)   Filing Date: 31/Aug/2011

Abstract:

The subject of the present invention is a stabilizer, a stabilized aqueous injectable vaccine composition and a method for preparing a dry vaccine composition enabling the IPV polio antigen to be dried without a large loss of titer during the drying process and enabling the dry product to be stored without a large loss of titer for at least 7 days at 37 DEG C and a stabilized dry vaccine composition comprising an inactivated poliovirus (IPV) of at least one serotype, characterized by an extraordinary thermostability.

Priority: FR20100056961 Applic. Date: 2010-09-02

Inventor: FRANCON ALAIN [FR]; CHOUVENC PIERRE [FR]; LELEU AMANDINE [FR]


Publication No.: WO2012028585A1  Published: 08/Mar/2012

Title: ADENOSINE A1 AGONISTS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION

Applicant/Assignee: BAYER PHARMA AKTIENGESELLSCHAFT

Application No.: WO2011EP64829 (PCT/EP2011/64829)   Filing Date: 29/Aug/2011

Abstract:

The present invention relates to the use of selective adenosine A1 agonists, in particular the dicyanopyridines of formula (I), for the treatment and/or prophylaxis of glaucoma and ocular hypertension as well as the their use for the production of a medicament for the treatment and/or prophylaxis of glaucoma and ocular hypertension.

Priority: EP20100175151 Applic. Date: 2010-09-02

Inventor: KLAR JUERGEN [DE]; VON DEGENFELD GEORGES [DE]; LERCHEN HANS-GEORG [DE]; ALBRECHT-KUEPPER BARBARA [DE]; KNORR ANDREAS [DE]; SANDNER PETER [DE]; MEIBOM DANIEL [DE]


Publication No.: WO2012028623A1  Published: 08/Mar/2012

Title: CROSSLINKED POLYSACCHARIDE BEADS AND THEIR BIOMEDICAL USES

Applicant/Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Application No.: WO2011EP64927 (PCT/EP2011/64927)   Filing Date: 30/Aug/2011

Abstract:

The present inventions relates to beads as biocompatible material adapted for use within the human or animal body. Said beads are highly useful for tissue engineering, in situ tissue regeneration, as well as for drug and/or cells delivery. In addition, said beads may support biotechnological applications such as cell carriers.

Priority: EP20100305931 Applic. Date: 2010-08-31

Inventor: LETOURNEUR DIDIER [FR]; LE VISAGE CATHERINE [FR]; DERKAOUI SIDI MOHAMMED [FR]


Publication No.: WO2012028683A1  Published: 08/Mar/2012

Title: ANTIBODY GEL SYSTEM FOR SUSTAINED DRUG DELIVERY

Applicant/Assignee: NOVARTIS AG

Application No.: WO2011EP65096 (PCT/EP2011/65096)   Filing Date: 01/Sep/2011

Abstract:

Antibody formulations, and methods for their manufacture, which (i) are capable of preserving an antibody in a native and therapeutically active state while achieving a depot effect without the use of polymers or other complex formulation reagents and (ii) provide very high loading capacity, thus offering the potential for increased dose per application to patient. These formulations take the form of a gel and are based on the surprising finding that some monoclonal antibodies have a gelation property under appropriate conditions.

Priority: US20100379522P Applic. Date: 2010-09-02

Inventor: RODRIGUES MARGARIDA [CH]; SCHOENHAMMER KARIN [CH]


Publication No.: WO2012028733A1  Published: 08/Mar/2012

Title: A WATER-IN-OIL TYPE EMULSION FOR TREATING A DISEASE OF THE EYE

Applicant/Assignee: NOVAGALI PHARMA SA

Application No.: WO2011EP65236 (PCT/EP2011/65236)   Filing Date: 02/Sep/2011

Abstract:

The invention relates to a composition for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. The invention also relates to a pharmaceutical composition or to a medicament comprising the composition of the invention, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of the composition of the invention. The invention also relates to a device comprising the composition of the invention.

Priority: US2010-875805 Applic. Date: 2010-09-03; EP20100175337 Applic. Date: 2010-09-03

Inventor: LALLEMAND FREDERIC [FR]; GARRIGUE JEAN-SEBASTIEN [FR]; PHILIPS BETTY [FR]


Publication No.: WO2012028745A1  Published: 08/Mar/2012

Title: PHARMACEUTICAL COMPOSITION SUITABLE FOR USE IN A DRY POWDER INHALER

Applicant/Assignee: PHARMATERIALS LIMITED

Application No.: WO2011EP65330 (PCT/EP2011/65330)   Filing Date: 05/Sep/2011

Abstract:

This invention relates to a pharmaceutical composition suitable for use in a dry powder inhaler comprising: (i) carrier particles

(ii) active particles on the surface of the carrier particles

and (iii) excipient on the surface of the carrier particles, wherein the excipient comprises phytosterol, phytosterol derivative, phytostanol, phytostanol derivative or combinations thereof. This invention relates to a method of applying the excipient particles onto the carrier particles.

Priority: EP20100175314 Applic. Date: 2010-09-03

Inventor: NYAMBURA BILDAD KIMANI [GB]


Publication No.: WO2012028863A1  Published: 08/Mar/2012

Title: BIOCOMPATIBLE COMPOSITIONS FOR TISSUE AUGMENTATION

Applicant/Assignee: FUJIFILM MANUFACTURING EUROPE BV, FUJIFILM IMAGING COLORANTS LIMITED

Application No.: WO2011GB51521 (PCT/GB2011/51521)   Filing Date: 12/Aug/2011

Abstract:

A crosslinked gelatin hydrogel composition for tissue augmentation.

Priority: GB20100014388 Applic. Date: 2010-08-31

Inventor: KLUIJTMANS SEBASTIANUS [NL]; BOUWSTRA JAN [NL]; HARMSEN MARCO [NL]; TUIN ANNEMARIE [NL]; VAN LUYN MARIA [NL]


Publication No.: WO2012030308A2  Published: 08/Mar/2012

Title: FORMULATION COMPRISING CELLOBIOSE

Applicant/Assignee:

Application No.: WO2011TR00198 (PCT/TR2011/00198)   Filing Date: 24/Aug/2011

Abstract:

The present invention relates to a pharmaceutical composition comprising a carrier and one or more than one active agents developed in order to be used in the treatment of respiratory tract diseases such as asthma and COPD.

Priority: TR20100007250 Applic. Date: 2010-09-01

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2012030309A2  Published: 08/Mar/2012

Title: FORMULATION OF CALCIUM CHANNEL BLOCKER

Applicant/Assignee:

Application No.: WO2011TR00199 (PCT/TR2011/00199)   Filing Date: 24/Aug/2011

Abstract:

The present invention relates to a dry powder formulation comprising at least one calcium channel blocker and tiotropium developed in order to be used in respiratory tract diseases such as asthma and COPD.

Priority: TR20100007251 Applic. Date: 2010-09-01

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2012030645A1  Published: 08/Mar/2012

Title: RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE

Applicant/Assignee: PULMATRIX, INC

Application No.: WO2011US49333 (PCT/US2011/49333)   Filing Date: 26/Aug/2011

Abstract:

The present invention relates to respirable dry powders that contain respirable dry particles that comprise about 20% (w/w) leucine, about 75% (w/w) calcium lactate, and about 5% (w/w) sodium chloride, or about 37.5% (w/w) leucine, about 58.6% (w/w) calcium lactate, and about 3.9% (w/w) sodium chloride, and methods for treating a subject using the respirable dry powders.

Priority: US201161431205P Applic. Date: 2011-01-10; US20100387797P Applic. Date: 2010-09-29; US20100378146P Applic. Date: 2010-08-30

Inventor: LIPP MICHAEL M [US]; SUNG JEAN C [US]


Publication No.: WO2012030647A1  Published: 08/Mar/2012

Title: TREATMENT OF CYSTIC FIBROSIS USING CALCIUM LACTATE, LEUCINE AND SODIUM CHLORIDE IN A RESPIRAPLE DRY POWDER

Applicant/Assignee: PULMATRIX, INC

Application No.: WO2011US49342 (PCT/US2011/49342)   Filing Date: 26/Aug/2011

Abstract:

The invention relates to a methods for treating cystic fibrosis, comprising administering an effective amount of a calcium salt formulation to the respiratory tract of an individual with cystic fibrosis. The calcium salt formulation is can be a dry powder formulation.

Priority: US201161431205P Applic. Date: 2011-01-10; US20100387797P Applic. Date: 2010-09-29; US20100378146P Applic. Date: 2010-08-30

Inventor: LIPP MICHAEL M [US]; CLARKE ROBERT W [US]; HAVA DAVID L [US]


Publication No.: WO2012030664A1  Published: 08/Mar/2012

Title: DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES

Applicant/Assignee: PULMATRIX, INC

Application No.: WO2011US49435 (PCT/US2011/49435)   Filing Date: 26/Aug/2011

Abstract:

The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.

Priority: US201161431242P Applic. Date: 2011-01-10; US20100387925P Applic. Date: 2010-09-29; US20100378146P Applic. Date: 2010-08-30

Inventor: LIPP MICHAEL M [US]; SUNG JEAN C [US]; CLARKE ROBERT W [US]; HAVA DAVID L [US]


Publication No.: WO2012030901A1  Published: 08/Mar/2012

Title: SMALL LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA

Applicant/Assignee: NOVARTIS AG

Application No.: WO2011US49873 (PCT/US2011/49873)   Filing Date: 31/Aug/2011

Abstract:

Nucleic acid immunisation is achieved by delivering RNA encapsulated within a liposome. The RNA encodes an immunogen of interest, and the liposome has a diameter in the range of 60-180nm, and ideally in the range 80-160nm. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer has a diameter in the range of 60-180nm

and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

Priority: US20100378831P Applic. Date: 2010-08-31

Inventor: GEALL ANDREW [US]; VERMA AYUSH [US]


Publication No.: WO2012031164A2  Published: 08/Mar/2012

Title: DRUG DELIVERY BY CARBON NANOTUBE ARRAYS

Applicant/Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY

Application No.: WO2011US50270 (PCT/US2011/50270)   Filing Date: 01/Sep/2011

Abstract:

The invention generally relates to carbon nanotube based drug delivery methods, devices, and compositions. More particularly, the invention relates to controlled drug delivery using anchored carbon nanotube arrays.

Priority: US20100379701P Applic. Date: 2010-09-02

Inventor: GHARIB MORTEZA [US]; ARIA ADRIANUS INDRAT [US]; BEIZAI MASOUD [US]


Publication No.: WO2012031457A1  Published: 15/Mar/2012

Title: A MEDICINE DELAYED RELEASE VASCULAR EMBOLIZATION GEL USED FOR TREATING TUMOR AND PREPARATION PROCESS THEREOF

Applicant/Assignee: SHANGHAI CANCER INSTITUTE

Application No.: WO2011CN01510 (PCT/CN2011/01510)   Filing Date: 06/Sep/2011

Abstract:

A medicine delayed release vascular embolization gel used for treating tumor, conducting angiography and preventing hemorrhea. The gel is made by coating and loading drugs with pharmaceutical carriers, wherein the drugs can be anti-tumor agents and the pharmaceutical carriers can include poloxamer, polyvinylpyrrolidone (PVP) or combinations thereof. The quality percentage of pharmaceutical carriers existed in the gel is 5-65%.

Priority: CN20111088056 Applic. Date: 2011-04-08; CN20101275424 Applic. Date: 2010-09-08

Inventor: DUAN YOURONG [CN]; WAN ZHIYONG [CN]; SHEN MING [CN]; SUN QIUFEN [CN]


Publication No.: WO2012031747A1  Published: 15/Mar/2012

Title: PERCUTANEOUS APPLICATION SYSTEM

Applicant/Assignee: MEDDROP TECHNOLOGY AG

Application No.: WO2011EP04497 (PCT/EP2011/04497)   Filing Date: 07/Sep/2011

Abstract:

The invention relates to an application system for trans-epidermal surface administration of drugs, comprising a container (1) for receiving a sprayable composition containing an active compound, a propellant gas source (3) for a gas under pressure, of which at least 25% by volume consists of oxygen, and a spraying device (2), wherein the container (1), propellant gas source (3) and spraying device (2) are connected fluidically to one another in such a way that when the spraying device (2) is activated, the propellant gas atomizes the sprayable composition and drives the latter out of the spraying device (2), wherein the composition is driven out of the spraying device (2) in a conical spray jet having an exit velocity = 100 m/s. With the aid of the application system according to the invention, it is possible to administer active compounds effectively via the skin without any injury to the skin. On account of the high exit velocity, the introduction rate is particularly effective even when relatively large molecules are applied.

Priority: DE201010044674 Applic. Date: 2010-09-08

Inventor: TESLENKO ALEXANDER [DE]; GULIK DIETER [DE]; VON HAHN FRIEDRICH [DE]


Publication No.: WO2012032182A1  Published: 15/Mar/2012

Title: ORAL VETERINARY PREPARATIONS

Applicant/Assignee: IDT BIOLOGIKA GMBH

Application No.: WO2011EP65698 (PCT/EP2011/65698)   Filing Date: 10/Sep/2011

Abstract:

The present invention relates to a container for storing veterinary preparations and administering veterinary preparations contained therein to a target animal species, especially for the oral delivery of active therapeutic agents to free-roaming animals. Described is also a bait for animals comprising at least one container surrounded by an encasement or a carrier, made from material having a texture that is at least soft or bendable or elastic or resilient at ambient temperature and wherein the container surrounded by the carrier is also made from material having a texture that is at least soft or bendable or elastic or resilient at ambient temperature. The bait contains in the carrier and/or on the surface of the container at least one additive enhancing the cohesion of carrier and container. In the bait there is at least one container is in form of single isolated container or two or more containers are present that are isolated or adhered to each other or are physically connected to each other or are connected to each other in form of a chain-like configuration. The bait can be easily adapted to many animal species and to a specific oral delivery of the active components.

Priority: US20100403100P Applic. Date: 2010-09-10; EP20100176308 Applic. Date: 2010-09-10

Inventor: VOS ADRIAN [FR]; SCHUSTER PETER [DE]; BOROWSKI KLAUS [DE]


Publication No.: WO2012032337A2  Published: 15/Mar/2012

Title: A TRANSDERMAL DRUG ADMINISTRATION DEVICE

Applicant/Assignee: OREXO AB

Application No.: WO2011GB51658 (PCT/GB2011/51658)   Filing Date: 05/Sep/2011

Abstract:

A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.

Priority: US20100380539P Applic. Date: 2010-09-07

Inventor: ENGQVIST HAAKAN [SE]; BREDENBERG SUSANNE [SE]; PETTERSSON ANDERS [SE]; LUNDQVIST THOMAS [SE]; DAHLGREN ANNA [SE]; SAAGSTROEM ANDERS [SE]


Publication No.: WO2012032364A1  Published: 15/Mar/2012

Title: STABILIZED SOLUTION OF ORTHO-SILICIC ACID BASED ON SALICYLIC ACID AS EFFECTIVE INHIBITOR OF ITS POLYMERIZATION, ITS PREPARATION AND USE

Applicant/Assignee: CREOGEN D.O.O

Application No.: WO2011HR00034 (PCT/HR2011/00034)   Filing Date: 31/Aug/2011

Abstract:

The present invention discloses a formulation that serves as a highly bioavailable silicon (Si) source consisting of: (i) ortho-silicic acid (H4SiO4), from 0.01-8% w/w

(ii) salicylic acid (1), from 1-2 molar equivalents to H4SiO4

(iii) pharmaceutically acceptable acid, from 0.1-4 molar equivalents to H4SiO4

or pharmaceutically acceptable base, in amounts of 2 molar equivalents to salicylic acid (1)

and (iv) diluent, selected from the group consisting of: purified water, 1, 2-propylene glycol, glycerol, ethanol, or their mixtures, in amounts of up to 100% w/w of the formulation. The present invention discloses the preparation and the use of the formulation that provides all known positive therapeutic effects of ortho-silicic and salicylic acid in human and animals, and benefits of use for plants.

Priority: HR20100000494 Applic. Date: 2010-09-06

Inventor: CEPANEC IVICA [HR]; LELAS ANTONIO [HR]; RAMLJAK MARIJAN [HR]


Publication No.: WO2012032418A2  Published: 15/Mar/2012

Title: ACTIVATED LEUKOCYTE CONDITIONED SUPERNATANT AND USES FOR WOUND HEALING

Applicant/Assignee: MACROCURE, LTD

Application No.: WO2011IB02756 (PCT/IB2011/02756)   Filing Date: 08/Sep/2011

Abstract:

Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.

Priority: US20100381296P Applic. Date: 2010-09-09

Inventor: SHIRVAN MITCHELL [IL]; BAIN EILAT [IL]; BUBIS MARINA [IL]; GINIS IRENE [IL]


Publication No.: WO2012032497A1  Published: 15/Mar/2012

Title: NOVEL GENE VACCINATION LIPOSOMES

Applicant/Assignee: CENTRE DE COOPERATION INTERNATIONALE EN RECHERCHEAGRONOMIQUE POUR LE DEVELOPPEMENT (CIRAD), INSTITUTO NACIONAL DE INVESTIGACION Y TECNOLOGIA AGRARIA Y ALIMENTARIA (INIA)

Application No.: WO2011IB53956 (PCT/IB2011/53956)   Filing Date: 09/Sep/2011

Abstract:

The present invention relates to liposomes composed of DOPE and/or of a variant of DOPE bearing at least one ligand for targeting dendritic cells, of DOTAP and/or of a variant of DOTAP bearing at least one ligand for targeting dendritic cells and of cardiolipin and/or of a variant of cardiolipin bearing at least one ligand for targeting dendritic cells

and to the use thereof as a genetic material carrier for preparing lipoplexes. The lipoplexes according to the invention are advantageous because of the limited cytotoxicity thereof in vivo

they are therefore of particular interest for gene vaccination

in a form encapsulated in a biodegradable and nonimmunogenic cell such as an alginate gel, they are particularly suitable in particular for oral vaccination of aquatic animals.

Priority: FR20100003622 Applic. Date: 2010-09-10

Inventor: MOCKEY MICHAEL [FR]; DEDIEU LAURENCE [FR]; TAFALLA CAROLINA [ES]; CUESTA ALBERTO [ES]


Publication No.: WO2012033538A1  Published: 15/Mar/2012

Title: METHOD OF MITIGATING ADVERSE DRUG EVENTS USING OMEGA-3 FATTY ACIDS AS A PARENTERAL THERAPEUTIC DRUG VEHICLE

Applicant/Assignee: STABLE SOLUTIONS LLC

Application No.: WO2011US01567 (PCT/US2011/01567)   Filing Date: 12/Sep/2011

Abstract:

A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.

Priority: US2010-923257 Applic. Date: 2010-09-10

Inventor: DRISCOLL DAVID F [US]


Publication No.: WO2012033730A2  Published: 15/Mar/2012

Title: PUNCTAL PLUG CONTAINING DRUG FORMULATION

Applicant/Assignee: JOHNSON & JOHNSON VISION CARE, INC

Application No.: WO2011US50493 (PCT/US2011/50493)   Filing Date: 06/Sep/2011

Abstract:

Disclosed are lacrimal inserts and their method of use for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or reservoir, at least partially within the body portion comprising a therapeutic agent that is configured to controlled release into the eye and is configured for release medication via a designated port, valve, or orifice in the insert housing and inhibits diffusion of medication via the housing itself.

Priority: US20100380737P Applic. Date: 2010-09-08; US201113197258 Applic. Date: 2011-08-03

Inventor: BEELEY NATHAN R F [US]; COLDREN BRET A [US]; LUST VICTOR [US]


Publication No.: WO2012034079A2  Published: 15/Mar/2012

Title: MACROLIDE DOSAGE FORMS

Applicant/Assignee: MICELL TECHNOLOGIES, INC

Application No.: WO2011US51092 (PCT/US2011/51092)   Filing Date: 09/Sep/2011

Abstract:

Provided is a drug delivery composition comprising at least one polymer and at least one active agent

wherein the active agent is present in crystalline form on at least one region of an outer surface of the composition and wherein active agent surface content is adjusted to provide a selected active agent release profile.

Priority: US20100381371P Applic. Date: 2010-09-09

Inventor: MCCLAIN JAMES B [US]; CARLYLE WENDA C [US]; TAYLOR CHARLES DOUGLAS [US]


Publication No.: WO2012034659A2  Published: 22/Mar/2012

Title: PHARMACEUTICAL COMPOSITION CONTAINING AN ELECTROCHEMICALLY ACTIVATED SALT SOLUTION

Applicant/Assignee: CALIOPA AG

Application No.: WO2011EP04470 (PCT/EP2011/04470)   Filing Date: 06/Sep/2011

Abstract:

The aim of the invention is to provide a pharmaceutical composition containing an active ingredient and a carrier substance, wherein the carrier substance comprises an electrochemically activated aqueous sodium chloride solution and is present in a phase separated from the active ingredient, wherein said pharmaceutical composition guarantees an especially long storage life and especially high long-term stability of the composition without unacceptable impairment of the effectiveness of the active ingredient. For this purpose, the carrier substance has a content of free chlorine of more than 500 mg/l, preferably of more than 600 mg/l, according to the invention.

Priority: EP20100009703 Applic. Date: 2010-09-16

Inventor: MATHE HANS-GEORG [CH]


Publication No.: WO2012035283A1  Published: 22/Mar/2012

Title: PHARMACEUTICAL COMPOSITION

Applicant/Assignee: CIPLA LIMITED, CURTIS, PHILIP, ANTHONY

Application No.: WO2011GB00785 (PCT/GB2011/00785)   Filing Date: 23/May/2011

Abstract:

A composition comprising rifaximin in the form of particles, wherein substantially all the particles have a particle size less than or equal to 2 micrometres.

Priority: IN2010MU02539 Applic. Date: 2010-09-14; IN2010MU02522 Applic. Date: 2010-09-13

Inventor: PURANDARE SHRINIVAS MADHUKAR [IN]; MALHORTA GEENA [IN]


Publication No.: WO2012035377A1  Published: 22/Mar/2012

Title: A NOVEL DERMACEUTICAL CREAM MADE USING SODIUM FUSIDATE, CLOTRIMAZOLE AND CLOBETASOL PROPIONATE, A PROCESS TO MAKE THE SAME AND A METHOD OF TREATMENT USING IT

Applicant/Assignee:

Application No.: WO2010IB56123 (PCT/IB2010/56123)   Filing Date: 30/Dec/2010

Abstract:

The invention discloses a dermaceutical cream containing Clobetasol Propionate as a steroid, Clotrimazole as an antifungal and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, Clotrimazole as an antifungal and Clobetasol Propionate as a steroid, in a cream base comprising a preservative, an acid, a co-solvent, emulsifiers and a waxy material along with water, preferably purified water.

Priority: IN2010MU02530 Applic. Date: 2010-09-14

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SENTHILKUMAR KUPPUSAMY [IN]


Publication No.: WO2012035378A1  Published: 22/Mar/2012

Title: A DERMACEUTICAL CREAM MADE USING SODIUM FUSIDATE, AND FLUTICASONE PROPIONATE, A PROCESS TO MAKE THE SAME AND A METHOD OF TREATMENT USING IT

Applicant/Assignee:

Application No.: WO2010IB56124 (PCT/IB2010/56124)   Filing Date: 30/Dec/2010

Abstract:

The invention discloses a dermaceutical cream containing Fluticasone Propionate as a corticosteroid, and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, and Fluticasone Propionate, in a cream base comprising a preservative, an acid, a co-solvent, emulsifiers and a waxy material along with water, preferably purified water.

Priority: IN2010MU02531 Applic. Date: 2010-09-14

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; GHOSH KAUSIK [IN]


Publication No.: WO2012035379A1  Published: 22/Mar/2012

Title: A NOVEL DERMACEUTICAL CREAM MADE USING SODIUM FUSIDATE, MICONAZOLE NITRATE AND FLUTICASONE PROPIONATE, A PROCESS TO MAKE THE SAME AND A METHOD OF TREATMENT USING IT

Applicant/Assignee:

Application No.: WO2010IB56125 (PCT/IB2010/56125)   Filing Date: 30/Dec/2010

Abstract:

The invention discloses a dermaceutical cream containing Fluticasone Propionate as a steroid, Miconazole Nitrate as an antifungal agent and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, Miconazole Nitrate as an antifungal and Fluticasone Propionate as a steroid, in a cream base comprising a preservative, an acid, a co-solvent, emulsifiers and a waxy material along with water, preferably purified water.

Priority: IN2010MU02532 Applic. Date: 2010-09-14

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]


Publication No.: WO2012035380A1  Published: 22/Mar/2012

Title: A NOVEL DERMACEUTICAL CREAM MADE USING SODIUM FUSIDATE, CLOTRIMAZOLE AND MOMETASONE FUROATE, A PROCESS TO MAKE THE SAME, AND A METHOD OF TREATMENT USING IT

Applicant/Assignee:

Application No.: WO2010IB56126 (PCT/IB2010/56126)   Filing Date: 30/Dec/2010

Abstract:

The invention discloses a dermaceutical cream containing Mometasone Furoate as a corticosteroid, an antifungal agent in the form of Clotrimazole and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen- free environment. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, Mometasone Furoate and Clotrimazole, in a cream base comprising a preservative, an acid, a co-solvent, emulsifiers and a waxy material along with water, preferably purified water.

Priority: IN2010MU02533 Applic. Date: 2010-09-14

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]


Publication No.: WO2012035381A1  Published: 22/Mar/2012

Title: A NOVEL DERMACEUTICAL CREAM MADE USING SODIUM FUSIDATE AND BETAMETHASONE VALERATE, A PROCESS TO MAKE THE SAME, AND A METHOD OF TREATMENT USING IT

Applicant/Assignee:

Application No.: WO2010IB56127 (PCT/IB2010/56127)   Filing Date: 30/Dec/2010

Abstract:

The invention discloses a dermaceutical cream containing Betamethasone Valerate as a corticosteroid, and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen- free environment. The cream of the present invention has greater shelf -life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention has greater shelf -life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, and Betamethasone Valerate, in a cream base comprising a preservative, an acid, a co-solvent, emulsifiers and a waxy material along with water, preferably purified water.

Priority: IN2010MU02534 Applic. Date: 2010-09-14

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; GHOSH KAUSIK [IN]


Publication No.: WO2012035429A2  Published: 22/Mar/2012

Title: REMOTELY CONTROLLED DRUG DELIVERY SYSTEMS

Applicant/Assignee: THE UNIVERSITY OF BRITISH COLUMBIA

Application No.: WO2011IB02535 (PCT/IB2011/02535)   Filing Date: 13/Sep/2011

Abstract:

Drug delivery devices responsive to at least one external stimulus are described, along with methods for their preparation and use. The devices can be configured to respond to the stimulus, providing "on demand" release of one or more deliverables such as pharmaceutical drugs.

Priority: US20100382351P Applic. Date: 2010-09-13

Inventor: CHIAO MU [CA]; JACKSON JOHN K [CA]; PIRMORADI FATEMEH N [CA]; OU KEVIN [CA]


Publication No.: WO2012035478A2  Published: 22/Mar/2012

Title: ANTIFUNGAL VARNISH COMPOSITION

Applicant/Assignee: PHARMAYEDA LTD

Application No.: WO2011IB53964 (PCT/IB2011/53964)   Filing Date: 11/Sep/2011

Abstract:

Disclosed are compositions and methods that in some embodiments are useful in the treatment of fungal infections of the fingernails and toenails.

Priority: US20100382293P Applic. Date: 2010-09-13

Inventor: LEVIN ORNA [IL]; FORMAN YOCHANAN [IL]; FRIEDMAN MICHAEL [IL]


Publication No.: WO2012036442A2  Published: 22/Mar/2012

Title: ADHESIVE COMPOSITION COMPRISING TANNIN, POLYETHYLENE GLYCOL, AND WATER, LOWER ALCOHOL OR MIXTURE THEREOF

Applicant/Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, INNOTHERAPY INC

Application No.: WO2011KR06737 (PCT/KR2011/06737)   Filing Date: 09/Sep/2011

Abstract:

The present invention relates to an adhesive composition comprising tannin, polyethylene glycol, and water, wherein the adhesive composition has little toxicity, can be adhered even without a thermosetting curing agent which is different from conventional tannin adhesives, and is poorly soluble in water to be resistant against moisture, and thus can be used as a medical adhesive. The adhesive of the present invention has little toxicity, can be adhered even without a thermosetting curing agent which is different from conventional tannin adhesives, and is poorly soluble in water to be resistant against moisture. Therefore, the adhesive of the present invention can be used as a medical adhesive, an extended release drug delivery system, an adhesion barrier, an agent for preventing the adsorption of cells and proteins, and a medical hemostatic which can be used in various wet environments.

Priority: KR20100090232 Applic. Date: 2010-09-14

Inventor: LEE HAESHIN [KR]; LEE MOON SUE [KR]; HONG SEONKI [KR]; KIM KEUMYEON [KR]


Publication No.: WO2012036589A1  Published: 22/Mar/2012

Title: HYDROGEL COMPOSITION FOR THE TREATMENT OF BURNS

Applicant/Assignee: FEDERALNOE GOSUDARSTVENNOE UNITARNOE PREDPRIYATIE"FARMZASCHITA"

Application No.: WO2011RU00617 (PCT/RU2011/00617)   Filing Date: 15/Aug/2011

Abstract:

The invention relates to the field of medicine, in particular to pharmacology, and specifically to remedies used for administering first aid for burns in emergency medicine and can be used for topical treatment of wounds at all stages of a combination treatment in patients with I-IIIA-degree radiation, thermal and solar radiation burns, as well as treatment of granulating wounds of different etiology for treating insect bites and stings. The technical result arising from the use of the invention consists in extending the range of possible uses for administering first aid for topical burns of different etiology including radiation burns at all stages in the provision of medical aid. The hydrogel composition for the treatment of burns comprises an active ingredient, auxiliary ingredients and a gel-forming component. The active ingredient in the composition is the medicinal substance 2-allyloxyethanol in a quantity of from 0.1 to 10.0 (mass%). The auxiliary ingredients in the composition are the medicinal substances lidocaine or anilocaine in a quantity of from 0.1 to 5.0 (mass%). The auxiliary ingredients in the composition are the medicinal substances lidocaine or anilocaine in a quantity of from 0.1 to 5.0 (mass%) and deoxynatum in a quantity of from 0.1 to 5.0 (mass%). The gel-forming component in the composition is hydroxypropyl cellulose in a quantity of from 0.1 to 5.0 (mass%). Immobilized active and auxiliary ingredients are used. The hydrogel composition also comprises at least one of the following substrates: a textile or a nonwoven material, a mesh fabric with a ratio by mass of said at least one substrate to the gel-forming component of 1:3 to 1:8.

Priority: RU20100138263 Applic. Date: 2010-09-16

Inventor: BOYARINTSEV VALERY VLADIMIROVICH [RU]; NAZAROV VIKTOR BORISOVICH [RU]; SAMOILOV ALEKSANDR SERGEEVICH [RU]; DRUZHKOV ALEKSEY VYACHESLAVOVICH [RU]; FRONCHEK EDUARD VALENTINOVICH [RU]; BELOVOLOV ANTON JURIEVICH [RU]; SAVVATEEVA OLGA JURIEVNA [RU]; SEREDA NATALYA VLADIMIROVNA [RU]


Publication No.: WO2012036697A1  Published: 22/Mar/2012

Title: MICRO DEVICES BIOMEDICAL APPLICATIONS AND USES OF THE SAME

Applicant/Assignee:

Application No.: WO2010US49298 (PCT/US2010/49298)   Filing Date: 17/Sep/2010

Abstract:

The present invention provide micro devices for biological applications and methods of using them, wherein each micro device comprises an oater membrane and a property and has a size ranging from approximately 1 angstrom to no greater than approximately millimeters.

Priority: WO2010US49298 Applic. Date: 2010-09-17

Inventor: YU CHRIS CHANG [US]; YU HE [US]


Publication No.: WO2012036746A1  Published: 22/Mar/2012

Title: SYSTEMS AND METHODS OF DELIVERY OF BIOACTIVE AGENTS USING BACTERIAL TOXIN-DERIVED TRANSPORT SEQUENCES

Applicant/Assignee:

Application No.: WO2011US01602 (PCT/US2011/01602)   Filing Date: 15/Sep/2011

Abstract:

A non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active pharmaceutical, therapeutics. The systems and methods described herein provide for the following: the ability to deliver macromolecule doses without injections

the ability to deliver cargo, such as (but not limited to) siRNA or antisense molecules into intracellular compartments where their activity is required

and the delivery of nanoparticles and dendrimer-based carriers across biological membranes, which otherwise would have been impeded due to the barrier properties of most such membranes.

Priority: US20100403394P Applic. Date: 2010-09-15

Inventor: MRSNY RANDALL J [US]; MAHMOOD TAHIR [US]


Publication No.: WO2012037530A1  Published: 22/Mar/2012

Title: STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL PH

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: WO2011US52048 (PCT/US2011/52048)   Filing Date: 16/Sep/2011

Abstract:

The present invention provides, among other aspects, storage stabile aqueous formulations of labile proteins at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing a labile therapeutic protein composition at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of labile proteins at mildly acidic to neutral pH useful for parenteral administration.

Priority: US20100384209P Applic. Date: 2010-09-17

Inventor: BUTTERWECK HARALD ARNO [AT]; BAUER THERESA FRIEDERIKE [AT]; HOFBAUER LUCIA [AT]; TESCHNER WOLFGANG [AT]; ZOCHLING OLIVER [AT]; SCHWARZ HANS-PETER [AT]; MAYER CHRISTA [AT]; HASSLACHER MEINHARD [AT]


Publication No.: WO2012037534A1  Published: 22/Mar/2012

Title: STABILIZATION OF IMMUNOGLOBULINS THROUGH AQUEOUS FORMULATION WITH HISTIDINE AT WEAK ACIDIC TO NEUTRAL PH

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: WO2011US52053 (PCT/US2011/52053)   Filing Date: 16/Sep/2011

Abstract:

The present invention provides, among other aspects, storage stabile aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of immunoglobulins at mildly acidic to neutral pH useful for parenteral administration.

Priority: US20100384209P Applic. Date: 2010-09-17

Inventor: BUTTERWECK HARALD ARNO [AT]; KOELBL BERNHARD [AT]; HOFBAUER LUCIA [AT]; TESCHNER WOLFGANG [AT]; SCHWARZ HANS-PETER [AT]


Publication No.: WO2012038371A1  Published: 29/Mar/2012

Title: CASPOFUNGIN COMPOSITION

Applicant/Assignee: XELLIA PHARMACEUTICALS APS

Application No.: WO2011EP66202 (PCT/EP2011/66202)   Filing Date: 19/Sep/2011

Abstract:

The present invention relates to a composition comprising caspofungin or a pharmaceutical acceptable salt thereof and succinate or lactate as a buffering agent.

Priority: US20100384333P Applic. Date: 2010-09-20

Inventor: SHIRODE SWAPNIL P [IN]; PATEL PIYSH [IN]; PATIL ATUL [IN]; GIDWANI SURESH [IN]; PARIKH NEIL [US]; MOCNIK ANITA BEVETEK [HR]


Publication No.: WO2012039788A1  Published: 29/Mar/2012

Title: MULTI-LAYERED ORALLY DISINTEGRATING TABLET AND THE MANUFACTURE THEREOF

Applicant/Assignee: MCNEIL-PPC, INC

Application No.: WO2011US29155 (PCT/US2011/29155)   Filing Date: 21/Mar/2011

Abstract:

The present invention features a tablet containing a first layer and a second layer, wherein: (i) the first layer includes a pharmaceutically active agent and the composition of the first layer is different from the composition of the second layer

(ii) the tablet has a density less than about 0.8 g/cc

and (iii) the tablet disintegrates in the mouth when placed on the tongue in less than about 30 seconds.

Priority: US2010-887552 Applic. Date: 2010-09-22; US201113052316 Applic. Date: 2011-03-21; US2010-887544 Applic. Date: 2010-09-22

Inventor: LUBER JOSEPH R [US]; BUNICK FRANK J [US]; SOWDEN HARRY S [US]; KRIKSUNOV LEO B [US]; SZYMCZAK CHRISTOPHER E [US]


Publication No.: WO2012039789A1  Published: 29/Mar/2012

Title: MANUFACTURE OF VARIABLE DENSITY DOSAGE FORMS UTILIZING RADIOFREQUENCY ENERGY

Applicant/Assignee: MCNEIL-PPC, INC

Application No.: WO2011US29158 (PCT/US2011/29158)   Filing Date: 21/Mar/2011

Abstract:

The present invention features the present invention features a tablet including at least one pharmaceutically active ingredient, wherein the shape of said tablet includes at least one major face wherein: (i) the peak penetration resistance at the perimeter of said major face of the tablet is at least about 10% greater than the peak penetration resistance at the center of said major face

and (ii) the tablet disintegrates in the mouth when placed on the tongue in less than about 30 seconds, and a machine and method for manufacture of such tablet.

Priority: US2010-887552 Applic. Date: 2010-09-22; US201113052219 Applic. Date: 2011-03-21; US2010-887544 Applic. Date: 2010-09-22; US2010-887569 Applic. Date: 2010-09-22

Inventor: SZYMCZAK CHRISTOPHER E [US]; BUNICK FRANK J [US]; SOWDEN HARRY S [US]; LUBER JOSEPH R [US]; KRIKSUNOV LEO B [US]


Publication No.: WO2012039790A1  Published: 29/Mar/2012

Title: MANUFACTURE OF TABLETS FROM ENERGY-APPLIED POWDER BLEND

Applicant/Assignee: MCNEIL-PPC, INC

Application No.: WO2011US29161 (PCT/US2011/29161)   Filing Date: 21/Mar/2011

Abstract:

The present invention features a process for making tablets containing one or more pharmaceutically active agent(s) and one or more binder(s), the method including the steps of (i) applying energy to a powder blend comprising the pharmaceutically active agent(s) and the binder(s)for a sufficient period of time to activate the binder(s) within the powder blend and (ii) forming a predetermined amount of the energy-applied powder blend into the tablets.

Priority: US201113052200 Applic. Date: 2011-03-21; US2010-887544 Applic. Date: 2010-09-22; US2010-887552 Applic. Date: 2010-09-22

Inventor: LUBER JOSEPH R [US]; SZYMCZAK CHRISTOPHER E [US]; BUNICK FRANK J [US]; SOWDEN HARRY S [US]; KRIKSUNOV LEO B [US]


Publication No.: WO2012040919A1  Published: 05/Apr/2012

Title: USE OF BAICALEIN IN MANUFACTURING MEDICAMENT FOR PREVENTING AND TREATING PARKINSON'S DISEASE

Applicant/Assignee: INSTITUTE OF MATARIA MEDICA , CHINESE ACADEMY OF MEDICAL SCIENCES

Application No.: WO2010CN77467 (PCT/CN2010/77467)   Filing Date: 29/Sep/2010

Abstract:

The use of baicalein (formula I) in manufacturing the medicament for preventing, ameliorating and/or treating Parkinson's diseases is disclosed, wherein baicalein can be formulated into various dosage forms alone or combined with other agents. By reducing the frequency and amplitude of tremor as well as protecting the dopaminergic neuron from being damaged, baicalein can prevent, ameliorate and/or treat Parkinson's diseases.

Priority: WO2010CN77467 Applic. Date: 2010-09-29

Inventor: DU GUANHUA [CN]; CHENG YINXIA [CN]; MU XIN [CN]; HE GUORONG [CN]; YU XIN [CN]; LI XIAOXIU [CN]; SHI LILI [CN]; LV YANG [CN]; YANG NING [CN]


Publication No.: WO2012041328A1  Published: 05/Apr/2012

Title: USE OF METEORIN FOR THE TREATMENT OF ALLODYNIA, HYPERALGESIA, SPONTANEOUS PAIN AND PHANTOM PAIN

Applicant/Assignee: NSGENE A/S

Application No.: WO2011DK50369 (PCT/DK2011/50369)   Filing Date: 30/Sep/2011

Abstract:

The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.

Priority: US20100390791P Applic. Date: 2010-10-07; DK20100070423 Applic. Date: 2010-10-01

Inventor: JOHANSEN TEIT E [DK]; WAHLBERG LARS ULRIK [US]; JOERGENSEN JESPER ROLAND [DK]


Publication No.: WO2012041717A1  Published: 05/Apr/2012

Title: USE OF MAGNESIUM STEARATE IN DRY POWDER FORMULATIONS FOR INHALATION

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: WO2011EP66062 (PCT/EP2011/66062)   Filing Date: 16/Sep/2011

Abstract:

The invention relates to the use of magnesium stearate in powder formulation for inhalation comprising carrier particles to inhibit or reduce chemical degradation of an active ingredient bearing a group susceptible to hydrolysis. A pharmaceutical formulation in form of dry powder for inhalation comprising (a) a carrier, (b) magnesium stearate, and a) an active ingredient substance susceptible to hydrolysis is also provided.

Priority: EP20100183018 Applic. Date: 2010-09-30

Inventor: COCCONI DANIELA [IT]; DAGLI ALBERI MASSIMILIANO [IT]; BUSCA ANDREA [IT]; SCHIARETTI FRANCESCA [IT]


Publication No.: WO2012041788A1  Published: 05/Apr/2012

Title: PROTECTIVE COATINGS FOR ACIDIC ACTIVE INGREDIENTS

Applicant/Assignee: BASF SE

Application No.: WO2011EP66627 (PCT/EP2011/66627)   Filing Date: 26/Sep/2011

Abstract:

The invention relates to dosage forms which are provided with protective coatings. A core containing at least one acidic active ingredient is provided with at least one inner and outer coating layer in said dosage forms. The outer layer contains a cationic polymer as component A, said polymer being an emulsion polymerizate of N,N-diethylaminoethylmethacrylate and other monomers.

Priority: EP20100179816 Applic. Date: 2010-09-27

Inventor: KOLTER KARL [DE]; ANGEL MAXIMILIAN [DE]


Publication No.: WO2012041966A1  Published: 05/Apr/2012

Title: OVULE FOR VAGINAL ADMINISTRATION OF ARASERTACONAZOLE

Applicant/Assignee: FERRER INTERNACIONAL, S.A

Application No.: WO2011EP66989 (PCT/EP2011/66989)   Filing Date: 29/Sep/2011

Abstract:

The invention relates to an ovule for vaginal administration of arasertaconazole mononitrate consisting of arasertaconazole mononitrate, colloidal silica and a fatty base

Priority: EP20100184461 Applic. Date: 2010-09-30

Inventor: SANTOS BENJAMIN [ES]; BALEEIRO TAHIS [ES]; MARTI NURIA [ES]


Publication No.: WO2012042331A1  Published: 05/Apr/2012

Title: DEVICE FOR LOCALLY ADMINISTERING AN ACTIVE INGREDIENT

Applicant/Assignee:

Application No.: WO2011IB02213 (PCT/IB2011/02213)   Filing Date: 23/Sep/2011

Abstract:

Device (1) for locally administering, on glans of male organ, at least one active ingredient (2) for the erection of said male organ, said device (1) comprising at least a first chamber (3) surrounding, at least partially, said glans of said male organ and containing said active ingredient (2) in solid condition, said at least one first chamber (3) being provided with at least one selective membrane (6) for passing of said active ingredient in a solid condition, disposed at the outer surface of said glans, and with at least one section (7) for entering a solvent (8) into said at least one first chamber for solubilization of said active ingredient in solid condition and passing said active ingredient in solution through said membrane (7).

Priority: IT2010PG00050 Applic. Date: 2010-09-27

Inventor: STAFFOLANI NICOLA


Publication No.: WO2012042446A2  Published: 05/Apr/2012

Title: FIBRES AND RELATIVE WOVEN AND NON WOVEN TISSUES FOR THE TOPIC TREATMENT OF SEXUAL DYSFUNCTIONS OF THE MALE GENITAL APPARATUS

Applicant/Assignee: PROMOGREEN.COM.S.R.L, NAPWER S.R.L

Application No.: WO2011IB54171 (PCT/IB2011/54171)   Filing Date: 22/Sep/2011

Abstract:

The present invention concerns fibres containing a powdered composition that is capable of emitting radiation in the far infrared in turn comprising a mixture of : a) aluminium or alumina, b) titanium metal or titanium dioxide, and/or silica c) at least one metal or a compound thereof selected among: Pt, Pd, Ir, Rh, which, once processed in yarns and woven so as to prepare male underwear, or processed in the form of non- woven fabric, are used for the topical treatment of sexual dysfunction of the male genital apparatus.

Priority: IT2010MI01749 Applic. Date: 2010-09-27

Inventor: LANDI FEDERICA [IT]


Publication No.: WO2012042467A2  Published: 05/Apr/2012

Title: A MAGNETIC HYBRID HYDROGEL

Applicant/Assignee: ISTITUTO ORTOPEDICO RIZZOLI

Application No.: WO2011IB54240 (PCT/IB2011/54240)   Filing Date: 27/Sep/2011

Abstract:

The present invention relates to a magnetic hybrid hydrogel comprising a biocompatible, bioreabsorbable polymer crosslinked with magnetic particles which act as crosslinking agents. The polymer can be a polysaccharide chosen from among carboxymethyl cellulose, hyaluronic acid, chitin, alginic acid, alginates, chitosan or combinations thereof

or else a synthetic polymer chosen from among polyacrylic acid, polylactic acid, polyvinylamine or combinations thereof. The magnetic nanoparticles can be nanoparticles of Fe2C>3, Fe304, Fe204 or else mixed nanoparticles of Fe and Co, Mn or Zn, preferably functionalized with -NH2, - COOH,-OH,-SH groups. The hydrogel is used in oncological medicine for the targeted administration and controlled release of a drug, or else in regenerative medicine for applications of cells or other factors for the purpose of regenerating or repairing a tissue or organ.

Priority: IT2010MI01752 Applic. Date: 2010-09-27

Inventor: BARBUCCI ROLANDO [IT]; GIARDINO ROBERTO [IT]


Publication No.: WO2012044736A1  Published: 05/Apr/2012

Title: MONOVALENT METAL CATION DRY POWDERS FOR INHALATION

Applicant/Assignee: PULMATRIX, INC

Application No.: WO2011US53829 (PCT/US2011/53829)   Filing Date: 29/Sep/2011

Abstract:

The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.

Priority: WO2011US49435 Applic. Date: 2011-08-26; US201161481879P Applic. Date: 2011-05-03; US20100387883P Applic. Date: 2010-09-29

Inventor: LIPP MICHAEL M [US]; SUNG JEAN C [US]


Publication No.: WO2012045801A1  Published: 12/Apr/2012

Title: LACTOFERRIN BASED COMPLEX COACERVATES AND THEIR USES

Applicant/Assignee: NESTEC S.A

Application No.: WO2011EP67434 (PCT/EP2011/67434)   Filing Date: 06/Oct/2011

Abstract:

Lactoferrin-based complex coacervate inducing delayed protein digestion and modified peptide profile for improving metabolic responses, gut inflammatory response, satiety and food intake in humans, in association with an increase in GLP-1 and PYY gut hormones.

Priority: EP20100186852 Applic. Date: 2010-10-07

Inventor: BOVETTO LIONEL [FR]; BREUILLE DENIS [CH]; DONATO LAURENCE [CH]; POUTEAU ETIENNE [CL]; SCHMITT CHRISTOPHE [CH]; PANCHAUD ALEXANDRE [CH]


Publication No.: WO2012045809A1  Published: 12/Apr/2012

Title: USE OF SUBSTITUTED METHOXYALKOXYPHENYLALKYL DERIVATIVES AS PRESERVATIVE, PRESERVING METHOD, COMPOUNDS AND COMPOSITION

Applicant/Assignee: L'OREAL

Application No.: WO2011EP67450 (PCT/EP2011/67450)   Filing Date: 06/Oct/2011

Abstract:

The present invention relates to the use as a preserving agent, in particular in cosmetic or dermatological composition, of at least one compound of formula (I): in which : - X represents =O or -OH

- R1 represents a hydrogen atom or a methyl

- R2 represents a hydrogen atom, a methyl or an ethyl

- R3 represents a C1 -C12, saturated or unsaturated, linear hydrocarbon-based radical, optionally substituted with a hydroxyl group (OH)

with the exclusion of the compound of formula (I) in which X represents =O, R1 = methyl, R2 = H and R3 = -(CH2)6-CH3. The invention also relates to certain novel compounds and to the cosmetic or dermatological compositions comprising same.

Priority: US20100392082P Applic. Date: 2010-10-12; FR20100058182 Applic. Date: 2010-10-08

Inventor: DALKO MARIA [FR]; GILBERT LAURENT [FR]


Publication No.: WO2012046009A1  Published: 12/Apr/2012

Title: COMPOSITION FOR INTRAOCULAR IMPLANTATION OF BEVACIZUMAB

Applicant/Assignee: UCL BUSINESS PLC

Application No.: WO2011GB01458 (PCT/GB2011/01458)   Filing Date: 07/Oct/2011

Abstract:

A solid, compressed pharmaceutical composition comprises i) a peptide active pharmaceutical ingredient, ii) a polysaccharide excipient and/or an albumin, and iii) an oligosaccharide excipient. The polysaccharide excipient may be hyaluronic acid, or the potassium salt thereof, and the oligosaccharide excipient may be trehalose.

Priority: GB20100017048 Applic. Date: 2010-10-08

Inventor: KHAW PENG T [GB]; BROCCHINI STEPHEN [GB]; KHALILI ASHKAN [GB]


Publication No.: WO2012046046A1  Published: 12/Apr/2012

Title: COMPOSITION FOR SKIN TREATMENT

Applicant/Assignee: BIO SKINCARE LIMITED

Application No.: WO2011GB51893 (PCT/GB2011/51893)   Filing Date: 05/Oct/2011

Abstract:

A composition comprising from 10 to 15 % by weight of sucrose palmitate. The composition can be used to treat eczema.

Priority: GB20110010653 Applic. Date: 2011-06-23; GB20100016834 Applic. Date: 2010-10-06

Inventor: JAMES KENNETH [GB]


Publication No.: WO2012046047A1  Published: 12/Apr/2012

Title: COMPOSITION FOR USE IN THE TREATMENT OF ACNE

Applicant/Assignee: BIO SKINCARE LIMITED

Application No.: WO2011GB51894 (PCT/GB2011/51894)   Filing Date: 05/Oct/2011

Abstract:

A composition comprising from 10 to 15 % by weight of sucrose palmitate which may be used in the treatment of acne.

Priority: GB20110010659 Applic. Date: 2011-06-23; GB20100016836 Applic. Date: 2010-10-06

Inventor: JAMES KENNETH [GB]


Publication No.: WO2012046066A1  Published: 12/Apr/2012

Title: SOUR GELLED EMULSIONS

Applicant/Assignee: PROBIO ASA, COCKBAIN, JULIAN

Application No.: WO2011GB51915 (PCT/GB2011/51915)   Filing Date: 06/Oct/2011

Abstract:

The invention relates to an orally administrable, sour-tasting chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and comprises at least one physiologically acceptable acid and at least one buffering agent and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.

Priority: GB20100016900 Applic. Date: 2010-10-06

Inventor: SIWEK ANDRZEJ [NO]


Publication No.: WO2012047763A2  Published: 12/Apr/2012

Title: STIMULATION OF NEUROREGENERATION BY FLAVONOID GLYCOSIDES

Applicant/Assignee:

Application No.: WO2011US54377 (PCT/US2011/54377)   Filing Date: 30/Sep/2011

Abstract:

Flavonoid glycosides, such as isoquercitrin, are shown to stimulate the formation of neuritis and neuronal synapses in neurons and neuronal progenitor (stem) cells.

Priority: US20100391018P Applic. Date: 2010-10-07

Inventor: ZENOBI-WONG MARCY [CH]


Publication No.: WO2012047845A1  Published: 12/Apr/2012

Title: BORTEZOMIB FORMULATIONS STABILISED WITH BORIC

Applicant/Assignee: APP PHARMACEUTICALS

Application No.: WO2011US54703 (PCT/US2011/54703)   Filing Date: 04/Oct/2011

Abstract:

A bortezomib composition includes bortezomib and boric acid in a mass ratio of boric acid to bortezomib is from 1:1 to 10:1. The composition is a solid, and may be prepared by forming a liquid mixture including a solvent, bortezomib and boric acid, and lyophilizing the liquid mixture.

Priority: US20100390046P Applic. Date: 2010-10-05

Inventor: USAYAPANT ARUNYA [US]; BOWMAN DAVID [US]


Publication No.: WO2012047989A1  Published: 12/Apr/2012

Title: TNF INHIBITOR FORMULATION FOR USE IN IMPLANTABLE INFUSION DEVICES

Applicant/Assignee: MEDTRONIC, INC

Application No.: WO2011US54911 (PCT/US2011/54911)   Filing Date: 05/Oct/2011

Abstract:

A formulation for use in an implantable infusion device includes between about 5 mg/ml and about 500 mg/ml (e.g., about10- 25 mg/ml) of a TNF inhibitor polypeptide, 10 mM-25 mM of a phosphate or citrate buffer, has an ionic strength of the combined buffer and an optional salt of the equivalent of about 0.1-0.2 NaCl (e.g., about 0.15 M), 5% to 10% of a carbohydrate (e.g., trehalose or sucrose), has a pH of between 6 and 7, is fluid at room temperature and at 37C, and has a viscosity of less than about 10 centipoise (e.g., between about 1 centipoise and 9 centipoise, between about 1 cp and about 5cp, between about 1 cp and about 3 cp, or between about 1 cp and about 2.5 cp) at room temperature.

Priority: US201113252745 Applic. Date: 2011-10-04; US20100390412P Applic. Date: 2010-10-06

Inventor: LANE DEANNA S [US]; LE LANCHI T [US]; LI JIANWEI [US]; YUAN CHARLENE X [US]


Publication No.: WO2012048104A1  Published: 12/Apr/2012

Title: IMPLANTABLE DRUG DELIVERY DEVICE WITH BLADDEN RETENTION FEATURE

Applicant/Assignee: TARIS BIOMEDICAL, INC

Application No.: WO2011US55090 (PCT/US2011/55090)   Filing Date: 06/Oct/2011

Abstract:

Implantable devices and methods for controlled drug delivery are provided. The device (100) includes a device structure (104) deformable between a retention shape and a low profile shape for deployment in the bladder of a patient and has a drug reservoir lumen (102) in which a drug formulation (112) is housed. The device also includes a buoyancy retention portion (140), which includes a volume of entrapped air or a gas - generating or effervescent powder which will generate a volume of entrapped air following contact with urine in the bladder. The buoyancy retention portion may include a water permeable and/or biodegradable wall, which can release the entrapped air following drug release, to cause the device to sink into the bladder neck to facilitate device expulsion without the need for a device retrieval medical procedure.

Priority: US20100390495P Applic. Date: 2010-10-06

Inventor: LEE HEEJIN [US]; HO DUC HONG LINH [US]


Publication No.: WO2012048114A1  Published: 12/Apr/2012

Title: TIME-SELECTIVE BIORESORBABLE OR COLLAPSIBLE DRUG DELIVERY SYSTEMS AND METHODS

Applicant/Assignee: TARIS BIOMEDICAL, INC

Application No.: WO2011US55111 (PCT/US2011/55111)   Filing Date: 06/Oct/2011

Abstract:

Implantable medical devices and treatment methods are provided, particularly for use iii the bladder. The device is configured for retention in the bladder for at least a portion of the drug delivery period and includes at least one biodegradable component such that following a biodegradation at a selected time, the retention function is lost and the device or portions thereof are resorbed and/or excreted. The method may include deploying into the bladder of a patient a device having a device structure housing a drug formulation comprising at a drug

releasing drug from the device structure into the bladder

and then, changing the composition of urine in the bladder, e.g., by altering the pH, to trigger degradation of at least part of the device structure to enable the device structure or parts thereof to be excreted from the bladder.

Priority: US20100390549P Applic. Date: 2010-10-06; US20100405379P Applic. Date: 2010-10-21

Inventor: LEE HEEJIN [US]; CIMA MICHAEL J [US]; LARRIVEE-ELKINS CHERYL [US]; GEISING DENNIS H [US]; ANDERSON JESSICA K [US]; DUDDU SARMA [US]


Publication No.: WO2012048333A1  Published: 12/Apr/2012

Title: ORAL VACCINE FAST-DISSOLVING DOSAGE FORM USING STARCH

Applicant/Assignee: R.P. SCHERER TECHNOLOGIES, LLC

Application No.: WO2011US55689 (PCT/US2011/55689)   Filing Date: 11/Oct/2011

Abstract:

A fast-dissolving dosage form (FDDF) for the delivery of a vaccine is prepared using a formulation containing a starch, optionally, along with at least one additional matrix forming agent, preferably, a combination of gelatin and mannitol, wherein an immune response is induced in a patient in need thereof.

Priority: US20100391238P Applic. Date: 2010-10-08

Inventor: TIAN WEI [GB]; MCLAUGHLIN ROSIE [GB]


Publication No.: WO2012048846A2  Published: 19/Apr/2012

Title: PHOSPHATE BINDER FORMULATION FOR SIMPLE INGESTION

Applicant/Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

Application No.: WO2011EP05069 (PCT/EP2011/05069)   Filing Date: 11/Oct/2011

Abstract:

The invention relates to a pharmaceutical composition in the form of a free-flowing granulate or a chewable tablet, containing at least one phosphate-binding substance and at least one effervescent agent which contains a carbonate and a solid organic edible acid or the acidic salt thereof, for use in the treatment of hyperphosphataemia in patients suffering from renal insufficiency, wherein the granulate is applied orally without the addition of water.

Priority: EP20100013578 Applic. Date: 2010-10-13

Inventor: STROTHMANN KAI [DE]; SCHULZE FRIEDRICH [DE]; BARTHOLOMAEUS JOHANNES [DE]; FRIES-SCHAFFNER EVA [DE]; OPPERMANN ASTRID [DE]


Publication No.: WO2012048914A1  Published: 19/Apr/2012

Title: SUCTION DEVICE

Applicant/Assignee: NESTEC S.A

Application No.: WO2011EP58756 (PCT/EP2011/58756)   Filing Date: 27/May/2011

Abstract:

The invention relates to a suction device (1, 10, 20, 30) comprising a suction portion (3, 13, 23, 33) to be sucked by a user's mouth, characterized in that probiotics (7, 17, 27, 37) are adhered to or immobilized on the outer surface of the suction device (1, 10, 20, 30) such that the probiotics (7, 17, 27, 37) are segregated from the outer surface by external factors when the suction device (1, 10, 20, 30) is sucked.

Priority: EP20100187383 Applic. Date: 2010-10-13

Inventor: HUBER-HAAG KARL-JOSEF [CH]; BUREAU-FRANZ ISABELLE [FR]


Publication No.: WO2012049156A1  Published: 19/Apr/2012

Title: NON-STARCH BASED SOFT CHEWABLES

Applicant/Assignee: BAYER ANIMAL HEALTH GMBH

Application No.: WO2011EP67699 (PCT/EP2011/67699)   Filing Date: 11/Oct/2011

Abstract:

The present invention generally relates to soft chewables, especially suitable for delivering active ingredients to animals and processes for the preparation thereof. In various embodiments, the soft chewable comprises a pharmaceutically effective amount of at least one active ingredient, a flavoring agent, a disintegrant, a humectant, an antioxidant, a preservative, and water. In accordance with preferred embodiments, the soft chewable is essentially free of starch, oil, glycols, waxes, and soy products.

Priority: US20100392150P Applic. Date: 2010-10-12

Inventor: VENKATA-RANGARAO KANIKANTI [DE]; HAMANN HANS-JUERGEN [DE]


Publication No.: WO2012049159A1  Published: 19/Apr/2012

Title: COMPOSITION FOR TREATING CANCER BY THE CONTROLLED RELEASE OF AN ACTIVE SUBSTANCE

Applicant/Assignee: BAYER TECHNOLOGY SERVICES GMBH

Application No.: WO2011EP67702 (PCT/EP2011/67702)   Filing Date: 11/Oct/2011

Abstract:

The invention relates to a novel composition for treating cancer, which allows the active substance to be released in the direct presence of the cells which are to be treated with the active substance. Said composition comprises an active substance carrier which is in the form of a liposome comprising a disulfide group, a cytostatic agent being contained in the active substance carrier. The invention also relates to a method for the locally defined release of a cytostatic agent.

Priority: DE201010042338 Applic. Date: 2010-10-12

Inventor: EGGER HOLGER [DE]; BUDDE BASTIAN [DE]; TEMMING KAI [DE]; ARBUZOVA ANNA [DE]; GRAMATICA ANDREA [DE]; HERRMANN ANDREAS [DE]; LIEBSCHER JUERGEN [DE]; BRODERSEN NICOLAI [DE]


Publication No.: WO2012049444A1  Published: 19/Apr/2012

Title: PHARMACEUTICAL COMPOSITION

Applicant/Assignee: CIPLA LIMITED, CURTIS, PHILIP, ANTHONY

Application No.: WO2011GB01115 (PCT/GB2011/01115)   Filing Date: 25/Jul/2011

Abstract:

A pharmaceutical composition comprising a beta2-agonist selected from indacaterol and formoterol in combination with a corticosteroid selected from fluticasone and ciclesonide, and, optionally, one or more pharmaceutically acceptable excipients.

Priority: IN2011MU00069 Applic. Date: 2011-01-10; IN2011MU00143 Applic. Date: 2011-01-17; IN2011MU00135 Applic. Date: 2011-01-14; IN2011MU00106 Applic. Date: 2011-01-12; IN2010MU02847 Applic. Date: 2010-10-12

Inventor: MALHOTRA GEENA [IN]; PURANDARE SHRINIVAS MADHUKAR [IN]


Publication No.: WO2012049541A1  Published: 19/Apr/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER AND A CORTICOSTEROID, AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2010IB56130 (PCT/IB2010/56130)   Filing Date: 30/Dec/2010

Abstract:

The present invention is directed to a medicinal composition for treating skin inflammations, bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises: a) a biopolymer in the form of Chitosan, b) Active Pharmaceutical Ingredients (APIs), in the form of fusidic acid that has been generated in situ from sodium fusidate & Hydrocortisone acetate, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants, and d) water. The invention also discloses a process to make medicinal cream containing Fusidic acid formed in situ from Sodium Fusidate by converting it into Fusidic acid under oxygen-free environment created using inert gas. The cream has greater shelf-life and the finer particle size of the API than the conventional creams containing Fusidic acid.

Priority: IN2010MU02866 Applic. Date: 2010-10-15

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SENTHILKUMAR KUPPUSAMY [IN]; SRINIVASAN MADHAVAN [IN]


Publication No.: WO2012049542A1  Published: 19/Apr/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, MOMETASONE AS A CORTICOSTEROID AND CLOTRIMAZOL AS ANTIFUNGAL AGENT, AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2010IB56131 (PCT/IB2010/56131)   Filing Date: 30/Dec/2010

Abstract:

A Medicinal Fusidic Acid Cream Made Using Sodium Fusidate, A Corticosteroid, And An Antifungal Agent, And Incorporating A Biopolymer, And A Process To Make It The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises a) a biopolymer in the form of Chitosan, b) active Pharmaceutical Ingredients (APIs), in the form of fusidic acid that has been generated in situ from sodium fusidate, Mometasone furoate & clotrimazole, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants, and d) water. The active ingredients, namely chitosan, Mometasone furoate, clotrimazole and fusidic acid, are incorporated in cream base for use in treating skin inflammations, fungal/ bacterial skin infections with allergy & itching, & wounds on human skin involving contacting human skin with the above identified composition. Fusidic acid of the cream is made in situ from Sodium Fusidate as the starting raw material, under oxygen-free environment.

Priority: IN2010MU02867 Applic. Date: 2010-10-15

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]


Publication No.: WO2012049543A1  Published: 19/Apr/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER AND A CORTICOSTEROID, AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2010IB56132 (PCT/IB2010/56132)   Filing Date: 30/Dec/2010

Abstract:

The present invention is directed to a medicinal composition for treating skin inflammations, bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises: a) a biopolymer in the form of Chitosan, b) active Pharmaceutical Ingredients (APIs), in the form of fusidic acid that has been generated in situ from sodium fusidate & Mometasone furoate, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants, and d) water. A process to make the medicinal cream containing Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material is also disclosed, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment created using inert gas. The cream has greater shelf-life and finer particle size of the API than the conventional creams.

Priority: IN2010MU02868 Applic. Date: 2010-10-15

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SENTHILKUMAR KUPPUSAMY [IN]


Publication No.: WO2012049544A1  Published: 19/Apr/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, A HYDROCORTISONE ACETATE AS A CORTICOSTEROID, AND CLOTRIMAZOLE AS AN ANTIFUNGAL AGENT, AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2010IB56133 (PCT/IB2010/56133)   Filing Date: 30/Dec/2010

Abstract:

The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises: a) a biopolymer in the form of Chitosan, b) active Pharmaceutical Ingredients (APIs), in the form of fusidic acid that has been generated in situ from sodium fusidate Hydrocortisone acetate & clotrimazole, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The invention also discloses a process to make medicinal cream containing Fusidic acid formed in situ from Sodium Fusidate by converting it into Fusidic acid under oxygen-free environment. The cream has greater shelf-life and the finer particle size of the API than the conventional creams containing Fusidic acid.

Priority: IN2010MU02869 Applic. Date: 2010-10-15

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]


Publication No.: WO2012049545A1  Published: 19/Apr/2012

Title: A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2010IB56134 (PCT/IB2010/56134)   Filing Date: 30/Dec/2010

Abstract:

The present invention is directed to a medicinal composition for treating bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises a) a biopolymer in the form of Chitosan, b) an Active Pharmaceutical Ingredient (API), in the form of fusidic, c) a cream base, and d) water. The invention also discloses a process to make the medicinal cream in which Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material, by converting it into Fusidic acid under oxygen-free environment created using inert gas, preferably nitrogen. The cream produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid and found to be surprisingly superior for use against skin infections with allergy & itching, & wounds on human skin than alternative creams currently available.

Priority: IN2010MU02825 Applic. Date: 2010-10-12

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SENTHILKUMAR KUPPUSAMY [IN]


Publication No.: WO2012049676A2  Published: 19/Apr/2012

Title: APPARATUSES AND METHODS OF INTRAVAGINAL SUPPORT AND/OR DISTENSION

Applicant/Assignee: CONTIPI LTD

Application No.: WO2011IL00796 (PCT/IL2011/00796)   Filing Date: 09/Oct/2011

Abstract:

An intravaginal support apparatus. The intravaginal support apparatus comprises a pessary ring having a substantially annular configuration and a narrowed configuration, a locking mechanism which retains and switches between the annular configuration and the narrowed configuration, and one or more expandable elements having expanded and unexpanded configurations, attached to one or more of the locking mechanism and the pessary ring. The pessary ring laterally expands from the narrowed configuration to the annular configuration

the expandable element expands outwardly of the pessary ring, from the unexpanded configuration to the expanded configuration.

Priority: US20100392540P Applic. Date: 2010-10-13

Inventor: ZIV ELAN [IL]; PERLE AMIR [IL]


Publication No.: WO2012050945A1  Published: 19/Apr/2012

Title: CATIONIC DRY POWDERS

Applicant/Assignee: PULMATRIX, INC

Application No.: WO2011US53833 (PCT/US2011/53833)   Filing Date: 29/Sep/2011

Abstract:

The invention relates to respirable dry particles that contain one or more divalent metal cations, such as calcium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.

Priority: WO2011US49435 Applic. Date: 2011-08-26; US20100387855P Applic. Date: 2010-09-29

Inventor: LIPP MICHAEL M [US]; SUNG JEAN C [US]


Publication No.: WO2012051941A1  Published: 26/Apr/2012

Title: USES OF 15-BENZYLIDENE-14-DEOXY-11,12-DEHYDROANDROGRAPHOLIDE DERIVATIVES IN THE PREPARATION OF ANTINEOPLASTIC DRUGS

Applicant/Assignee: ZHENGZHOU UNIVERSITY

Application No.: WO2011CN80966 (PCT/CN2011/80966)   Filing Date: 19/Oct/2011

Abstract:

Disclosed in the present invention are applications for 15-benzylidene-14-deoxy-11, 12-dehydroandrographolide derivatives in the preparation of antineoplastic drugs.

Priority: CN20101516322 Applic. Date: 2010-10-22

Inventor: DAI GUIFU [CN]; XU HAIWEI [CN]; ZHU LIPING [CN]; DONG RUIJING [CN]; WU FENGJUAN [CN]; WANG YANAN [CN]; JIANG ZHIWEN [CN]; YAN LIJUN [CN]; LI WEIYI [CN]; LIU HONGMIN [CN]


Publication No.: WO2012052418A1  Published: 26/Apr/2012

Title: LIQUID PHARMACEUTICAL COMPOSITION FOR THE DELIVERY OF ACTIVE INGREDIENTS

Applicant/Assignee: NOVALIQ GMBH

Application No.: WO2011EP68141 (PCT/EP2011/68141)   Filing Date: 18/Oct/2011

Abstract:

The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.

Priority: EP20100188242 Applic. Date: 2010-10-20

Inventor: THEISINGER BASTIAN [DE]; THEISINGER SONJA [DE]; GUENTHER BERNHARD [DE]


Publication No.: WO2012052472A1  Published: 26/Apr/2012

Title: PHARMACEUTICAL TOPICAL COMPOSITION OF MUPIROCIN

Applicant/Assignee: LABORATORIOS OJER PHARMA S.L

Application No.: WO2011EP68242 (PCT/EP2011/68242)   Filing Date: 19/Oct/2011

Abstract:

Anhydrous topical gel composition of mupirocin or its salts comprising: a) a lipophilic base selected from the group consisting of petrolatum, medium- chain triglycerides, isopropyl myristate and mixtures thereof

b) a bioadhesive selected from the group comprising polyvinylpyrrolidone and polymethacrylates

and c) a solvent selected from the group comprising ethanol, propanol, and isopropanol

which is stable and shows an increased residence time of the active ingredient in the skin, resulting in an improved clinical effect in the treatment of bacterial skin infections while maintaining the safety profile of the commercial pharmaceutical product.

Priority: EP20100382274 Applic. Date: 2010-10-20

Inventor: GONZALEZ OJER CARLOS [ES]; GONI ALLO BEATRIZ [ES]; PASTOR FERNANDEZ FIONA [ES]; YARNOZ DE MIGUEL CAYETANA [ES]


Publication No.: WO2012052478A2  Published: 26/Apr/2012

Title: TOPICAL GEL COMPOSITION

Applicant/Assignee: GALDERMA S.A

Application No.: WO2011EP68261 (PCT/EP2011/68261)   Filing Date: 19/Oct/2011

Abstract:

Improved topical gel compositions, such as those containing brimonidine for the treatment of skin disorders are described. The gel compositions contain carbomer and paraben, and are substantially free of paraben crystalline particles after an extended period of storage.

Priority: US20100405382P Applic. Date: 2010-10-21; FR20100058611 Applic. Date: 2010-10-21

Inventor: BUGE JEAN-CHRISTOPHE [FR]; NADAU FOURCADE KARINE [FR]; MEUNIER CYRIL [FR]


Publication No.: WO2012052479A2  Published: 26/Apr/2012

Title: BRIMONIDINE GEL COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: GALDERMA S.A

Application No.: WO2011EP68263 (PCT/EP2011/68263)   Filing Date: 19/Oct/2011

Abstract:

Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.

Priority: US20100405388P Applic. Date: 2010-10-21; FR20100058612 Applic. Date: 2010-10-21

Inventor: BUGE JEAN-CHRISTOPHE [FR]; NADAU FOURCADE KARINE [FR]; MEUNIER CYRIL [FR]


Publication No.: WO2012052955A1  Published: 26/Apr/2012

Title: PROCESS FOR MAKING MULTIPARTICULATE GASTRORETENTIVE DOSAGE FORMS

Applicant/Assignee: MELIATYS

Application No.: WO2011IB54689 (PCT/IB2011/54689)   Filing Date: 20/Oct/2011

Abstract:

The instant: invention relates to a process for making inherent Sow density particles., comprising the steps of (i) providing a powder mixture comprising a swelling agent

(ii) granulating the powder of step (i) with a granulating solution comprising a lipophilie agent into granules and (iii) drying the granules of step (ii). The instant invention further relates to multiparticulate oral gastro-retentive dosage forms comprising the inherent low density particles: obtainable by the process.

Priority: EP20100290570 Applic. Date: 2010-10-22

Inventor: KIRKORIAN JOEL SYLVAIN MICHEL [FR]


Publication No.: WO2012053006A2  Published: 26/Apr/2012

Title: IMPROVED ORAL FAST DISSOLVING FILMS COMPRISING COMBINATION OF POLYMERS AND METHOD OF PREPARATION THEREOF

Applicant/Assignee: PANACEA BIOTEC LTD

Application No.: WO2011IN00715 (PCT/IN2011/00715)   Filing Date: 17/Oct/2011

Abstract:

The invention relates to an oral film having reduced adherence to oral cavity comprising water-soluble polymer as an essential polymer base in combination with film former, wherein the ratio of water-soluble polymer to the film former is about 25: 1 to about 250: 1 that is suitable for delivering drugs from various pharmacological categories ranging from conventional small molecules to proteins or peptides. In particular the invention relates to oral films which are bioequivalent to conventional immediate release oral dosage forms and exhibiting one or more favorable properties such as fast dissolution time, improved drug loading, improved mechanical properties (burst strength, tensile strength, modules of elongation).

Priority: IN2010MU02887 Applic. Date: 2010-10-18

Inventor: JAIN RAJESH [IN]; SINGH SARABJIT [IN]; SINGH PARAMJIT [IN]; SAILDESAI MANSI [IN]


Publication No.: WO2012053011A2  Published: 26/Apr/2012

Title: OPHTHALMIC COMPOSITIONS COMPRISING BRINZOLAMIDE

Applicant/Assignee: USV LIMITED

Application No.: WO2011IN00720 (PCT/IN2011/00720)   Filing Date: 18/Oct/2011

Abstract:

Disclosed herein is a novel process for preparation of ophthalmic suspensions of Carbonic anhydrase inhibitor such as Brinzolamide. Said process is characterized in that it does not involve autoclaving of the active ingredient Brinzolamide. The invention further discloses ophthalmic suspensions comprising Brinzolamide and combination of Brinzolamide and beta-blocker prepared by the novel process.

Priority: IN2010MU02894 Applic. Date: 2010-10-18

Inventor: OMRAY ASHOK [IN]; CHOUDHARY VARSHA SHASHANK [IN]; BHIDE YOGESH SHARAD [IN]; PARSAI DINESH YASHAWANT [IN]


Publication No.: WO2012054090A1  Published: 26/Apr/2012

Title: METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUNDS

Applicant/Assignee: API GENESIS, LLC

Application No.: WO2011US01802 (PCT/US2011/01802)   Filing Date: 24/Oct/2011

Abstract:

The subject invention relates to novel soluble forms of planar ring structured organic compounds including flavonoids, and their production. The invention also includes the use of these novel formulations of planar ring structured organic compounds in the preparation of formulations and products. The invention also relates to a wide variety of applications of the formulations of the invention. The subject invention includes novel soluble forms and various formulations of flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.

Priority: WO2010US02821 Applic. Date: 2010-10-22; US201113064882 Applic. Date: 2011-04-22

Inventor: BIRBARA PHILIP J [US]


Publication No.: WO2012055568A1  Published: 03/May/2012

Title: LIPOSOMAL DRUG COMPOSITION CONTAINING A POLYMERIC GUANIDINE DERIVATIVE

Applicant/Assignee: MINDINVEST HOLDINGS LTD

Application No.: WO2011EP05453 (PCT/EP2011/05453)   Filing Date: 28/Oct/2011

Abstract:

A liposomal drug composition comprising: a dimeric or polymeric guanidine derivative or a pharmaceutically acceptable salt thereof as drug substance, and a lipid modified by polyethylene glycole (PEG). The drug composition have cytostatic and antimicrobial activity.

Priority: AT20100001796 Applic. Date: 2010-10-29

Inventor: SCHMIDT OSKAR [AT]; WAGNER ANDREAS [AT]; RUPP-STANSCHITZ BARBARA [AT]


Publication No.: WO2012055571A1  Published: 03/May/2012

Title: OPHTHALMIC COMPOSITION

Applicant/Assignee: OMNIVISION GMBH

Application No.: WO2011EP05463 (PCT/EP2011/05463)   Filing Date: 28/Oct/2011

Abstract:

The present invention relates to an aqueous ophthalmic composition comprising (i) a prostaglandin

and (ii) one or more anionic surfactants, characterized in that the concentration of anionic surfactant in the ophthalmic composition is from 0.001 to 0.5 g/L.

Priority: US20100410530P Applic. Date: 2010-11-05; EP20100380137 Applic. Date: 2010-10-29

Inventor: RIZZO TAMARO ADRIANA [ES]


Publication No.: WO2012055933A1  Published: 03/May/2012

Title: LIPOSOME-BASED CONSTRUCT COMPRISING A PEPTIDE MODIFIED THROUGH HYDROPHOBIC MOIETIES

Applicant/Assignee: AC IMMUNE S.A

Application No.: WO2011EP68797 (PCT/EP2011/68797)   Filing Date: 26/Oct/2011

Abstract:

The present invention relates to method for preparing liposome-based constructs comprising a peptide, particularly an antigenic peptide, of interest modified through hydrophobic moieties reconstituted in liposomes and to the antigenic constructs obtained with said method. The invention further relates to the use of said constructs for the therapeutic and diagnostic use in the treatment of diseases and disorders, which are caused by or associated with proteopathy such as Alzheimer's Disease.

Priority: EP20100188832 Applic. Date: 2010-10-26

Inventor: REIS PEDRO [CH]; HICKMAN DAVID [CH]; PIHLGREN BOSCH MARIA [CH]; MUHS ANDREAS [CH]; PFEIFER ANDREA [CH]


Publication No.: WO2012055944A1  Published: 03/May/2012

Title: ORAL PHARMACEUTICAL FILM FORMULATION FOR BITTER-TASTING DRUGS

Applicant/Assignee: HEXAL AG

Application No.: WO2011EP68813 (PCT/EP2011/68813)   Filing Date: 27/Oct/2011

Abstract:

The invention relates to a pharmaceutical film formulation comprising one or more bitter-tasting drug(s) or pharmaceutically acceptable salts thereof, one or more film formers, a bitterness masker containing one or more inorganic and/or organic salt(s) and at least two monocyclic monoterpenes, and one or more sweetening agent(s).

Priority: DE201010049708 Applic. Date: 2010-10-28

Inventor: KOHR THOMAS [DE]; OBERMEIER PETRA [DE]


Publication No.: WO2012056031A1  Published: 03/May/2012

Title: MODIFIED STARCH DERIVATIVE-BASED MATRIX FOR COLON TARGETING

Applicant/Assignee: ROQUETTE FRERES

Application No.: WO2011EP69060 (PCT/EP2011/69060)   Filing Date: 28/Oct/2011

Abstract:

The invention provides a controlled-release oral pharmaceutical composition of at least an active agent, comprising : a) a lipophilic matrix consisting of lipophilic compounds and/or amphiphilic compounds

b) an hydrophilic matrix, wherein the hydrophilic matrix comprises at least an indigestible polysaccharide, the active ingredient being dispersed in the lipophilic and/or the hydrophilic matrix. The present invention also relates to a process for the preparation of such a pharmaceutical composition.

Priority: EP20100306189 Applic. Date: 2010-10-29

Inventor: HAEUSLER OLAF [FR]; DEGRAVE MARIE-HELENE [FR]; WILS DANIEL [FR]; KRENZLIN STEFANIE [DE]; SIEPMANN JUERGEN [FR]


Publication No.: WO2012056229A1  Published: 03/May/2012

Title: INFLAMMATORY DISEASE

Applicant/Assignee: BIOCOPEA LIMITED

Application No.: WO2011GB52073 (PCT/GB2011/52073)   Filing Date: 25/Oct/2011

Abstract:

The invention relates to the treatment of inflammatory diseases, and especially Th-1 mediated inflammatory diseases. In particular, the invention relates to the treatment of Th- 1 mediated inflammatory diseases using a range of related 1-phenyl-2-amino ethanol, ethanal and ethane derivatives, and to the use of these compounds in methods of treatment.

Priority: GB20100018302 Applic. Date: 2010-10-29

Inventor: BANNISTER ROBIN MARK [GB]; BREW JOHN [GB]


Publication No.: WO2012056251A1  Published: 03/May/2012

Title: INFLAMMATORY DISEASE

Applicant/Assignee: BIOCOPEA LIMITED

Application No.: WO2011GB52115 (PCT/GB2011/52115)   Filing Date: 31/Oct/2011

Abstract:

The invention relates to the treatment of inflammatory diseases, and especially Th-1 mediated inflammatory diseases. In particular, the invention relates to the treatment of Th-1 mediated inflammatory diseases using a range of compositions, and to the use of these compositions in methods of treatment. The invention extends to adjuvants, for use in treating a wide variety of medical conditions. The invention also provides pharmaceutical compositions and medicaments comprising the adjuvant, and to uses of the adjuvant in methods of treatment and for eliciting an immune response.

Priority: GB20110013728 Applic. Date: 2011-08-10; GB20100018289 Applic. Date: 2010-10-29

Inventor: BANNISTER ROBIN MARK [GB]; BREW JOHN [GB]; STOLOFF GREGORY ALAN [GB]; CAPAROSS-WANDERLEY WILSON [GB]; PLEGUEZUELOS MATEO OLGA [GB]


Publication No.: WO2012056299A1  Published: 03/May/2012

Title: NASAL COMPOSITIONS OF VITAMIN B12

Applicant/Assignee: TROIKAA PHARMACEUTICALS LIMITED

Application No.: WO2011IB02546 (PCT/IB2011/02546)   Filing Date: 28/Oct/2011

Abstract:

Vitamin B-12 deficiency is very common among population. The main causes of B- 12 deficiency include lack of intrinsic factors and other intestinal factors (e.g. malabsorption), rare genetic disorders, and inadequate intake. The present invention relates to intranasal formulations of vitamin B derivatives such as methylcobalamin, Cyanocobalamin which provide enhanced transnasal absorption.

Priority: IN2010MU02169 Applic. Date: 2010-10-29

Inventor: PATEL KETAN R [IN]; PATEL MILAN R [IN]; SHAH PRAKASHCHANDRA J [IN]


Publication No.: WO2012056387A2  Published: 03/May/2012

Title: A DERMACEUTICAL GEL MADE USING SODIUM FUSIDATE AND A PROCESS TO MAKE IT

Applicant/Assignee:

Application No.: WO2011IB54729 (PCT/IB2011/54729)   Filing Date: 24/Oct/2011

Abstract:

The invention discloses a process to make dermaceutical gel containing Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment comprising an inert gas, preferably nitrogen. The gel produced by the process of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The gel also contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, in a gel base

said gel base comprising a natural, semi-synthetic or synthetic polymers, a preservative, an acid, an alkali, a co-solvent, along with water, preferably purified water. The gel produced by the process of the present invention further optionally contains an ingredient selected from a group comprising, an anti oxidant, a chelating agent, and a humectant, or any combination thereof.

Priority: IN2010MU02352 Applic. Date: 2010-10-26

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASAN MADHAVAN [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SELVARAJ BALKRISHNANA [IN]; HARIDAS SANKAR [IN]


Publication No.: WO2012056452A2  Published: 03/May/2012

Title: PHARMACEUTICAL COMPOSITIONS AND DELIVERY DEVICES COMPRISING STINGING CELLS OR CAPSULES

Applicant/Assignee: NANOCYTE (ISRAEL) LTD

Application No.: WO2011IL00831 (PCT/IL2011/00831)   Filing Date: 27/Oct/2011

Abstract:

A pharmaceutical composition is provided. The pharmaceutical composition comprises as an active ingredient a tropane alkaloid drug or a muscarinic receptor antagonist and stinging cells or capsules.

Priority: US20100407073P Applic. Date: 2010-10-27

Inventor: ECKHOUSE SHIMON [IL]; LOTAN TAMAR [IL]; AYALON ARI [IL]


Publication No.: WO2012058464A2  Published: 03/May/2012

Title: MULTIPHASIC POLYMERIC PARTICLES CAPABLE OF SHAPE-SHIFTING VIA ENVIRONMENTAL STIMULATION

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Application No.: WO2011US58142 (PCT/US2011/58142)   Filing Date: 27/Oct/2011

Abstract:

Provided herein are methods of making and controlling multiphasic polymeric micro-components capable of shape-shifting. Such a multiphasic micro-component comprises a first phase (that can include a first polymer) and at least one additional phase distinct from said first phase (that can include a second polymer). One or more of the first phase and additional phase comprises a component that is responsive to an external stimulus. Thus, the micro-component exhibits a substantial physical deformation in response to: (i) the presence of the external stimulus or (ii) a change in the external stimulus. Exemplary external stimuli include temperature, pressure, light, pH, ionic strength, hydrophobicity/hydrophilicity, solvent, concentration, a stimulator chemical, sonic energy, electric energy, pressure, magnetic fields, and combinations thereof.

Priority: US20100407793P Applic. Date: 2010-10-28

Inventor: LAHANN JOERG [US]; YOON JAEWON [US]; BHASKAR SRIJANANI [US]; LEE KYUNGJIN [US]


Publication No.: WO2012059815A1  Published: 10/May/2012

Title: ACCORDION PILL COMPRISING LEVODOPA FOR AN IMPROVED TREATMENT OF PARKINSON'S DISEASE SYMPTOMS

Applicant/Assignee: INTEC PHARMA LTD

Application No.: WO2011IB02888 (PCT/IB2011/02888)   Filing Date: 01/Nov/2011

Abstract:

The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.

Priority: US20100408985P Applic. Date: 2010-11-01

Inventor: NAVON NADAV [IL]; KIRMAYER DAVID [IL]; SHVETZ JULIA [IL]; KLUEV ELENA [IL]; ABRAMOV EVA [IL]; WEISS ZEEV [IL]; CARNI GIORA [IL]


Publication No.: WO2012060786A2  Published: 10/May/2012

Title: CEFPODOXIME PROXETIL FORMULATIONS COMPRISING VISCOSITY AGENT

Applicant/Assignee:

Application No.: WO2011TR00251 (PCT/TR2011/00251)   Filing Date: 03/Nov/2011

Abstract:

The present invention relates to pharmaceutical formulations comprising cefpodoxime proxetil.

Priority: TR20100009168 Applic. Date: 2010-11-05

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2012061377A1  Published: 10/May/2012

Title: BIOERODIBLE SILICON-BASED DEVICES FOR DELIVERY OF THERAPEUTIC AGENTS

Applicant/Assignee: PSIVIDA US, INC, PSIMEDICA LIMITED, PSIVIDA CORP

Application No.: WO2011US58774 (PCT/US2011/58774)   Filing Date: 01/Nov/2011

Abstract:

This invention discloses bioerodible devices, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies, in a controlled manner. The devices comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The device may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The device may be used for treating or preventing conditions of a patient such as chronic diseases.

Priority: US201161470299P Applic. Date: 2011-03-31; US20100408934P Applic. Date: 2010-11-01

Inventor: ASHTON PAUL [US]; CANHAM LEIGH T [GB]; BARNETT CHRISTIAN [GB]


Publication No.: WO2012061547A1  Published: 10/May/2012

Title: SYSTEM AND METHOD FOR DIFFERENTIALLY TIMED LOCAL DELIVERY OF A COMBINATION PHARMACEUTICAL PREPARATION FOR ORAL THERAPY

Applicant/Assignee: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK

Application No.: WO2011US59048 (PCT/US2011/59048)   Filing Date: 03/Nov/2011

Abstract:

The present invention is directed to a system and method for treating oral diseases in a subject. This method comprises the following steps

diagnosing the subject, and choosing one or a combination of medications, their dosing and desired time course and then delivering the medications to the desired site in the periodontal pocket by administering a plurality of microcapsules, the microcapsules comprising one or more pharmaceutical agent(s) that are released in a predetermined manner and in accordance with the pathophysiology of the targeted disease.

Priority: US20100410619P Applic. Date: 2010-11-05

Inventor: ENGEBRETSON STEVEN P [US]; BLUMBERG NATHAN [US]


Publication No.: WO2012061787A1  Published: 10/May/2012

Title: A2A ANTAGONISTS AS COGNITION AND MOTOR FUNCTION ENHANCERS

Applicant/Assignee: BIOTIE THERAPIES, INC

Application No.: WO2011US59466 (PCT/US2011/59466)   Filing Date: 04/Nov/2011

Abstract:

Methods are described for inducing cognition and motor function enhancement in patients suffering from Parkinson's disease by administering an effective amount of an Adenosine 2a antagonist. The Adenosine 2a antagonist can optionally be administered in combination with a dopamine precursor, such as levodopa, or a dopamine receptor agonist,

Priority: WO2010US55681 Applic. Date: 2010-11-05

Inventor: BANDAK STEPHEN I [US]; BLACK KEVIN J [US]; CAMPBELL MEGHAN C [US]


Publication No.: WO2012062676A1  Published: 18/May/2012

Title: LISURIDE, TERGURIDE AND DERIVATIVES THEREOF FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF FIBROTIC CHANGES

Applicant/Assignee: SINOXA PHARMA UG

Application No.: WO2011EP69480 (PCT/EP2011/69480)   Filing Date: 04/Nov/2011

Abstract:

The present invention relates to the use of 5-HT2 receptor antagonists and in particular of 8-a-ergolines such as lisuride, terguride and the derivatives thereof as 5-HT2B and 5-HT2A receptor antagonists and antioxidants in preferably higher-dosed and preferably continuous use for the treatment, progression prophylaxis and general prophylaxis of organ fibroses and other pathological organ remodeling caused by mesenchymal proliferation.

Priority: DE201010051391 Applic. Date: 2010-11-11; EP20110075179 Applic. Date: 2011-07-27

Inventor: HOROWSKI REINHARD [DE]; PALLA HEINZ [DE]; TACK JOHANNES [DE]


Publication No.: WO2012062834A1  Published: 18/May/2012

Title: LIQUID PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A POSTERIOR EYE DISEASE

Applicant/Assignee: NOVALIQ GMBH

Application No.: WO2011EP69795 (PCT/EP2011/69795)   Filing Date: 10/Nov/2011

Abstract:

The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.

Priority: EP20100190832 Applic. Date: 2010-11-11

Inventor: WILSON CLIVE G [GB]


Publication No.: WO2012063509A1  Published: 18/May/2012

Title: AMPHIPATHIC LIQUID CRYSTAL COMPOUND, MICELLE, AND USE OF THE COMPOUND OR THE MICELLE

Applicant/Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY, A SCHOOL CORPORATION KANSAI UNIVERSITY

Application No.: WO2011JP60748 (PCT/JP2011/60748)   Filing Date: 10/May/2011

Abstract:

Provided is a compound which can form a micelle in water, wherein a liquid crystal phase is formed in the micelle. This compound can form a micelle in water, wherein a liquid crystal phase is formed in the micelle.

Priority: JP20100252923 Applic. Date: 2010-11-11

Inventor: MIYATA TAKASHI; URAGAMI TADASHI


Publication No.: WO2012064300A2  Published: 18/May/2012

Title: DESLORATADINE GRANULES

Applicant/Assignee:

Application No.: WO2011TR00242 (PCT/TR2011/00242)   Filing Date: 03/Nov/2011

Abstract:

The present invention relates to granules comprising a therapeutically effective amount of desloratadine or a pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof and production method thereof.

Priority: TR20100009396 Applic. Date: 2010-11-11

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2012064307A1  Published: 18/May/2012

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING ROSUVASTATIN

Applicant/Assignee:

Application No.: WO2011TR00249 (PCT/TR2011/00249)   Filing Date: 03/Nov/2011

Abstract:

The present invention relates to pharmaceutical formulations comprising rosuvastatin and/or a pharmaceutically acceptable salt thereof as active agent and use of these formulations in the treatment and/or prophylaxis of atherosclerosis, hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, myocardial infarction.

Priority: TR20100009397 Applic. Date: 2010-11-11

Inventor: MAHMUT BILGIC [TR]


Publication No.: WO2012065751A1  Published: 24/May/2012

Title: BIO-FUNCTIONALIZED STIMULUS-RESPONSIVE DISSOLVABLE PEG-HYDROGELS

Applicant/Assignee: UNIVERSITAETSKLINIKUM FREIBURG, ALBERT-LUDWIGS-UNIVERSITAT FREIBURG

Application No.: WO2011EP05820 (PCT/EP2011/05820)   Filing Date: 18/Nov/2011

Abstract:

The present invention is directed to a bio-functionalized stimulus-responsive dissolvable PEG-hydrogel. This inventive stimulus-responsive dissolvable PEG-hydrogel comprises a matrix of PEG-polymers, which are modified to contain at least one multifunctional fusion protein, the multifunctional fusion protein preferably comprising as components a substrate binding peptide (SBP), preferably a repetitive RGD-binding peptide and/or a ZZ-binding domain, preferably a tag for purification, and at least one N- and/or C-terminal linker. The present invention is furthermore directed to the use of such inventive stimulus-responsive dissolvable PEG-hydrogels in the treatment of lesions, in surgical dressings, for wound treating, for soft and hard tissue regeneration, for the treatment of wounds in the oral cavity, in the field of ophthalmology, in the field of periodontal defects, etc. The invention also describes a method of treatment for such diseases. Additionally, the present invention provides a kit comprising the inventive stimulus-responsive dissolvable PEG-hydrogel and optionally further components.

Priority: EP20100014788 Applic. Date: 2010-11-19

Inventor: STEINBERG THORSTEN [DE]; WEBER WILFRIED [DE]; GUEBELI RAPHAEL [CH]; TOMAKIDI PASCAL [DE]; LAIRD DOUGAL [DE]


Publication No.: WO2012065998A1  Published: 24/May/2012

Title: POLYURETHANE COPOLYMER

Applicant/Assignee: DSM IP ASSETS B.V

Application No.: WO2011EP70162 (PCT/EP2011/70162)   Filing Date: 15/Nov/2011

Abstract:

The invention is directed to a polyurethane copolymer, wherein the copolymer has the structure according to formula (I): The invention is further directed to a process for the production of polyurethane copolymers and to drug delivery devices comprising the polyurethane copolymers.

Priority: US20100413927P Applic. Date: 2010-11-15

Inventor: WARD ROBERT S [US]; WANG SHANGER [NL]; LI LI [NL]; CHALASANI DURGAPRASAD [NL]


Publication No.: WO2012066000A1  Published: 24/May/2012

Title: INTRAVAGINAL DRUG DELIVERY DEVICE COMPRISING A POLYURETHANE COPOLYMER

Applicant/Assignee: DSM IP ASSETS B.V

Application No.: WO2011EP70164 (PCT/EP2011/70164)   Filing Date: 15/Nov/2011

Abstract:

The invention is directed to an intravaginal drug delivery device comprising at least one pharmaceutically active substance, and a polyurethane copolymer, wherein the copolymer has the structure according to formula (I). The invention is further directed to administering one or more pharmaceutically active substances to a patient in need thereof.

Priority: US20100413929P Applic. Date: 2010-11-15

Inventor: WARD ROBERT S [US]; WANG SHANGER [NL]; LI LI [NL]; CHALASANI DURGAPRASAD [NL]; KISER PATRICK [US]; CLARK MEREDITH ROBERTS [US]


Publication No.: WO2012066334A1  Published: 24/May/2012

Title: SONOSENSITIVE NANOPARTICLES

Applicant/Assignee: ISIS INNOVATION LIMITED

Application No.: WO2011GB52244 (PCT/GB2011/52244)   Filing Date: 17/Nov/2011

Abstract:

A method of delivering a therapeutic substance to tissue comprises delivering the therapeutic substance and nanoparticles to the tissue, the nanoparticles having a diameter in the range from 10 to 1000nm and surface features having a depth in the range from 5 to 50nm, and insonating the tissue with pressure waves. Corresponding particles, and associated methods of controlling and imaging the treatment and delivery are also disclosed.

Priority: GB20100019434 Applic. Date: 2010-11-17

Inventor: WAGSTAFFE SARAH JAYNE [GB]; SCHIFFTER-WEINLE HEIKO ALEXANDER [GB]; MOLINARI MICHAEL BERNARD [GB]; ARORA MANISH [GB]; COUSSIOS CONSTANTIN-CASSIOS [GB]


Publication No.: WO2012066401A1  Published: 24/May/2012

Title: STABLE ORAL PHARMACEUTICAL COMPOSITIONS OF MONTELUKAST

Applicant/Assignee: LUPIN LIMITED

Application No.: WO2011IB02661 (PCT/IB2011/02661)   Filing Date: 10/Nov/2011

Abstract:

A stable liquid oral pharmaceutical composition comprising montelukast, a vehicle comprising mineral oil, desiccant and optionally pharmaceutically acceptable additives is provided. The invention also relates to kit for dispensing of oral pharmaceutical compositions of Montelukast. The kit comprises montelukast, a vehicle comprising mineral oil, desiccant and optionally pharmaceutically acceptable additives. The kit comprises a first container comprising pharmaceutical composition of montelukast and optionally desiccant, a second container comprising a vehicle comprising mineral oil, optionally desiccant and pharmaceutically acceptable additives, and instructions for use. montelukast and mineral oil occupy pre-measured volume into the respective unit of the kit.

Priority: IN2010KO01301 Applic. Date: 2010-11-16

Inventor: TATIYA KIRTIKUMAR ABHAY [IN]; SAOJI DILIP GOPALKRISHNA [IN]; KULKARNI CHINTAN SHARAD [IN]


Publication No.: WO2012066506A2  Published: 24/May/2012

Title: METHOD

Applicant/Assignee: UNIVERSITY COLLEGE CORK

Application No.: WO2011IB55175 (PCT/IB2011/55175)   Filing Date: 18/Nov/2011

Abstract:

The present invention relates to a method for fabricating a microneedle which comprises the steps of spraying a composition into a mould, drying the composition and removal of the dried composition from the mould, thereby forming a microneedle that, when applied to the skin of a subject, pierces the stratum corneum to access the underlying tissue of the subject. The present invention also relates to a method for coating a microneedle which comprises the steps of spraying a composition onto a microneedle and drying the composition at an ambient temperature, thereby forming a coated microneedle that, when applied to the skin of a subject, pierces the stratum corneum to deliver the sprayed material to the underlying tissue of the subject

Priority: GB20100019577 Applic. Date: 2010-11-18; US20100458167P Applic. Date: 2010-11-18

Inventor: CREAN ABINA M [IE]; MCGRATH MARIE G [IE]; O'MAHONY CONOR [IE]; VRDOLJAK ANTO [HR]; MOORE ANNE CLARE [IE]; CAREY JOHN [IE]


Publication No.: WO2012068958A1  Published: 31/May/2012

Title: ANTIANXIETY AND SLEEP DISORDER IMPROVING USE OF ALBIFLORIN OR METABOLITE THEREOF IN

Applicant/Assignee:

Application No.: WO2011CN81984 (PCT/CN2011/81984)   Filing Date: 09/Nov/2011

Abstract:

Disclosed is a use of albiflorin or a metabolite thereof in preparation of antianxiety and sleep disorder improving drugs or health-care food. Tests prove that albiflorin has significant antianxiety effects and sleep disorder improving effects achieved by prolonging SWS and low the toxic side effects, thus being a safety monomer compound capable of effectively treating anxiety and sleep disorder.

Priority: CN20101558722 Applic. Date: 2010-11-25

Inventor: ZHANG ZUOGUANG [CN]


Publication No.: WO2012069322A1  Published: 31/May/2012

Title: PROTECTIVE HYDROCOLLOID FOR ACTIVE INGREDIENTS

Applicant/Assignee: DSM IP ASSETS B.V

Application No.: WO2011EP69862 (PCT/EP2011/69862)   Filing Date: 10/Nov/2011

Abstract:

(Modified) sorghum protein is used as novel protective hydrocolloid for active ingredients, especially fat-soluble active ingredients and/or colorants. Included are compositions comprising (modified) sorghum protein and at least one active ingredient and to their manufacture, as well as to the (modified) sorghum protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions, and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a (modified) sorghum protein and such a composition, respectively.

Priority: CH20100002001 Applic. Date: 2010-11-26

Inventor: SCHAEFER CHRISTIAN [CH]


Publication No.: WO2012069591A1  Published: 31/May/2012

Title: FAST DISINTEGRATING COMPOSITIONS COMPRISING NABILONE AND RANDOMLY METHYLATED BETA CYCLODEXTRIN

Applicant/Assignee: AOP ORPHAN PHARMACEUTICALS AG

Application No.: WO2011EP70951 (PCT/EP2011/70951)   Filing Date: 24/Nov/2011

Abstract:

The present invention provides a novel composition comprising Nabilone and randomly methylated ss-cyclodextrin (RAMEB), wherein the weight ratio (dry weight to dry weight) between Nabilone and RAMEB is about 1:60 - 1:140. The present invention further provides methods for increasing the bioavailability of Nabilone.

Priority: EP20100192497 Applic. Date: 2010-11-25

Inventor: VIERNSTEIN HELMUT [AT]; TOEGEL STEFAN [AT]; SCHUELLER REGINA [AT]


Publication No.: WO2012069658A2  Published: 31/May/2012

Title: IMMUNOMODULATORY COMPOSITIONS

Applicant/Assignee: SIGMOID PHARMA LIMITED

Application No.: WO2011EP71088 (PCT/EP2011/71088)   Filing Date: 25/Nov/2011

Abstract:

Immunomodulator formulations for use in the treatment of disease of the Gl tract. The formulations comprise a hydroxylase inhibitor and/or an immunosuppressant. Exemplary formulations comprise hydralazine as a hydroxylase inhibitor and/or cyclosporin A as an immunosuppressant.

Priority: GB20100020032 Applic. Date: 2010-11-25

Inventor: AVERSA VINCENZO [IE]; COULTER IVAN [IE]; ROSA MONICA TORRES [IE]; MCDONALD BERNARD FRANCIS [IE]


Publication No.: WO2012069820A1  Published: 31/May/2012

Title: MULTI-LAYERED TRANSDERMAL PATCH

Applicant/Assignee:

Application No.: WO2011GB52290 (PCT/GB2011/52290)   Filing Date: 22/Nov/2011

Abstract:

A transdermal patch consists of two or more layers 1,2. These layers 1,2 are brought into contact with each other at the point of use, and remain separated during storage. Separation of the layers 1,2 may be to protect one or more formulation components from instability induced by any one or more other components due to chemical or physical incompatibilities, such as between Rivastigmine and oxidising functional groups present in the polymer matrix layer. Separation may also be to achieve a delay in the onset of drug permeation from one layer through the skin to allow another active agent such as another drug or permeation enhancer from a second layer to affect the skin prior to arrival of the drug at the patch-skin interface. A mechanism 4,5,15 is described for ensuring accurate, robust, reproducible, operator independent processes for bringing the layers into contact with each other at the point of use.

Priority: GB20100019761 Applic. Date: 2010-11-22; GB20110001526 Applic. Date: 2011-01-30; GB20110003750 Applic. Date: 2011-03-07; GB20110015920 Applic. Date: 2011-09-14

Inventor: CHOWDHURY DEWAN FAZLUL HOQUE [GB]


Publication No.: WO2012069870A1  Published: 31/May/2012

Title: A COUMPOUND COMPRISING ALPHA-MSH FOR USE IN ENDODONTIC REGENERATION

Applicant/Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE STRASBOURG ( ETABLISSEMENT PUBLIC NATIONAL A CARACTERE SCIENTIFIQUE, CULTUREL ET PROFE

Application No.: WO2010IB03458 (PCT/IB2010/03458)   Filing Date: 26/Nov/2010

Abstract:

The present invention concerns a compound comprising an a-MSH peptide, coupled to a polypeptide consisting of a chain of about 15 to about 400 amino acids, for use in endodontic regeneration and/or for the treatment of dental inflammatory diseases. The invention further concerns pharmaceutical compositions, in particular nanostructured compositions, comprising such a compound.

Priority: WO2010IB03458 Applic. Date: 2010-11-26

Inventor: BENKIRANE-JESSSEL NADIA [FR]; MENDOZA PALOMARES CARLOS; FIORETTI FLORENCE


Publication No.: WO2012071476A2  Published: 31/May/2012

Title: DRUG ELUTING OCULAR IMPLANT

Applicant/Assignee:

Application No.: WO2011US61967 (PCT/US2011/61967)   Filing Date: 22/Nov/2011

Abstract:

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Priority: US20100417154P Applic. Date: 2010-11-24

Inventor: HAFFNER DAVID [US]; CURRY KEN [US]; HEITZMANN HAROLD [US]; APPLEGATE DAVID [US]


Publication No.: WO2012071535A2  Published: 31/May/2012

Title: PEDIATRIC FORMULATION

Applicant/Assignee: AMGEN INC

Application No.: WO2011US62085 (PCT/US2011/62085)   Filing Date: 23/Nov/2011

Abstract:

The present invention is directed to pediatric formulation of (R)-N-[-1-(1-naphthyl)-ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine hydrochloride (hereinafter referred to as Cinacalcet HC1) and method of administering the same.

Priority: US20100416662P Applic. Date: 2010-11-23

Inventor: BI MINGDA [US]; ALVAREZ-NUNEZ FERNANDO [US]; ALVAREZ FRANCISCO JAVIER [US]


Publication No.: WO2012071654A1  Published: 07/Jun/2012

Title: TREATMENT AND PREVENTION OF ECZEMA

Applicant/Assignee: BIO-K PLUS INTERNATIONAL INC

Application No.: WO2011CA01319 (PCT/CA2011/01319)   Filing Date: 29/Nov/2011

Abstract:

The present invention broadly relates to the use of probiotics for the treatment and prevention of dermatitis. More particularly, the present invention relates to the use of a composition comprising Lactobacillus acidophilus strain I-1492 deposited at the CNCM, a Lactobacillus casei LBC80R TM strain and a carrier for treating or preventing hand dermatitis.

Priority: US20100418158P Applic. Date: 2010-11-30

Inventor: CHEVALIER CLAUDE [CA]; CARRIERE SERGE [CA]


Publication No.: WO2012072374A1  Published: 07/Jun/2012

Title: PRIMING SOLUTIONS FOR CARDIOPULMONARY BYPASS

Applicant/Assignee: XVIVO PERFUSION AB

Application No.: WO2011EP69524 (PCT/EP2011/69524)   Filing Date: 07/Nov/2011

Abstract:

The present invention relates to priming solutions used during cardiopulmonary bypass procedures. In particular, the present invention relates to a cardiopulmonary bypass priming solution comprising a balanced salt solution and a combination of oncotic and non-oncotic dextran molecules. The present invention also relates to the use of the priming solution in a cardiopulmonary bypass method, a method of maintaining oncotic pressure in a patient during a cardiopulmonary bypass procedure, and a combination of cardiopulmonary bypass priming solution and cardiopulmonary bypass apparatus.

Priority: GB20100020300 Applic. Date: 2010-11-30

Inventor: STEEN STIG [SE]


Publication No.: WO2012072587A1  Published: 07/Jun/2012

Title: BIODEGRADABLE NATURAL FILMS BASED ON CO-PRODUCTS DERIVED FROM INDUSTRIAL SEED-PROCESSING PROCESSES

Applicant/Assignee: SOJASUN TECHNOLOGIES

Application No.: WO2011EP71196 (PCT/EP2011/71196)   Filing Date: 28/Nov/2011

Abstract:

A biodegradable film (4) characterized in that it is prepared from at least one co-product derived from a soya bean-processing process aimed at obtaining soya-based final products by ultrafiltration, said co-product being selected from the group comprising the okara and the permeate. Such a film can be used as a food or pharmaceutical film, in particular for preparing a product for topical administration (1) of a pharmaceutical active ingredient, such as oestrogens.

Priority: FR20100059871 Applic. Date: 2010-11-29

Inventor: EFSTATHIOU THEO [FR]; AUDIC JEAN-LUC [FR]; DIVERS THOMAS [FR]


Publication No.: WO2012072692A2  Published: 07/Jun/2012

Title: USE OF CYTOKINE-RELEASING, BIODEGRADABLE PARTICLES IN HYALURONIC ACID FOR THE TREATMENT OF CARTILAGE DEFECTS, IN PARTICULAR OF OSTEOARTHROSIS

Applicant/Assignee: CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Application No.: WO2011EP71412 (PCT/EP2011/71412)   Filing Date: 30/Nov/2011

Abstract:

The present invention relates to a composition comprising, or consisting of, 2 - 50 mg/ml hyaluronic acid, 0.1 - 500 mg/ml of biodegradable particles with an average mean particle diameter of 1 nm - 500 [mu]m, 1 pg/ml - 10 [mu]g/ml cytokines, where the concentrations specified are based in each case on the total volume (w/v) of the composition and where the cytokines are enclosed in the biodegradable particles, and to their use in the treatment of cartilage defects, for example traumatic cartilage defects or osteoarthrosis.

Priority: DE201010062288 Applic. Date: 2010-12-01

Inventor: SITTINGER MICHAEL [DE]; RINGE JOCHEN [DE]; ANDREAS KRISTIN [DE]


Publication No.: WO2012073191A1  Published: 07/Jun/2012

Title: TOPICAL COMPOSITIONS FOR PRESERVING OR RESTORING THE INTEGRITY OF MUCOSAE

Applicant/Assignee: RICERFARMA S.R.L

Application No.: WO2011IB55364 (PCT/IB2011/55364)   Filing Date: 29/Nov/2011

Abstract:

The present invention relates to topical compositions containing choline alfoscerate for use in maintaining and restoring the integrity of the mucous membranes.

Priority: IT2010MI02218 Applic. Date: 2010-11-30

Inventor: DI SCHIENA MICHELE GIUSEPPE [IT]


Publication No.: WO2012075174A2  Published: 07/Jun/2012

Title: COMPOUNDS AND METHODS FOR SKIN REPAIR

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US62691 (PCT/US2011/62691)   Filing Date: 30/Nov/2011

Abstract:

The disclosure provides compositions and methods for treating a skin blemish. The compositions comprise a therapeutically effective amount of a compound useful for treating skin blemishes such as wounds, scars and wrinkles.

Priority: US20100419115P Applic. Date: 2010-12-02

Inventor: BURK ROBERT M [US]; IM WHA BIN [US]; WHITCUP SCOTT M [US]


Publication No.: WO2012075296A1  Published: 07/Jun/2012

Title: DISSOLVABLE PHARMACEUTICAL IMPLANT

Applicant/Assignee: MEDTRONIC, INC

Application No.: WO2011US62902 (PCT/US2011/62902)   Filing Date: 01/Dec/2011

Abstract:

A pharmaceutical implant may include at least one pharmaceutical and at least one excipient. The at least one excipient may dissolve after implantation of the pharmaceutical implant in the body of the patient and release the pharmaceutical. The at least one excipient may be selected to provide a desired release profile of the pharmaceutical. For example, the pharmaceutical implant may be configured to dissolve and release the pharmaceutical over a length of time between about one day and about 30 days. In some examples, the pharmaceutical implant may be implanted in the body of the patient proximate to an implantable medical device.

Priority: US2010-960091 Applic. Date: 2010-12-03

Inventor: GALLAGHER GENEVIEVE L [US]; CHAFFIN KIMBERLY A [US]; YANG ZHONGPING C [US]


Publication No.: WO2012075319A2  Published: 07/Jun/2012

Title: PHARMACEUTICAL CREAM COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2011US62936 (PCT/US2011/62936)   Filing Date: 01/Dec/2011

Abstract:

Embodiments relating to cream formulations as well as oxymetazoline creams and methods for treating rosacea and symptoms associated with rosacea, including, for example, papules, pustules, phymas (skin thickening), telangiectasias or erythema associated with rosacea, other skin erythemas, telangiectasias, purpura or the like, and other manifestations associated therewith

other inflammatory conditions of the skin including, but not limited to, keratosis pilaris, lupus miliaris dissemniatus faciei, eczema, dermatitis, such as contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, generalized exfoliative dermatitis, statis dermatitis, neurodermatitis, lichen simplex chronicus, xerosis and xerotic dermatitis, dyshidrosis and dyshidrotic dermatitis, asteototic dermatitis or other conditions characterized by sensitive skin or a disturbance of the epidermal barrier

disorders characterized by rough, dry, cracked or fissured skin, disorders characterized by hyperkeratotic skin such as keratodermas and ichthyosisis and ichthyosiform dermatoses

disorders of hair follicles and sebaceous glands, such as acne, perioral dermatitis, and pseudofolliculitis barbae

disorders of sweat glands, such as miliaria, including, but not limited to, miliaria crystallina, miliaria rubra, miliaria profunda, miliaria pustulosa

sunburn, chronic actinic damage, poikiloderma, radiation dermatitis, actinic purpura ("solar purpura")

other inflammatory dermatoses, reactions and conditions of the skin, including, but not limited to, psoriasis, drug eruptions, erythema multiforme, erythema nodosum, and granuloma annulare

diseases and conditions characterized by bleeding or bruising such as petechiae, ecchymosis, purpura and the like including any accumulation of blood in the skin due to vascular extravasation, irrespective of size or cause, bleeding or bruising due to any skin injury which may include any trauma including surgical or procedural trauma

infection, inflammatory dermatoses or inflammation due to any cause using such creams are described herein.

Priority: US20100419693P Applic. Date: 2010-12-03; US20100419697P Applic. Date: 2010-12-03

Inventor: SHANLER STUART D [US]; POWALA CHRISTOPHER [US]; RIOS LUIS [US]


Publication No.: WO2012075337A2  Published: 07/Jun/2012

Title: DIRECTED DELIVERY OF AGENTS TO NEURAL ANATOMY

Applicant/Assignee: SPINAL MODULATION, INC

Application No.: WO2011US62958 (PCT/US2011/62958)   Filing Date: 01/Dec/2011

Abstract:

The present invention is directed generally to systems, devices and methods for direct delivery of agents, e.g., pharmaceutical agents, to target spinal and neuronal anatomies, e.g., the dorsal root ganglia (DRG), for the treatment of various disorders, particularly pain and pain related disorders, such as chronic itch, sensory disorders, multiple sclerosis, post-herpetic neuralgia and the like. The system, devices and methods of the invention encompass the agents to be delivered to the target anatomy alone or in combination with electrical stimulation. The delivery device and systems and methods as disclosed herein place the distal end of the delivery element, which comprises at least one agent delivery structure, and optionally at least one electrode, in close proximity, or in contact with or next to the target spinal anatomy, e.g., DRG.

A variety of agents can be delivered using the device, including sodium channel blockers, biologics, neuroinflammatory modulators, toxins etc., to selectively neuromodulate the neurons. Agent delivery and/or electrical stimulation can be automated and/or can be controlled automatically or by a pre-determined program, or by a patient control pump (PCA).

Priority: US20100418721P Applic. Date: 2010-12-01

Inventor: KRAMER JEFFERY [US]; IMRAN MIR A [US]


Publication No.: WO2012075414A2  Published: 07/Jun/2012

Title: APTAMER BIOCONJUGATE DRUG DELIVERY DEVICE

Applicant/Assignee: ECOSYNTHETIX LTD

Application No.: WO2011US63102 (PCT/US2011/63102)   Filing Date: 02/Dec/2011

Abstract:

A delivery device for an active agent comprises nanoparticles based on a biopolymer such as starch. The delivery device may also be in the form of an aptamer-biopolymer-active agent conjugate wherein the aptamer targets the device for the treatment of specific disorders. The nanoparticles may be made by applying a high shear force in the presence of a crosslinker. The particles may be predominantly in the range of 50-150 nm and form a colloidal dispersion of crosslinked hydrogel particles in water. The biopolymer may be functionalized. The aptamer may be conjugated directly to the cross-linked biopolymers. The active agent may be a drug useful for the treatment of cancer. The delivery device survives for a period of time in the body sufficient to allow for the sustained release of a drug and for the transportation and uptake of the conjugate into targeted cells.

However, the biopolymer is biocompatible and resorbable.

Priority: US20100419106P Applic. Date: 2010-12-02

Inventor: BLOEMBERGEN STEVEN [US]; MCLENNAN IAN J [CA]; JONES NATHAN [CA]; WAGNER RYAN [CA]; GANESH SHERMON AAREET KRSNA [CA]; ELSAYED ABDEL RAHMAN [CA]; LIU JUEWEN [CA]


Publication No.: WO2012076443A1  Published: 14/Jun/2012

Title: LIPOSOMAL FORMULATION OF DALCETRAPIB

Applicant/Assignee: F. HOFFMANN-LA ROCHE AG

Application No.: WO2011EP71698 (PCT/EP2011/71698)   Filing Date: 05/Dec/2011

Abstract:

The present invention relates to a novel stable S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate liposomal composition, a process for the preparation thereof and its use in the treatment of diseases.

Priority: EP20100194219 Applic. Date: 2010-12-08

Inventor: GROSS GUENTER [DE]; TARDIO JOSEPH [FR]


Publication No.: WO2012076717A1  Published: 14/Jun/2012

Title: PHARMACEUTICAL COMPOSITION COMPRISING TRANS-CINNAMALDEHYDE AND ITS USE IN THE TREATMENT OF INFECTIONS

Applicant/Assignee: SOCIETE DE DEVELOPPEMENT SCIENTIFIQUE - SDS

Application No.: WO2011EP72389 (PCT/EP2011/72389)   Filing Date: 09/Dec/2011

Abstract:

This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram - bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent, and to the potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.

Priority: US20100421362P Applic. Date: 2010-12-09; EP20100306388 Applic. Date: 2010-12-09

Inventor: TESSE NICOLAS [FR]


Publication No.: WO2012076718A1  Published: 14/Jun/2012

Title: ANTI-MICROBIAL COMPOSITION

Applicant/Assignee: SOCIETE DE DEVELOPPEMENT SCIENTIFIQUE - SDS

Application No.: WO2011EP72390 (PCT/EP2011/72390)   Filing Date: 09/Dec/2011

Abstract:

This invention pertains to an anti-microbial, in particular anti-bacterial and/or anti-fungal composition comprising cinnamaldehyde, trans-2-methoxy cinnamaldehyde, cinnamyl acetate and linalool. In particular this composition is intended for preventing and/or treating microbial infection in an animal.

Priority: EP20100306385 Applic. Date: 2010-12-09; US20100421315P Applic. Date: 2010-12-09

Inventor: TESSE NICOLAS [FR]


Publication No.: WO2012077127A1  Published: 14/Jun/2012

Title: A PROTEIN FREE SURFACTANT COMPOSITION FOR PULMONARY DISEASES AND A PROCESS FOR PREPARING THE SAME

Applicant/Assignee: INDIAN INSTITUTE OF TECHNOLOGY, BOMBAY

Application No.: WO2011IN00691 (PCT/IN2011/00691)   Filing Date: 04/Oct/2011

Abstract:

A protein free surfactant composition comprising dipalmitoylphosphatidyl choline (DPPC) and eugenol having a ratio in the range of 10:5 to 4:2 with >99% airway patency in the presence of albumin, for treating acid lung injury, adult respiratory distress syndrome and meconium aspiration syndrome.

Priority: IN2010MU03370 Applic. Date: 2010-12-10

Inventor: BANERJEE RINTI [IN]; KAVIRATNA ANUBHAV [IN]


Publication No.: WO2012077131A1  Published: 14/Jun/2012

Title: A STABLE READY-TO-USE CETRORELIX INJECTION

Applicant/Assignee: ASTRON RESEARCH LIMITED

Application No.: WO2011IN00825 (PCT/IN2011/00825)   Filing Date: 05/Dec/2011

Abstract:

The present invention discloses a stable ready-to-use aqueous pharmaceutical preparation containing Cetrorelix or its pharmaceutically acceptable salt, wherein the preparation does not contain any surfactant. Further, the present invention discloses process for the preparation of said stable ready-to-use aqueous pharmaceutical preparation.

Priority: IN2010MU03306 Applic. Date: 2010-12-06

Inventor: PATEL PANKAJ [IN]; PATEL BHAVESH [IN]; SEHGAL ASHISH [IN]; MANDAL JAYANTA KUMAR [IN]


Publication No.: WO2012078605A1  Published: 14/Jun/2012

Title: TOPICAL COMBINATION FORMULATIONS OF MACROCYCLIC LACTONES WITH SYNTHETIC PYRETHROIDS

Applicant/Assignee: MERIAL LIMITED

Application No.: WO2011US63497 (PCT/US2011/63497)   Filing Date: 06/Dec/2011

Abstract:

The present invention provides pyrethroid / macrocyclic lactone-containing topical formulations that are effective against animal pests, including ecto- and endoparasites. The formulations may be used for combating parasites in or on birds and mammals. The invention also provides for an improved method for eradicating, controlling and preventing parasite and/or pest infestation of birds and mammals.

Priority: US20100420744P Applic. Date: 2010-12-07

Inventor: HOLMES ROBERT [NZ]


Publication No.: WO2012078815A1  Published: 14/Jun/2012

Title: SUSTAINED RELEASE IMPLANTS CONTAINING A BIODEGRADABLE POLYMER, CYCLODEXTRIN AND POORLY WATER SOLUBLE ACTIVE COMPOUNDS

Applicant/Assignee: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC

Application No.: WO2011US63840 (PCT/US2011/63840)   Filing Date: 07/Dec/2011

Abstract:

We have disclosed an implantable sustained release composition comprising, a biocompatible, biodegradable polymer, a cyclodextrin inclusion complex of a poorly water soluble pharmaceutical agent present, and a plasticizer, where the polymer is the minority phase of the formulation. Furthermore, we disclose an implantable sustained release composition that provides a detectable plasma level of an otherwise poorly soluble drug for at least 28 days.

Priority: US2010-963012 Applic. Date: 2010-12-08

Inventor: SCHACHTER DEBORAH M [US]; ZHANG QIAN [US]; VAN REMOORTERE PETER [US]; LI YUFU [US]


Publication No.: WO2012078999A1  Published: 14/Jun/2012

Title: COMPOSITIONS FOR TREATING DERMATITIS AND ICHTHYOSIS, AND METHODS FOR TREATING DERMATITIS AND ICHTHYOSIS

Applicant/Assignee: SKINVISIBLE PHARMACEUTICALS, INC

Application No.: WO2011US64190 (PCT/US2011/64190)   Filing Date: 09/Dec/2011

Abstract:

A skin disorder treatment composition and method for treating a skin disorder or symptoms of a skin disorder are provided. The composition includes: about 0.0001 wt.% to about 5 wt.% of a serine protease inhibitor

about 2 wt.% to about 10 wt.% of a hydrophobic polymer/hydrophilic polymer complex comprising a poly(vinylpyrrolidone-alkylene) polymer wherein the alkylene group contains at least 10 carbon atoms and a cellulose containing polymer

about 0.5 wt.% to about 20 wt.% of a release agent

and at least about 50 wt.% water. The skin disorder or the symptom of skin disorder from ichthyosis, dermatitis, eczema, rosacea, psoriasis, inflammation, xerosis, or urticaria.

Priority: US20100421823P Applic. Date: 2010-12-10

Inventor: ROSZELL JAMES A [US]


Publication No.: WO2012079232A1  Published: 21/Jun/2012

Title: COMPOUNDS USED FOR TREATING CANCER AND THE USE THEREOF

Applicant/Assignee:

Application No.: WO2010CN79835 (PCT/CN2010/79835)   Filing Date: 15/Dec/2010

Abstract:

The invention discloses compounds used for treating cancer and the use thereof. The compounds comprise ammonium pyrrolidinedithiocarbamate, (E)3-((4- tertbutytphenyl) sulfonyl)-2-acrylonitrile, (2'Z,3'Z)-6-bromoindirubin-3'-oxime, ?-4-dihydroxyl-2-(6-hydroxyl-1-heptenyl)-4-cyclopentanecrotonic acid?.- lactone, butalamol, calcimycin, bis(4-chlorophenyl)methyl)-3-(2-(2,4-dichlorophenyl)-2-((2,4- dichlorophenoxy)ethyl-1H-imidazolium salts, chelerythrine chloride, 4,5,6,7- tetrabromo-benzimidazole, N2-(cis-cyclohexaneamine)-N6-(3-chlorophenyl)-9-ethyl- 9H-purin-2,6-diamine hydrochloride, 7-trifluoromethyl-4-(4-methyl-1-piperazinyl)- pyrrolo[1,2-a]quinoxaline maleate, dequalinium dichloride, dihydroouabain, diphenyleneiodonium chloride, emetine dihydrochloride hydrate, N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4- triazol-3-yl)[1,1'-biphenyl]-4-carboxamide hydrochloride, 2,2-dimethyl- 3,4-dihydro -2H-benzo[1,2B]chromene-5,6-dione, niclosamide, nifedipine, 6-nitroso-1,2- benzopyrone, palmitoyl-DL-carnitine chloride, parthenolide, 4- (4-fluorophenyl) -2-(4-nitrophenyl)-5-(4-pyridine)-1H-imidazol, 1,10-phenanthroline monohydrate, 4-phenyl-3-furoxancarbonitrile, prazosin hydrochloride, protoporphyrin disodium, quinacrine dihydrochloride, ouabaim, retinoic acid p-hydroxyanilide, rottlerin, sanguinarine chloride, tetraethylthium, 3-[1-(3H-imidazol-4-yl)-meth- (Z)-ylidene]-5-methoxy- 1,3-dihydro-2-indolinone. The invention also discloses the use of the compounds for preparing medicament of treating cancer and inhibiting the growth of cancer cell and cancer stem cell.

Priority: WO2010CN79835 Applic. Date: 2010-12-15

Inventor: LAI HUNG-CHENG [CN]


Publication No.: WO2012079721A1  Published: 21/Jun/2012

Title: TERPENOID SPIRO KETAL COMPOUNDS WITH LXR AGONISTS ACTIVITY, THEIR USE AND FORMULATIONS WITH THEM

Applicant/Assignee: INTERMED DISCOVERY GMBH

Application No.: WO2011EP06157 (PCT/EP2011/06157)   Filing Date: 08/Dec/2011

Abstract:

The invention relates to the use, or methods (especially with regard to animals, especially human, that are in need of such treatment) comprising the use, respectively, of an extract and/or especially one or more natural spiro triterpenoids and derivatives thereof, especially from the blazeispirol family, obtainable from Agaricus species, alone or as supplement, as active ingredient in the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to the modulation of Liver X receptor, either in humans or in other mammals, and/or to the use of said extract and/or natural compound(s) or mixtures for the treatment of said disease, disorder or condition, as well as corresponding methods of treatment, or their use in the manufacture of a pharmaceutical or nutraceutical formulation for said treatment.

The invention relates also to said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disorder, disorder or condition, as well as their preparation. It also relates to pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment. They can also be used for non-therapeutic, e.g. cosmetic, purposes only.

Priority: EP20100015607 Applic. Date: 2010-12-14

Inventor: GROTHE TORSTEN [DE]; STADLER MARC [DE]; KOEPCKE BAERBEL [DE]; ROEMER ERNST [DE]; BITZER JENS [DE]; WABNITZ PHILIPP [DE]; KUEPER THOMAS [DE]


Publication No.: WO2012080176A2  Published: 21/Jun/2012

Title: PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: NOVARTIS AG, DEBIOPHARM S.A

Application No.: WO2011EP72463 (PCT/EP2011/72463)   Filing Date: 12/Dec/2011

Abstract:

The invention provides lipid-based pharmaceutical compositions comprising alisporivir.

Priority: US20100422499P Applic. Date: 2010-12-13; WO2011IB00319 Applic. Date: 2011-02-18; WO2011IB00653 Applic. Date: 2011-03-25

Inventor: GONCALVES ELISABETE [CH]; RAPP KARIN [CH]; SUTTER BERTRAND [CH]; STOWASSER FRANK [CH]; TRUPP BJOERN [CH]; CHABAUT SEBASTIAN [CH]; THORENS JULIEN [CH]


Publication No.: WO2012080184A2  Published: 21/Jun/2012

Title: LIQUID PHARMACEUTICAL COMPOSITIONS WHICH CAN BE ADMINISTERED ORALLY AND CONTAIN 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)-PHENYL]-1,3-OXAZOLIDIN-5-YL}-METHYL)-2-THIOPHENE CARBOXAMIDE

Applicant/Assignee: BAYER PHARMA AKTIENGESELLSCHAFT

Application No.: WO2011EP72479 (PCT/EP2011/72479)   Filing Date: 12/Dec/2011

Abstract:

The present invention relates to liquid pharmaceutical compositions which contain 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide, to the production thereof and to the use thereof for the prophylaxis and/or treatment of diseases.

Priority: DE201010063127 Applic. Date: 2010-12-15

Inventor: MOTZKUS SUSANNE [DE]; KRAUSE MICHAEL [DE]


Publication No.: WO2012080216A1  Published: 21/Jun/2012

Title: ORALLY DISINTEGRATING TABLET HAVING A TASTE MASKING EFFECT

Applicant/Assignee: HEXAL AG

Application No.: WO2011EP72555 (PCT/EP2011/72555)   Filing Date: 13/Dec/2011

Abstract:

The present invention is directed to an orally disintegrating tablet having a taste masking effect, comprising at least one unpleasant-tasting pharmaceutically active ingredient having a particle size d (0.1) of 50 [mu]m or more.

Priority: EP20100195186 Applic. Date: 2010-12-15

Inventor: STORM KLAUS [DE]; OTTO INA [DE]


Publication No.: WO2012080329A1  Published: 21/Jun/2012

Title: FORMULATIONS OF N-(3,5-DICHLOROPYRIDIN-4-YL)-[1-(4-FLUOROBENZYL)-7-AZAINDOL-3-YL)]GLYOXYLIC ACID AMIDE

Applicant/Assignee: BIOTIE THERAPIES GMBH

Application No.: WO2011EP72750 (PCT/EP2011/72750)   Filing Date: 14/Dec/2011

Abstract:

The present invention relates to a pharmaceutical composition comprising (i) N-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide (ELB353, Ronomilast), (ii) a binder material and (iii) a carrier material. The invention also relates to a process for preparing the composition. Further, the invention relates to the composition for use particularly in the treatment and/or prophylaxis of chronic obstructive pulmonary disease (COPD).

Priority: US201061424142P Applic. Date: 2010-12-17

Inventor: RUPP ROLAND [DE]; HARTENHAUER HELGE [DE]; HOEFGEN NORBERT [DE]; GASPARIC ANTJE [DE]; DOST RITA [DE]


Publication No.: WO2012080365A1  Published: 21/Jun/2012

Title: TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING AN ACTIVE SUBSTANCE

Applicant/Assignee: ACINO AG

Application No.: WO2011EP72812 (PCT/EP2011/72812)   Filing Date: 14/Dec/2011

Abstract:

The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, said system being suitable for an application period of at least three days, comprising the layers arranged in the following order with respect to each other: a) a cover layer, b) an active substance layer comprising a polymer matrix containing the active substance, c) an adhesive layer comprising a contact adhesive, which consists of a mixture of one or more polyisobutylenes and one or more polybutenes, and d) a pull-off layer.

Priority: EP20100194968 Applic. Date: 2010-12-14

Inventor: SCHROEDER BRITTA [DE]; SCHURAD BJOERN [DE]; HAUSNER HEIKE [DE]


Publication No.: WO2012080399A1  Published: 21/Jun/2012

Title: ZOLPIDEM-BASED ORODISPERSIBLE PHARMACEUTICAL TABLET

Applicant/Assignee: SANOFI

Application No.: WO2011EP72918 (PCT/EP2011/72918)   Filing Date: 15/Dec/2011

Abstract:

The field of the present invention is that of oral pharmaceutical forms for rapid disintegration which make it possible to prevent possible misuse of the Zolpidem present therein. The present invention thus relates to a zolpidem-based orodispersible tablet formulation intended to prevent abuse of use of the tablet at the expense of a third party.

Priority: FR20100060654 Applic. Date: 2010-12-16

Inventor: MARTINEZ ANNICK [FR]; ROUGEOT OLIVIER [FR]; YAGUCHI YOSHIKATSU [FR]


Publication No.: WO2012080408A1  Published: 21/Jun/2012

Title: PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INTENDED TO PREVENT MISUSE

Applicant/Assignee: SANOFI

Application No.: WO2011EP72933 (PCT/EP2011/72933)   Filing Date: 15/Dec/2011

Abstract:

The field of the present invention is that of oral pharmaceutical forms, the composition of which makes it possible to prevent possible misuse of the active principle present therein. The present invention thus relates to a pharmaceutical composition for oral administration intended to prevent abuse of use at the expense of a third party.

Priority: FR20100060655 Applic. Date: 2010-12-16

Inventor: MARTINEZ ANNICK [FR]; ROUGEOT OLIVIER [FR]; YAGUCHI YOSHIKATSU [FR]


Publication No.: WO2012080466A2  Published: 21/Jun/2012

Title: INGENOLS FOR TREATING SEBORRHEIC KERATOSIS

Applicant/Assignee: LEO PHARMA A/S

Application No.: WO2011EP73046 (PCT/EP2011/73046)   Filing Date: 16/Dec/2011

Abstract:

The invention provides ingenol compounds for treating seborrheic keratosis.

Priority: US201061424409P Applic. Date: 2010-12-17

Inventor: ZIBERT JOHN [DK]; SKAK KRESTEN [DK]; BOE INGE [DK]


Publication No.: WO2012080718A1  Published: 21/Jun/2012

Title: NOVEL PHARMACEUTICAL FORMULATION COMPRISING NSAID AND CYCLODEXTRIN

Applicant/Assignee: RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITED

Application No.: WO2011GB52457 (PCT/GB2011/52457)   Filing Date: 12/Dec/2011

Abstract:

The present invention provides a liquid composition in comprising an aqueous solution of an NSAID and one or more cyclodextrins.

Priority: GB20100021267 Applic. Date: 2010-12-15

Inventor: BEECH EDWARD [GB]; RODWELL ALDEN [GB]; SQUIRES MARK [GB]


Publication No.: WO2012080882A1  Published: 21/Jun/2012

Title: SOLID COMPOSITIONS CONTAINING NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, THE PROCESSES FOR THEIR PREPARATION AND THEIR USE.

Applicant/Assignee: ALFA WASSERMANN S.P.A

Application No.: WO2011IB55320 (PCT/IB2011/55320)   Filing Date: 28/Nov/2011

Abstract:

This invention refers to solid compositions for the preparation of oral dosage forms comprising pharmaceutical active ingredients, such as non steroidal anti-inflammatory drug (NSAIDs), in particular, but not exclusively flurbiprofen (FP), processes for their manufacture and their use as medicine. The solid compositions, comprising FP in association with pharmaceutically acceptable excipients, are particularly suitable for the preparation of oral dosage forms, such as for example, lozenges, which are suitable for use in the treatment of inflammation of the oral cavity, being characterized by good tolerability, stability, and palatability.

Priority: IT2010BO00731 Applic. Date: 2010-12-13

Inventor: PAOLA MAFFEI [IT]; MASCIA FEDERICI [IT]; VITTORIA LAURO [IT]; MARCO MASCAGNI [IT]; GIUSEPPE CLAUDIO VISCOMI [IT]


Publication No.: WO2012080915A1  Published: 21/Jun/2012

Title: STERILE INJECTABLE AQUEOUS FORMULATION USED IN OPHTHALMOLOGY

Applicant/Assignee: ANTEIS S.A

Application No.: WO2011IB55549 (PCT/IB2011/55549)   Filing Date: 08/Dec/2011

Abstract:

The subject matter of the present invention is an intraocularly injectable sterile aqueous formulation based on a mixture of hyaluronic acid and alginate, or a salt thereof, used in ophthalmology and having specific viscoelasticity, spreading, covering and ocular tissue adhesion properties and also a high capacity for neutralizing free radicals, said properties enabling said composition to strongly protect the eye tissues.

Priority: FR20100060707 Applic. Date: 2010-12-17

Inventor: GAVARD MOLLIARD SAMUEL [FR]


Publication No.: WO2012080986A1  Published: 21/Jun/2012

Title: PROCESS FOR PREPARING NANOPARTICLES OF TWO POLYAMINO ACIDS OF OPPOSITE CHARGE, ONE OF THE TWO OF WHICH IS IN CHARGE SURPLUS

Applicant/Assignee: FLAMEL TECHNOLOGIES

Application No.: WO2011IB55727 (PCT/IB2011/55727)   Filing Date: 16/Dec/2011

Abstract:

The present invention relates to a novel process for preparing nanoparticles having a diameter of less than or equal to 500 nm, which comprises bringing a solution (1) comprising nanoparticles of a first polyelectrolyte in the charged state, bearing hydrophobic side groups, into contact with (2) at least a second polyelectrolyte which has a polarity opposite to that of the first polyelectrolyte, characterized in that the ratio Z of the number of cationic groups to the number of anionic groups in the mixture of the two polyelectrolytes is between 0.1 and 0.75 or between 1.3 and 2, and the total concentration by weight C of polyelectrolytes is strictly less than 2 mg/g of the mixture.

Priority: US201061424282P Applic. Date: 2010-12-17; FR20100060685 Applic. Date: 2010-12-17

Inventor: DROGOZ ALEXANDRE [FR]; CONSTANCIS ALAIN [FR]


Publication No.: WO2012080987A1  Published: 21/Jun/2012

Title: NANOPARTICLES COMPRISING AT LEAST ONE ACTIVE AGENT AND AT LEAST TWO POLYELECTROLYTES

Applicant/Assignee: FLAMEL TECHNOLOGIES

Application No.: WO2011IB55728 (PCT/IB2011/55728)   Filing Date: 16/Dec/2011

Abstract:

The present invention relates to novel nanoparticles consisting of at least one active agent and at least two polyelectrolytes having opposite polarities, characterised in particular in that at least one of the two polyelectrolytes has hydrophobic lateral groupings and at least one of the two polyelectrolytes has polyalkylene glycol lateral groupings, said nanoparticles having a mean diameter of 10 to 100 nm and including an amount of polyalkylene glycol groupings such that the weight ratio (w PAG) of polyalkylene glycol relative to the total polymer is no lower than 0.05.

Priority: US201061424280P Applic. Date: 2010-12-17; FR20100060684 Applic. Date: 2010-12-17

Inventor: BONNET-GONNET CECILE [FR]; MEYRUEIX REMI [FR]


Publication No.: WO2012082209A1  Published: 21/Jun/2012

Title: PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION

Applicant/Assignee: MERRION RESEARCH III LIMITED

Application No.: WO2011US52963 (PCT/US2011/52963)   Filing Date: 23/Sep/2011

Abstract:

The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from 4 to 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in a subject after oral administration comprising orally administering a pharmaceutical composition as described above.

Priority: US20100423261P Applic. Date: 2010-12-15

Inventor: LEONARD THOMAS W [US]; COUGHLAN DAVID C [IE]; CULLEN ALAN [IE]


Publication No.: WO2012082631A1  Published: 21/Jun/2012

Title: DELIVERY OF FUNCTIONAL COMPOUNDS

Applicant/Assignee: KRAFT FOODS GLOBAL BRANDS LLC

Application No.: WO2011US64438 (PCT/US2011/64438)   Filing Date: 12/Dec/2011

Abstract:

Functional ingredients including a modified portion are microencapsulated in an enteric matrix. The modified functional ingredient portion increases the microencapsulation efficiency and reduces undesired organoleptic properties of the microencapsulated material while providing a desired release rate. The process includes forming an emulsion in water and titrating the emulsion with a precipitating agent to produce a particulate precipitate.

Priority: US20100422439P Applic. Date: 2010-12-13

Inventor: AKASHE AHMAD [US]; WEST LESLIE G [US]; GAONKAR ANILKUMAR GANAPATI [US]; LAWRENCE LES [US]; LOPEZ AMADO R [US]; HAAS GEORGE W [US]; SEBESTA DANA [US]; WANG YAN [US]; ZELLER BARY LYN [US]


Publication No.: WO2012083017A2  Published: 21/Jun/2012

Title: CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF

Applicant/Assignee: CELGENE CORPORATION

Application No.: WO2011US65151 (PCT/US2011/65151)   Filing Date: 15/Dec/2011

Abstract:

Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.

Priority: US20100424003P Applic. Date: 2010-12-16

Inventor: CHEN MING J [US]; HUI HO-WAH [US]; SHEN XIOLE [US]


Publication No.: WO2012083532A1  Published: 28/Jun/2012

Title: METHOD FOR ULTRASOUND CONTROLLED RELEASING MEDICINE-CARRYING CONTRAST MICRO-BUBBLES AND MONITOR-IMAGING THEREOF AND METHOD FOR ESTIMATING DAMAGED QUANTITY OF MICROBUBBLES

Applicant/Assignee: XI'AN JIAOTONG UNIVERSITY

Application No.: WO2010CN80119 (PCT/CN2010/80119)   Filing Date: 22/Dec/2010

Abstract:

A method for ultrasound controlled releasing medicine-carrying contrast micro-bubbles and monitor-imaging thereof and a method for estimating damaged quantity of micro-bubbles. According to the method for ultrasound controlled releasing medicine-carrying micro-bubbles and monitor-imaging thereof, the medicine-carrying contrast micro-bubbles are controlled to locally, point-fixedly and shape-fittingly release on the basis of the present full-digitized ultrasound imaging system, and the micro-bubbles before and after releasing the medicine in the focus region are monitored via monitor-imaging of low-energy encoded excitation, and then the released quantity of the medicine is estimated on the basis of the radio frequency echo data of the monitor-imaging and the change of the concentration of the scattering phonons. According to the method for estimating damage quantity of micro-bubbles, a time-parameter m curve of the region of interest is drawn by imaging the parameter m of Nakagami statistical model, and the decrement of the micro-bubbles is analyzed on the basis of the curve to determine the released quantity of the medicine in the region.

Priority: WO2010CN80119 Applic. Date: 2010-12-22

Inventor: WAN MINGXI [CN]; XU SHANSHAN [CN]; XU ZHI AN [CN]; ZONG YUJIN [CN]


Publication No.: WO2012083801A1  Published: 28/Jun/2012

Title: STREOIDAL ANTI-PROGESTERONE COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF

Applicant/Assignee: REGENEX CORPORATION

Application No.: WO2011CN83853 (PCT/CN2011/83853)   Filing Date: 12/Dec/2011

Abstract:

A streoidal anti-progesterone composition, a preparation method therefor, and a use thereof. The steroidal anti-progesterone composition comprises a fast-release system and a sustained-release adhesion system, wherein the mass ratio of streoidal anti-progesterone in the fast-release system to that in the sustained-release adhesion system is 70:30-80:20, wherein 70% or more of streoidal anti-progesterone in the fast-release system is released

and no more than 30% of streoidal anti-progesterone in the sustained-release adhesion system is released in 45 min. The streoidal anti-progesterone composition overcomes the pH-dependence of dissolution and absorption of anti-progesterone, and improves the bioavailability of anti-progesterone.

Priority: CN20101597343 Applic. Date: 2010-12-20; CN20111030660 Applic. Date: 2011-01-28

Inventor: LU ZHIJUN [CN]; YANG WEI [CN]; DENG ZIJIE [CN]; XIE HENG [CN]; YANG SHUJUAN [CN]; YANG LIWEN [CN]; HUANG FANG [CN]


Publication No.: WO2012084754A2  Published: 28/Jun/2012

Title: PHARMACEUTICAL GLP-1 COMPOSITIONS HAVING AN IMPROVED RELEASE PROFILE

Applicant/Assignee: IPSEN PHARMA S.A.S

Application No.: WO2011EP73156 (PCT/EP2011/73156)   Filing Date: 19/Dec/2011

Abstract:

The invention relates to pharmaceutical compositions containing a peptide analogue of glucagon-like peptide-1 or salts thereof having an improved release profile and to method for preparing such compositions.

Priority: EP20100196161 Applic. Date: 2010-12-21

Inventor: KRIMMER SIEGFRIED [DE]; LINDENBERG MARC [DE]; MIESCH ANNIE [FR]; MUELLER ROBERT [CH]; MUMENTHALER MARCO [CH]


Publication No.: WO2012085160A1  Published: 28/Jun/2012

Title: FORMULATIONS OF ANTIPARASITIC AGENTS FOR TOPICAL ADMINISTRATION TO SWINE

Applicant/Assignee: NORBROOK LABORATORIES LIMITED

Application No.: WO2011EP73696 (PCT/EP2011/73696)   Filing Date: 21/Dec/2011

Abstract:

The present invention relates to an antiparasitic composition for use in the systemic treatment of parasitic infestations in pigs via topical administration, said composition comprising: an antiparasitic agent that comprises a macrocyclic lactone

a penetration enhancer

and a pharmaceutically or veterinarilly acceptable solvent

wherein the penetration enhancer is present in an amount of at least 10% w/v of the composition.

Priority: GB20100021836 Applic. Date: 2010-12-21

Inventor: HILLAN ANDREW [GB]; UMRETHIA MANISH [GB]


Publication No.: WO2012085185A1  Published: 28/Jun/2012

Title: AQUEOUS SOLUTION OF AMBROXOL

Applicant/Assignee: ADVANCE HOLDINGS LIMITED

Application No.: WO2011EP73754 (PCT/EP2011/73754)   Filing Date: 22/Dec/2011

Abstract:

The present invention relates to an aqueous solution comprising an acid addition salt of ambroxol, wherein the ambroxol content is ranging from 0.1% to 7% (w/v), the total content of polyalcohols selected from polyols and polyalkyleneglycols is at least 20% (w/v), the total content of alcohols is lower than 1% (w/v), and said aqueous solution is free of benzoic acid and/or salts thereof with organic or inorganic bases.

Priority: US201061428269P Applic. Date: 2010-12-30; EP20100196711 Applic. Date: 2010-12-23

Inventor: PASSETTI GIANLUIGI [IT]


Publication No.: WO2012085559A1  Published: 28/Jun/2012

Title: ANTIBACTERIAL OR ANTI-ACNE FORMULATIONS CONTAINING USNIC ACID OR AN USNATE AND A METAL SALT

Applicant/Assignee: EVOCUTIS PLC

Application No.: WO2011GB52530 (PCT/GB2011/52530)   Filing Date: 20/Dec/2011

Abstract:

An antibacterial or anti-acne formulation suitable for topical or local application to human skin containing (a) either usnic acid or an usnate and (b) a metal salt selected from copper salts, bismuth salts, and mixtures thereof, wherein if the component (a) is an usnate, the components (a) and (b) are not the same compound.

Priority: GB20100021745 Applic. Date: 2010-12-22

Inventor: EADY ELIZABETH ANNE [GB]; FITZGERALD DANIEL JAMES [GB]


Publication No.: WO2012085609A1  Published: 28/Jun/2012

Title: TREATMENT OF OSTEOARTHRITIS BY CONTINUOUS INTRA-ARTICULAR INJECTION OF ALGINATE GEL

Applicant/Assignee: DEPT. OF PATHOBIOLOGY, DORKOOSH, FARID, ABEDIN

Application No.: WO2010IB03303 (PCT/IB2010/03303)   Filing Date: 20/Dec/2010

Abstract:

The various embodiments herein provide a new method of treatment of osteoarthritis comprising continuously injecting a composition containing a therapeutically effective amount of alginate gel or solution into a joint of a subject in need thereof. The alginate is selected from a group comprising of alginic acid, sodium alginate, potassium alginate, magnesium alginate, calcium alginate and combinations thereof. The alginate gel is injected 3-5 times per week continuously for the atleast six months. The preset amount of the alginate gel to be injected to the subject is 40mg/2ml/syringe depending on the patient's clinical status.

Priority: WO2010IB03303 Applic. Date: 2010-12-20

Inventor: MIRSHAFIEY ABBAS [IR]


Publication No.: WO2012085919A2  Published: 28/Jun/2012

Title: METHOD AND SYSTEM FOR DRUG DELIVERY

Applicant/Assignee: EXONOID MEDICAL DEVICES LTD

Application No.: WO2011IL50071 (PCT/IL2011/50071)   Filing Date: 22/Dec/2011

Abstract:

There is provided in accordance with an exemplary embodiment of the invention, a device and a method for controlled extraction of at least one active substance from at least one type of plant matter by application of heat, the device comprising : a heating element adapted to apply heat to an area of the plant matter to extract the substance

and a mechanism adapted for moving the plant matter relative to the heating element. Optionally, the active substance is a restricted substance. There is also provided in accordance with an exemplary embodiment of the invention, a method of monitoring and controlling inhalation of a restricted substance. There is provided in accordance with an exemplary embodiment of the invention, a method of manufacturing a tape of plant matter comprising an active substance.

Priority: US201061425962P Applic. Date: 2010-12-22

Inventor: DAVIDSON PERRY [IL]; SCHORR AARON [IL]; HOLTZ ARIE [IL]; PONG WILL [IL]


Publication No.: WO2012087326A1  Published: 28/Jun/2012

Title: FLUID COMPOSITIONS COMPRISING A STRUCTURING AGENT

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: WO2010US61960 (PCT/US2010/61960)   Filing Date: 23/Dec/2010

Abstract:

Described herein are oral fluid compositions comprising one or more structuring agents, and methods of making and using the same.

Priority: WO2010US61960 Applic. Date: 2010-12-23

Inventor: PIMENTA PALOMA [US]; NESTA JASON [US]


Publication No.: WO2012087517A2  Published: 28/Jun/2012

Title: COSMETIC FILMS

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: WO2011US62622 (PCT/US2011/62622)   Filing Date: 30/Nov/2011

Abstract:

Personal care products, including cosmetics, are provided as solid, water-soluble polymeric films which adhere to a human integument when wetted. The invention also relates to such films having plural laminated layers, at least two of which possess different cosmetic or therapeutic characteristics.

Priority: US201061426140P Applic. Date: 2010-12-22

Inventor: ZHENG TAO [US]; FLEISSMAN LEONA GIAT [US]; WEI XIAOLAN [US]


Publication No.: WO2012087606A1  Published: 28/Jun/2012

Title: A DRUG ELUTING PATCH FOR THE TREATMENT OF LOCALIZED TISSUE DISEASE OR DEFECT

Applicant/Assignee: SAINT JOSEPH'S TRANSLATIONAL RESEARCH INSTITUTE, INC

Application No.: WO2011US64115 (PCT/US2011/64115)   Filing Date: 09/Dec/2011

Abstract:

A polymeric matrix for delivery of an HMG CoA reductase inhibitor such as a statin to tissue such as cardiac tissue in need thereof for the treatment or prevention of a disease or defect such as atrial fibrillation has been developed. In the preferred embodiment, a statin is delivered by means of a patch sutured to cardiac tissue at the time of cardiothoracic surgery. In the most preferred embodiment, the patch is a biodegradable material providing controlled or sustained release over a prolonged period of time, such as a week. Suitable materials include extracellular matrix, or other biodegradable hydrogels or polymeric materials providing sustained or controlled release of statin at the site of application.

Priority: US201061425172P Applic. Date: 2010-12-20

Inventor: SINGH JAIPAL [US]; CHRONOS NICOLAS [US]


Publication No.: WO2012087669A1  Published: 28/Jun/2012

Title: PILL CATCHERS

Applicant/Assignee: ETHICON ENDO-SURGERY, INC

Application No.: WO2011US64634 (PCT/US2011/64634)   Filing Date: 13/Dec/2011

Abstract:

Devices are provided for the controlled delivery of a therapeutic to a targeted location within a body. More particularly, devices are provided for controlling the rate of passage of an orally administered pill through a body, as well as for controlling the delivery of a therapeutic within the pill at a specific location within the body. Various types of devices, generally referred to herein as "catchers," are provided that can actively catch a pill as it passes through a body. The catcher can hold the pill at a specific location within the body until a predetermined event occurs, such as partial or complete administration of a therapeutic within the pill. The catcher can then release the pill upon command and/or upon the occurrence of the predetermined event to allow the pill to pass out of the body. In other embodiments, various types of pills are provided that can actively engage a catcher and remain engaged with the catcher until a predetermined event occurs.

Priority: US2010-976761 Applic. Date: 2010-12-22

Inventor: ORTIZ MARK S [US]; HESS CHRISTOPHER J [US]; HARRIS JASON L [US]; VOEGELE JAMES W [US]; ZEINER MARK S [US]; OVERMYER MARK D [US]; KRAIMER JOSEPH BERNARD [US]; SHIMIZU JEFF [US]; CRIVELLI ROCCO [CH]; TARDY YANIK [CH]; UTARD THIERRY [CH]; BURGER JUERGEN [CH]; BORK TORALF [CH]; PFLEIDERER MARTIN [CH]; CHOSSAT OLIVIER [FR]


Publication No.: WO2012087927A1  Published: 28/Jun/2012

Title: NOVEL PREPARATION OF AN ENTERIC RELEASE SYSTEM

Applicant/Assignee: KRAFT FOODS GLOBAL BRANDS LLC

Application No.: WO2011US65828 (PCT/US2011/65828)   Filing Date: 19/Dec/2011

Abstract:

Hydrophobic liquids are microencapsulated by an enteric matrix in an environment substantially free of organic solvents. The process includes forming an emulsion of the enteric material and hydrophobic liquid in water, titrating the emulsion with an acid to form a particulate precipitate and optionally coating the particulate with a combination of enteric material and plasticizer.

Priority: US2010-976614 Applic. Date: 2010-12-22

Inventor: AKASHE AHMAD [US]; GAONKAR ANILKUMAR GANAPATI [US]; LAWRENCE LES [US]; LOPEZ AMADO R [US]; HAAS GEORGE W [US]; SEBESTA DANA [US]; WANG YAN [US]


Publication No.: WO2012088306A2  Published: 28/Jun/2012

Title: TWO-PIECE INJECTABLE DRUG DELIVERY DEVICE WITH HEAT-CURED SEAL

Applicant/Assignee: PSIVIDA US, INC

Application No.: WO2011US66573 (PCT/US2011/66573)   Filing Date: 21/Dec/2011

Abstract:

The invention provides a drug delivery device for latanoprost or latanoprost acid. The device has a core of latanoprost or latanoprost acid which is surrounded by an internal and external sheath. The external sheath has a first cap that is permeable to latanoprost or latanoprost acid. The first cap may comprise polyvinyl alcohol (PVA), and the PVA may be heat cured. In certain aspects, there are one or more additional caps on the ends of the sheaths formed from one or more polymers. In certain aspects, one or more portions of the drug delivery device is substantially impermeable to latanoprost or latanoprost acid. In certain aspects, the latanoprost or latanoprost acid elutes through the first cap into a biological environment. The invention further provides methods for manufacturing the drug delivery device.

Priority: US201061425925P Applic. Date: 2010-12-22

Inventor: NAZZARO MARTIN [US]; YORK JOSH [US]; ASHTON PAUL [US]


Publication No.: WO2012089115A1  Published: 05/Jul/2012

Title: MOISTURE-RETAINING CHINESE HERBAL MEDICINE COMPOSITION AND PREPARATION METHOD AND USE THEREOF

Applicant/Assignee: SHANGHAI JAHWA UNITED CO., LTD

Application No.: WO2011CN84772 (PCT/CN2011/84772)   Filing Date: 27/Dec/2011

Abstract:

Disclosed is a Chinese herbal medicine composition having a moisture-retaining effect, containing water and/or solvent extracts of raw materials in the following parts by weight: 20-50 Asparagus cochinchinensis, 20-50 rehmannia root, 10-40 Dendrobium nobile, and 10-40 Dioscorea opposita. The composition can assist skin against drying in a dry environment, and prevent moisture loss.

Priority: CN20101621928 Applic. Date: 2010-12-31

Inventor: CHENG KANG [CN]; CHEN MO [CN]; ZHU LE [CN]; XIONG WEIGUO [CN]; ZHAO YA [CN]; FANG CHENG [CN]; LV LUO [CN]; WEI SHAOMIN [CN]


Publication No.: WO2012089175A2  Published: 05/Jul/2012

Title: TRADITIONAL CHINESE MEDICINAL TEA MADE BY MICROBIAL FERMENTATION

Applicant/Assignee: WINRICH ASIA GROUP LIMITED

Application No.: WO2012CN71223 (PCT/CN2012/71223)   Filing Date: 16/Feb/2012

Abstract:

The invention relates to a kind of Traditional Chinese medicinal tea made by microbial fermentation, which belongs to the technical field of Traditional Chinese medicine, it is characterized by:using Traditional Chinese medicine extract which has bacteriostasic activity as the fermentation broth and fermenting, then preparing it into tea which can be decocted, or compressing it into brick tea which can be brewed, or preparing it into tea bag

said bacteriostasis Traditional Chinese medicine refers to the Traditional Chinese medicine which is found have bacteriostasic activity,such as Bulbus Allii, Sucus Zingberis, Fructus Zanthoxyli, Radix Curcumae, Radix Salviae Miltiorrhizae, Flos Lonicerae, Radix Isatidis, Folium Isatidis, Galla Chinensis, Resina Toxicodendri, Rhizoma Polygoni Cuspidati, Flos Magnoliae Officinalis, Semen Hydnocarpi, Rhizoma Coptidis, Radix Sophorae Flavescentis, Fructus Forsythiae, Radix Et Rhizoma Rhei, Rehmannia Glutinosa Libosch, Rhizoma Anemarrhenae, Bulbus Allii Macrostemonis, etc

the Traditional Chinese medicinal tea can contain or not contain tea in it, and also can have other Traditional Chinese medicines, it can be decocted and brewed,said Traditional Chinese medicinal tea has high compliance and availability

it has the effect of dispelling wind, relieving exterior syndrome, removing dampness, and can be used to treat seasonal cold, heatstroke, fever, abdominal or body ache, vomiting or diarrhea.

Priority: CN20101618059 Applic. Date: 2010-12-31

Inventor: KE SHUQUAN [CN]; KE SHAOBIN [CN]


Publication No.: WO2012089537A1  Published: 05/Jul/2012

Title: HYALURONIC ACID COMPOSITIONS STABILISED AGAINST THE DEGRADING EFFECT OF HEAT OR ENZYMES

Applicant/Assignee: ALTERGON S.A, INDENA S.P.A

Application No.: WO2011EP73079 (PCT/EP2011/73079)   Filing Date: 16/Dec/2011

Abstract:

The invention relates to the use of an additive to stabilise hyaluronic acid formulated in an aqueous composition against the degrading effect of heat or of enzymes such as hyaluronidase, characterised in that said additive comprises one or more polysaccharides having a molecular weight equal to or greater than 20,000 daltons and solubility in water at least equal to or greater than 1 g/l, the total concentration of said polysaccharide(s) and hyaluronic acid in the composition giving it a viscosity of at least 500 cP, which is particularly suitable for intra-articular, intradermal or intraocular administration to humans or animals.

Priority: IT2010MI02404 Applic. Date: 2010-12-27

Inventor: VERNASCA CARLO [CH]; GIORI ANDREA MARIA [IT]; TOGNI STEFANO [IT]


Publication No.: WO2012089738A1  Published: 05/Jul/2012

Title: A COMBINATION OF AN OPIOID AGONIST AND AN OPIOID ANTAGONIST IN THE TREATMENT OF PARKINSON'S DISEASE

Applicant/Assignee: EURO-CELTIQUE S.A

Application No.: WO2011EP74103 (PCT/EP2011/74103)   Filing Date: 27/Dec/2011

Abstract:

The present invention provides a pharmaceutical dosage form comprising an opioid agonist and an opioid antagonist for use in the treatment of Parkinson's disease. The present invention also refers to the use of an opioid agonist and an opioid antagonist in such a dosage form.

Priority: EP20100197210 Applic. Date: 2010-12-28

Inventor: HOPP MICHAEL [DE]; TRENKWALDER CLAUDIA [DE]


Publication No.: WO2012089759A1  Published: 05/Jul/2012

Title: FORMULATIONS OF CETYL MYRISTATE AND/OR CETYL PALMITATE PARTICLES

Applicant/Assignee: DEVA HOLDING ANONIM SIRKETI

Application No.: WO2011EP74139 (PCT/EP2011/74139)   Filing Date: 28/Dec/2011

Abstract:

This invention is related to spray drying or melt granulation or dissolving or dispersing treatment of cetyl myristate or cetyl palmitate or combination of cetyl myristate and cetyl palmitate.

Priority: EP20100197295 Applic. Date: 2010-12-29

Inventor: HAAS PHILIPP DANIEL [TR]; FIRAT OMER FARUK [TR]; KANDEMIR LEVENT [TR]; KOC FIKRET [TR]; SIVASLIGIL RAMAZAN [TR]


Publication No.: WO2012089762A1  Published: 05/Jul/2012

Title: CETYL MYRISTATE AND/OR CETYL PALMITATE GRANULES HAVING HIGH BULK DENSITY

Applicant/Assignee: DEVA HOLDING ANONIM SIRKETI

Application No.: WO2011EP74142 (PCT/EP2011/74142)   Filing Date: 28/Dec/2011

Abstract:

This invention is related to a preparation method of cetyl myristate or cetyl palmitate or combination of cetyl myristate and cetyl palmitate by using dry granulation techniques wherein obtained granules having a bulk density equal or greater than 0.30 g/mL.

Priority: EP20100197298 Applic. Date: 2010-12-29

Inventor: HAAS PHILIPP DANIEL [TR]; FIRAT OMER FARUK [TR]; KANDEMIR LEVENT [TR]; KOC FIKRET [TR]; SIVASLIGIL RAMAZAN [TR]


Publication No.: WO2012089763A1  Published: 05/Jul/2012

Title: SEPARATED FORMULATIONS AND GRANULATIONS OF CETYL MYRISTATE AND CETYL PALMITATE COMBINATION

Applicant/Assignee: DEVA HOLDING ANONIM SIRKETI

Application No.: WO2011EP74143 (PCT/EP2011/74143)   Filing Date: 28/Dec/2011

Abstract:

This invention is related to bilayer tablet, inlay tablet, tablet in tablet, tablet in capsule, capsule in capsule, separated granulation and kit of combination of cetyl myristate and cetyl palmitate.

Priority: EP20100197297 Applic. Date: 2010-12-29

Inventor: HAAS PHILIPP DANIEL [TR]; FIRAT OMER FARUK [TR]; KANDEMIR LEVENT [TR]; KOC FIKRET [TR]; SIVASLIGIL RAMAZAN [TR]


Publication No.: WO2012089764A1  Published: 05/Jul/2012

Title: A PREPARATION METHOD FOR SUSPENSION OF CETYL MYRISTATE AND/OR CETYL PALMITATE

Applicant/Assignee: DEVA HOLDING ANONIM SIRKETI

Application No.: WO2011EP74145 (PCT/EP2011/74145)   Filing Date: 28/Dec/2011

Abstract:

This invention is related to a preparing method for pharmaceutical and/or dietary supplement suspension formulations of cetyl myristate or cetyl palmitate or combination of cetyl myristate and cetyl palmitate.

Priority: EP20100197296 Applic. Date: 2010-12-29

Inventor: HAAS PHILIPP DANIEL [TR]; FIRAT OMER FARUK [TR]; KANDEMIR LEVENT [TR]; KOC FIKRET [TR]; SIVASLIGIL RAMAZAN [TR]


Publication No.: WO2012089765A1  Published: 05/Jul/2012

Title: SUSPENSION FORMULATIONS OF CETYL MYRISTATE AND/OR CETYL PALMITATE

Applicant/Assignee: DEVA HOLDING ANONIM SIRKETI

Application No.: WO2011EP74146 (PCT/EP2011/74146)   Filing Date: 28/Dec/2011

Abstract:

This invention is related to pharmaceutical or dietary supplement suspension formulations of cetylated fatty acids, especially cetyl myristate or cetyl palmitate or combination of cetyl myristate and cetyl palmitate.

Priority: EP20100197294 Applic. Date: 2010-12-29

Inventor: HAAS PHILIPP DANIEL [TR]; FIRAT OMER FARUK [TR]; KANDEMIR LEVENT [TR]; KOC FIKRET [TR]; SIVASLIGIL RAMAZAN [TR]


Publication No.: WO2012091153A2  Published: 05/Jul/2012

Title: ORALLY DISINTEGRATING TABLET

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: WO2011JP80568 (PCT/JP2011/80568)   Filing Date: 26/Dec/2011

Abstract:

Provided is an orally disintegrating tablet obtained by tableting fine granules showing controlled release of lansoprazole and an additive, which is capable of suppressing breakage of the fine granules during tableting, and can control the release of lansoprazole for a long time, and can maintain a therapeutically effective concentration for a prolonged time, and shows superior disintegration property in the oral cavity.

An orally disintegrating tablet containing (i) fine granules showing controlled release of a pharmaceutically active ingredient, which contains fine granules containing a pharmaceutically active ingredient and a coating layer containing a methacrylic acid/methyl acrylate/methyl methacrylate copolymer, wherein the fine granules containing a pharmaceutically active ingredient are coated with more than 80 wt% and not more than 300 wt% of the copolymer, and (ii) fine granules showing controlled release of a pharmaceutically active ingredient, which contains the pharmaceutically active ingredient and a coating layer comprising (a) an ethyl acrylate/methyl methacrylate copolymer, and (b) one or more kinds of polymers selected from the group consisting of methacrylic acid/ethyl acrylate copolymer, hypromellose phthalate, carboxymethylethylcellulose, polyvinyl acetate phthalate,

hydroxypropyl methylcellulose acetate succinate and cellulose acetate phthalate, wherein the fine granules (i) and fine granules (ii) have an average particle size of not more than 500 micrometer, and the pharmaceutically active ingredient is lansoprazole or an optically active form thereof or a salt thereof.

Priority: US201061427384P Applic. Date: 2010-12-27

Inventor: ISHII SHIRO [JP]; EBISAWA YUTAKA [JP]; OKABE TAKAYUKI [JP]


Publication No.: WO2012091680A1  Published: 05/Jul/2012

Title: A DEVICE FOR CONTROLLED RELEASE OF A BIOACTIVE AGENT

Applicant/Assignee: NANYANG TECHNOLOGICAL UNIVERSITY

Application No.: WO2011SG00457 (PCT/SG2011/00457)   Filing Date: 29/Dec/2011

Abstract:

Present invention relates to a device for controlled release of a bioactive agent. The device comprises a thin film located on the surface of the device, wherein said thin film comprises a bioactive agent-containing layer comprising a polymeric matrix and at least one bioactive agent.

Priority: US201061428514P Applic. Date: 2010-12-30; US201061428531P Applic. Date: 2010-12-30

Inventor: STEELE TERRY W J [SG]; LOO SAY CHYE JOACHIM [SG]; VENKATRAMAN SUBRAMANIAN [SG]; BOEY YIN CHIANG FREDDY [SG]


Publication No.: WO2012091748A2  Published: 05/Jul/2012

Title: THERAPEUTIC AGENT RESERVOIR DELIVERY SYSTEM

Applicant/Assignee: MEDTRONIC, INC

Application No.: WO2011US34609 (PCT/US2011/34609)   Filing Date: 29/Apr/2011

Abstract:

A therapeutic agent reservoir comprises a reservoir body comprising a polymer and a therapeutic agent mixed within the polymer, and an outer coating enclosing the reservoir body, wherein at least a portion of the outer coating comprises a rate-controlling membrane configured to provide a predetermined release rate of the therapeutic agent through the rate-controlling membrane.

Priority: US2010-979580 Applic. Date: 2010-12-28

Inventor: SEILER PETER M [US]; COBIAN KENNETH E [US]; GALLAGHER GENEVIEVE L [US]; YANG ZHONGPING C [US]


Publication No.: WO2012092283A1  Published: 05/Jul/2012

Title: DRUG DELIVERY DISPERSION AND FILM FORMED THEREFROM

Applicant/Assignee: DOW CORNING CORPORATION, DOW CORNING FRANCE SAS

Application No.: WO2011US67400 (PCT/US2011/67400)   Filing Date: 27/Dec/2011

Abstract:

An active agent delivery dispersion includes water, 1 to 98 weight percent of a plurality of encapsulated particles dispersed in the water, and 0.1 to 20 weight percent of an active agent, each based on a total weight of the dispersion. The active agent is dispersed in the water independently from the plurality of encapsulated particles. Each of the particles includes a core and a layer including a silica disposed about the core. The plurality includes first and second populations of encapsulated particles. The core of the first population includes a first organopolysiloxane having at least two silicon-bonded alkenyl groups per molecule and a hydrosilylation catalyst. The core of the second population includes an organohydrogensiloxane having an average of greater than two silicon bonded hydrogen atoms per molecule and a second organopolysiloxane having at least two silicon-bonded alkenyl groups per molecule.

Priority: EP20100306521 Applic. Date: 2010-12-27

Inventor: CAPRASSE VIRGINIE [BE]; GALEONE FABRIZIO S [BE]; MARTEAUX LEON ANDRE [BE]; SIEG ANKE [BE]; THOMAS XAVIER JEAN-PAUL [FR]


Publication No.: WO2012092421A2  Published: 05/Jul/2012

Title: COMPOSITION FOR INTRAVASCULAR DELIVERY OF THERAPEUTIC COMPOSITION

Applicant/Assignee: SURMODICS, INC

Application No.: WO2011US67717 (PCT/US2011/67717)   Filing Date: 29/Dec/2011

Abstract:

The present invention relates to a pharmaceutical composition for intravascular delivery of a therapeutic agent, such as paclitaxel, rapamycin, or an analog thereof. The composition includes the therapeutic agent and a biocompatible solvent, such as glycofurol. The composition can aid tissue penetration by the therapeutic agent. A catheter assembly that protects the pharmaceutical composition from the surroundings can be used for its intravascular delivery.

Priority: US201061428397P Applic. Date: 2010-12-30

Inventor: CHAPPA RALPH A [US]


Publication No.: WO2012092490A1  Published: 05/Jul/2012

Title: DIAGNOSIS OF PROSTATE CANCER

Applicant/Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED

Application No.: WO2011US67880 (PCT/US2011/67880)   Filing Date: 29/Dec/2011

Abstract:

The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual

(b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer

and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.

Priority: US201061428750P Applic. Date: 2010-12-30

Inventor: SANDERS HEATHER R [US]


Publication No.: WO2012092718A1  Published: 12/Jul/2012

Title: PHOTO-RESPONSIVE SUPRAMOLECULAR HYDROGELS

Applicant/Assignee: NANJING UNIVERSITY

Application No.: WO2011CN70084 (PCT/CN2011/70084)   Filing Date: 07/Jan/2011

Abstract:

Compounds of the formula (I) are provided, wherein the stereochemical configuration of the double bond "a" is cis-or trans-, Ak is an alkylenyl, and R is a series of two or more naturally occurring or synthetic amino acid residues. The compounds can form photo-responsive hydrogels.

Priority: WO2011CN70084 Applic. Date: 2011-01-07

Inventor: ZHANG YAN [CN]


Publication No.: WO2012092990A2  Published: 12/Jul/2012

Title: MEDICAL PRODUCT FOR IMPROVING THE ABILITY OF A MAMMAL TO CONCEIVE

Applicant/Assignee:

Application No.: WO2011EP68762 (PCT/EP2011/68762)   Filing Date: 26/Oct/2011

Abstract:

The present invention relates to a composition comprising the following individual constituents: 25% to 75% by weight of glycerol, 0.05% to 30% by weight of alkali metal carbonate, alkali metal hydrogencarbonate or a mixture thereof, the composition preferably having a pH in the range from 9.0 to 9.5. The present invention further relates to a vaginal pessary or a vaginal gel for enhancing the capacity of a mammal, including humans, to conceive, and also to the use of an alkali metal carbonate, an alkali metal hydrogencarbonate or a mixture thereof for producing a medicinal product for enhancing the capacity of a mammal, including humans, to conceive.

Priority: DE201110007956 Applic. Date: 2011-01-05

Inventor: WENSKE UDO [DE]; SCHMELZ ULRICH [DE]


Publication No.: WO2012093117A1  Published: 12/Jul/2012

Title: METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATORY DISEASES

Applicant/Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Application No.: WO2012EP50049 (PCT/EP2012/50049)   Filing Date: 03/Jan/2012

Abstract:

The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease.

Priority: EP20110305007 Applic. Date: 2011-01-03

Inventor: BEHAR-COHEN FRANCINE [FR]; BOUSQUET ELODIE [FR]


Publication No.: WO2012093171A1  Published: 12/Jul/2012

Title: METHOD FOR PREPARING AQUEOUS PHARMACEUTICAL SUSPENSIONS INCLUDING A DRUG THAT IS EFFECTIVE IN TREATING RHINITIS

Applicant/Assignee: SUBSTIPHARM DEVELOPPEMENT

Application No.: WO2012EP50189 (PCT/EP2012/50189)   Filing Date: 06/Jan/2012

Abstract:

The present invention relates to an industrial method for preparing an aqueous suspension of an anti-inflammatory steroidal agent including a dispersant, a suspending agent, and one or more carriers selected from within the group consisting of antimicrobial agents, chelating agents, iso-osmotic agents, antioxidant agents, and the mixtures thereof, characterized in that it includes the following consecutive steps: a) preparing, in a reactor (1), a dispersion including water, said one or more carriers, the dispersant which is a hydrophilic non-ionic surfactant, and the anti-inflammatory steroidal agent in the form of particles

b) adding, to the dispersion obtained as a result of step a) and in said reactor (1), the suspension agent as is

and c) if necessary, diluting by adding water into said reactor (1), and/or adjusting the pH of said suspension obtained as a result of step b), and recovering the aqueous suspension. The anti-inflammatory steroidal agent is advantageously selected from within the group consisting of triamcinolone acetonide and mometasone furuoate monohydrate, and is preferably triamcinolone acetonide.

Priority: FR20110050104 Applic. Date: 2011-01-06

Inventor: ANDRIEUX FLORENCE [FR]; TERRASSIN LAURENT [FR]


Publication No.: WO2012093252A1  Published: 12/Jul/2012

Title: PHARMACEUTICAL COMPOSITION

Applicant/Assignee: CIPLA LIMITED, TURNER, CRAIG ROBERT

Application No.: WO2012GB00011 (PCT/GB2012/00011)   Filing Date: 06/Jan/2012

Abstract:

The present invention relates to a pharmaceutical composition comprising an inhaled corticosteroid and an anticholinergic. In particular, to a pharmaceutical composition comprising tiotropium bromide and fluticasone furoate. The invention also relates to a process for preparing the pharmaceutical composition, therapeutic uses thereof in the treatment and / or prevention of respiratory, inflammatory or obstructive airway disease.

Priority: IN2011MU00053 Applic. Date: 2011-01-06

Inventor: PURANDARE SHRINIVAS MADHUKAR [IN]; MALHOTRA GEENA [IN]


Publication No.: WO2012093404A2  Published: 12/Jul/2012

Title: PARENTERAL FORMULATIONS OF LEVOSIMENDAN

Applicant/Assignee: GUFIC BIOSCIENCES LIMITED

Application No.: WO2011IN00893 (PCT/IN2011/00893)   Filing Date: 26/Dec/2011

Abstract:

The present invention discloses an alcohol and acid free pharmaceutical composition for parental administration comprising

(i) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient

(ii) 10% solution of Kollidone PF- 12 in aqueous solution as a solubilizing agent

and (iii) pharmaceutically acceptable alkalinizing or buffering agent

wherein said composition is stable at a pH in the range of 6-8.

Priority: IN2011MU00011 Applic. Date: 2011-01-03

Inventor: DAVE MAFATIAL TRIBHOVANDAS [IN]; CHOKSI JAYESH PANALAL [IN]; CHOKSI PRANAV JAYESCH [IN]


Publication No.: WO2012093971A2  Published: 12/Jul/2012

Title: EFFERVESCENT COMPOSITIONS COMPRISING AMLODIPINE

Applicant/Assignee:

Application No.: WO2012TR00002 (PCT/TR2012/00002)   Filing Date: 06/Jan/2012

Abstract:

The present invention relates to easy-to-use effervescent formulations with improved stability comprising amlodipine or a pharmaceutically acceptable derivative thereof and use of these formulations in treatment of hypertension.

Priority: TR20110000152 Applic. Date: 2011-01-06

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2012093972A1  Published: 12/Jul/2012

Title: WATER SOLUBLE DOSAGE FORMS

Applicant/Assignee:

Application No.: WO2012TR00003 (PCT/TR2012/00003)   Filing Date: 06/Jan/2012

Abstract:

The present invention relates to effervescent pharmaceutical formulations comprising acarbose and use of these compositions in diabetes, adiposity and hyperlipoidemia.

Priority: TR20110000150 Applic. Date: 2011-01-06

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2012094020A1  Published: 12/Jul/2012

Title: METHODS AND COMPOSITIONS FOR DELIVERY OF TAXANES IN STABLE OIL-IN-WATER EMULSIONS

Applicant/Assignee: INNOPHARMA, INC

Application No.: WO2011US20575 (PCT/US2011/20575)   Filing Date: 07/Jan/2011

Abstract:

The present invention provides methods and compositions for delivery of taxanes in stable oil-in-water emulsion. The inventive emulsion formulation includes an oil phase, aqueous and emulsifier phases. The oil portion includes all or substantial amount of taxane, vegetable oil and medium chain triglycerides

aqueous phase includes an emulsion stabilizer

emulsifier phase reduces the surface tension between oil and aqueous phases to produce a stable oil-in-water emulsion. The inventive compositions produce minimal side effects upon administration.

Priority: US20100293195P Applic. Date: 2010-01-07

Inventor: DESU HARI [IN]; PATEL KANAIYALAL [US]; PEJAVER SATISH [US]; PURI NAVNEET [US]


Publication No.: WO2012094833A1  Published: 19/Jul/2012

Title: PETROLEUM ETHER EXTRACT OF TRADITIONAL CHINESE MEDICINE FOR PREVENTION AND TREATMENT OF SUGAR AND LIPID METABOLISM DISORDERS AND PREPARATION METHOD THEREOF

Applicant/Assignee: GUANGDONG PHARMACEUTICAL UNIVERSITY

Application No.: WO2011CN70317 (PCT/CN2011/70317)   Filing Date: 17/Jan/2011

Abstract:

The petroleum ether extract of traditional Chinese medicine for the prevention and treatment of sugar and lipid metabolism disorders, wherein the active ingredients of the extract are composed of 1-cerotol, ss-sitosterol, n-hexacosanoic acid, atractylenolide III, oleanolic acid, berberine, jateorrhizine, salvianolic acid B, cyclotetracosane, 9,12-octadecadienoic acid, 5,7-dimethoxycoumarin, ginsenoside Rb1. The preparative method comprises extracting crude drug Radix Salviae Miltiorrhizae, Fructus Ligustri Lucidi, Rhizoma Coptidis, Herba Cirsii Japonici, Cortex Eucommiae, Rhizoma Atractylodis Macrocephalae, Radix Notoginseng and Fructus Citri Sarcodactylis with C1-3 alcohol and/or water, combining total extracts, extracting the total extracts with petroleum ether to obtain the petroleum ether extract.

Priority: CN20111007864 Applic. Date: 2011-01-14

Inventor: GUO JIAO [CN]; BEI WEIJIAN [CN]


Publication No.: WO2012095500A2  Published: 19/Jul/2012

Title: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES, CANCER, OR SKIN DISEASES BY TOPICAL ADMINISTRATION

Applicant/Assignee: DAFRA PHARMA RESEARCH&DEVELOPMENT BVBA

Application No.: WO2012EP50456 (PCT/EP2012/50456)   Filing Date: 12/Jan/2012

Abstract:

The present invention relates to pharmaceutical compositions for the treatment of parasitic diseases, cancer, or skin diseases by topical administration and especially ointments for the treatment of leishmaniasis. The present invention further relates to the use of the present ointments for the treatment of parasitic diseases, cancer, or skin diseases and especially ointments for the treatment of leishmaniasis in both humans and animals. Specifically, the present invention relates to pharmaceutical compositions such as ointments and cremes for the treatment of parasitic diseases, cancer, or skin diseases by topical administration comprising 0.1 to 20 weight%, preferably 0.1 to 10 weight%, more preferably 0.1 to 7 weight%, most preferably 0.5 to 5 weight%, of the pharmaceutical composition oleyl phosphocholine as an active ingredient.

Priority: WO2011EP50442 Applic. Date: 2011-01-14

Inventor: JANSEN FRANS HERWIG [BE]; FORTIN ANNIE MARIE [CA]


Publication No.: WO2012095523A1  Published: 19/Jul/2012

Title: ANALGESIC COMPOSITION FOR TRANSBUCCAL ADMINISTRATION

Applicant/Assignee: THERALPHA

Application No.: WO2012EP50501 (PCT/EP2012/50501)   Filing Date: 13/Jan/2012

Abstract:

The present invention relates to a pharmaceutical composition comprising a peptide of 5 to 50 amino acids which comprises the amino acid sequence NPFPTX1X2KRX3X4 (SEQ ID NO: 2) wherein X1, X2, X3, and X4 may be the same or different and each is an amino acid residue, wherein said composition is in a form suitable for a transbuccal administration and use thereof for preventing or treating pain.

Priority: EP20110305033 Applic. Date: 2011-01-13; US201113006119 Applic. Date: 2011-01-13

Inventor: LAZDUNSKI MICHEL [FR]


Publication No.: WO2012095536A1  Published: 19/Jul/2012

Title: IMPLANT COMPRISING A CORE AND A TUBE ENCASING THE CORE

Applicant/Assignee: UNIVERSITE CATHOLIQUE DE LOUVAIN, UNIVERSITE DE LIEGE

Application No.: WO2012EP50581 (PCT/EP2012/50581)   Filing Date: 16/Jan/2012

Abstract:

The present invention relates to an implant comprising: - a core material comprising polydimethylsiloxane or at least one hydrogel polymer

- a tube encasing said core material comprising an ethylene vinyl acetate polymer or at least one hydrogel polymer

- a sealant for closure of the open ends of said tube comprising polydimethylsiloxane or a mono-, di-, or triacetoxy derivative thereof, or at least one hydrogel polymer

and - at least one active ingredient

wherein said at least one active ingredient is selected from the group comprising celecoxib, sulindac, tamoxifen, oestrogen, oestradiol, ethinyl oestradiol, mestranol, dienogest, norgestrel, levonorgestrel, desogestrel, norgestimate, ethynodiol diacetate, leuprorelin, buserelin, gonrelin, triptorelin, nafarelin, deslorelin, histrelin, and supprelin

and with the proviso that when the sealant is said at least one hydrogelpolymer, the core material comprises polydimethylsiloxane. Furthermore, the invention relates to an implant for use as a medicament. In particular, the invention relates to an implant for use in the treatment of endometriosis.

Priority: EP20110151024 Applic. Date: 2011-01-14

Inventor: DONNEZ JACQUES [BE]; VAN LANGENDONKT ANNE [BE]; DEFRERE SYLVIE [BE]; FOIDART JEAN-MICHEL [BE]; JEROME CHRISTINE [BE]; EVRARD BRIGITTE [BE]; RIVA RAPHAEL [BE]; KRIER FABRICE [BE]; MESTDAGT MELANIE [BE]


Publication No.: WO2012095877A1  Published: 19/Jul/2012

Title: CORNEAL DELIVERY OF CROSS-LINKING AGENTS BY IONTOPHORESIS FOR THE TREATMENT OF KERATOCONUS AND RELATED OPHTHALMIC COMPOSITIONS

Applicant/Assignee: SOOFT ITALIA SPA

Application No.: WO2011IT00010 (PCT/IT2011/00010)   Filing Date: 12/Jan/2011

Abstract:

The present invention relates to the use of iontophoresis to deliver ophthalmic compositions (in particular. collyriums) preferably containing riboflavin, or other cross-linking agents, designed to imbibe the corneal stroma in the practice of the corneal collagen cross-linking (CXL) for the keratoconus treatment, and also relates to the corresponding ophthalmic compositions adapted to be administrated by iontophoresis in the treatment of keratoconus by corneal collagen cross-linking. According to the invention it is provided an ophthalmic composition for the treatment of keratoconus by corneal iontophoresis characterized by the fact to comprise cross-linking agents having buffering properties and whose initial pH value is comprised between 5 and 6, and/or bio-enhancers, and/or photo- enhancers.

Priority: WO2011IT00010 Applic. Date: 2011-01-12

Inventor: FOSCHINI FULVIO [IT]; ROY PIERRE [FR]; STAGNI EDOARDO [IT]; CAVALLO GIOVANNI [IT]; LUCIANI GIULIO [IT]


Publication No.: WO2012096985A1  Published: 19/Jul/2012

Title: LIDOCAINE REGIMEN FOR THE USE OF SUSTAINED TREATMENT OF BLADDER PAIN AND IRRITATIVE VOIDING

Applicant/Assignee: TARIS BIOMEDICAL, INC

Application No.: WO2012US20813 (PCT/US2012/20813)   Filing Date: 10/Jan/2012

Abstract:

Method are provided for treating a patient having bladder pain and/or irritative voiding symptoms. The method includes administering to the patient's bladder lidocaine or another anesthetic agent continuously over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect which is sustained beyond the end of the treatment period.

Priority: US201161431334P Applic. Date: 2011-01-10; US201161551923P Applic. Date: 2011-10-26

Inventor: HIMES JULIE [US]; GIESING DENNIS [US]; LARRIVEEE-ELKINS CHERYL [US]; CIMA MICHAEL J [US]; SARMA PURNANAND [US]; GOLDENHEIM PAUL [US]


Publication No.: WO2012097222A1  Published: 19/Jul/2012

Title: HIGH DRUG LOAD TABLET FORMULATION OF BRIVANIB ALANINATE

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: WO2012US21199 (PCT/US2012/21199)   Filing Date: 13/Jan/2012

Abstract:

The present invention is directed to a high drug load tablet formulation of [ (1R), 2S] - 2 - aminopropionic acid 2 - [4 - (4 - fluoro- 2 -methyl - 1H- indol - 5 -yloxy) - 5 -methylpyrrolo [2, 1 - f] [1,2,4] triazin- 6 -yloxy] - 1 -methylethyl ester, and to methods of using the formulation in the treatment of cancer. The tablet is obtained by means of a wet granulation process.

Priority: US201161432801P Applic. Date: 2011-01-14

Inventor: NARANG AJIT S [US]; BADAWY SHERIF IBRAHIM FARAG [US]; SUBRAMANIAN GANESHKUMAR A [US]; LAMARCHE KEIRNAN RYAN [US]; BINDRA DILBIR S [US]; RAO VENKATRAMANA M [US]


Publication No.: WO2012097264A2  Published: 19/Jul/2012

Title: PHARMACEUTICAL COMPOSITIONS FOR TOPICAL DELIVERY OF PHOTOSENSITIZERS AND USES THEREOF

Applicant/Assignee: QLT INC

Application No.: WO2012US21263 (PCT/US2012/21263)   Filing Date: 13/Jan/2012

Abstract:

The invention includes and provides compositions comprising photosensitizing agents and their use in photodynamic therapy for the treatment of dermatological conditions.

Priority: US201161432453P Applic. Date: 2011-01-13

Inventor: MORRIS JEROME A [US]; UTKHEDE DEEPANK [CA]; HUNT DAVID W C [CA]


Publication No.: WO2012097763A2  Published: 26/Jul/2012

Title: A CARRIER FOR OROMUCOSAL, ESPECIALLY SUBLINGUAL ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE SUBSTANCES

Applicant/Assignee: ELMARCO S.R.O, UNIVERZITA KARLOVA V PRAZE

Application No.: WO2011CZ00116 (PCT/CZ2011/00116)   Filing Date: 12/Dec/2011

Abstract:

The invention relates to a carrier for oromucosal, especially sublingual administration of physiologically active substances, especially of medicinal drugs, which consists of at least one elastic layer (1) of polymer nanofibres workable according to the shape of the selected wall of mouth cavity to which it should be applied and in this elastic layer (1) of polymer nanofibres a drug and/or other physiologically active substance are deposited in a releasable manner.

Priority: CZ20110000024 Applic. Date: 2011-01-17

Inventor: STRANSKA DENISA [CZ]; KLABANOVA ADELA [CZ]; DOLEZAL PAVEL [CZ]; VRBATA PETR [CZ]; BERKA PAVEL [CZ]; MUSILOVA MARIE [CZ]


Publication No.: WO2012098187A1  Published: 26/Jul/2012

Title: GLP-1 COMPOSITIONS

Applicant/Assignee: NOVO NORDISK A/S

Application No.: WO2012EP50784 (PCT/EP2012/50784)   Filing Date: 19/Jan/2012

Abstract:

The present invention relates to pharmaceutical compositions comprising a GLP-1 compound, a divalent metal and a polycationic compound. The invention is characterised in that the GLP-1:divalent metal molar ratio is 1:>2. The compositions of the invention are particularly useful in the treatment of diabetes.

Priority: US201161436785P Applic. Date: 2011-01-27; EP20110151455 Applic. Date: 2011-01-19

Inventor: DRUSTRUP JOERN [DK]; HUUS KASPER [DK]; BALSCHMIDT PER [DK]


Publication No.: WO2012098188A1  Published: 26/Jul/2012

Title: GLP-1 PARTICLES AND COMPOSITIONS

Applicant/Assignee: NOVO NORDISK A/S

Application No.: WO2012EP50785 (PCT/EP2012/50785)   Filing Date: 19/Jan/2012

Abstract:

The present invention relates to compositions and particles comprising a GLP-1 compound, a divalent metal and a polycationic compound. The invention is characterised that the particle comprises a core and a surrounding layer, the core comprising the GLP-1 compound and the divalent metal, and the surrounding layer comprising the polycationic compound. The invention is particularly useful for the treatment of metabolic diseases, including diabetes.

Priority: US201161436804P Applic. Date: 2011-01-27; EP20110151456 Applic. Date: 2011-01-19

Inventor: BALSCHMIDT PER [DK]; DRUSTRUP JOERN [DK]; HUUS KASPER [DK]


Publication No.: WO2012098562A2  Published: 26/Jul/2012

Title: LIQUID ORAL COMPOSITIONS OF LANTHANUM SALTS

Applicant/Assignee: PANACEA BIOTEC LIMITED

Application No.: WO2012IN00041 (PCT/IN2012/00041)   Filing Date: 17/Jan/2012

Abstract:

The present invention relates to liquid oral pharmaceutical compositions of lanthanum and its pharmaceutically acceptable salts thereof. The present invention further relates to preparation of liquid oral pharmaceutical compositions of lanthanum and its salts and also provides use of such compositions in treating hyperphosphatemia in patients.

Priority: IN2011DE00125 Applic. Date: 2011-01-19

Inventor: JAIN RAJESH [IN]; SINGH SARABJIT [IN]; SINGH PARAMJIT [IN]; SINGH PIRTHI PAL [IN]


Publication No.: WO2012099260A1  Published: 26/Jul/2012

Title: ORALLY DISPERSIBLE TABLET

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: WO2012JP51279 (PCT/JP2012/51279)   Filing Date: 16/Jan/2012

Abstract:

The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol

and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture.

Priority: JP20110007371 Applic. Date: 2011-01-17; JP20110227333 Applic. Date: 2011-10-14

Inventor: TANOUE YUTAKA [JP]; MATSUURA TETSUYA [JP]; YAMAGATA YUTAKA [JP]; NAGAHARA NAOKI [JP]


Publication No.: WO2012100459A1  Published: 02/Aug/2012

Title: PHOSPHORUS SUBSTITUTED GROUP-CONTAINING QUINOLINE-LIKE COMPOUND, ITS PREPARATION PROCESS, MEDICAL COMPOSITION CONTAINING THE COMPOUND AND APPLICATION

Applicant/Assignee: GUANGZHOU ESA BIOTECH CO., LTD

Application No.: WO2011CN72456 (PCT/CN2011/72456)   Filing Date: 06/Apr/2011

Abstract:

Phosphorus substituted group-containing quinoline-like compound of formula (I) are provided in the present invention. The preparation process and application of the compound, and pharmaceutical formulation comprising phosphorus substituted group-containing quinoline-like compound are also disclosed. The compounds are protein kinase inhibitor and can be used for treating protein kinase abnormal activity-associated diseases, such as neoplasm, etc.

Priority: CN20111036623 Applic. Date: 2011-01-28

Inventor: YUN ZIWEI [CN]; WANG HONGTAO [CN]


Publication No.: WO2012101016A1  Published: 02/Aug/2012

Title: TESTOSTERONE FORMULATIONS

Applicant/Assignee: FERRING B.V

Application No.: WO2012EP50695 (PCT/EP2012/50695)   Filing Date: 18/Jan/2012

Abstract:

The subject invention provides improved testosterone gel formulations.

Priority: US201161436207P Applic. Date: 2011-01-26; EP20110152210 Applic. Date: 2011-01-26

Inventor: GRENIER ARNAUD [FR]; CARRARA DARIO N [CH]


Publication No.: WO2012101181A1  Published: 02/Aug/2012

Title: COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION

Applicant/Assignee: UNIVERSITE CATHOLIQUE DE LOUVAIN

Application No.: WO2012EP51157 (PCT/EP2012/51157)   Filing Date: 25/Jan/2012

Abstract:

The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one antithrombin activator, preferably unfractionated heparin, as well as at least one thrombin inhibitor, preferably bivalirudin.

Priority: EP20110152119 Applic. Date: 2011-01-25

Inventor: STEPHENNE XAVIER [BE]; SOKAL ETIENNE [BE]; NAJIMI MUSTAPHA [BE]; EECKHOUDT STEPHANE [BE]; HERMANS CEDRIC [BE]


Publication No.: WO2012101218A1  Published: 02/Aug/2012

Title: FOOD SUPPLEMENT AND INJECTABLE MATERIAL FOR PROPHYLAXIS AND THERAPY OF OSTEOPOROSIS AND OTHER BONE DISEASES

Applicant/Assignee: NANOTECMARIN GMBH

Application No.: WO2012EP51238 (PCT/EP2012/51238)   Filing Date: 26/Jan/2012

Abstract:

The invention relates to the application of inorganic polyphosphates (polyP) and complexes of polyP and calcium [polyP (Ca2+ complex)] for prophylaxis and treatment of osteoporosis and other bone diseases by inducing hydroxyapatite formation and decreasing osteoclastogenesis. PolyP and polyP (Ca2+ complex) can be used both as a drug or food supplement and as a material to be injected into bone tissue.

Priority: EP20110152208 Applic. Date: 2011-01-26

Inventor: MUELLER WERNER E G [DE]; SCHROEDER HEINZ C [DE]; WANG XIAOHONG [DE]


Publication No.: WO2012101242A1  Published: 02/Aug/2012

Title: NOVEL PHARMACEUTICAL SUSPENSION FOR PARENTERAL APPLICATION

Applicant/Assignee: CAPSULUTION PHARMA AG

Application No.: WO2012EP51288 (PCT/EP2012/51288)   Filing Date: 27/Jan/2012

Abstract:

The present invention relates to an injectable pharmaceutical suspension comprising a polyelectrolyte and a nanoparticular, poorly soluble pharmaceutically active compound, wherein said polyelectrolyte comprises a methacrylate polymer. Furthermore, the present invention relates to a method for stabilizing a poorly soluble active pharmaceutical compound in an injectable pharmaceutical suspension comprising the steps of: a) suspending in a liquid dispersion medium a poorly soluble pharmaceutically active compound without the presence of a detergent, b) mechanically treating said suspension to obtain particles comprising the active compound with an effective average size of less than about 5000 nm, preferably less than about 4000 nm, more preferably less than about 3000 nm, even more preferably less than about 1000 nm and most preferably less than about 800 nm, c) contacting said active compound or suspension with a methacrylate polymer or with a polyelectrolyte complex comprising a methacrylate polymer during and/or before mechanically treating. The present invention also relates to the injectable pharmaceutical suspension according to the invention for use of the in the treatment of a disease.

Priority: EP20110152405 Applic. Date: 2011-01-27

Inventor: KROEHNE LUTZ [DE]; DUNMANN CHRISTOPH [DE]


Publication No.: WO2012101500A1  Published: 02/Aug/2012

Title: EFFERVESCENT COMPOSITION IN SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS

Applicant/Assignee: PROBIOTICAL S.P.A

Application No.: WO2012IB00095 (PCT/IB2012/00095)   Filing Date: 24/Jan/2012

Abstract:

The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.

Priority: IT2011MI00107 Applic. Date: 2011-01-28; IT2011MI00316 Applic. Date: 2011-03-01

Inventor: MOGNA GIOVANNI [IT]; STROZZI GIAN PAOLO [IT]; MOGNA LUCA [IT]


Publication No.: WO2012101587A1  Published: 02/Aug/2012

Title: CARRIERS FOR THE LOCAL RELEASE OF HYDROPHILIC PRODRUGS

Applicant/Assignee: KONINKLIJKE PHILIPS ELECTRONICS N.V

Application No.: WO2012IB50347 (PCT/IB2012/50347)   Filing Date: 25/Jan/2012

Abstract:

Disclosed is a carrier for the local, targeted administration of a hydrophobic drug. The hydrophobic drug is rendered in to a hydrophilic prodrug thereof, and is contained in the lumen of a thermosensitive liposome or polymersome. Upon administration of the carrier, heat can be applied at the locus where the drug is to be released. After release of the prodrug, it will be activated so as to turn into the active drug.

Priority: EP20110152529 Applic. Date: 2011-01-28

Inventor: GRUELL HOLGER [NL]; LANGEREIS SANDER [NL]; SIO CHARLES FREDERIK [NL]


Publication No.: WO2012101657A1  Published: 02/Aug/2012

Title: PROCESS FOR PREPARATION OF A HERBAL EXTRACT

Applicant/Assignee: PIRAMAL LIFE SCIENCES LTD

Application No.: WO2012IN00059 (PCT/IN2012/00059)   Filing Date: 27/Jan/2012

Abstract:

A process for preparing an extract of Momordica charantia, including: a) preparing crude juice

b) filtering to obtain filtered juice

c) modifying pH

d) allowing the pH modified juice to stabilize

e) neutralizing the stabilized juice

f) allowing the neutralized juice to stand for 20-30 minutes

g) rechecking the pH level

and h) drying the juice to obtain the extract. The process said above is simple, cost effective, which does not employ any harmful organic solvents and which enhances the potency of the constituents. A simple and potent formulation showing anti-diabetic activity comprising active constituents of Momordica charantia is also provided.

Priority: IN2011MU00246 Applic. Date: 2011-01-28

Inventor: SHARMA SOMESH [IN]; CHAUHAN VIJAY SINGH [IN]; SUTHAR ASHISH [IN]


Publication No.: WO2012102799A2  Published: 02/Aug/2012

Title: METHOD, COMPOSITION AND PACKAGE FOR BOWEL CLEANSING

Applicant/Assignee:

Application No.: WO2011US64670 (PCT/US2011/64670)   Filing Date: 13/Dec/2011

Abstract:

The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy.

Priority: US201161462094P Applic. Date: 2011-01-28

Inventor: SHAVER WILLIAM A [US]


Publication No.: WO2012102936A1  Published: 02/Aug/2012

Title: HIGHLY PENETRATING COMPOSITIONS AND METHODS FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

Applicant/Assignee: QUADEX PHARMACEUTICALS LLC

Application No.: WO2012US21877 (PCT/US2012/21877)   Filing Date: 19/Jan/2012

Abstract:

Compositions and methods for treating disordered tissues, such as caused by pathogens and/or by toxins. The treatment compositions include an anti-infective active agent, a liquid carrier, and benzocaine in an amount so that the treatment composition penetrates more quickly into disordered tissue compared to the treatment composition in the absence of the benzocaine. In addition, the benzocaine can increase residence time of the anti-infective active in the treatment area. The preferred anti-infective active agent can be an organohalide, such as a quaternary ammonium halide compound, an example of which is benzalkonium chloride. The treatment compositions and methods may employ the use of an applicator adapted for use in promoting penetration of the treatment composition and/or agitation of the disordered tissue to further enhance penetration.

Priority: US201113012719 Applic. Date: 2011-01-24

Inventor: JOHNSON B RON [US]; MCCARTHY JAMES P [US]


Publication No.: WO2012103186A2  Published: 02/Aug/2012

Title: ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US22508 (PCT/US2012/22508)   Filing Date: 25/Jan/2012

Abstract:

The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.

Priority: US201161436274P Applic. Date: 2011-01-26

Inventor: TROGDEN JOHN T [US]; SALAMEH ADNAN K [US]; PUJARA CHETAN P [US]; GORE ANURADHA V [US]; GIYANANI JAYA [US]


Publication No.: WO2012103985A2  Published: 09/Aug/2012

Title: PHARMACEUTICAL COMPOSITION CONSISTING OF RNA HAVING ALKALI METAL AS COUNTER ION AND FORMULATED WITH DICATIONS

Applicant/Assignee:

Application No.: WO2011EP73151 (PCT/EP2011/73151)   Filing Date: 16/Dec/2011

Abstract:

The present invention relates to a biologically active RNA - alkali metal - dication formulation, a pharmaceutical composition containing said complexes and to a method of producing the same. The formulation of the present invention is particularly useful to introduce RNA and eventual attached cargo in cells allowing its biological intracellular activities: e.g. immunostimulation (immunomodulation), RNA interference or gene expression.

Priority: EP20100195493 Applic. Date: 2010-12-16

Inventor: PASCOLO STEVE [CH]


Publication No.: WO2012104025A2  Published: 09/Aug/2012

Title: BALNEOTHERAPEUTIC LIPID-CONTAINING PROBIOTIC PREPARATIONS AND THEIR APPLICATIONS

Applicant/Assignee: MERZ PHARMA GMBH & CO. KGAA

Application No.: WO2012EP00250 (PCT/EP2012/00250)   Filing Date: 19/Jan/2012

Abstract:

The present invention relates to solid or liquid cosmetic, dermatological or medicinal balneotherapeutic preparations for bathing or showering which are essentially anhydrous (with a low water content of less than 1% by weight) and have a lipid content with preferably at least one liquid lipid, furthermore dispersants, and which have a content of probiotic active substances, selected mainly among bacteria of the genus Lactobacillus and Bifidobacteria. When applying these preparations, skin regions which are brought into contact with them can, surprisingly, be provided topically with the probiotic active substances in the meaning of a care effect by maintaining and, if appropriate, restoring the healthy microbial status of the skin while in additional simultaneously cleansing and providing the skin with lipids. In this context, the stability of the microorganisms in the preparations which is required for the above-described effect does not require any further special measures.

Priority: DE201110009798 Applic. Date: 2011-01-31

Inventor: EBINGER JUERGEN [DE]; HOLZEM MARTINA [DE]


Publication No.: WO2012104419A1  Published: 09/Aug/2012

Title: Hyaluronic acid composition

Applicant/Assignee: Q-MED AB

Application No.: WO2012EP51875 (PCT/EP2012/51875)   Filing Date: 03/Feb/2012

Abstract:

The present invention relates toan injectable hyaluronic acid composition comprising a hyaluronic acid

a local anesthetic selected from the group consisting of amide and ester type local anesthetics or a combination thereof

and an ascorbic acid derivativein an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G' of the composition caused by the local anesthetic upon sterilization by heat. The present invention further relates to the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition. Figure

Priority: EP20110153232 Applic. Date: 2011-02-03

Inventor: EDSMAN KATARINA [SE]; WIEBENSJOE AASA [SE]


Publication No.: WO2012104617A1  Published: 09/Aug/2012

Title: IMPROVEMENTS IN AND RELATING TO COMPOSITIONS

Applicant/Assignee: NORGINE BV

Application No.: WO2012GB50195 (PCT/GB2012/50195)   Filing Date: 31/Jan/2012

Abstract:

The present invention concerns aqueous solutions comprising polyethylene glycol for use as a medicament, particularly in the treatment of constipation and faecal impaction. The solutions may be preserved to suppress the growth of microbial organisms. Kits comprising a preserved aqueous solution and a separate tablet or capsule comprising electrolytes are also provided.

Priority: GB20110001666 Applic. Date: 2011-01-31; GB20110001738 Applic. Date: 2011-02-01; GB20120000637 Applic. Date: 2012-01-13

Inventor: SELDON CHRIS [GB]; PADFIELD DAWN [GB]; MORRISSEY FRANCES [GB]


Publication No.: WO2012104654A1  Published: 09/Aug/2012

Title: COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES

Applicant/Assignee: BIOCOPEA LIMITED

Application No.: WO2012GB50241 (PCT/GB2012/50241)   Filing Date: 03/Feb/2012

Abstract:

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.

Priority: WO2011GB52115 Applic. Date: 2011-10-31; GB20110013730 Applic. Date: 2011-08-10; GB20110013728 Applic. Date: 2011-08-10; GB20110013729 Applic. Date: 2011-08-10; GB20110001937 Applic. Date: 2011-02-04

Inventor: BANNISTER ROBIN MARK [GB]; BREW JOHN [GB]; DILLY SUZANNE JANE [GB]; STOLOFF GREGORY ALAN [GB]; CAPARROS-WANDERLEY WILSON [GB]


Publication No.: WO2012104655A2  Published: 09/Aug/2012

Title: COMPOSTIONS AND METHODS FOR TREATING CHRONIC INFLAMMATION AND INFLAMMATORY DISEASES

Applicant/Assignee: BIOCOPEA LIMITED

Application No.: WO2012GB50242 (PCT/GB2012/50242)   Filing Date: 03/Feb/2012

Abstract:

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Priority: WO2011GB52115 Applic. Date: 2011-10-31; GB20110013730 Applic. Date: 2011-08-10; GB20110013729 Applic. Date: 2011-08-10; GB20110013728 Applic. Date: 2011-08-10; GB20110001937 Applic. Date: 2011-02-04

Inventor: BANNISTER ROBIN MARK [GB]; BREW JOHN [GB]; CAPARROS-WANDERLEY WILSON [GB]; STOLOFF GREGORY ALAN [GB]; DILLY SUZANNE JANE [GB]; SZUCS GEMMA [GB]; PLEGUEZUELOS MATEO OLGA [GB]


Publication No.: WO2012104730A1  Published: 09/Aug/2012

Title: PHARMACEUTICAL PREPARATION

Applicant/Assignee:

Application No.: WO2012IB00391 (PCT/IB2012/00391)   Filing Date: 01/Mar/2012

Abstract:

The invention relates to a pharmaceutical formulation that contains a complex of a propofol salt with a cyclodextrin. The invention makes it possible to provide propofol in a formulation that can be stored and that can be administered intravenously without problems.

Priority: EP20110153452 Applic. Date: 2011-02-04

Inventor: ROEWER NORBERT [DE]; BROSCHEIT JENS [DE]


Publication No.: WO2012104818A1  Published: 09/Aug/2012

Title: ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BEPOTASTINE

Applicant/Assignee: LUPIN LIMITED

Application No.: WO2012IB50506 (PCT/IB2012/50506)   Filing Date: 03/Feb/2012

Abstract:

The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.

Priority: IN2011KO00157 Applic. Date: 2011-02-03

Inventor: DESHMUKH ASHISH ASHOKRAO [IN]; BHUTADA PRAVIN MEGHRAJJI [IN]; CHANDRAN SAJEEV [IN]; KULKARNI SHIRISHKUMAR [IN]


Publication No.: WO2012106118A2  Published: 09/Aug/2012

Title: METHOD OF MAKING OPHTHALMIC DEVICES AND COMPONENTS THEREOF FROM HYDROPHOBIC ACRYLIC (HA) POLYMERS WITH REDUCED OR ELIMINATED GLISTENINGS

Applicant/Assignee: KEY MEDICAL TECHNOLOGIES, INC

Application No.: WO2012US21690 (PCT/US2012/21690)   Filing Date: 18/Jan/2012

Abstract:

This invention relates to the fields of polymer chemistry, materials science and ophthalmology. More particularly it relates to optical components and method(s) of preparing same from hydrophobic acrylic (HA) monomer(s) that exhibit reduced or eliminated glistenings when implanted in a patient's eye. The method of this invention uses a mixture of one or more low temperature initiators (LTI) combined with one or more high temperature initiators (HTI), to polymerize one or more HA monomers to produce an optical HA polymer which, when used to manufacture an optical component and implanted as with an intraocular lens (IOL), exhibit reduced glistenings to the patient.

Priority: US201113017093 Applic. Date: 2011-01-31

Inventor: MENTAK KHALID [US]


Publication No.: WO2012106575A1  Published: 09/Aug/2012

Title: DRY POWDER FORMULATIONS OF PARTICLES THAT CONTAIN TWO OR MORE ACTIVE INGREDIENTS FOR TREATING OBSTRUCTIVE OR INFLAMMATORY AIRWAYS DISEASES

Applicant/Assignee: NOVARTIS AG

Application No.: WO2012US23727 (PCT/US2012/23727)   Filing Date: 03/Feb/2012

Abstract:

Dry powder formulations for inhalation comprising spray-dried particles and their use in the treatment of an obstructive or inflammatory airways disease. Each particle has a core of a first active ingredient in substantially crystalline form that is coated with a layer of a second active ingredient in substantially amorphous form that is dispersed in a pharmaceutically acceptable hydrophobic excipient. A process for preparing such formulations is also described.

Priority: US201161439527P Applic. Date: 2011-02-04

Inventor: WEERS JEFFRY [US]


Publication No.: WO2012107093A1  Published: 16/Aug/2012

Title: STORAGE-STABLE FORMULATION OF PARACETAMOL IN AQUEOUS SOLUTION

Applicant/Assignee: NEOGEN N.V

Application No.: WO2011EP51971 (PCT/EP2011/51971)   Filing Date: 10/Feb/2011

Abstract:

The present invention relates to a method for the production of a formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent, comprising the steps of (i) dissolving paracetamol in an aqueous solvent comprising an isotonic agent that is sodium chloride and a buffer agent that is sodium citrate, having a temperature between 65 DEG C and 95 DEG C and having pH between 5.0 and 6.0 in a reaction vessel, (ii) replacing the remaining air in the vessel by an inert gas, such as nitrogen, and cooling the solution so formed to a temperature below 38 DEG C, (iii) adding cysteine hydrochloride to the solution without mechanical agitation, and (iv) closing the reaction vessel and mechanically agitating the solution in a nitrogen atmosphere. The further relates to a formulation prepared according to the method.

Priority: WO2011EP51971 Applic. Date: 2011-02-10

Inventor: AL DANDACHI ATASSI KHALED [BE]


Publication No.: WO2012107202A1  Published: 16/Aug/2012

Title: SWEETENER, SWEETENER COMPOSITIONS, METHODS OF MAKING THE SAME AND CONSUMABLES CONTAINING THE SAME

Applicant/Assignee: NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH

Application No.: WO2012EP00538 (PCT/EP2012/00538)   Filing Date: 07/Feb/2012

Abstract:

The present invention relates to the use of tormentic acid or a derivative or a stereoisomer, or a salt or a hydrate thereof as a sweetener, to sweetener compositions comprising tormentic acid or a derivative or a stereoisomer, or a salt or a hydrate thereof, and, optionally, a pregelatinized starch, to methods of making the sweetener compositions and to tabletop sweetener compositions comprising tormentic acid or a derivative or a stereoisomer, or a salt or a hydrate thereof. Further, the invention relates to consumables comprising a consumable product and tormentic acid or a derivative or a stereoisomer, or a salt or a hydrate thereof. Preferred consumable products are water-based consumables, solid dry consumables, dairy products, dairy-derived products and dairy-alternative products.

Priority: US201161440764P Applic. Date: 2011-02-08; EP20110001014 Applic. Date: 2011-02-08

Inventor: KROHN MICHAEL [DE]; SEIBERT SIMON [DE]; KLEBER ALICE [DE]; WONSCHIK JOHANN [DE]


Publication No.: WO2012107207A1  Published: 16/Aug/2012

Title: SWEETENER AND/OR A SWEETNESS ENHANCER, SWEETENER COMPOSITIONS, METHODS OF MAKING AND USING SAME, AND CONSUMABLES CONTAINING SAME

Applicant/Assignee: NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH

Application No.: WO2012EP00543 (PCT/EP2012/00543)   Filing Date: 07/Feb/2012

Abstract:

The present invention relates to the use of a compound of formula (I) in which one or more hydrogen atoms in the phenyl group or benzyl group may be substituted by C1-6-alkyl or Ci-6-alkoxy and one or more hydroxyl groups may be substituted by C1-6-alkoxy or C1-6-acyloxy, or a derivative or a stereoisomer or a salt or a hydrate thereof, as a sweetener and/or a sweetness enhancer, to sweetener compositions comprising a compound of formula (I) or a derivative or a stereoisomer or a salt or a hydrate thereof, and, optionally, a pregelatinized starch, to methods of making the sweetener compositions and to tabletop sweetener compositions comprising a compound of formula (I) or a derivative or a stereoisomer or a salt or a hydrate thereof. Further, the invention relates to consumables comprising a consumable product and a compound of formula (I) or a derivative or a stereoisomer or a salt or a hydrate thereof. Preferred consumable products are water-based consumables, solid dry consumables, dairy products, dairy-derived products and dairy-alternative products.

Priority: US201161440815P Applic. Date: 2011-02-08; EP20110001011 Applic. Date: 2011-02-08

Inventor: KROHN MICHAEL [DE]; SEIBERT SIMON [DE]; KLEBER ALICE [DE]; WONSCHIK JOHANN [DE]


Publication No.: WO2012107356A1  Published: 16/Aug/2012

Title: AQUEOUS PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING ALLERGICALLY IRRITATED NASAL MUCOSA AND USE THEREOF

Applicant/Assignee: URSAPHARM ARZNEIMITTEL GMBH

Application No.: WO2012EP51833 (PCT/EP2012/51833)   Filing Date: 03/Feb/2012

Abstract:

The invention relates to an aqueous pharmaceutical composition, which comprises an anti-inflammatory and/or antiallergic agent, oil, and at least one viscosity regulator. The invention further relates to the use of said pharmaceutical composition for preventing and/or treating allergically irritated nasal mucosa.

Priority: DE201110010668 Applic. Date: 2011-02-08

Inventor: HOLZER FRANK [DE]; KLEIN MARTIN [FR]


Publication No.: WO2012107363A1  Published: 16/Aug/2012

Title: NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS

Applicant/Assignee: SCIPHARM SARL

Application No.: WO2012EP51880 (PCT/EP2012/51880)   Filing Date: 03/Feb/2012

Abstract:

The present invention provides a composition comprising at least one prostacyclin or prostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.

Priority: EP20110153541 Applic. Date: 2011-02-07

Inventor: FREISSMUTH MICHAEL [AT]; GLOECKEL CHRISTINA [AT]; KOENIG XAVER [AT]; KEUERLEBER SIMON [AT]


Publication No.: WO2012107364A1  Published: 16/Aug/2012

Title: NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS

Applicant/Assignee: SCIPHARM SARL

Application No.: WO2012EP51881 (PCT/EP2012/51881)   Filing Date: 03/Feb/2012

Abstract:

The present invention provides a composition comprising at least one prostacyclin orprostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one compound selected from the group consisting of leukotriene antagonists, prostaglandin antagonists and duramycin or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides a composition comprising Treprostiniland a compound from the group consisting of leukotriene antagonists, prostaglandin antagonists and duramycinor a pharmaceutically acceptable salt thereof.

Priority: EP20110153542 Applic. Date: 2011-02-07

Inventor: FREISSMUTH MICHAEL [AT]


Publication No.: WO2012107493A1  Published: 16/Aug/2012

Title: DUAL DRUG PEN-INJECTION DEVICE WITH MICRO-RESERVOIRS CARRYING SECONDARY DRUG FOR EMERGENCY INJECTION

Applicant/Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH

Application No.: WO2012EP52136 (PCT/EP2012/52136)   Filing Date: 08/Feb/2012

Abstract:

An injection device (7) to deliver at least two medicaments is disclosed where a first medicament is delivered in settable doses with a first medicament dose delivery mechanism (6) and a second medicament is delivered from micro-reservoirs (8) upon activation of a second medicament delivery system, whereby activation of the second medicament delivery system locks out the first medicament dose delivery mechanism.

Priority: US201161441266P Applic. Date: 2011-02-09

Inventor: KOHLI AMIT [FR]; LERCHE CHRISTIAN [DE]


Publication No.: WO2012107564A1  Published: 16/Aug/2012

Title: NOVEL FORMULATIONS FOR DERMAL, TRANSDERMAL AND MUCOSAL USE 1

Applicant/Assignee: MOBERG DERMA AB

Application No.: WO2012EP52325 (PCT/EP2012/52325)   Filing Date: 10/Feb/2012

Abstract:

A dermal, transdermal and/or mucosal formulation for topical application on skin, comprising an active pharmaceutical ingredient and a pharmaceutically acceptable solvent, and an anti-solvent

wherein the active pharmaceutical ingredient is soluble in the solvent in the absence of the anti-solvent, and wherein the active pharmaceutical ingredient is substantially in the solid state in the presence of the anti-solvent. A method for increasing the stability of an active pharmaceutical ingredient.

Priority: US201161441346P Applic. Date: 2011-02-10

Inventor: LINDAHL AAKE [SE]; KAUFMANN PETER [SE]


Publication No.: WO2012107565A1  Published: 16/Aug/2012

Title: NOVEL ANTIFUNGAL COMPOSITION

Applicant/Assignee: MOBERG DERMA AB

Application No.: WO2012EP52327 (PCT/EP2012/52327)   Filing Date: 10/Feb/2012

Abstract:

There is provided a pharmaceutical composition for the treatment of fungal infection of the nail comprising a antifungal allylamine compound present in an amount of about 10%, an organic acid or an ester thereof, a diol and a sequestering agent where the pharmacological composition is essentially water-free

Priority: SE20110050107 Applic. Date: 2011-02-11

Inventor: LINDAHL AAKE [SE]


Publication No.: WO2012107573A1  Published: 16/Aug/2012

Title: NOVEL FORMULATIONS FOR DERMAL, TRANSDERMAL AND MUCOSAL USE 3

Applicant/Assignee: MOBERG DERMA AB

Application No.: WO2012EP52337 (PCT/EP2012/52337)   Filing Date: 10/Feb/2012

Abstract:

A dermal, transdermal, and/or mucosal formulation comprising at least one active pharmaceutical ingredient

a pharmaceutically acceptable solvent and/or solvent system

and a pharmaceutically acceptable anti-solvent, said formulation exhibiting a continuous and a non-continuous phase, wherein the active pharmaceutical ingredient is soluble in the solvent and/or solvent system in the absence of said anti-solvent, and substantially contained in the non-continuous phase in said formulation in the presence of said anti-solvent. A method for increasing the stability of an active pharmaceutical ingredient.

Priority: US201161441346P Applic. Date: 2011-02-10

Inventor: LINDAHL AAKE [SE]; KAUFMANN PETER [SE]


Publication No.: WO2012107575A1  Published: 16/Aug/2012

Title: NOVEL FORMULATIONS FOR DERMAL, TRANSDERMAL AND MUCOSAL USE 2

Applicant/Assignee: MOBERG DERMA AB

Application No.: WO2012EP52340 (PCT/EP2012/52340)   Filing Date: 10/Feb/2012

Abstract:

A dermal, transdermal and/or mucosal formulation comprising an active pharmaceutical ingredient, a pharmaceutically acceptable solvent, and an anti-solvent, wherein the active pharmaceutical ingredient is soluble in the solvent in the absence of the anti-solvent, and wherein the active pharmaceutical ingredient is in the solid state in the solvent in the presence of the anti-solvent. A method for increasing the stability of an active pharmaceutical ingredient.

Priority: US201161441346P Applic. Date: 2011-02-10

Inventor: LINDAHL AAKE [SE]; KAUFMANN PETER [SE]


Publication No.: WO2012107585A1  Published: 16/Aug/2012

Title: NOVEL CONCENTRATED AND STABLE TOPICAL ANTIPARASITIC COMPOSITIONS

Applicant/Assignee: CEVA SANTE ANIMALE SA

Application No.: WO2012EP52364 (PCT/EP2012/52364)   Filing Date: 10/Feb/2012

Abstract:

The present invention relates to a particular solvent system including at least 35% dimethylsulfoxide (DMSO) for preparing a veterinary composition for topical application for controlling parasites in domestic animals. The topical composition according to the present invention includes, as the active ingredient, a high concentration of neonicotinoids of the tetrahydrofuran family and has excellent stability and persistence.

Priority: FR20110051157 Applic. Date: 2011-02-11

Inventor: GUIMBERTEAU FLORENCE [FR]; FORGET PATRICK [FR]


Publication No.: WO2012107648A1  Published: 16/Aug/2012

Title: ANTI-INFLAMMATORY EFFECT OF MICROFIBRILLATED CELLULOSE

Applicant/Assignee: UPM-KYMMENE CORPORATION

Application No.: WO2012FI50129 (PCT/FI2012/50129)   Filing Date: 10/Feb/2012

Abstract:

The invention relates to use of microfibrillated cellulose as an anti-inflammatory agent for treatment of skin disorders.

Priority: FI20110005135 Applic. Date: 2011-02-11

Inventor: HERRANEN KAISA [FI]; LOHMAN MIA [FI]


Publication No.: WO2012107652A1  Published: 16/Aug/2012

Title: EFFERVESCENT GAMMA-HYDROXYBUTYRIC ACID GRANULES

Applicant/Assignee: DEBREGEAS ET ASSOCIES PHARMA

Application No.: WO2012FR00046 (PCT/FR2012/00046)   Filing Date: 03/Feb/2012

Abstract:

The present invention relates to a granule including a solid core on which an active principle supported, said active principle being selected from among gamma-hydroxybutyric acid or one of the pharmaceutically acceptable salts thereof, said granule further including one or more compounds which are supported on said solid core and which are capable of releasing gas, and one or more diluents, said granule being characterized in that it is coated with a membrane and in that the solid core is 15 to 50 wt % with respect to the total weight of the granule.

Priority: FR20110000433 Applic. Date: 2011-02-11

Inventor: SUPLIE PASCAL [FR]; LECOUSTEY SYLVIE [FR]


Publication No.: WO2012107765A2  Published: 16/Aug/2012

Title: PARTICLE FORMULATION

Applicant/Assignee: KUECEPT LTD, LENA NANOCEUTICS LTD

Application No.: WO2012GB50283 (PCT/GB2012/50283)   Filing Date: 09/Feb/2012

Abstract:

The present inventions relates to combination particle formulations suitable for use in an inhaler formulation comprising a plurality of pharmacologically active ingredients characterized in that the pharmacologically active ingredients are crystalline. The present invention further comprises a particle formulation suitable for use in an inhalation formulation comprising a plurality of pharmacologically active ingredients, for example crystalline pharmacologically active ingredients characterized in that the ratio of the pharmacologically active substances has a distribution of less than +-5% of the target ratio as measured by Impactor testing. Particularly particle formulations prepared from nanoparticles, for example by spray drying of an aqueous suspension of nanoparticles.

The invention further comprises methods for making said particle formulations and method of using said particle formulations in therapeutic treatments to achieve co-localisation of agents in the body, particularly when delivered as inhaled formulations to the human airways and lungs.

Priority: GB20110002237 Applic. Date: 2011-02-09

Inventor: SAUNDERS MARK HENRY [GB]; DE MATAS MARCEL [GB]; JONES JASON ROBERT [GB]


Publication No.: WO2012109387A1  Published: 16/Aug/2012

Title: COMPOSITION AND LIPID FORMULATION OF A HYALURONAN-DEGRADING ENZYME AND THE USE THEREOF FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Applicant/Assignee: HALOZYME, INC

Application No.: WO2012US24376 (PCT/US2012/24376)   Filing Date: 08/Feb/2012

Abstract:

Provided are compositions and formulations or co-formulations containing a hyaluronan degrading enzyme. The compositions, formulations or co-formulations can also contain another therapeutic agent, such as one that is suitable for treatment of Benign Prostatic Hyperplasia, for example, a 5-alpha reductase inhibitors. The compositions and formulations can be used for the treatment of Benign Prostatic Hyperplasia. The compositions and formulations can be provided in combinations with one or more other agents for the treatment of Benign Prostatic Hyperplasia.

Priority: US201161462875P Applic. Date: 2011-02-08

Inventor: LI XIAOMING [US]; RAMPRASAD MYSORE [US]; THOMPSON CURTIS [US]; SHEPARD HAROLD MICHAEL [US]; BOOKBINDER LOUIS HOWARD [US]; FROST GREGORY IAN [US]


Publication No.: WO2012109685A1  Published: 23/Aug/2012

Title: PHARMACEUTICAL PREPARATION CONTAINING SELENITE OR SELENITE-CONTAINING COMPOUNDS FOR TREATING CERVICAL DYSPLASIA OR CARCINOMAS

Applicant/Assignee: SELO MEDICAL GMBH

Application No.: WO2012AT00032 (PCT/AT2012/00032)   Filing Date: 16/Feb/2012

Abstract:

The invention relates to compositions containing selenite-containing compounds and pharmaceutically acceptable acids, selected from citric acid, acetic acid, malic acid, carbonic acid, sulphuric acid, nitric acid, hydrochloric acid, fruit acids or mixtures thereof, for use for treating cervical inflammations, dysplasia and/or carcinomas.

Priority: AT20110000201 Applic. Date: 2011-02-16

Inventor: FUCHS NORBERT [AT]


Publication No.: WO2012110057A1  Published: 23/Aug/2012

Title: CEFUROXIME SAFETY KIT

Applicant/Assignee: CHEMISCHES INSTITUT SCHAEFER AG

Application No.: WO2011EP00848 (PCT/EP2011/00848)   Filing Date: 15/Feb/2011

Abstract:

The present invention relates to safety kits for intracameral administration of an appropriate dose of cefuroxime subsequent to cataract and other eye surgery. A preferred embodiment of an cefuroxime safety kit according to the invention comprises (a) a perforable sterile vial sterile-filled with a measured amount of cefuroxime, (b) a sterilized reconstitution syringe, and (c) one or more sterilized delivery syringes.

Priority: WO2011EP00848 Applic. Date: 2011-02-15

Inventor: SCHAEFER ROLF [CH]


Publication No.: WO2012110222A1  Published: 23/Aug/2012

Title: RAPIDLY DISINTEGRATING ORAL FILM FORMULATION FOR OLANZAPIN

Applicant/Assignee: LABTEC GMBH

Application No.: WO2012EP00624 (PCT/EP2012/00624)   Filing Date: 13/Feb/2012

Abstract:

An orally disintegrating film (ODF) which comprises olanzapine or a salt or solvate thereof, polyvinyl alcohol, polyethylene glycol, one or more plasticizers and whereas at least one of the plasticisers is not PEG1000.

Priority: EP20110154395 Applic. Date: 2011-02-14

Inventor: BREITENBACH ARMIN [DE]; SCHWIER NINA [DE]


Publication No.: WO2012110430A1  Published: 23/Aug/2012

Title: NOVEL COMPOSITION FOR TOPICAL USE ON A NAIL

Applicant/Assignee: MOBERG DERMA AB

Application No.: WO2012EP52354 (PCT/EP2012/52354)   Filing Date: 10/Feb/2012

Abstract:

A composition for topical application on a nail comprising urea, a diol and lactic acid or an ester thereof and a volatile vehicle characterized in that urea is soluble in the solvent in the absence of the volatile vehicle, and that urea is in the solid state in the solvent in the presence of the volatile vehicle. Furthermore, a method for the stabilization of urea in a liquid formulation is shown.

Priority: US201161443307P Applic. Date: 2011-02-16; US201161441346P Applic. Date: 2011-02-10

Inventor: LINDAHL AAKE [SE]; KAUFMANN PETER [SE]; WOLPERT PETER [SE]


Publication No.: WO2012110462A1  Published: 23/Aug/2012

Title: LIQUID PROPELLANT-FREE FORMULATION COMPRISING AN ANTIMUSCARINIC DRUG

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: WO2012EP52425 (PCT/EP2012/52425)   Filing Date: 13/Feb/2012

Abstract:

The invention relates to a liquid, propellant-free pharmaceutical formulation for administration by nebulisation comprising a antimuscarinic drug as active ingredient. The invention also relates to the process for the preparation of the formulation and to its use in the prevention and/or treatment of a wide range of conditions including respiratory disorders.

Priority: EP20110154862 Applic. Date: 2011-02-17

Inventor: SOLIANI RASCHINI ANNAMARIA [IT]; LUTERO EMILIO [IT]


Publication No.: WO2012110471A1  Published: 23/Aug/2012

Title: CEFUROXIME SAFETY DELIVERY SYSTEM

Applicant/Assignee: CHEMISCHES INSTITUT SCHAEFER AG

Application No.: WO2012EP52442 (PCT/EP2012/52442)   Filing Date: 14/Feb/2012

Abstract:

The present invention relates to safety delivery systems for intracameral administration of an appropriate dose of cefuroxime subsequent to cataract and other eye surgery. A preferred embodiment of an cefuroxime safety delivery system according to the invention comprises (a) a perforable sterile vial sterile-filled with a measured amount of cefuroxime, (b) a reconstitution syringe with a male luer fitting sterile-filled with 0.1 ml of isotonic salt solution per mg cefuroxime in the perforable vial and a vial adapter with a female luer fitting or one or more needles with female luer fitting, and (c) one or more sterilized delivery syringes with male luer fitting, each delivery syringe being capable of holding at least 0.1 ml of ejectable liquid and containing a marking indicating a fill volume of 0.1 ml of ejectable liquid.

Priority: WO2011EP00848 Applic. Date: 2011-02-15

Inventor: SCHAEFER ROLF [CH]


Publication No.: WO2012110631A1  Published: 23/Aug/2012

Title: PHARMACEUTICAL FORMULATION FOR TOPICAL ADMINISTRATION COMPRISING B220

Applicant/Assignee: VIRONOVA AB

Application No.: WO2012EP52763 (PCT/EP2012/52763)   Filing Date: 17/Feb/2012

Abstract:

A pharmaceutical composition for topical administration comprising 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier. The composition is useful for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject.

Priority: US201161444275P Applic. Date: 2011-02-18; EP20110154979 Applic. Date: 2011-02-18

Inventor: HOMMAN MOHAMMED [SE]; BERGMAN JAN [SE]


Publication No.: WO2012110886A1  Published: 23/Aug/2012

Title: CONTROLLED-RELEASE FORMULATION COMPRISING HCG

Applicant/Assignee: SANZYME LIMITED

Application No.: WO2012IB00272 (PCT/IB2012/00272)   Filing Date: 16/Feb/2012

Abstract:

A controlled-release formulation comprising human chorionic gonadotropin (hCG) or hCG variants, a process of preparation of thereof and use of the formulation are provided herein. The formulation as disclosed in the present invention avoids the need for repeated injections.

Priority: IN2010MU02298 Applic. Date: 2011-02-16

Inventor: PRASAD KOMPELLA VENKATA SUBRAHMANYA [IN]; SOMAN JAY LAXMAN [IN]; VAVIA PRADEEP RATILAL [IN]; VORA LALITKUMAR KHIMJIBHAI [IN]


Publication No.: WO2012112140A1  Published: 23/Aug/2012

Title: EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION COMPRISING METHYLPHENIDATE

Applicant/Assignee: TRIS PHARMA, INC

Application No.: WO2011US24873 (PCT/US2011/24873)   Filing Date: 15/Feb/2011

Abstract:

An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50% or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate - ion exchange resin complex, a barrier coated methylphenidate - ion exchange resin complex - matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 Lo about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.

Priority: WO2011US24873 Applic. Date: 2011-02-15

Inventor: MEHTA KETAN [US]; TU YU-HSING [US]; PERUMAL ASHOK [US]


Publication No.: WO2012112348A1  Published: 23/Aug/2012

Title: METHODS FOR CONTROLLING PAIN IN CANINES USING A TRANSDERMAL SOLUTION OF FENTANYL

Applicant/Assignee: ELI LILLY AND COMPANY

Application No.: WO2012US24218 (PCT/US2012/24218)   Filing Date: 08/Feb/2012

Abstract:

This invention provides methods of controlling pain in a canine comprising transdermally administering a composition comprising fentanyl, a penetration enhancer, and a volatile liquid, wherein the composition is a solution. The invention also provides a single unit dose of the composition.

Priority: US201161442884P Applic. Date: 2011-02-15

Inventor: NEWBOUND GARRET CONRAD [US]; CLARK TERRENCE PATRICK [US]


Publication No.: WO2012112355A1  Published: 23/Aug/2012

Title: METHODS FOR CONTROLLING PAIN IN EQUINES USING A TRANSDERMAL SOLUTION OF FENTANYL

Applicant/Assignee: ELI LILLY AND COMPANY

Application No.: WO2012US24252 (PCT/US2012/24252)   Filing Date: 08/Feb/2012

Abstract:

This invention provides methods of controlling pain in an equine for an effective period of time comprising transdermally administering a composition comprising fentanyl, a penetration enhancer, and a volatile liquid, wherein the composition is a solution. The invention also provides a single unit dose of the composition.

Priority: US201161442878P Applic. Date: 2011-02-15

Inventor: MARR AMY LOUISE [US]; MOUZIN DOUGLAS EUGENE [US]; OWENS JANE GRANVILLE [US]; RIGGS KARI LYNETTE [US]


Publication No.: WO2012112531A1  Published: 23/Aug/2012

Title: STATIN AND OMEGA 3 FATTY ACIDS (EPA, DHA AND DPA) FOR USE IN CARDIOVASCULAR DISEASES

Applicant/Assignee: PIVOTAL THERAPEUTICS, INC

Application No.: WO2012US25026 (PCT/US2012/25026)   Filing Date: 14/Feb/2012

Abstract:

A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught. EPA + DHA are about 80% of the total formulation and about 89% of the total omega 3 fatty acid content of the composition. The formulation may further contain specific amounts of arachidonic acid (AA) and of omega-3 fatty acids having 18 carbon atoms, including one or more of stearidonic acid (SDA) and alpha-linolenic acid (ALA). The application further teaches methods of administering such combinations, and is directed towards unit dosages of such combinations for the reduction of apolipoprotein-B levels.

Priority: US201161457267P Applic. Date: 2011-02-16

Inventor: JACKOWSKI GEORGE [CA]; MACSWEENY RACHELLE [CA]; SHAIKH NISAR [CA]; YANTHA JASON [CA]; SCHINI-KERTH VALERIE [FR]


Publication No.: WO2012112566A1  Published: 23/Aug/2012

Title: PHARMACEUTICAL CREAM COMPOSITIONS OF OXYMETAZOLINE FOR TREATING SYMPTOMS OF ROSACEA

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US25068 (PCT/US2012/25068)   Filing Date: 14/Feb/2012

Abstract:

The present invention is directed to: a) a method of treating telangiectasia

b) a method of treating inflammatory lesions

and c) a method of treating two or more symptoms of rosacea selected from erythema, telangiectasia, or inflammatory lesions comprising topical administration of a pharmaceutical composition comprising oxymetazoline and a pharmaceutically acceptable excipient.

Priority: US201161443210P Applic. Date: 2011-02-15

Inventor: SHANLER STUART D [US]; POWALA CHRISTOPHER [US]


Publication No.: WO2012113060A1  Published: 30/Aug/2012

Title: APPARATUS FOR THE CONTROLLED RELEASE OF TOPICAL NITRIC OXIDE

Applicant/Assignee: UNIVERSITY OF WINDSOR

Application No.: WO2012CA00157 (PCT/CA2012/00157)   Filing Date: 22/Feb/2012

Abstract:

A stable delivery system for the therapeutic release and application of nitric oxide to a patient suffering from a cutaneous injury or wound includes a S-nitrosothiol and transition element nanoparticles. The transition metal nanoparticles are selected to react with the S- nitrosothiol to release and diffuse nitric oxide into the injury or wound.

Priority: US201161457318P Applic. Date: 2011-02-25

Inventor: MUTUS BULENT [CA]; JAROSZ ARTHUR [CA]; FACCENDA ADAM [CA]; ZHANG XUEJI [US]


Publication No.: WO2012113564A1  Published: 30/Aug/2012

Title: STABILIZED GRANULES CONTAINING GLYCERYL TRINITRATE

Applicant/Assignee: G. POHL-BOSKAMP GMBH & CO. KG

Application No.: WO2012EP00803 (PCT/EP2012/00803)   Filing Date: 24/Feb/2012

Abstract:

Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight% glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer.

Priority: DE201110012491 Applic. Date: 2011-02-25

Inventor: ZIMMECK THOMAS [DE]; UECK HENNING [DE]; ZSCHERPE JULIA [DE]


Publication No.: WO2012113894A1  Published: 30/Aug/2012

Title: PHARMACEUTICAL COMBINATION OF BETAHISTINE AND TRIMETAZIDINE

Applicant/Assignee: DEVA HOLDING ANONIM SIRKETI

Application No.: WO2012EP53122 (PCT/EP2012/53122)   Filing Date: 24/Feb/2012

Abstract:

This invention is related to pharmaceutical combination of betahistine or pharmaceutically acceptable salts thereof and trimetazidine or pharmaceutically acceptable salts thereof.

Priority: EP20110155916 Applic. Date: 2011-02-25

Inventor: HAAS PHILIPP DANIEL [TR]; KOC FIKRET [TR]; SIVASLIGIL RAMAZAN [TR]; KANDEMIR LEVENT [TR]


Publication No.: WO2012114051A1  Published: 30/Aug/2012

Title: CUTANEOUS PHARMACEUTICAL COMPOSITIONS FOR THE LOCAL TREATMENT OF CANINE ATOPIC DERMATITIS

Applicant/Assignee: PHYSICA PHARMA SAS

Application No.: WO2012FR50392 (PCT/FR2012/50392)   Filing Date: 24/Feb/2012

Abstract:

The invention relates to a topical pharmaceutical composition which can be administered by applying same to the skin, for the use thereof as a cutaneous veterinary drug for the local treatment of canine atopic dermatitis. The composition contains cyclosporin A as an active ingredient. In a particular embodiment, said composition contains sodium N-cocoyl alaninate.

Priority: FR20110000579 Applic. Date: 2011-02-24

Inventor: POUGNAS JEAN-LUC [FR]; COURIERE LAURIE [FR]; BEUVRY VINCENT [FR]; BROUSSAUD OLIVIER [FR]


Publication No.: WO2012114054A1  Published: 30/Aug/2012

Title: LOCALLY ACTING PHARMACEUTICAL COMPOSITIONS WHICH CAN BE ADMINISTERED BY CUTANEOUS APPLICATION

Applicant/Assignee: PHYSICA PHARMA SAS

Application No.: WO2012FR50397 (PCT/FR2012/50397)   Filing Date: 24/Feb/2012

Abstract:

Locally acting pharmaceutical compositions which can be administered by cutaneous application, comprising a product for condensation of a specific amino acid with at least one fatty acid included in coconut oil and a therapeutic agent.

Priority: FR20110000577 Applic. Date: 2011-02-24

Inventor: POUGNAS JEAN-LUC [FR]; BROUSSAUD OLIVIER [FR]


Publication No.: WO2012114131A1  Published: 30/Aug/2012

Title: LECITHIN:CHOLESTEROL ACYLTRANSFERASE (LCAT) AND ITS ROLE IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Applicant/Assignee: UNIVERSITY OF PATRAS

Application No.: WO2011GR00026 (PCT/GR2011/00026)   Filing Date: 08/Jul/2011

Abstract:

Lecithin:cholesterol acyltransferase (LCAT) is responsible for the esterification of the free cholesterol of plasma lipoproteins. In the present invention, we describe the role of LCAT in hepatic triglyceride accumulation and the development of diet-induced nonalcoholic fatty liver disease (NAFLD). LCAT is described as a novel therapeutic agent for the treatment of NAFLD.

Priority: GR20110100124 Applic. Date: 2011-02-25

Inventor: KYPREOS KYRIAKOS E [GR]; PAPACHRISTOU DIONYSIOS J [GR]


Publication No.: WO2012115207A1  Published: 30/Aug/2012

Title: BIOLOGICALLY ACTIVE NONAQUEOUS COMPOSITION FOR MICRONEEDLE DEVICES, AND BIOLOGICALLY ACTIVE NONAQUEOUS COMPOSITION ADHERING TO MICRONEEDLE

Applicant/Assignee: HISAMITSU PHARMACEUTICAL CO., INC

Application No.: WO2012JP54464 (PCT/JP2012/54464)   Filing Date: 23/Feb/2012

Abstract:

A biologically active nonaqueous composition for microneedle devices, which contains a polyhydric alcohol, a biologically active substance, and at least one compound that is selected from the group consisting of hydroxypropyl cellulose, polyethylene glycol, chondroitin sulfate, hyaluronic acid, dextran, croscarmellose sodium and metal chlorides.

Priority: JP20110038692 Applic. Date: 2011-02-24

Inventor: MATSUDO TOSHIYUKI [JP]; MORIMOTO KUMI [JP]; NISHIMURA SHINPEI [JP]; TOKUMOTO SEIJI [JP]


Publication No.: WO2012115640A1  Published: 30/Aug/2012

Title: LIQUID INSULIN- CONTAINING COMPOSITIONS AND METHODS OF MAKING THE SAME

Applicant/Assignee: ELONA BIOTECHNOLOGIES

Application No.: WO2011US25928 (PCT/US2011/25928)   Filing Date: 23/Feb/2011

Abstract:

Disclosed herein are novel and improved preparations and methods for manufacturing substantially liquid preparations of recombinant human insulin API. The purified recombinant human insulin Active Pharamaceutical Ingredient (API) preparations are substantially free of by not products associated with the lyophilization and/or crystallization. The methods for manufacturing the substantially liquid recombinant human insulin API preparations are provided with optional steps for subjecting the recombinant insulin preparation to lyophilization and/or crystallization. Enhanced yield of recombinant insulin of greater purity are thereby provided according to the present invention. Highly purified formulations of recombinant human insulin of the API insulin preparations disclosed herein are also provided. Stably transformed E. coli cell banks (MCB) capable of expressing the recombinant human insulin are also provided.

Priority: WO2011US25928 Applic. Date: 2011-02-23

Inventor: ZIMMERMAN RONALD E [US]; STOKELL DAVID JOHN [US]; AKERS MICHAEL PATRICK [US]


Publication No.: WO2012115771A2  Published: 30/Aug/2012

Title: SYSTEMS AND METHODS FOR THERAPY OF KIDNEY DISEASE AND/OR HEART FAILURE USING CHIMERIC NATRIURETIC PEPTIDES

Applicant/Assignee: MEDTRONIC, INC

Application No.: WO2012US24203 (PCT/US2012/24203)   Filing Date: 07/Feb/2012

Abstract:

Medical systems and methods for treating kidney disease alone, heart failure alone, kidney disease with concomitant heart failure, or cardiorenal syndrome are described. The systems and methods are based on delivery of a chimeric natriuretic peptide to a patient. Methods for increasing peptide levels include direct peptide delivery via either an external or implantable programmable pump.

Priority: US201161447001P Applic. Date: 2011-02-25; US201161548689P Applic. Date: 2011-10-18; US201161548708P Applic. Date: 2011-10-18

Inventor: VAN ANTWERP WILLIAM [US]; MANDA VENKATESH R [US]; WALSH ANDREW J L [US]; BURNES JOHN [US]; EVANS DARON [US]; LIEU HSIAO [US]


Publication No.: WO2012116272A2  Published: 30/Aug/2012

Title: POLYMER CONJUGATED PROTEIN MICELLES

Applicant/Assignee: SOUTH DAKOTA STATE UNIVERSITY

Application No.: WO2012US26484 (PCT/US2012/26484)   Filing Date: 24/Feb/2012

Abstract:

The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. The invention also encompasses a prolamine protein conjugated to a polymer, such as a polyethylene glycol (PEG) chain, which conjugates can be used to prepare micelle assemblies. The invention further encompasses methods of encapsulating molecules using the conjugates of the invention. The micelle assemblies can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of an encapsulated agent in vivo, protecting an encapsulated agent against degradation, and enhancing the water solubility of a drug or other agent.

Priority: US201161446931P Applic. Date: 2011-02-25

Inventor: PERUMAL OMATHANU P [US]; PODARALLA SATHEESH [US]; AVERINENI RANJITH KUMAR [US]


Publication No.: WO2012116714A1  Published: 07/Sep/2012

Title: VACCINATION IN ELDERLY PATIENTS

Applicant/Assignee: CUREVAC GMBH

Application No.: WO2011EP01043 (PCT/EP2011/01043)   Filing Date: 02/Mar/2011

Abstract:

The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Priority: WO2011EP01043 Applic. Date: 2011-03-02

Inventor: KALLEN KARL-JOSEF [DE]; KRAMPS THOMAS [DE]; SCHNEE MARGIT [DE]; PETSCH BENJAMIN [DE]; STITZ LOTHAR [DE]


Publication No.: WO2012116715A1  Published: 07/Sep/2012

Title: VACCINATION IN NEWBORNS AND INFANTS

Applicant/Assignee: CUREVAC GMBH

Application No.: WO2011EP01047 (PCT/EP2011/01047)   Filing Date: 02/Mar/2011

Abstract:

The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Priority: WO2011EP01047 Applic. Date: 2011-03-02

Inventor: KALLEN KARL-JOSEF [DE]; KRAMPS THOMAS [DE]; SCHNEE MARGIT [DE]; PETSCH BENJAMIN [DE]; STITZ LOTHAR [DE]


Publication No.: WO2012116744A1  Published: 07/Sep/2012

Title: CHEMICAL COMPOSITION WITH HYDROGEN PEROXIDE AND A NANOEMULSION OF LONG-CHAINED ALCOHOLS

Applicant/Assignee: PIBED LIMITED

Application No.: WO2011EP53100 (PCT/EP2011/53100)   Filing Date: 02/Mar/2011

Abstract:

The present invention provides a chemical composition comprised of hydrogen peroxide and a nanoemulsion of long-chained alcohols which in combination these constituents act synergisticaliy boost the kill-time rate of hydrogen peroxide. The peroxide based nanoemulsion formulation for application to skin includes a cosmetically approved peroxide containing compound present in a range to give from about 0.1 to about 4 wt./wt. % released hydrogen peroxide, an organic acid present in a concentration from about 0.01 to about 5 wt./wt. % for adjusting a pH of the formulation in a range from about pH 1 to about pH 4, a long-chained (C9 to C22) aryl and/or alky! alcohol, present in a concentration from about 0.1 to about 20 wt./wt. %, and an emollient present in a concentration from about 0.1 to about 40 wt./wt. %, and an emulsifier present in a concentration from about 0.1 to about 20 wt./wt. % to render the formulation a nanoemulsion.

Priority: WO2011EP53100 Applic. Date: 2011-03-02

Inventor: GRASCHA PIERRE BRUNO [FR]; BATTUT MYLENE [FR]


Publication No.: WO2012116810A1  Published: 07/Sep/2012

Title: VACCINATION IN NEWBORNS AND INFANTS

Applicant/Assignee: CUREVAC GMBH

Application No.: WO2012EP00877 (PCT/EP2012/00877)   Filing Date: 29/Feb/2012

Abstract:

The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Priority: WO2011EP01047 Applic. Date: 2011-03-02

Inventor: KALLEN KARL-JOSEF [DE]; KRAMPS THOMAS [DE]; SCHNEE MARGIT [DE]; PETSCH BENJAMIN [DE]; STITZ LOTHAR [DE]


Publication No.: WO2012116811A1  Published: 07/Sep/2012

Title: VACCINATION IN ELDERLY PATIENTS

Applicant/Assignee: CUREVAC GMBH

Application No.: WO2012EP00878 (PCT/EP2012/00878)   Filing Date: 29/Feb/2012

Abstract:

The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

Priority: WO2011EP01043 Applic. Date: 2011-03-02

Inventor: KALLEN KARL-JOSEF [DE]; KRAMPS THOMAS [DE]; SCHNEE MARGIT [DE]; PETSCH BENJAMIN [DE]; STITZ LOTHAR [DE]


Publication No.: WO2012116976A1  Published: 07/Sep/2012

Title: PRUCALOPRIDE ORAL SOLUTION

Applicant/Assignee: SHIRE - MOVETIS NV

Application No.: WO2012EP53341 (PCT/EP2012/53341)   Filing Date: 28/Feb/2012

Abstract:

The present invention is concerned with an oral aqueous solution comprising prucalopride or pharmaceutically acceptable acid addition salts thereof having good organoleptic properties.

Priority: GB20110003397 Applic. Date: 2011-02-28

Inventor: EMBRECHTS ROGER CAROLUS AUGUSTA [BE]


Publication No.: WO2012117140A1  Published: 07/Sep/2012

Title: THERMOSENSITIVE COMPOUND FOR THE CONTROLLED RELEASE OF ACTIVE OR INDICATOR SUBSTANCES

Applicant/Assignee: UNIVERSIDAD POLITECNICA DE VALENCIA

Application No.: WO2012ES70120 (PCT/ES2012/70120)   Filing Date: 28/Feb/2012

Abstract:

The invention relates to a thermosensitive compound for the controlled release of at least one active or indicator substance, characterised in that it comprises: (a) a porous substrate comprising a set of pores containing said active or indicator substance

and (b) an interface layer comprising molecules of a lipophilic nature, said molecules comprising a first end covalently bound to the porous substrate and a second end consisting of lipophilic organic chains bound by non-covalent interactions to a thermosensitive superficial layer situated above the surface of the porous substrate, covering the pores, each thermosensitive superficial layer comprising organic substances of a non-polymeric, lipophilic nature, that, above a threshold value, decrease the interaction thereof with the interface layer, unblocking the pores of the porous substrate and releasing the active or indicator substance. The invention also relates to the method for producing said compound and to the use of said compound for the controlled release of active and indicator substances.

Priority: ES20110030265 Applic. Date: 2011-03-01

Inventor: AZNAR GIMENO ELENA [ES]; MARCOS MARTINEZ MARIA DOLORES [ES]; MARTINEZ MANEZ RAMON [ES]; ROS LIS JOSE VICENTE [ES]; SANCENON GALARZA FELIX [ES]; SOTO CAMINO JUAN [ES]


Publication No.: WO2012117257A1  Published: 07/Sep/2012

Title: DIETHYLSTILBESTROL DOSAGE FORM AND USE FOR THE TREATMENT OF PROSTATE OR BREAST CANCER

Applicant/Assignee: NAL PHARMACEUTICALS LTD, WALLACE, SHEILA JANE

Application No.: WO2012GB50475 (PCT/GB2012/50475)   Filing Date: 02/Mar/2012

Abstract:

Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly diethylstilbestrol and pharmaceutically acceptable salts thereof to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.

Priority: US201113040143 Applic. Date: 2011-03-03

Inventor: CHOW DIANA SHU-LIAN [US]; AKO ROLAND A [US]; RYOO JE PHIL [US]; CHU CHUN KWONG [CN]; WANG ZHENG [US]


Publication No.: WO2012119059A1  Published: 07/Sep/2012

Title: NON-AQUEOUS SILICONE-BASED OPHTHALMIC FORMULATIONS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US27443 (PCT/US2012/27443)   Filing Date: 02/Mar/2012

Abstract:

Non-aqueous compositions including a silicone based excipient and methods of their use are provided. The non-aqueous compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases

Priority: US201161448899P Applic. Date: 2011-03-03; US201161448890P Applic. Date: 2011-03-03; US201161529553P Applic. Date: 2011-08-31; US201161565447P Applic. Date: 2011-11-30

Inventor: WARNER KEVIN [US]; PARASHAR AJAY [US]


Publication No.: WO2012119070A2  Published: 07/Sep/2012

Title: SILICONE-BASED OPHTHALMIC FORMULATIONS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US27462 (PCT/US2012/27462)   Filing Date: 02/Mar/2012

Abstract:

Compositions, products and methods including silicone based excipients are provided. The compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases.

Priority: US201161448899P Applic. Date: 2011-03-03; US201161448890P Applic. Date: 2011-03-03; US201161529553P Applic. Date: 2011-08-31; US201161565447P Applic. Date: 2011-11-30

Inventor: WARNER KEVIN [US]; PARASHAR AJAY [US]


Publication No.: WO2012119560A1  Published: 13/Sep/2012

Title: PREPARATION METHOD FOR EXTRACTIVE OF JINXUAN HEMORRHOID WASHING POWDER BOTANICALS

Applicant/Assignee: MAYINGLONG PHARMACEUTICAL GROUP CO., LTD

Application No.: WO2012CN72093 (PCT/CN2012/72093)   Filing Date: 08/Mar/2012

Abstract:

A preparation method for extractive of Jinxuan Hemorrhoid Washing Powder botanicals comprises the steps: A, honeysuckle, schizonepeta, and purslane in the prescription of Jinxuan Hemorrhoid Washing Powder are mixed, ground, and passed through a mesh

the medicinal powder obtained from supercritical extraction is soaked in alcohol, then undergoes percolation extraction, and the percolate is collected

B, the alcohol percolate is concentrated, left stand, and suction filtrated to obtain a filtrate

C, the filtrate macroporously adsorpts to a resin column at a flow velocity, is then removed of impurity by water washing, and undergoes elution with alcohol to obtain an alcohol eluent

D, alcohol is recovered from the eluent, the remaining liquid is concentrated, and the concentrated liquid is dried to obtain the extractive of Jinxuan Hemorrhoid Washing Powder botanicals. The method is simple and produces high active substance content at a lower production cost and energy consumption. The total content of flavones, saponins, and organic acids exceeds 70%. The extractive has substantial anti-inflammatory and pain relieving effects.

Priority: CN20111055689 Applic. Date: 2011-03-08

Inventor: LIU YANWEN [CN]; CHEN SHUHE [CN]; WANG HUI [CN]; LI YAPING [CN]; ZHOU LU [CN]; ZHANG WENYING [CN]; LIU WEI [CN]


Publication No.: WO2012119727A1  Published: 13/Sep/2012

Title: AQUEOUS PHARMACEUTICAL FORMULATION OF TAPENTADOL FOR ORAL ADMINISTRATION

Applicant/Assignee: GRUENENTHAL GMBH

Application No.: WO2012EP00904 (PCT/EP2012/00904)   Filing Date: 02/Mar/2012

Abstract:

The invention relates to an aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.

Priority: EP20110003601 Applic. Date: 2011-05-03; US201161449287P Applic. Date: 2011-03-04

Inventor: REINHOLD ULRICH [DE]; SCHILLER MARC [DE]; WULSTEN EVA [DE]; INGHELBRECHT SABINE KARINE KATRIEN [BE]; EMBRECHTS ROGER CAROLUS AUGUSTA [BE]


Publication No.: WO2012119728A1  Published: 13/Sep/2012

Title: PARENTERAL ADMINISTRATION OF TAPENTADOL

Applicant/Assignee: GRUENENTHAL GMBH

Application No.: WO2012EP00905 (PCT/EP2012/00905)   Filing Date: 02/Mar/2012

Abstract:

The invention relates to an aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4.

Priority: US201161449317P Applic. Date: 2011-03-04; EP20110003602 Applic. Date: 2011-05-03

Inventor: CHRISTOPH THOMAS [DE]; INGHELBRECHT SABINE KARINE KATRIEN [BE]; EMBRECHTS ROGER CAROLUS AUGUSTA [BE]


Publication No.: WO2012119729A1  Published: 13/Sep/2012

Title: SEMISOLID AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING TAPENTADOL

Applicant/Assignee: GRUENENTHAL GMBH

Application No.: WO2012EP00906 (PCT/EP2012/00906)   Filing Date: 02/Mar/2012

Abstract:

The invention relates to a semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.

Priority: US201161449329P Applic. Date: 2011-03-04; EP20110003603 Applic. Date: 2011-05-03

Inventor: REINHOLD ULRICH [DE]; SCHILLER MARC [DE]; WULSTEN EVA [DE]; INGHELBRECHT SABINE KARINE [BE]; EMBRECHTS ROGER CAROLUS AUGUSTA [BE]


Publication No.: WO2012119781A2  Published: 13/Sep/2012

Title: NOVEL LIPIDS, PHOSPHOLIPIDS, PHOSPHOLIPID AND LIPID COMPOSITIONS AND THEIR USE

Applicant/Assignee: UNIVERSITY OF GENEVA, UNIVERSITY HOSPITALS OF GENEVA, UNIVERSITY OF BASEL

Application No.: WO2012EP01053 (PCT/EP2012/01053)   Filing Date: 09/Mar/2012

Abstract:

The invention relates to a composition comprising or consisting of 1,3-diamidophospholipids or/and 1,2-diamidophospholipids or/and 2,3-diamidophospholopids or/and another lipid and preferably at least a further compound which compound is i. at least one natural lipid, ii. at least one synthetic lipid, iii. cholesterol or a cholesterol derivative or/and a surfactant, methods of making same, nanoparticles comprising same and their medical and non-medical use.

Priority: US201161451153P Applic. Date: 2011-03-10

Inventor: SAXER TILL [FR]; ZUMBUEHL ANDREAS [CH]; MULLER BERT [CH]; FEDOTENKO ILLYA [CH]; HOLME MARGARET [CH]; ZAFFALON PIERRE-LEONARD [FR]


Publication No.: WO2012119907A1  Published: 13/Sep/2012

Title: METHOD OF PROTECTING BIOLOGICALLY ACTIVE SUBSTANCES AGAINST DENATURATION

Applicant/Assignee:

Application No.: WO2012EP53454 (PCT/EP2012/53454)   Filing Date: 29/Feb/2012

Abstract:

A method of protecting a biologically active substance against denaturation, wherein a liquid (14) containing the active substance and a matrix-forming substance is deposited on a target surface (18) and dried so as to form a solid amorphous matrix (26) with the molecules of the active substance embedded therein, wherein an ink jet printer (10) is used for depositing the liquid (14) on the target surface (16) in the form of droplets (12) having a volume small enough to cause the liquid to dry when it impinges on the target surface (16) and to be held on the target surface through adhesion.

Priority: EP20110157399 Applic. Date: 2011-03-09

Inventor: BIEMANS ROGIER [NL]


Publication No.: WO2012119997A1  Published: 13/Sep/2012

Title: PHARMACEUTICAL FORMULATION FOR PRODUCING RAPIDLY DISINTEGRATING TABLETS

Applicant/Assignee: BASF SE

Application No.: WO2012EP53771 (PCT/EP2012/53771)   Filing Date: 06/Mar/2012

Abstract:

Pharmaceutical formulation in the form of granules comprising a) 60% - 96% by weight of non-film-forming sugars or sugar alcohols, b) 1% - 10% by weight of film-forming sugars or sugar alcohols, c) 3% - 25% by weight of disintegrants, d) 0% - 10% by weight of water-insoluble, film-forming polymers, e) 0% - 15% by weight of further, customary pharmaceutical excipients, the sum of components a) to e) being 100% by weight.

Priority: EP20110157458 Applic. Date: 2011-03-09

Inventor: KOLTER KARL [DE]; GEBERT SILKE [DE]; KRUSE SANDRA [DE]; SCHOENHERR MICHAEL [DE]


Publication No.: WO2012120082A1  Published: 13/Sep/2012

Title: ADENOSINE AND DERIVATIVES THEREOF FOR USE IN PAIN THERAPY

Applicant/Assignee: ARISTOCON GMBH & CO. KG

Application No.: WO2012EP54016 (PCT/EP2012/54016)   Filing Date: 08/Mar/2012

Abstract:

This invention relates to the use of adenosine and derivatives thereof for the treatment of pain. Adenosine and derivatives have proved to be effective in the treatment of neuropathic pain. On local treatment in particular, good results have been achieved. This invention presents not only suitable uses but also medicaments which can be used advantageously.

Priority: DE201110005232 Applic. Date: 2011-03-08

Inventor: WEITSCHIES WERNER [DE]; MUTSCHLER ERNST [DE]; BLUME HENNING [DE]


Publication No.: WO2012120139A1  Published: 13/Sep/2012

Title: IMPLANTABLE BIO-RESORBABLE POLYMER CHARGED WITH FRAGILE MACROMOLECULES

Applicant/Assignee: OCCLUGEL, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS DIDEROT - PARIS 7

Application No.: WO2012EP54178 (PCT/EP2012/54178)   Filing Date: 09/Mar/2012

Abstract:

The present invention relates to a macromolecule-loaded bioresorbable crosslinked polymer wherein the polymer is obtainable from the polymerization of: (i) at least one monomer of formula (I) (CH2=CR1)CO-K wherein: - K represents O-Z or NH-Z, Z representing (CR2R3)m-CH3, (CH2-CH2-O)m-H, (CH2-CH2-O)m-CH3, (CH2)m-NR4R5 with m representing an integer from 1 to 30

- R1, R2, R3, R4 and R5 independently represent H or a C1 -C6 alkyl

and (ii) at least one bio-resorbable block copolymer cross-linker, and wherein the macromolecule is chosen in the group consisting of proteins and nucleic acids.

Priority: EP20110305253 Applic. Date: 2011-03-09; US201161450733P Applic. Date: 2011-03-09

Inventor: MAGNON LAURENCE [FR]; LAURENT ALEXANDRE [FR]; WASSEF MICHEL [FR]; BEDOUET LAURENT [FR]; LOUGUET STEPHANIE [FR]; VERRET VALENTIN [FR]; SERVAIS EMELINE [FR]


Publication No.: WO2012120284A1  Published: 13/Sep/2012

Title: USE OF GLYCOPYRROLATE FOR TREATING TACHYCARDIA

Applicant/Assignee: SOSEI R&D LTD

Application No.: WO2012GB50478 (PCT/GB2012/50478)   Filing Date: 05/Mar/2012

Abstract:

The invention relates to a novel use of the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the invention relates to glycopyrrolate for use as a heart rate lowering agent and more particularly, but not exclusively, for use in patients suffering from respiratory conditions such as chronic obstructive pulmonary disease.

Priority: GB20110003770 Applic. Date: 2011-03-04; GB20120002256 Applic. Date: 2012-02-09

Inventor: SNAPE SUSAN [GB]; TANSLEY ROBERT [GB]


Publication No.: WO2012120337A1  Published: 13/Sep/2012

Title: Aqueous paracetamol compositions and method of preparation

Applicant/Assignee: EMP PHARMA GMBH

Application No.: WO2011IB50994 (PCT/IB2011/50994)   Filing Date: 10/Mar/2011

Abstract:

The invention relates to a liquid composition suitable for parenteral administration, comprising at least 1 mg/ml of acetaminophen. The invention also relates to a method of preparation of such a composition. The liquid composition may comprise at least one pharmaceutically acceptable chelating agent and/or a tonicity agent and/or an antioxidant and/or a solubilising agent, and is suitable for intravenous injection and/or intramuscular injection.

Priority: WO2011IB50994 Applic. Date: 2011-03-10

Inventor: PSARRAKIS YANNIS [GR]; LIOUMIS KOSTA [GR]


Publication No.: WO2012121988A2  Published: 13/Sep/2012

Title: METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS

Applicant/Assignee: CELGENE CORPORATION

Application No.: WO2012US27368 (PCT/US2012/27368)   Filing Date: 02/Mar/2012

Abstract:

Methods of treating a disease selected from dermatomyositis, prurigo nodularis, pyoderma gangrenosum, alopecia areata, hidradenitis suppurtiva, rosacea, lichen planus, giant cell arteritis, Sjogren's syndrome, gout, chronic prostatitis, posterior uveitis, vulvodynia and interstitial cystitis in a human are disclosed. Specific methods encompass the administration of (+)-2-[l-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-l,3-dione, cyclopropyl {2-[(15)-l-(3-ethoxy-4-methoxyphenyl)-2- (methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide or a combination thereof, or a pharmaceutically acceptable prodrug, metabolite, polymorph, salt, solvate or clathrate thereof.

Priority: US201161449716P Applic. Date: 2011-03-07

Inventor: SCHAFER PETER H [US]; SHANKAR SAI [US]


Publication No.: WO2012122162A1  Published: 13/Sep/2012

Title: MICRONEEDLE DEVICES AND METHODS

Applicant/Assignee: 3M INNOVATIVE PROPERTIES COMPANY

Application No.: WO2012US27857 (PCT/US2012/27857)   Filing Date: 06/Mar/2012

Abstract:

A medical device, comprising: an array of microneedles, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof

and a local anesthetic dose-extending component selected from the group consisting of alpha 1 adrenergic agonists, alpha 2 adrenergic agonists, and a combination thereof

wherein the local anesthetic is present in an amount of at least 1 wt-% based upon total weight of solids in the coating, and wherein the dose-extending component/local anesthetic weight ratio is at least 0.0001

a medical device, comprising an array of dissolvable microneedles, the microneedles comprising: a dissolvable matrix material

at least 1 wt-% of a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof

and a local anesthetic dose-extending component selected from the group consisting of alpha 1 adrenergic agonists, alpha 2 adrenergic agonists, and a combination thereof

wherein the dose-extending component/local anesthetic weight ratio is at least 0.0001, and wherein wt-% is based upon total weight of solids in all portions of the dissolvable microneedles which contain the local anesthetic

a method of extending a topically delivered local anesthetic dose in mammalian tissue using the devices

and methods of making the devices are provided.

Priority: US201161449993P Applic. Date: 2011-03-07

Inventor: ZHANG YING [US]; HANSEN KRISTEN J [US]; DETERMAN AMY S [US]


Publication No.: WO2012122163A1  Published: 13/Sep/2012

Title: MICRONEEDLE DEVICES AND METHODS

Applicant/Assignee: 3M INNOVATIVE PROPERTIES COMPANY

Application No.: WO2012US27858 (PCT/US2012/27858)   Filing Date: 06/Mar/2012

Abstract:

A medical device, comprising: an array of microneedles, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof

and a local anesthetic dose-extending component selected from the group consisting of tetracaine, ropivacaine, bupivacaine, procaine and a combination thereof

wherein the local anesthetic is present in an amount of at least 1 wt-% based upon total weight of solids in the coating, and wherein the local anesthetic and dose-extending component are in a non-eutectic weight ratio

a medical device, comprising an array of dissolvable microneedles, the microneedles comprising: a dissolvable matrix material

at least 1 wt-% of a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof

and a local anesthetic dose-extending component selected from the group consisting of tetracaine, ropivacaine, bupivacaine, procaine and a combination thereof

wherein the local anesthetic and dose-extending component are in a non-eutectic weight ratio, and wherein wt-% is based upon total weight of solids in all portions of the dissolvable microneedles which contain the local anesthetic

a method of extending a topically delivered local anesthetic dose in mammalian tissue using the devices

and methods of making the devices are provided.

Priority: US201161449988P Applic. Date: 2011-03-07

Inventor: ZHANG YING [US]; HANSEN KRISTEN J [US]; DETERMAN AMY S [US]


Publication No.: WO2012122295A2  Published: 13/Sep/2012

Title: TREATMENT FOR PANCREATIC ADENOCARCINOMA AND OTHER CANCERS OF EPITHELIAL ORIGIN

Applicant/Assignee: NED BIOSYSTEMS, INC

Application No.: WO2012US28112 (PCT/US2012/28112)   Filing Date: 07/Mar/2012

Abstract:

The present invention is directed to compositions and methods for the treatment of pancreatic cancer. Compositions comprising a plurality of nutraceutical and non-chemotherapeutic drug components directed to addressing cancer-supportive processes in a patient are disclosed.

Priority: US201161450049P Applic. Date: 2011-03-07

Inventor: LAMBERT REBECCA [US]


Publication No.: WO2012122535A2  Published: 13/Sep/2012

Title: STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS

Applicant/Assignee: XERIS PHARMACEUTICALS, INC

Application No.: WO2012US28621 (PCT/US2012/28621)   Filing Date: 09/Mar/2012

Abstract:

Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.

Priority: US201161451568P Applic. Date: 2011-03-10; US201161478692P Applic. Date: 2011-04-25; US201161553388P Applic. Date: 2011-10-31; US201261609123P Applic. Date: 2012-03-09

Inventor: PRESTRELSKI STEVEN [US]; KINZELL JOHN [US]


Publication No.: WO2012123466A1  Published: 20/Sep/2012

Title: USE OF A SPRAYABLE COMPOSITION COMPRISING AMBROXOL

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: WO2012EP54406 (PCT/EP2012/54406)   Filing Date: 13/Mar/2012

Abstract:

The present invention relates to ambroxol hydrochloride for the treatment of acute pharyngitis, where ambroxol hydrochloride as a sprayable composition comprising up to 30 mg/ml ambroxol hydrochloride is administered locally in a dose of 1 to 20 mg.

Priority: EP20110158043 Applic. Date: 2011-03-14

Inventor: SAUERLAND SANDRA [DE]; BONI JULIA [DE]; PLOHMANN BERND [DE]


Publication No.: WO2012123515A1  Published: 20/Sep/2012

Title: AN OPHTHALMIC COMPOSITION

Applicant/Assignee: DRUG DELIVERY SOLUTIONS LIMITED

Application No.: WO2012EP54498 (PCT/EP2012/54498)   Filing Date: 14/Mar/2012

Abstract:

An ophthalmic composition comprising a polyaphron dispersion.

Priority: EP20110158099 Applic. Date: 2011-03-14

Inventor: STEELE FRASER [GB]


Publication No.: WO2012123539A1  Published: 20/Sep/2012

Title: TREATMENT OF VAGINAL ATROPHY AS NOVEL INDICATION FOR MYRRH

Applicant/Assignee: SONIA PHARMA GMBH

Application No.: WO2012EP54548 (PCT/EP2012/54548)   Filing Date: 15/Mar/2012

Abstract:

The invention relates to a novel medical indication of myrrh, namely the treatment of vaginal atrophy as menopausal symptom. The invention further relates to a pharmaceutical preparation in vaginal dosage form for the treatment of vaginal atrophy and a method for preparing a pharmaceutical preparation against vaginal atrophy as menopausal symptom.

Priority: EP20110158593 Applic. Date: 2011-03-17; US201113050225 Applic. Date: 2011-03-17

Inventor: BRANDT EVA [DE]


Publication No.: WO2012123720A1  Published: 20/Sep/2012

Title: COLONOSCOPY - PREPARATION

Applicant/Assignee: NORGINE BV

Application No.: WO2012GB50526 (PCT/GB2012/50526)   Filing Date: 09/Mar/2012

Abstract:

The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid,or a mixture thereof

and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: -administering to the subject an effective amount of a first cleansing solution

and then after a time interval -administering to the subject an effective amount of a second cleansing solution, where in the two cleansing solutions are as described in the specification.

Priority: GB20110004202 Applic. Date: 2011-03-11; GB20110004200 Applic. Date: 2011-03-11; GB20110014629 Applic. Date: 2011-08-23

Inventor: HALPHEN MARC [GB]; GRUSS HANS-JUERGEN [GB]; COX IAN [GB]; COCKETT ALASDAIR [GB]; STEIN PETER [GB]; UNGAR ALEX [GB]


Publication No.: WO2012125020A1  Published: 20/Sep/2012

Title: METHOD FOR TREATING NEUROTRAUMA

Applicant/Assignee: N.V. NUTRICIA

Application No.: WO2011NL50176 (PCT/NL2011/50176)   Filing Date: 14/Mar/2011

Abstract:

The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof

ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6

DHA), eicosapentaenoic acid (20:5

EPA) and docosapentaenoic acid (22:5

DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight% of a- linolenic acid (ALA), calculated on the weight of all fatty acids

iii) choline, or salts or esters thereof

for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.

Priority: WO2011NL50176 Applic. Date: 2011-03-14

Inventor: DE WILDE MATTHEUS CORNELIS [NL]; SIJBEN JOHANNES WILHELMUS CHRISTINA [NL]; KAMPHUIS PATRICK JOSEPH GERARDUS HENDRIKUS [NL]; HAGEMAN ROBERT JOHAN JOSEPH [NL]


Publication No.: WO2012125034A1  Published: 20/Sep/2012

Title: METHOD FOR TREATING NEUROTRAUMA

Applicant/Assignee: N.V. NUTRICIA

Application No.: WO2012NL50158 (PCT/NL2012/50158)   Filing Date: 14/Mar/2012

Abstract:

The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof

ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6

DHA), eicosapentaenoic acid (20:5

EPA) and docosapentaenoic acid (22:5

DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight% of ?- linolenic acid (ALA), calculated on the weight of all fatty acids

iii) choline, or salts or esters thereof

for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsyand spinal cord injury.

Priority: WO2011NL50176 Applic. Date: 2011-03-14

Inventor: DE WILDE MATTHEUS CORNELIS [NL]; SIJBEN JOHANNES WILHELMUS CHRISTINA [NL]; KAMPHUIS PATRICK JOSEPH GERARDUS HENDRIKUS [NL]; HAGEMAN ROBERT JOHAN JOSEPH [NL]


Publication No.: WO2012125214A1  Published: 20/Sep/2012

Title: TOPICAL NITRIC OXIDE SYSTEMS AND METHODS OF USE THEREOF

Applicant/Assignee: TRANSDERMAL BIOTECHNOLOGY, INC

Application No.: WO2012US00151 (PCT/US2012/00151)   Filing Date: 17/Mar/2012

Abstract:

The present invention generally relates to compositions and methods for transdermal drug delivery. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction, treating wounds, or causing or promoting hair growth. For example, in one aspect, the present invention is generally directed to compositions for delivery of nitric oxide, transdermally and/or to a mucosal surface. The composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid "stick," etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances. In some embodiments, a composition comprising nitric oxide is unexpectedly stable and can be stored long-term. Thus, for example, a composition of the invention may exhibit a long shelf life, with little loss or reaction of nitric oxide. This may be particularly useful for certain applications such as consumer products, including those described herein. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Priority: US201161453836P Applic. Date: 2011-03-17

Inventor: PERRICONE NICHOLAS V [US]; SAYED YOUSRY ABDELREHIM [US]


Publication No.: WO2012125297A1  Published: 20/Sep/2012

Title: POROUS DISINTEGRATABLE SOLID SUBSTRATE FOR PERSONAL HEALTH CARE APPLICATIONS

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: WO2012US27162 (PCT/US2012/27162)   Filing Date: 01/Mar/2012

Abstract:

A personal health care article. More particularly, a personal health care article comprising at least one porous disintegratable solid substrate comprising: from about 1% to about 70%, by weight of said substrate, of a surfactant, from about 10% to about 70%, by weight of said substrate, of one or more polymers, from about 0.025% to about 85%, by weight of said substrate, of one or more health care actives, optionally a plasticizer, and optionally an aesthetic agent wherein said article is ingestible. The invention also comprises a process for making a personal health care article.

Priority: US201161447737P Applic. Date: 2011-03-01; US201161447738P Applic. Date: 2011-03-01

Inventor: DARCY TREVOR JOHN [US]; GILBERT STEVEN RAY [US]; GLENN ROBERT WAYNE JR [US]; STELLA MARK EDWARD [US]


Publication No.: WO2012125408A1  Published: 20/Sep/2012

Title: PEGYLATED APELIN AND USES THEREOF

Applicant/Assignee: GENZYME CORPORATION

Application No.: WO2012US28298 (PCT/US2012/28298)   Filing Date: 08/Mar/2012

Abstract:

[0098] The invention provides compositions and methods for treating a disease or disorder associated with Apelin. Specifically, the invention relates to a pegylated form of Apelin to provide extended circulating life and inotropic effects, and thereby efficiently treat diseases or disorders associated with Apelin.

Priority: US201161451623P Applic. Date: 2011-03-11

Inventor: JIA ZHIQIANG [US]; HOU LIHUI [US]; PAN CLARK Q [US]; AKITA GEOFFREY Y [US]


Publication No.: WO2012125856A1  Published: 20/Sep/2012

Title: MAINTAINING ANTIBODY-BINDING ACTIVITY OF IMMUNOSUPPRESSANT DRUG CONJUGATES

Applicant/Assignee: SIEMENS HEALTHCARE DIAGNOSTICS INC

Application No.: WO2012US29278 (PCT/US2012/29278)   Filing Date: 15/Mar/2012

Abstract:

Methods and reagents are disclosed for maintaining the antibody-binding activity of a conjugate of an immunosuppressant drug and a conjugative moiety. The method comprises combining with the conjugate an effective amount of a chelating agent. Compositions include in an aqueous medium (i) a conjugate of an immunosuppressant drug and a conjugative moiety and (ii) a chelating agent in an amount effective to maintain an antibody-binding activity of the conjugate of the immunosuppressant drug and the conjugative moiety. The compositions may be employed in assays for the determination of analytes that include immunosuppressant drug analytes and antibodies for an immunosuppressant drug.

Priority: US201113049617 Applic. Date: 2011-03-16

Inventor: WEI TIE Q [US]; CRAIG ALAN R [US]; CELANO FIORE M III [US]; JANAS SAMANTHA [US]


Publication No.: WO2012126140A1  Published: 27/Sep/2012

Title: REVERSELY THERMO-REVERSIBLE HYDROGEL COMPOSITIONS

Applicant/Assignee: BRODA TECHNOLOGIES CO., LTD

Application No.: WO2011CN00462 (PCT/CN2011/00462)   Filing Date: 21/Mar/2011

Abstract:

A reversely thermo-reversible hydrogel composition comprises a water soluble block copolymer and at least one correlation gel adjuvant, wherein said water soluble block copolymer comprises at least two polyethylene oxide block and one polypropylene oxide block, said correlation gel adjuvant has a water solubility less than 0.5g/100ml, preferably less than 0.3g/100ml, and can form water soluble intermolecular composites with water soluble block copolymer in water. Said hydrogel composition exhibits improved gelling rate, and improved dissolvability and/or stability of slightly water soluble and/or water-insoluble medicine preparation. Said hydrogel composition can be used in various medical and cosmetic products and applications, such as esophagus, ear, vagina, rectum, ophthalmology and the treatment of various skin diseases and defects.

Priority: WO2011CN00462 Applic. Date: 2011-03-21

Inventor: LV SHAOXIANG [CN]; LV JEFFREY [CN]


Publication No.: WO2012126231A1  Published: 27/Sep/2012

Title: USE OF POLY(4-STYRENE SULFONIC ACID-COPOLY-MALEIC ACID) SODIUM SALT AND PHARMACEUTICAL COMPOSITION THEREOF

Applicant/Assignee: SUZHOU VIROSEC CO., LTD, NANJING UNIVERSITY

Application No.: WO2011CN78371 (PCT/CN2011/78371)   Filing Date: 12/Aug/2011

Abstract:

Use of poly(4-styrene sulfonic acid-copoly-maleic acid) sodium salt in the preparation of pharmaceutical inhibiting infection of HIV-1 and pharmaceutical composition thereof. Said pharmaceutical composition comprises poly(4-styrene sulfonic acid-copoly-maleic acid) sodium salt as active ingredient and conventional pharmaceutical carrier.

Priority: CN20111065559 Applic. Date: 2011-03-18

Inventor: WU ZHIWEI [CN]; QIU MIN [CN]; SUN YIBIN [CN]; JIANG HAIYAN [CN]


Publication No.: WO2012126277A1  Published: 27/Sep/2012

Title: EXTERNAL REVERSE THERMO-SENSITIVE REVERSIBLE AQUAGEL COMPOSITION FOR TREATING HAIR LOSS

Applicant/Assignee: BRODA TECHNOLOGIES CO., LTD

Application No.: WO2012CN00348 (PCT/CN2012/00348)   Filing Date: 20/Mar/2012

Abstract:

An external reverse thermo-sensitive reversible aquagel composition for treating and/or preventing hair loss, recovering and/or promoting hair growth and the preparation method thereof. The external reverse thermo-sensitive reversible aquagel composition contains:(a) a water soluble block copolymer comprising at least two polyethylene oxide blocks and at least one polypropylene oxide block

(b)at least one associated gel adjuvant, which has a water solubility less than 0.5 g/l00ml at 20 DEG C, and which can form a water-soluble intermolecular complex with the water soluble block copolymer

and(c) at least one anti-hair loss agent for prevention or treatment.

Priority: WO2011CN00462 Applic. Date: 2011-03-21

Inventor: LU SHAOXIANG [CN]; LU JEFFREY [CN]; LIU LETIAN [CN]


Publication No.: WO2012126278A1  Published: 27/Sep/2012

Title: TERBINAFINE REVERSE THERMO-SENSITIVE REVERSIBLE AQUAGEL COMPOSITION

Applicant/Assignee: BRODA TECHNOLOGIES CO., LTD

Application No.: WO2012CN00349 (PCT/CN2012/00349)   Filing Date: 20/Mar/2012

Abstract:

The present invention provides a more effective reverse thermo-sensitive reversible aquagel composition comprising terbinafine or the acid addition salt thereof for treating a fungal infection of skin or skin appendages, and a method of using the reverse thermo-sensitive reversible aquagel composition

the composition comprises:(a) a water soluble block copolymer comprising at least two polyethylene oxide blocks and at least one polypropylene oxide block

and (b) at least one associated gel adjuvant, which has a water solubility less than 0.5 g/l00 ml at 20 DEG C, preferably less than 0.3 g/100 ml, and which can form a water-soluble intermolecular complex with the abovementoned water soluble block copolymer

and (c) an effective dose of terbinafine or the acid addition salt thereof. The aquagel composition of the present invention is effective in treating a fungal infection of skin or skin appendages.

Priority: WO2011CN00462 Applic. Date: 2011-03-21

Inventor: LU SHAOXIANG [CN]; LU MEIBO [CN]; LIU LETIAN [CN]


Publication No.: WO2012126770A1  Published: 27/Sep/2012

Title: DOXYLAMINE RESINATE COMPLEX

Applicant/Assignee: LABORATORIOS DEL DR. ESTEVE, S.A

Application No.: WO2012EP54364 (PCT/EP2012/54364)   Filing Date: 13/Mar/2012

Abstract:

The invention refers to a new doxylamine resinate complex comprising doxylamine bound to a weakly acidic synthetic cation exchange resin, such as a copolymer of methacrylic acid and divinylbenzene The invention discloses a process for its preparation which comprises contacting a weakly acidic synthetic cation exchange resin with doxylamine or a pharmaceutically acceptable salt thereof and its use for the preparation of pharmaceutical compositions, such as chewable tablets or oral disintegrating tablets of immediate release. Further the invention refers to the doxylamine resinate complex for use as a medicament, preferably as a medicament for use in the treatment of occasional insomnia.

Priority: EP20110382072 Applic. Date: 2011-03-18

Inventor: FONT COT JORDI [ES]; FALIVENE ALDEA ALBERT [ES]; SOLER RANZANI LUIS [ES]; CASADEVALL PUJALS GEMMA [ES]


Publication No.: WO2012126941A1  Published: 27/Sep/2012

Title: A COMPOSITION AND METHOD

Applicant/Assignee: NORDBLOOM LTD

Application No.: WO2012EP54986 (PCT/EP2012/54986)   Filing Date: 21/Mar/2012

Abstract:

A method of preparing a mucoadhesive film formulation by preparing a film forming composition comprising lambda carrageenan as a film forming polymer, at a concentration of about 1-7 % by weight, a plasticizer at a concentration of about 1-15 % by weight, a biologically active substance, and purified water

distributing the film forming composition as a wet film layer onto a solid surface

and allowing the film layer to dry. A mucoadhesive film obtained by the method and a film dosage unit.

Priority: US201161466203P Applic. Date: 2011-03-22; EP20110159232 Applic. Date: 2011-03-22

Inventor: STENBERG KJELL [SE]


Publication No.: WO2012127037A2  Published: 27/Sep/2012

Title: A COMPOSITION COMPRISING LIPID NANOPARTICLES AND A CORTICOSTEROID OR VITAMIN D DERIVATIVE

Applicant/Assignee: LEO PHARMA A/S

Application No.: WO2012EP55222 (PCT/EP2012/55222)   Filing Date: 23/Mar/2012

Abstract:

A pharmaceutical composition comprises, as a therapeutically active ingredient, a corticosteroid and/or vitamin D derivative incorporated as a solid solution or dispersion in lipid nanopartides, said lipid nanopartides being solid at ambient temperature and comprising a first lipid with a melting point above body temperature, the first lipid being a wax selected from the group consisting of esters of C12-24 alcohols and C12-24 fatty acids, glyceryl mono-, di- or triesters of C12-24 fatty acids, C12-24 fatty alcohols, and cholesterol, optionally a second lipid which is an oil at ambient temperature and miscible with the first lipid, and a pharmaceutically acceptable surfactant.

Priority: US201161467192P Applic. Date: 2011-03-24

Inventor: JENSEN LOUISE BASTHOLM [DK]; PETERSSON KARSTEN [DK]


Publication No.: WO2012127407A1  Published: 27/Sep/2012

Title: PHARMACEUTICAL COMPOSITION FOR USE IN NASAL ADMINISTRATION CONTAINING CORTICOID, AND A QUINOLONE OR FUSIDIC ACID

Applicant/Assignee: DOS SANTOS, ANTONIO, KENYON, MICHAEL

Application No.: WO2012IB51310 (PCT/IB2012/51310)   Filing Date: 19/Mar/2012

Abstract:

The invention relates to a pharmaceutical composition of unit dose for inhalation by a human subject comprising a topical corticoid and a quinolone or fucidic acid, characterized in that the ratio of the weight of the topical corticoid to the weight of the quinolone or fucidic acid is between 0.02 and 20 and the amount of quinolone or of fucidic acid is less than 1 mg. This composition can be administered by nasal spray and is used for treating the upper and lower respiratory tract, in particular sinusitis and nasal polyps.

Priority: EP20110159067 Applic. Date: 2011-03-21

Inventor: KRAYENBUHL MATTHEW [CH]


Publication No.: WO2012127496A1  Published: 27/Sep/2012

Title: STABLE PHARMACEUTICAL COMPOSITIONS OF LORNOXICAM OR SALTS THEREOF

Applicant/Assignee: CADILA HEALTHCARE LIMITED

Application No.: WO2012IN00143 (PCT/IN2012/00143)   Filing Date: 01/Mar/2012

Abstract:

The present invention relates to pharmaceutical compositions of lornoxicam for treatment of inflammatory conditions exhibiting greater permeability, and enhanced therapeutic efficacy. The invention also relates to process of preparing such compositions.

Priority: IN2011MU00577 Applic. Date: 2011-03-01

Inventor: ROY SUNILENDU BHUSHAN [IN]; SHEIKH SHAFIQ [IN]; KOTHARI JAY SHANTILAL [IN]; PATEL JITENDRA DASHARATHLAL [IN]; PANCHOLI JINESH SURESH [IN]


Publication No.: WO2012127497A1  Published: 27/Sep/2012

Title: STABLE PHARMACEUTICAL COMPOSITIONS OF KETOROLAC OR SALTS THEREOF

Applicant/Assignee: CADILA HEALTHCARE LIMITED

Application No.: WO2012IN00152 (PCT/IN2012/00152)   Filing Date: 05/Mar/2012

Abstract:

Pharmaceutical compositions of ketorolac or salts thereof, having improved storage stability as compared to known compositions. The process of manufacturing thereof is also provided. The compositions are particularly suitable for topical administration into the nose in the treatment of pain or inflammation.

Priority: IN2011MU00605 Applic. Date: 2011-03-04

Inventor: ROY SUNILENDU BHUSHAN [IN]; PUROHIT RAVINDRA NANDLAL [IN]; PATEL SHAILESH ARVINDBHAI [IN]


Publication No.: WO2012128394A1  Published: 27/Sep/2012

Title: A PHARMACEUTICAL COMPOSITION FOR TREATING A DISEASE IN THE ORAL CAVITY COMPRISING REBAMIPIDE

Applicant/Assignee: OTSUKA PHARMACEUTICAL CO., LTD

Application No.: WO2012JP58280 (PCT/JP2012/58280)   Filing Date: 22/Mar/2012

Abstract:

The present invention is directed to a pharmaceutical composition comprising rebamipide having a mean particle size of less than 500 nm, a dispersing agent, and a viscosity enhancing agent wherein the viscosity enhancing agent has no aggregative action for the rebamipide particles, which is used as a gargle or a liquid preparation for swish and swallow comprising rebamipide for preventing and/or treating stomatitis caused by radiotherapy.

Priority: JP20110066353 Applic. Date: 2011-03-24

Inventor: MATSUDA TAKAKUNI [JP]; SAKO NOBUTOMO [JP]; NAKASHIMA TAKAKO [JP]; SAKURAI KAZUSHI [JP]


Publication No.: WO2012129156A1  Published: 27/Sep/2012

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERS

Applicant/Assignee: ALKERMES, INC

Application No.: WO2012US29625 (PCT/US2012/29625)   Filing Date: 19/Mar/2012

Abstract:

The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that ate useful for the delivery of anti-psychotic drugs.

Priority: US201161454008P Applic. Date: 2011-03-18

Inventor: HICKEY MAGALI B [US]; PERRY JASON M [US]; DEAVER DANIEL R [US]; REMENAR JULIUS F [US]; VANDIVER JENNIFER [US]


Publication No.: WO2012129759A1  Published: 04/Oct/2012

Title: ORAL DOSAGE FORMULATIONS CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS FOR TREATING NEURODEGENERATIVE DISORDERS

Applicant/Assignee: CENTER LABORATORIES, INC

Application No.: WO2011CN72158 (PCT/CN2011/72158)   Filing Date: 25/Mar/2011

Abstract:

Oral dosage formulations containing both sustained-release and immediate-release drugs for treating patients suffering from central nervous system disorders. Said sustained-release drug is memantine and the immediate-release drug is an acetylcholinesterase inhibitor (AChEL), preferably, donepezil hydrochloride.

Priority: WO2011CN72158 Applic. Date: 2011-03-25

Inventor: SHANE GUANG-TZUU [CN]; CHEN CHIEN-FEN [CN]; DIN CHUEN-LIN [CN]; TSAI HUI-LING [CN]; TSAI PEI-CHEN [CN]


Publication No.: WO2012130193A1  Published: 04/Oct/2012

Title: NON-COVALENT SOLUBLE COMPLEXES OF TERIPARATIDE WITH POLYSACCHARIDES AND A DOSAGE FORM OF TERIPARATIDE FOR ORAL ADMINISTRATION

Applicant/Assignee: ZENTIVA, K.S

Application No.: WO2012CZ00025 (PCT/CZ2012/00025)   Filing Date: 16/Mar/2012

Abstract:

The present invention relates to stabilization of teriparatide for oral administration by forming of water-soluble complexes with soluble polysaccharides, e.g. ss-glucan, chitosan, alginic acid, or their salts. Orally administered peptide medicaments such as teriparatide exhibit very low biological availability, which is mainly caused by rapid degradation in the digestive tract by proteolytic enzymes, as well as low efficiency of transport through the intestinal wall to the blood circulation. It is an advantage of the pharmaceutical composition according to the invention that teriparatide in the complex form is protected from being digested by proteases, the complex not preventing absorption of teriparatide from the gastrointestinal tract to the blood at the same time.

Priority: CZ20110000180 Applic. Date: 2011-03-31

Inventor: ANTOSOVA ZUZANA [CZ]; JUNKOVA PETRA [CZ]; PETKOVA GALINA [BG]; RICHTEROVA KLARA [CZ]; REZANKA PAVEL [CZ]; MACKOVA MARTINA [CZ]; FLIEGER MIROSLAV [CZ]; KRAL VLADIMIR [CZ]


Publication No.: WO2012130336A1  Published: 04/Oct/2012

Title: DELIVERY OF LARGE MOLECULAR WEIGHT BIOLOGICALLY ACTIVE SUBSTANCES

Applicant/Assignee: PRINCIPIUM EUROPE S.R.L, PHOTOKINETIX INC

Application No.: WO2011EP58293 (PCT/EP2011/58293)   Filing Date: 20/May/2011

Abstract:

The invention relates generally to intradermal, transdermal, and/or transmembrane delivery of biologically active substances in the epidermis and/or through the skin, sub-dermal tissues, blood vessels and cellular membranes without causing damage to the cellular surface, tissue or membrane. The biologically active substances may have a molecular weight no less than about 5.8 kDa to about 2,500 kDa, such as Hyaluronic Acid (HA). The biologically active substances may be deposited in a dermal patch containing a red algae polysaccharide-based matrix, wherein the red algae polysaccharide is an extract of Chondrus crispus at 2% by weight of the dermal patch. The invention provides systems and methods for enhanced intradermal, transdermal, and/or transmembrane delivery of such biologically active substances using pulsed incoherent light. The invention further provides a device for the application of the pulsed incoherent light to cellular surfaces and membranes using those compositions and methods.

Priority: US201161468755P Applic. Date: 2011-03-29

Inventor: JANSON JULIEN [IT]; KRAFT EDWARD R [US]; KULP GABRIELA [US]; MALANCHIN ROSELLA [IT]


Publication No.: WO2012130819A1  Published: 04/Oct/2012

Title: OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY

Applicant/Assignee: SANOFI

Application No.: WO2012EP55361 (PCT/EP2012/55361)   Filing Date: 27/Mar/2012

Abstract:

The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

Priority: US201161499941P Applic. Date: 2011-06-22; EP20110305347 Applic. Date: 2011-03-29

Inventor: KAMM WALTER [DE]; BUSSEMER TILL [DE]; ANDERT DORIS [DE]; KUEHN BERND [DE]; TODT ERNST-JOSEF [DE]


Publication No.: WO2012131347A1  Published: 04/Oct/2012

Title: USNIC ACID TOPICAL FORMULATION

Applicant/Assignee: EVOCUTIS PLC

Application No.: WO2012GB50664 (PCT/GB2012/50664)   Filing Date: 26/Mar/2012

Abstract:

Topical skin treatment formulation containing usnic acid or an usnate salt, dissolved in a solvent system comprising (i) dimethyl isosorbide

(ii) a C1 to C9 alkyl salicylate

and (iii) a glyceryl fatty acid ester. The solvent system may also comprise an alcohol, a polyoxyalkylene-based solvent, and/or a C1 to C4 alkyl glucose ester. The formulation may be used in the treatment of microbial conditions, in particular acne. The solvent system assists in the effective dissolution of the usnic acid or usnate and in targeting its delivery to relevant sites on the skin.

Priority: GB20110005410 Applic. Date: 2011-03-31; GB20110011013 Applic. Date: 2011-06-29

Inventor: ABBOTT STEVEN JOHN [GB]; DONOGHUE GAVIN [GB]; EADY ELIZABETH ANNE [GB]


Publication No.: WO2012131348A1  Published: 04/Oct/2012

Title: SALICYLIC ACID TOPICAL FORMULATION

Applicant/Assignee: EVOCUTIS PLC

Application No.: WO2012GB50665 (PCT/GB2012/50665)   Filing Date: 26/Mar/2012

Abstract:

Topical skin treatment formulation containing salicylic acid or a derivative thereof, dissolved in a solvent system comprising (i) dimethyl isosorbide

(ii) a C1 to C9 alkyl salicylate

and (iii) a glyceryl fatty acid ester. The solvent system may also comprise an alcohol, a polyoxyalkylene-based solvent, and/or a C1 to C4 alkyl glucose ester. The formulation may be used in the treatment of acne. The solvent system improves the targeted delivery of the salicylic acid or derivative to relevant sites on the skin.

Priority: GB20110005410 Applic. Date: 2011-03-31; GB20110011013 Applic. Date: 2011-06-29

Inventor: ABBOTT STEVEN JOHN [GB]; COVE JONATHAN HOWARD [GB]; DONOGHUE GAVIN [GB]; GREGORY SARAH-JAYNE [GB]


Publication No.: WO2012131412A2  Published: 04/Oct/2012

Title: PHARMACEUTICAL COMPOSITION CONTAINING NO, PROCESS FOR THE PREPARATION AND USE THEREOF

Applicant/Assignee:

Application No.: WO2012HU00023 (PCT/HU2012/00023)   Filing Date: 30/Mar/2012

Abstract:

The invention relates to a pharmaceutical composition comprising NO, wherein the composition comprises as NO-source a zeolite-free transition metal complex, preferably a ferrous-nitroso-sulphate, furthermore one or more lipophil carrier(s) and optionally one or more pharmaceutically acceptable excipient(s). The invention further relates to the process for the preparation of the above-mentioned pharmaceutical composition, and the use thereof as a medicine.?

Priority: HU20110000176 Applic. Date: 2011-03-31

Inventor: SZABO LASZLO GABOR [HU]; PILLER ISTVAN [HU]


Publication No.: WO2012136369A1  Published: 11/Oct/2012

Title: OPHTHALMIC PREPARATIONS BASED ON PACAP (PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE) WHICH RESTORE THE NORMAL VISUAL FUNCTION IN EARLY GLAUCOMA

Applicant/Assignee: HMFRA HUNGARY LIMITED LIABILITY COMPANY

Application No.: WO2012EP01514 (PCT/EP2012/01514)   Filing Date: 05/Apr/2012

Abstract:

The present invention relates to ophthalmic preparations in the form of eyedrops based on PACAP (Pituitary Adenylate Cyclase Activating Polypeptide) which restore the normal visual function in retinal dystrophy/retinopathy and optic neuropathy, with special reference to glaucoma. Said preparations can be administered topically to the intact eye surface, and are useful in the treatment of various forms of retinal dystrophy/retinopathy and optic neuropathy, such as glaucoma.

Priority: IT2011MI00583 Applic. Date: 2011-04-08

Inventor: DOMENICI LUCIANO [IT]; SANSO' MARCO [IT]; GIOVANNINI LUCA [IT]


Publication No.: WO2012136934A2  Published: 11/Oct/2012

Title: HEALING COMPOSITION FOR TOPICAL APPLICATION

Applicant/Assignee: BIOPASS S.A

Application No.: WO2012FR50735 (PCT/FR2012/50735)   Filing Date: 05/Apr/2012

Abstract:

The present invention relates to a hygiene product or pharmaceutical composition in the form of a gel or dressing, for topical application to the skin or mucosa including glycerol, at least one poly(meth)acrylate polymer, at least one polyethylene glycol with a molecular weight of less than 1000 g/mol, octanediol and water. The composition or dressing can be used for healing treatment of chronic dermal ulcers, healing and soothing treatment of eczema and psoriatic conditions, healing treatment of anal fissures, treatment of mouth injuries, resorption and healing of labial herpes (cold sores) and treatment of dermatitis. The hygiene product can be a shaving or aftershave product for sensitive or hypersensitive skin types, a nasal decongestant or a product for ear hygiene.

Priority: FR20110052997 Applic. Date: 2011-04-06

Inventor: GREFF DANIEL [FR]


Publication No.: WO2012136969A2  Published: 11/Oct/2012

Title: OPHTHALMIC TREATMENTS

Applicant/Assignee:

Application No.: WO2012GB00330 (PCT/GB2012/00330)   Filing Date: 05/Apr/2012

Abstract:

Aqueous compositions suitable for topical administration to the human or animal eye contain at least one water-soluble polymeric ophthalmic lubricant, such as hyaluronate, carbomer gel or hypromellose, together with a water-soluble analgesic. The analgesic may be an opiod, particularly an opioid having an affinity for 5-HT receptors, such as tramadol. Typical tramadol levels would be in the range of 0.5% to 1.0% w/v. The aqueous compositions may for example be used as artificial tears, and as general ophthalmic lubricants for treating conditions such as dry eye or blepharitis. Further compositions combine ophthalmologically- active agents, such as pharmaceuticals, with opioids, such as tramadol in particular. These compositions may be used to treat the eye while reducing pain or discomfort that would normally be produced by administering these particular pharmaceuticals to the eye, and increasing the efficacy of the pharmaceuticals. Compositions are also disclosed, containing opioids with 5-HT receptor activity, which are of general use in alleviating pain in and around the eye.

Priority: GB20110005731 Applic. Date: 2011-04-05; GB20110005732 Applic. Date: 2011-04-05

Inventor: SHARMA ANANT [GB]


Publication No.: WO2012137054A1  Published: 11/Oct/2012

Title: PHARMACEUTICAL COMPOSITION CONTAINING CYCLOBENZAPRINE SUITABLE TO INTRANASAL ADMINISTRATION

Applicant/Assignee: CAMPIGLIO CONSULTING SRL

Application No.: WO2012IB00657 (PCT/IB2012/00657)   Filing Date: 02/Apr/2012

Abstract:

A pharmaceutical composition, containing as active principle cyclobenzaprine hydrochloride, 3- (5H-dibenzo [a, d] cyclo-epten- 5-yliden) -N, N-dimethyl-l-propanamine hydrochloride, in form suitable to be administered by itranasal route, is described. Said pharmaceutical composition allows a remarkable absorption rapidity of the active principle, does not undergo the first hepatic passage, has an excellent tolerability with low tonicity formulations and does not show any contraindication in the short period administrations.

Priority: IT2011MI00558 Applic. Date: 2011-04-06

Inventor: BORSA MASSIMILIANO [IT]


Publication No.: WO2012137106A1  Published: 11/Oct/2012

Title: THE TREATMENT OF VIRAL INFECTIONS

Applicant/Assignee: ENVIRON SKIN CARE (PTY) LTD

Application No.: WO2012IB51483 (PCT/IB2012/51483)   Filing Date: 28/Mar/2012

Abstract:

The invention provides low concentration, stable compositions for the treatment of lesions associated with herpes viral infections. The compositions are in a form selected from creams and gels containing trichloroacetic acid in an amount of between 2.5 % (m/m) and 6% (w/w) of the weight of the cream or gel. Preferably the cream contains about 5% and the gel about 2,5% of the trichloroacetic acid.

Priority: ZA20110002483 Applic. Date: 2011-04-04

Inventor: FERNANDES DESMOND BRIAN [ZA]; ELLWOOD PAMELA LEE [ZA]


Publication No.: WO2012138326A1  Published: 11/Oct/2012

Title: CLEAR OR TRANSLUCENT COMPOSITION

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: WO2011US31207 (PCT/US2011/31207)   Filing Date: 05/Apr/2011

Abstract:

The present disclosure relates to a clear or translucent composition which takes the form of a solid, a semi-solid or a viscous gel. The inventive composition contains a mixture of at least two amino acid - based gelatinizing agents, at least one polyamide resin, a non ionic, unsaturated fatty alcohol in an amount which reduces the dissolution temperature of the gelatinizing agents to allow processing at or below 115 DEG C, an alkyl dimethicone, and an oil and/or a polymer component. Additional ingredients depending on the application may also be included in the clear or translucent composition. The present disclosure also relates to methods of producing the clear or translucent composition of the disclosure and uses thereof.

Priority: US201113080034 Applic. Date: 2011-04-05

Inventor: DO THI N [US]; MCNAMARA WILLIAM E [US]; HALES KELLY [US]; TRAVKINA IRINA [US]


Publication No.: WO2012138341A1  Published: 11/Oct/2012

Title: CONTROLLED DELIVERY OF MOLECULES FROM A BIOINTERFACE

Applicant/Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC

Application No.: WO2011US31604 (PCT/US2011/31604)   Filing Date: 07/Apr/2011

Abstract:

A drug delivery system comprising an implantable device with a biointerface comprising a polymer and a bioactive molecule attached to the polymer via a silyl ether linker.

Priority: WO2011US31604 Applic. Date: 2011-04-07

Inventor: TAPSAK MARK A [US]


Publication No.: WO2012138467A1  Published: 11/Oct/2012

Title: PHOTOSTABILIZATION OF RESVERATROL WITH ALKOXYCRYLENE COMPOUNDS

Applicant/Assignee: HALLSTAR INNOVATIONS CORP

Application No.: WO2012US29620 (PCT/US2012/29620)   Filing Date: 19/Mar/2012

Abstract:

The photostabilizing electronic excited state energy - particularly singlet state energy from resveratrol compounds - has been found to be readily transferred to (accepted by) a- cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter "alkoxycrylenes") on one of the phenyl rings having the formula (I): wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, preferably C1-C8, more preferably methoxy, and the non-alkoxy radical R1 or R2 is hydrogen

and R3 is a straight or branched chain C1-C30 alkyl radical, preferably C2-C20. The alkoxycrylene compounds of formula (I) significantly increase the photostability of resveratrol compounds in a composition by at least 3-fold and as much as 10-fold or greater. The ability of the alkoxycrylene compounds to stabilize the resveratrol compound is concentration dependent, with the amount of resveratrol photostabilization increasing with the concentration of the alkoxycrylene compound.

Priority: US201113080247 Applic. Date: 2011-04-05

Inventor: BONDA CRAIG A [US]; PAVLOVIC ANNA [US]; ZHANG JEAN [US]


Publication No.: WO2012139223A1  Published: 18/Oct/2012

Title: SYSTEM AND METHOD FOR MULTIPHASIC RELEASE OF GROWTH FACTORS

Applicant/Assignee: INDUCE BIOLOGICS INC

Application No.: WO2012CA50234 (PCT/CA2012/50234)   Filing Date: 11/Apr/2012

Abstract:

A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth factor in a sustained release profile. The initial release profile releases at least one growth factor over a period of hours to days, wherein the growth factor is released in a large amount initially, with the remainder being released in progressively lower amounts. The sustained release profile releases at least one growth factor over a period of days to weeks, wherein the growth factor is released at a generally constant amount over such period. The system of the invention is particularly suited for applications on bioimplants. The invention also comprises methods and kits for multiphasic delivery of at least one growth factor.

Priority: US201161474049P Applic. Date: 2011-04-11

Inventor: CLOKIE CAMERON M L [CA]; PEEL SEAN A F [CA]


Publication No.: WO2012139918A1  Published: 18/Oct/2012

Title: METHODS FOR TREATING BACTERIAL INFECTION

Applicant/Assignee: INNOCOLL TECHNOLOGIES LIMITED

Application No.: WO2012EP55995 (PCT/EP2012/55995)   Filing Date: 02/Apr/2012

Abstract:

This invention relates to methods for treating bacterial infection, which methods find utility in the treatment of, for example, infected ulcers, optionally infected diabetic ulcers. In particular, this invention relates to treating bacterial infection, for example, infected diabetic ulcers by topical administration of at least one aminoglycoside antibiotic at the site of infection, in combination with at least one antibacterial agent, which antibacterial agent is administered remote from the site of infection, preferably administered systemically. In a particular embodiment, the present invention relates to a composition for use in treating bacterial infection, the composition comprising gentamicin sulphate (a water-soluble broad-spectrum aminoglycoside antibiotic) uniformly dispersed in a type-I collagen matrix

incombination with at least one systemically-administered antibacterial agent. The present invention provides bactericidal activity against most strains of aerobic gram-negative and gram-positive and facultative anaerobic gram-negative pathogens, including methicillin-resistant Staphylococcus aureus.

Priority: EP20110161898 Applic. Date: 2011-04-11; US201113085585 Applic. Date: 2011-04-13

Inventor: PRIOR DAVID [IE]


Publication No.: WO2012140155A1  Published: 18/Oct/2012

Title: FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY

Applicant/Assignee: NOVO NORDISK A/S

Application No.: WO2012EP56708 (PCT/EP2012/56708)   Filing Date: 12/Apr/2012

Abstract:

The present invention relates to fatty acid acylated amino acids (FA-aa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-aa's.

Priority: US201161477719P Applic. Date: 2011-04-21; EP20110162411 Applic. Date: 2011-04-14

Inventor: FOEGER FLORIAN ANDERS [DK]; MAKHLOF ABDALLAH [DK]; HOYER HERBERT [DE]


Publication No.: WO2012140220A1  Published: 18/Oct/2012

Title: FREEZE DRIED DRUG NANOSUSPENSIONS

Applicant/Assignee: JANSSEN PHARMACEUTICA NV, FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG

Application No.: WO2012EP56818 (PCT/EP2012/56818)   Filing Date: 13/Apr/2012

Abstract:

The present invention relates to a freeze-dried (also called lyophilized) drug nanosuspension. The present freeze-dried drug nanosuspension composition has an acceptable stability of the particle size distribution during storage, including long term storage.

Priority: US201161475811P Applic. Date: 2011-04-15

Inventor: INGHELBRECHT SABINE KARINE KATRIEN [BE]; GIESELER HENNING [DE]; BEIROWSKI JAKOB ANDREAS [DE]


Publication No.: WO2012140392A1  Published: 18/Oct/2012

Title: ORAL PHARMACEUTICAL DISPERSION COMPOSITIONS

Applicant/Assignee: AYANDA GROUP AS, COCKBAIN, JULIAN

Application No.: WO2011GB52027 (PCT/GB2011/52027)   Filing Date: 19/Oct/2011

Abstract:

The invention provides an oral pharmaceutical composition, optionally in dose unit form, comprising a lipophilic drug substance in dispersion in a physiologically tolerable aqueous carrier, preferably an aqueous gel, wherein said drug substance contains a functional electrostatic group having a pKa value of from 2 to 10, characterised in that said aqueous carrier has a pH at least 0.3 below or above said pKa value, said pH being below said pKa where said group is acidic and above said pKa where said group is basic.

Priority: WO2011GB00563 Applic. Date: 2011-04-11

Inventor: DRAGET KURT INGAR [NO]; ENGELSEN STEINAR JOHAN [NO]; SETERNES TORE [NO]; HATTREM MAGNUS [NO]; HAUG INGVILD JOHANNE [NO]


Publication No.: WO2012141741A1  Published: 18/Oct/2012

Title: ORAL COMBINATION DRUG FORMULATION COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND A COMPLEMENTARY LOW DOSE OF TRANEXAMIC ACID FOR THE TREATMENT OF MENSTRUAL PAIN ACCOMPANIED WITH EXCESSIVE MENSTRUAL BLOOD LOSS

Applicant/Assignee: ARSTAT, INC

Application No.: WO2011US60643 (PCT/US2011/60643)   Filing Date: 14/Nov/2011

Abstract:

The present invention relates to the relief of menstrual pain and the reduction of menstrual blood loss by an oral combination drug formulation comprising a non-steroidal anti-inflammatory drug (NSAID) and a complementary low-dose antifibrinolytic medication, tranexamic acid. This treatment can be used by women with painful menstrual periods (including those clinically diagnosed with dysmenorrhea) accompanied with heavy menstrual bleeding (including those clinically diagnosed with menorrhagia).

Priority: US201161474392P Applic. Date: 2011-04-12

Inventor: RUBIN ARKADY [US]


Publication No.: WO2012141972A1  Published: 18/Oct/2012

Title: DUAL LANE COATING

Applicant/Assignee: MONOSOL RX, LLC

Application No.: WO2012US32342 (PCT/US2012/32342)   Filing Date: 05/Apr/2012

Abstract:

The present invention relates to methods and apparatuses for forming an active-containing film product, while significantly reducing the amount of wasted active material. The resulting product is an active-containing film product that meets the user's predetermined criteria of physical properties and is suitable for use.

Priority: US201113084681 Applic. Date: 2011-04-12

Inventor: BOGUE BEUFORD A [US]


Publication No.: WO2012142159A2  Published: 18/Oct/2012

Title: STRUCTURAL MUTATIONS IN TITIN CAUSE DILATED CARDIOMYOPATHY

Applicant/Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC, PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Application No.: WO2012US33122 (PCT/US2012/33122)   Filing Date: 11/Apr/2012

Abstract:

Provided herein are diagnostic markers and methods for identifying a subject having an increased susceptibility for developing or having dilated cardiomyopathy. The method comprises determining if the subject has a mutation in the TTN nucleic acid or titin polypeptide. Further provided herein are methods of treating subjects having or at risk of having dilated cardiomyopathy.

Priority: US201161474106P Applic. Date: 2011-04-11

Inventor: SEIDMAN JONATHAN G [US]; SEIDMAN CHRISTINE E [US]; HERMAN DANIEL S [US]


Publication No.: WO2012142318A1  Published: 18/Oct/2012

Title: MULTILAYER THIN FILM DRUG DELIVERY DEVICE AND METHODS OF MAKING AND USING THE SAME

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: WO2012US33366 (PCT/US2012/33366)   Filing Date: 12/Apr/2012

Abstract:

Multilayer thin film devices that include a bioactive agent for elution to the surrounding tissue upon administration to a subject are provided. The multilayer thin film devices are useful as medical devices, such as ocular devices. Also provided are methods and kits for localized delivery of a bioactive agent to a tissue of a subject, and methods of preparing the subject devices. The multilayer thin film medical device includes a first layer, a bioactive agent and a second layer. The first and the second layers may be porous or non-porous. The devices have a furled structure, suitable for administration to a subject.

Priority: US201161475373P Applic. Date: 2011-04-14

Inventor: DESAI TEJAL A [US]; STEEDMAN MARK RORY [US]; BHISITKUL ROBERT B [US]; BERNARDS DANIEL A [US]; LANCE KEVIN D [US]


Publication No.: WO2012142501A1  Published: 18/Oct/2012

Title: COMPOSITIONS AND METHODS FOR INHIBITING AND/OR MODULATING EFFECTOR T-CELLS INVOLVED IN INFLAMMATORY NEURODEGENERATIVE DISEASE

Applicant/Assignee: REVALESIO CORPORATION

Application No.: WO2012US33644 (PCT/US2012/33644)   Filing Date: 13/Apr/2012

Abstract:

Provided are methods for treating inflammatory neurodegenerative diseases or at least one symptom thereof in a subject by administering a therapeutic composition comprising at least one electrokinetically-altered fluids (e.g., electrokinetically-generated oxygen-enriched fluids) of the present invention. Particular aspects provide methods for inhibiting and/or modulating the function and/or activity of effector T-cells, and/or for cell-based tolerogenic therapy. In certain aspects such methods comprise ex vivo exposure of T- cells and/or APC to at least one electrokinetically-altered fluid as disclosed herein. Combination therapies are additionally provided.

Priority: US201161475119P Applic. Date: 2011-04-13; US201161497882P Applic. Date: 2011-06-16

Inventor: WATSON RICHARD L [US]


Publication No.: WO2012142724A1  Published: 26/Oct/2012

Title: NEW LOW SIDE EFFECT PHARMACEUTICAL COMPOSITION CONTAINING ANTITUBERCULOSIS DRUGS

Applicant/Assignee: NATIONAL DEFENSE EDUCATION AND RESEARCH FOUNDATION

Application No.: WO2011CN00688 (PCT/CN2011/00688)   Filing Date: 20/Apr/2011

Abstract:

A pharmaceutical composition for treating tuberculotic diseases with no side effect /low side effect is provided by the present invention, which contains pharmaceutically effective amount of one or more compounds chosen from isoniazid, rifampin, pyrazinamide and ethambutol, and pharmaceutically effective amount of substances which can reduce the side effect of the antituberculosis agents.

Priority: WO2011CN00688 Applic. Date: 2011-04-20

Inventor: HU OLIVER YAOPU [CN]; YOUNG TONHO [CN]; HSIONG CHENGHUEI [CN]; CHANG WENLIANG [CN]; SHIH TUNGYUAN [CN]; HO HSINTIEN [CN]


Publication No.: WO2012142926A1  Published: 26/Oct/2012

Title: CAMPTOTHECIN COMPOUND CONTAINING STABLE 7-MEMBERED LACTONE RING, PREPARATION METHOD AND USE

Applicant/Assignee: EAST CHINA NORMAL UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Application No.: WO2012CN73983 (PCT/CN2012/73983)   Filing Date: 13/Apr/2012

Abstract:

Provided are a camptothecin compound containing a 7-membered lactone ring, as shown in general formula I, and pharmaceutically acceptable salt thereof, as well as preparation method and use thereof. In general formula I, R1 is H, a C1 (approx.) C3 alkyl, acetyl or propionyl

R2 is H, a C1 (approx.) C6 alkyl, a C3 (approx.) C6 cycloalkyl, piperidyl, or a C1 (approx.) C6 alkyl substituted by an amino

R3 is H, a C1 (approx.) C3 alkyl, or a C1 (approx.) C6 alkyl substituted by an amino

R4 is H, a hydroxyl, or a C1 (approx.) C6 alkoxy

R5 is H, or a C1 (approx.) C6 alkoxy

or, R4 and R5 are linked to each other to form -OCH2O- or -OCH2CH2O-. The compound has good antitumor activity, and can be clinically used via oral administration, intravenous injection, and intramuscular injection, among others.

Priority: CN20111097364 Applic. Date: 2011-04-18

Inventor: LV WEI [CN]; YU SHANBAO [CN]; LUO YU [CN]; CHEN YI [CN]; DING JIAN [CN]


Publication No.: WO2012143008A1  Published: 26/Oct/2012

Title: REDUCTION OF THE LEVEL OF FREE PHOSPHORUS COMPOUNDS IN THE DIGESTIVE JUICE

Applicant/Assignee: GUMLINK A/S

Application No.: WO2011DK00035 (PCT/DK2011/00035)   Filing Date: 20/Apr/2011

Abstract:

The invention relates to the non-medical use of a combination of a phosphorus compound binding agent and an organic acid in a slow release oral delivery system comprising at least one delivery vehicle and/or excipient, wherein said phosphorus compound binding agent is chitosan, for reducing the level of free phosphorus compounds in the digestive juice.

Priority: WO2011DK00035 Applic. Date: 2011-04-20

Inventor: STEENBERG LARS CHRISTIAN KURE [DK]


Publication No.: WO2012143011A1  Published: 26/Oct/2012

Title: CHEWING GUM COMPRISING CHITOSAN FOR USE IN REDUCTION OF THE LEVEL OF FREE PHOSPHORUS COMPOUNDS IN THE DIGESTIVE JUICE

Applicant/Assignee: GUMLINK A/S

Application No.: WO2012DK00050 (PCT/DK2012/00050)   Filing Date: 20/Apr/2012

Abstract:

The invention relates to the non-medical use of a phosphorus compound binding agent in a slow release oral delivery system comprising chewing gum, wherein said phosphorus compound binding agent is chitosan, for reducing the level of free phosphorus compounds in the digestive juice.

Priority: DK20110000945 Applic. Date: 2011-12-05; WO2011DK00035 Applic. Date: 2011-04-20; DK20110000963 Applic. Date: 2011-12-12

Inventor: STEENBERG LARS CHRISTIAN KURE [DK]; NIELSEN KENNETH DUE [DK]; BRUUN HEIDI ZIEGLER [DK]


Publication No.: WO2012143013A1  Published: 26/Oct/2012

Title: IMPROVED WOUND CARE PRODUCT

Applicant/Assignee: RIGSHOSPITALET COPENHAGEN UNIVERSITY HOSPITAL, DANMARKS TEKNISKE UNIVERSITET, BISPEBJERG HOSPITAL

Application No.: WO2012DK50130 (PCT/DK2012/50130)   Filing Date: 18/Apr/2012

Abstract:

The present invention pertains to use of sodium diacetate (NaHAc 2) as an antimicrobial agent against bacteria growing in biofilms. The aspects of the invention include a wound care product comprising sodium diacetate, a kit comprising a wound care product,and a methodof treating an infected wound.

Priority: EP20110162912 Applic. Date: 2011-04-18

Inventor: BJARNSHOLT THOMAS [DK]; KIRKETERP-MOELLER KLAUS [DK]; GIVSKOV MICHAEL CHRISTIAN [DK]


Publication No.: WO2012143868A1  Published: 26/Oct/2012

Title: SUSPENSION TYPE TOPICAL FORMULATIONS COMPRISING CYCLIC DEPSIPEPTIDE

Applicant/Assignee: NOVARTIS AG

Application No.: WO2012IB51946 (PCT/IB2012/51946)   Filing Date: 18/Apr/2012

Abstract:

The invention relates to novel topical pharmaceutical compositions in which the active agent is a cyclic depsipeptide of formula (II) and to methods for manufacturing such compositions. The application discloses in particular hydrophobic ointments comprising a hydrophobic base and a consistency agent, preferably isopropyl myristate

Priority: US201161477297P Applic. Date: 2011-04-20

Inventor: HAUG CLAIRE [CH]


Publication No.: WO2012143875A1  Published: 26/Oct/2012

Title: METHOD OF PREPARATION OF CHITIN AND ACTIVE PRINCIPLES COMPLEXES AND THE SO OBTAINED COMPLEXES

Applicant/Assignee: MAVI SUD S.R.L

Application No.: WO2012IB51961 (PCT/IB2012/51961)   Filing Date: 19/Apr/2012

Abstract:

The present invention relates to chitin nanofibrils complexes in association with at least one negatively charged polymer and one or more active ingredients

pharmaceutical or cosmetic compositions comprising such complexes, kit for concomitant or sequential administration comprising said compositions in a form suitable for topical administration and in a form suitable for oral administration, and uses thereof.

Priority: IT2011RM00199 Applic. Date: 2011-04-19

Inventor: MORGANTI PIERFRANCESCO [IT]


Publication No.: WO2012143876A1  Published: 26/Oct/2012

Title: A STERILE AND INJECTABLE AQUEOUS FORMULATION FOR ADMINISTRATION IN THE INTRA-ARTICULAR SPACE OF AN INTRA-ARTICULAR JOINT

Applicant/Assignee: ANTEIS S.A

Application No.: WO2012IB51962 (PCT/IB2012/51962)   Filing Date: 19/Apr/2012

Abstract:

The present invention relates generally to the treatment and/or prevention of pain associated with an intra-articular joint degeneration or disease. This invention concerns in particular a sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint of a subject, in the form of a gel.

Priority: US201161476843P Applic. Date: 2011-04-19

Inventor: GAVARD MOLLIARD SAMUEL [FR]; BENOIT OLIVIER [FR]


Publication No.: WO2012145355A1  Published: 26/Oct/2012

Title: VACCINE DELIVERY METHOD

Applicant/Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC

Application No.: WO2012US34012 (PCT/US2012/34012)   Filing Date: 18/Apr/2012

Abstract:

The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

Priority: US201161476431P Applic. Date: 2011-04-18

Inventor: HARN DONALD A [US]; QUEIROZ RAFAELLA [US]; MCEWEN LISA [US]


Publication No.: WO2012145428A2  Published: 26/Oct/2012

Title: ALTERING PROTEIN CONCENTRATIONS IN CEREBROSPINAL FLUID AND/OR BRAIN INTERSTITIAL FLUID

Applicant/Assignee: WASHINGTON UNIVERSITY

Application No.: WO2012US34120 (PCT/US2012/34120)   Filing Date: 18/Apr/2012

Abstract:

Devices and methods of altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid are disclosed. Devices include a support having at least one protease attached to the support. The device may further include a housing. Devices may be implantable for use in an in vivo active flow system or for use in an in vivo passive system. Devices may also be used in an ex vivo active flow system. Devices may also be used in a passive system to treat cerebrospinal fluid and/or brain interstitial fluid that is withdrawn, or in a passive system that is implanted surgically. Methods include contacting cerebrospinal fluid and/or brain interstitial fluid with a support including at least one protease attached to the support. Proteins contained in the cerebrospinal fluid and/or brain interstitial fluid are cleaved by the protease resulting in the reduction of protein in cerebrospinal fluid and/or brain interstitial fluid. Additionally, methods are disclosed for treating neurodegenerative diseases and neurological disorders.

Priority: US201161477839P Applic. Date: 2011-04-21

Inventor: LEUTHARDT ERIC C [US]; MORAN DAN [US]; HOLTZMAN DAVID [US]; BAYLY PHILLIP [US]; BRODY DAVID [US]; DACEY RALPH G [US]; FOK SAM [US]; GARRISON JEREMIAH [US]; GENIN GUY M [US]; LUSIS ERIKS [US]; PAPPU ROHIT [US]; XIE JINGWEI [US]; ZIPFEL GREG [US]


Publication No.: WO2012145460A2  Published: 26/Oct/2012

Title: OPHTHALMIC COMPOSITION WITH A VISCOSITY ENHANCEMENT SYSTEM HAVING TWO DIFFERENT VISCOSITY ENHANCING AGENTS

Applicant/Assignee: ALCON RESEARCH, LTD

Application No.: WO2012US34171 (PCT/US2012/34171)   Filing Date: 19/Apr/2012

Abstract:

An ophthalmic composition is disclosed having a viscosity enhancement system comprised of two different viscosity enhancing agents. The aqueous composition contains a first viscosity enhancing agent that provides enhanced viscosity upon dispensing of the composition to the eye and a second viscosity agent that increases viscosity (e.g., gels or partially gels) after dispensing of the composition to the eye to provide extended viscosity enhancement of the composition.

Priority: US201161478081P Applic. Date: 2011-04-22

Inventor: CHOWHAN MASOOD A [US]; GHOSH MALAY [US]


Publication No.: WO2012145470A2  Published: 26/Oct/2012

Title: OPHTHALMIC COMPOSITION WITH A VISCOSITY ENHANCEMENT SYSTEM HAVING TWO DIFFERENT VISCOSITY ENHANCING AGENTS

Applicant/Assignee: ALCON RESEARCH, LTD

Application No.: WO2012US34187 (PCT/US2012/34187)   Filing Date: 19/Apr/2012

Abstract:

An ophthalmic composition is disclosed having a viscosity enhancement system comprised of two different viscosity enhancing agents. The aqueous composition contains a first viscosity enhancing agent that provides enhanced viscosity upon dispensing of the composition to the eye and a second viscosity agent that increases viscosity (e.g., gels or partially gels) after dispensing of the composition to the eye to provide extended viscosity enhancement of the composition.

Priority: US201161478084P Applic. Date: 2011-04-22

Inventor: CHOWHAN MASOOD A [US]; GHOSH MALAY [US]


Publication No.: WO2012146049A1  Published: 01/Nov/2012

Title: TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING ORAL CAVITY DISEASE AND THE PREPARATION TECHNOLOGY AND THE QUALITY TESTING METHOD THEREOF

Applicant/Assignee: GUILIN SANJIN PHARMACEUTICAL CO., LTD

Application No.: WO2012CN00386 (PCT/CN2012/00386)   Filing Date: 27/Mar/2012

Abstract:

A medicine composition for treating oral ulcer and the preparation method and the quality testing method thereof, and the raw material of said composition consists of 0.5-5 parts by weight of Citrulli Degelatinatum, 0.5-5 parts by weight of Broneolum Syntheticum, 50-500 parts by weight of Herba Centellae and 50-500 parts by weight of Mahonia bealei.

Priority: CN20111105310 Applic. Date: 2011-04-26

Inventor: ZOU JIEMING [CN]


Publication No.: WO2012146314A1  Published: 01/Nov/2012

Title: THIN GELATIN CAPSULES FOR RAPID DRUG RELEASE IN THE MOUTH

Applicant/Assignee: REFARMED CHEMICALS SA

Application No.: WO2011EP56883 (PCT/EP2011/56883)   Filing Date: 29/Apr/2011

Abstract:

A new pharmaceutical composition is disclosed, suitable for the buccal administration of drugs. The composition consists of small-sized fluid cores containing a drug, the cores being singly entrapped within a thin gelatine-based shell, further detailed in the description. The composition dissolves rapidly in the mouth, allows a quick buccal absorption of the drug, and ensures a quick onset of action. The composition is particularly suitable for the administration of drugs needed for urgent medication and/or which are unstable in the acidic gastric fluids.

Priority: WO2011EP56883 Applic. Date: 2011-04-29

Inventor: RESCINITI MARCO [CH]; NONNI GIUSEPPE [CH]; GATTI FABIO [IT]


Publication No.: WO2012146642A1  Published: 01/Nov/2012

Title: ADMINISTRATION OF ILOPROST AS AEROSOL BOLUS

Applicant/Assignee: ACTIVAERO GMBH

Application No.: WO2012EP57615 (PCT/EP2012/57615)   Filing Date: 26/Apr/2012

Abstract:

The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient- friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.

Priority: EP20110163659 Applic. Date: 2011-04-26

Inventor: GESSLER TOBIAS [DE]; SCHMEHL THOMAS [DE]; SEEGER WERNER [DE]; VOSWINCKEL ROBERT [DE]


Publication No.: WO2012146763A1  Published: 01/Nov/2012

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING A LOCAL ANAESTHETIC SUCH AS BUPIVACAINE FOR LOCAL ADMINISTRATION TO THE MOUTH OR THROAT

Applicant/Assignee: ORACAIN II APS

Application No.: WO2012EP57864 (PCT/EP2012/57864)   Filing Date: 27/Apr/2012

Abstract:

The present invention relates to compositions comprising a lipophilic local anaesthetic, preferably bupivacaine or a pharmaceutically active salt thereof, which are formulated for local administration to the mouth or throat of a subject. The compositions are useful in the treatment or alleviation of pain, burning or xerostomia of the oral cavity, pharynx, oral mucosa and pharyngeal mucosa or for use in providing local anesthesia of the oral cavity, pharynx, oral mucosa and pharyngeal mucosa. In particular in the treatment of pain, burning or xerostomia, which is caused by a disease such as oral mucositis, Burning Mouth Syndrome, Sjogren's syndrome, xerostomia, periodontitis, toothache, tonsillectomy, throat infection or mononucleosis, canker sores and aphthous stomatitis.

Priority: DK20110070213 Applic. Date: 2011-04-29; DK20110070225 Applic. Date: 2011-05-06

Inventor: ANDERSEN OVE [DK]; MOGENSEN STINE [DK]; TRELDAL CHARLOTTE [DK]; MOGENSEN TORBEN [DK]; PULIS SYLVIA [DK]


Publication No.: WO2012148799A1  Published: 01/Nov/2012

Title: IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME

Applicant/Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Application No.: WO2012US34361 (PCT/US2012/34361)   Filing Date: 20/Apr/2012

Abstract:

There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases.

Priority: US201161480259P Applic. Date: 2011-04-28

Inventor: ANDERSSON BORGE S [US]; VALDEZ BENIGNO C [US]; TARRANT JEFFREY [US]


Publication No.: WO2012149278A1  Published: 01/Nov/2012

Title: SUSTAINED RELEASE LATANOPROST IMPLANT

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US35398 (PCT/US2012/35398)   Filing Date: 27/Apr/2012

Abstract:

The present invention provides a sustained release, biodegradable intraocular latanoprost implant for reducing elevated intraocular pressure in an individual in need thereof. The implant can be configured as a film (e.g., a rolled film) or extruded filament, either of which can be inserted into the eye of the individual to provide for extended release of latanoprost for several days. Upon insertion into the eye, a rolled film may unroll to provide a film having a high surface area to volume ratio for drug diffusion.

Priority: US201161480657P Applic. Date: 2011-04-29; US201161480630P Applic. Date: 2011-04-29

Inventor: GHEBREMESKEL ALAZAR N [US]; SPADA LON T [US]


Publication No.: WO2012149287A1  Published: 01/Nov/2012

Title: SOLVENT CAST FILM SUSTAINED RELEASE LATANOPROST IMPLANT

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US35411 (PCT/US2012/35411)   Filing Date: 27/Apr/2012

Abstract:

The present invention provides a sustained release latanoprost implant in the form of a thin film comprising latanoprost incorporated in a biodegradible polymer matrix. Preferably, said implant is an intraocular implant comprising a thin film comprising latanoprost incorporated in a biodegradible polymer matrix wherein said implant is configured as a disc or a rolled film that can be inserted into the eye and unrolls to provide a film having a high surface area to volume ratio.

Priority: US201161480630P Applic. Date: 2011-04-29; US201161480657P Applic. Date: 2011-04-29

Inventor: GHEBREMESKEL ALAZAR N [US]; SPADA LON T [US]


Publication No.: WO2012150130A1  Published: 08/Nov/2012

Title: A TOPICAL FORMULATION COMPRISING A CORTICOSTEROID AS ACTIVE INGREDIENT

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: WO2012EP57065 (PCT/EP2012/57065)   Filing Date: 18/Apr/2012

Abstract:

The present invention relates to the use of a formulation in form of aqueous suspension of drug particles of a corticosteroid for topical administration for the prophylaxis and/or treatment of a dermatological disease such as atopic dermatitis, acne and psoriasis.

Priority: EP20110164815 Applic. Date: 2011-05-04

Inventor: CRISCIONE SALVATORE [IT]


Publication No.: WO2012150131A1  Published: 08/Nov/2012

Title: IMPROVED SUSPENSION FORMULATION OF A CORTICOSTEROID FOR ADMINISTRATION BY INHALATION

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: WO2012EP57068 (PCT/EP2012/57068)   Filing Date: 18/Apr/2012

Abstract:

The present invention relates to a formulation in form of aqueous suspension of drug particles of a corticosteroid to be administered by nebulisation, characterised by an optimal particle size distribution.

Priority: EP20110164575 Applic. Date: 2011-05-03

Inventor: CANTARELLI ANNA MARIA [IT]; MINARI STEFANO [IT]; BASSI BARBARA [IT]


Publication No.: WO2012150255A1  Published: 08/Nov/2012

Title: BIS-(ALPHA-AMINO-DIOL-DIESTER) CONTAINING POLYESTERAMIDE FOR OPHTAMOLOGY

Applicant/Assignee: DSM IP ASSETS B.V

Application No.: WO2012EP58015 (PCT/EP2012/58015)   Filing Date: 02/May/2012

Abstract:

The present invention relates to an ocular polymer delivery composition comprising at least one ophthalmologic agent dispersed in at least one biodegradable polymer, wherein the polymer comprises at least one of a poly (ester amide) (PEA) having a chemical formula described by structural formula (I).

Priority: EP20110164479 Applic. Date: 2011-05-02

Inventor: FRANKEN ASTRID [NL]; MIHOV GEORGE [NL]; THIES JENS CHRISTOPH [NL]


Publication No.: WO2012150450A1  Published: 08/Nov/2012

Title: ORAL COMPOSITIONS COMPRISING CREATINE

Applicant/Assignee:

Application No.: WO2012GB50955 (PCT/GB2012/50955)   Filing Date: 01/May/2012

Abstract:

The present invention relates to rehydration and nutritional products comprising creatine and/or its salts, or analogues or precursors thereof, in ready to use aqueous oral compositions, such as gels, pastes and the like, and products for reconstitution in water, for use by humans and animals, together with processes for their preparation and uses thereof.

Priority: GB20110007308 Applic. Date: 2011-05-03; US201161521840P Applic. Date: 2011-08-10; GB20120001012 Applic. Date: 2012-01-23

Inventor: O'GORMAN EDWARD NIALL STEPHEN [GB]


Publication No.: WO2012150607A2  Published: 08/Nov/2012

Title: ORAL LIQUID COMPOSITION COMPRISING DIVALPROEX SODIUM AND PROCESS FOR PREPARING THEREOF

Applicant/Assignee: ABBOTT HEALTHCARE PRIVATE LIMITED

Application No.: WO2012IN00307 (PCT/IN2012/00307)   Filing Date: 26/Apr/2012

Abstract:

The present invention is directed to palatable oral liquid composition comprising divalproex sodium and process for preparing thereof. Particularly, the present invention relates to a stable oral liquid composition, such as solution comprising divalproex sodium and process for preparing thereof.

Priority: IN2011MU01365 Applic. Date: 2011-05-02

Inventor: SAHANA DIPAK [IN]; PATIL PRASAD [IN]; PHADTARE GANESH NARAYAN [IN]; GROVER MANISH [IN]; JATHAR SHRIPAD [IN]


Publication No.: WO2012151438A1  Published: 08/Nov/2012

Title: ANTIMICROBIAL SILVER HYDROGEL COMPOSITION FOR THE TREATMENT OF BURNS AND WOUNDS

Applicant/Assignee: CELACARE TECHNOLOGIES, LLC

Application No.: WO2012US36384 (PCT/US2012/36384)   Filing Date: 03/May/2012

Abstract:

An antimicrobial therapeutic hydrogel composition comprises a pharmaceutical and/or medical grade silver salt, and an Aloe vera gel or extract. The composition could also include stabilizing agents, a non-ionic surfactant, polyol, and hydrophilic hygroscopic polymers. The resulting product has potent antimicrobial activity against bacteria, protozoa, fungi and viruses. The antimicrobial therapeutic composition can serve as a treatment for burns and as a wound/lesion dressing that either donates or receives moisture to provide a physiologic environment for accelerated wound healing and the relief of pain.

Priority: US201113101724 Applic. Date: 2011-05-05

Inventor: YATES KENNETH M [US]; PROCTOR CELIA A [US]; ATCHLEY DAN H [US]


Publication No.: WO2012151517A1  Published: 08/Nov/2012

Title: COCHLEATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME

Applicant/Assignee: COORDINATED PROGRAM DEVELOPMENT, LLC, UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

Application No.: WO2012US36576 (PCT/US2012/36576)   Filing Date: 04/May/2012

Abstract:

The present invention provides, in part, cochleate compositions and methods for making and using same.

Priority: US201161547325P Applic. Date: 2011-10-14; US201161482996P Applic. Date: 2011-05-05; US201261608272P Applic. Date: 2012-03-08; US201261636793P Applic. Date: 2012-04-23; US201261620656P Applic. Date: 2012-04-05; US201161570067P Applic. Date: 2011-12-13; US201261590531P Applic. Date: 2012-01-25; US201161534075P Applic. Date: 2011-09-13

Inventor: LU RUYING [US]; MANNINO RAPHAEL [US]


Publication No.: WO2012151544A1  Published: 08/Nov/2012

Title: MICELLES FOR THE SOLUBILIZATION OF GOSSYPOL

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: WO2012US36635 (PCT/US2012/36635)   Filing Date: 04/May/2012

Abstract:

The invention provides biocompatible micelles loaded with one or more active agents. The micelles can encapsulate anticancer drugs such as gossypol, and combinations of drugs, such as gossypol and paclitaxel, gossypol and 17-AAG, gossypol and cyclopamine, gossypol, paclitaxel, and 17-AAG, and gossypol, paclitaxel, and cyclopamine. The micelle compositions provide effective solubilization of difficult to solubilize drug combinations without the need for additional surfactants that can be toxic to patients. Thus, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity.

Priority: US201161482864P Applic. Date: 2011-05-05

Inventor: KWON GLEN S [US]; SHIN HO-CHUL [US]; CHO HYUNAH [US]


Publication No.: WO2012152707A1  Published: 15/Nov/2012

Title: MICROEMULSIONS

Applicant/Assignee: VAXCINE LTD

Application No.: WO2012EP58273 (PCT/EP2012/58273)   Filing Date: 04/May/2012

Abstract:

The present invention relates to preparations of substances in hydrophobic solvents in which they would not normally be soluble and to processes for obtaining these preparations. In particular, the invention relates to preparations of hydrophilic species in hydrophobic solvents such as oils and an amphiphile comprising a polyoxyethylene - 3 headgroup and a straight - chain hydrocarbon containing twelve carbons such as polyoxyethylene - 3 dodecyl ether with an HLB of 8.3. The use of these preparations in vaccines and other pharmaceutical compositions is also described.

Priority: GB20110007630 Applic. Date: 2011-05-06

Inventor: NEW ROGER [GB]


Publication No.: WO2012152910A1  Published: 15/Nov/2012

Title: NOVEL PHARMACEUTICAL FORMULATION

Applicant/Assignee:

Application No.: WO2012EP58738 (PCT/EP2012/58738)   Filing Date: 11/May/2012

Abstract:

The present invention provides novel compositions comprising chitosan and vitamin D or chlorhexidin and vitamin D for the treatment of mucosal and epithelial wounds and for the treatment or prevention of oral, mucosal or dermal infections or inflammations.

Priority: EP20110165857 Applic. Date: 2011-05-12

Inventor: VOCKNER HELMUT [AT]


Publication No.: WO2012153110A1  Published: 15/Nov/2012

Title: USE OF BETHANECHOL FOR TREATMENT OF XEROSTOMIA

Applicant/Assignee: ACACIA PHARMA LIMITED

Application No.: WO2012GB50976 (PCT/GB2012/50976)   Filing Date: 04/May/2012

Abstract:

A formulation for topical administration, comprises bethanechol and a penetration enhancer. The formulation is preferably used by being maintained in the buccal cavity for a period of time prior to being swallowed.

Priority: GB20110007533 Applic. Date: 2011-05-06

Inventor: WALKER IAN [GB]; FRODSHAM MICHAEL [GB]


Publication No.: WO2012153301A1  Published: 15/Nov/2012

Title: FORMULATIONS FOR TOPICAL USE CONTAINING LACTOFERRIN, THEIR PREPARATION AND USE

Applicant/Assignee: FARMACEUTICI DAMOR S.P.A

Application No.: WO2012IB52349 (PCT/IB2012/52349)   Filing Date: 11/May/2012

Abstract:

Formulations for topical use containing lactoferrin are described, wherein said lactoferrin is maintained in a totally anhydrous environment, at least until the moment of use.

Priority: IT2011FI00100 Applic. Date: 2011-05-11

Inventor: RICCIO RODOLFO [IT]


Publication No.: WO2012154122A2  Published: 15/Nov/2012

Title: A TOPICAL FORMULATION FOR TREATMENT OF HYPERKERATOTIC SKIN

Applicant/Assignee: AUXILIUM CURA INNOVATIO

Application No.: WO2012SE50514 (PCT/SE2012/50514)   Filing Date: 14/May/2012

Abstract:

The present invention relates in general to topical compositions having improved antimicrobial effect useful for the treatment of hyperkeratotic skin conditions. More specifically, the present invention relates to topical compositions comprising a combination of one or more alfa-hydroxy acids, urea, glycerol, and panthenol, as well as the use of such compositions for the treatment of hyperkeratotic skin conditions, in particular on the feet, and also on other body areas where thick skin is noted and where infections should be avoided.

Priority: EP20110165916 Applic. Date: 2011-05-12; US201161485287P Applic. Date: 2011-05-12

Inventor: SUNDBOM NILSSON JOHAN [SE]; LODEN MARIE [SE]


Publication No.: WO2012154340A1  Published: 15/Nov/2012

Title: USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS

Applicant/Assignee: GILEAD SCIENCES, INC

Application No.: WO2012US32378 (PCT/US2012/32378)   Filing Date: 05/Apr/2012

Abstract:

Provided are methods of improving the cardiac condition of post-myocardial infarction (MI) patients and reducing cardiovascular death and hospitalization due to heart failure or arrhythmias, by administering a therapeutically effective amount of an A2B adenosine receptor antagonist.

Priority: US201161473110P Applic. Date: 2011-04-07; US201161494222P Applic. Date: 2011-06-07; US201161578728P Applic. Date: 2011-12-21; US201261618581P Applic. Date: 2012-03-30

Inventor: BELARDINELLI LUIZ [US]; ZHONG HONGYAN [US]; ZENG DEWAN [US]


Publication No.: WO2012154427A1  Published: 15/Nov/2012

Title: PUNCTAL PLUGS FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTS

Applicant/Assignee: JOHNSON & JOHNSON VISION CARE, INC

Application No.: WO2012US35516 (PCT/US2012/35516)   Filing Date: 27/Apr/2012

Abstract:

Lacrimal inserts such as punctal plugs may be utilized for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core ( 200 ), or reservoir, at least partially within the body portion comprising a therapeutic agent that is configured for controlled, pulsatile release into the eye.

Priority: US201213409210 Applic. Date: 2012-03-01; US201161483157P Applic. Date: 2011-05-06

Inventor: COLDREN BRET A [US]; VAN DEN BEKEROM PETER PAUL WILLEM LEONARD [NL]; DE LAAT ANTONIUS WILHELMUS MARIA [NL]; WEEKAMP JOHANNES WILHELMUS [NL]; LUST VICTOR [US]; YEWEY GERALD [US]


Publication No.: WO2012154483A1  Published: 15/Nov/2012

Title: DRY POWDER FOSFOMYCIN/TOBRAMYCIN FORMULATION FOR INHALATION

Applicant/Assignee: GILEAD SCIENCES, INC

Application No.: WO2012US36260 (PCT/US2012/36260)   Filing Date: 03/May/2012

Abstract:

The present invention provides an inhaled dry powder formulation containing a combination of fosfomycin salt and tobramycin-leucine compound particles. The use of such formulation for the treatment of patients who have Chronic Obstructive Pulmonary Disease (COPD) and who are experiencing or at risk of experiencing acute exacerbation, as well as patients who have other bacterial infections of the respiratory tract, particularly the lower respiratory tract, and methods for treating the same are also provided.

Priority: US201161483452P Applic. Date: 2011-05-06

Inventor: LAI JOHNNY [US]; BROWN JOSIAH [US]; STAPLETON KEVIN WALTER [US]


Publication No.: WO2012154770A1  Published: 15/Nov/2012

Title: COMBINATIONS OF TOLTERODINE AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER

Applicant/Assignee: THERAVIDA, INC

Application No.: WO2012US36997 (PCT/US2012/36997)   Filing Date: 09/May/2012

Abstract:

Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

Priority: US201161484655P Applic. Date: 2011-05-10

Inventor: PABORJI MEHDI [US]; DUCHIN KENNETH L [US]; HERNANDEZ WENDY JADE LIMAYO [US]; FLUGEL ROGER S [US]


Publication No.: WO2012154771A1  Published: 15/Nov/2012

Title: COMBINATIONS OF FESOTERODINE AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER

Applicant/Assignee: THERAVIDA, INC

Application No.: WO2012US36998 (PCT/US2012/36998)   Filing Date: 09/May/2012

Abstract:

Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release fesoterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release fesoterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release fesoterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

Priority: US201161484657P Applic. Date: 2011-05-10

Inventor: PABORJI MEHDI [US]; DUCHIN KENNETH L [US]; FLUGEL ROGER S [US]


Publication No.: WO2012154774A1  Published: 15/Nov/2012

Title: COMBINATIONS OF SOLIFENACIN AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER

Applicant/Assignee: THERAVIDA, INC

Application No.: WO2012US37006 (PCT/US2012/37006)   Filing Date: 09/May/2012

Abstract:

Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release solifenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

Priority: US201161484658P Applic. Date: 2011-05-10

Inventor: PABORJI MEHDI [US]; HERNANDEZ WENDY JADE LIMAYO [US]; DUCHIN KENNETH L [US]; FLUGEL ROGER S [US]


Publication No.: WO2012154778A1  Published: 15/Nov/2012

Title: COMBINATIONS OF IMIDAFENACIN AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER

Applicant/Assignee: THERAVIDA, INC

Application No.: WO2012US37013 (PCT/US2012/37013)   Filing Date: 09/May/2012

Abstract:

Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of immediate release or orally disintegrating imidafenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release or orally disintegrating imidafenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of immediate release or orally disintegrating imidafenacin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

Priority: US201161484661P Applic. Date: 2011-05-10

Inventor: PABORJI MEHDI [US]; HERNANDEZ WENDY JADE LIMAYO [US]; DUCHIN KENNETH L [US]; FLUGEL ROGER S [US]


Publication No.: WO2012154779A1  Published: 15/Nov/2012

Title: COMBINATIONS OF OXYBUTYNIN AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER

Applicant/Assignee: THERAVIDA. INC

Application No.: WO2012US37014 (PCT/US2012/37014)   Filing Date: 09/May/2012

Abstract:

Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release oxybutynin, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

Priority: US201161484662P Applic. Date: 2011-05-10

Inventor: PABORJI MEHDI [US]; DUCHIN KENNETH L [US]; HERNANDEZ WENDY JADE LIMAYO [US]; FLUGEL ROGER S [US]


Publication No.: WO2012154892A1  Published: 15/Nov/2012

Title: COMBINATIONS OF PROPIVERINE AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER

Applicant/Assignee: THERAVIDA, INC

Application No.: WO2012US37174 (PCT/US2012/37174)   Filing Date: 09/May/2012

Abstract:

Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release propiverine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release propiverine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release propiverine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

Priority: US201161484663P Applic. Date: 2011-05-10

Inventor: PABORJI MEHEDI [US]; DUCHIN KENNETH L [US]; FLUGEL ROGER S [US]; HERNANDEZ WENDY JADE LIMAYO [US]


Publication No.: WO2012154986A1  Published: 15/Nov/2012

Title: IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF SUFENTANIL

Applicant/Assignee: ANTECIP BIOVENTURES II LLC

Application No.: WO2012US37373 (PCT/US2012/37373)   Filing Date: 10/May/2012

Abstract:

Extended release of sufentanil is provided by implanting a device containing sufentanil into a mammal or human being. The device may include a solid biocompatible polymer matrix, and sufentanil may be encapsulated within the polymer matrix. The polymer matrix comprises a plurality of pores configured to allow contact between the sufentanil and a physiological fluid of a mammal into which the device is implanted to thereby release sufentanil in vivo from the device into the mammal. The devices may be used to treat opioid addiction or pain.

Priority: US201161484222P Applic. Date: 2011-05-10

Inventor: TABUTEAU HERRIOT [US]


Publication No.: WO2012155027A1  Published: 15/Nov/2012

Title: WOUND DEBRIDEMENT COMPOSITIONS CONTAINING SEAPROSE AND METHODS OF WOUND TREATMENT USING SAME

Applicant/Assignee: HEALTHPOINT, LTD

Application No.: WO2012US37480 (PCT/US2012/37480)   Filing Date: 11/May/2012

Abstract:

Wound debridement compositions containing the proteolytic enzyme Seaprose and use of such compositions in wound treatment for the enzymatic debridement of wounds.

Priority: US201161485503P Applic. Date: 2011-05-12

Inventor: SHI LEI [US]; JOVANOVIC ALEKSA [US]; CARSON DENNIS [US]


Publication No.: WO2012156317A2  Published: 22/Nov/2012

Title: INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE

Applicant/Assignee: EURO-CELTIQUE S.A

Application No.: WO2012EP58792 (PCT/EP2012/58792)   Filing Date: 11/May/2012

Abstract:

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to = 0.5 mg naloxone HCl dissolved in an application fluid of a volume of = 250 [mu]l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Priority: EP20110166076 Applic. Date: 2011-05-13

Inventor: STRANG JOHN [GB]; OKSCHE ALEXANDER [DE]; HARRIS STEPHEN [US]; SMITH KEVIN [GB]; MOTTIER LUCIE HELENE JEANNE [GB]


Publication No.: WO2012156372A1  Published: 22/Nov/2012

Title: INTRAOCULAR TISSUE STAINING SYSTEM

Applicant/Assignee: BIOFTALMIK S.L

Application No.: WO2012EP58937 (PCT/EP2012/58937)   Filing Date: 14/May/2012

Abstract:

The invention describes a composition comprising a plurality of microparticles of a biodegradable polymer (PLGA, PGA y/o PLA) with size and surface porosity characteristics useful for viewing intraocular tissues and which can be applied in ocular surgery.

Priority: EP20110382147 Applic. Date: 2011-05-13

Inventor: VEGA CHAPARRO SANDRA CLARISSA [ES]; SUAREZ CORTES TATIANA [ES]; CORCOSTEGUI CRESPO INIGO [ES]


Publication No.: WO2012156561A1  Published: 22/Nov/2012

Title: CONTROLLED-RELEASE INJECTABLE MICROPARTICLE

Applicant/Assignee: CONICET - CONS. NAC. DE INVESTIGACIONES CIENTIFICAS Y TECNICAS, IPCVA - INSTITUTO DE PROMOCION DE LA CARNE VACUNAARGENTINA, UNL - UNIVERSIDAD NACIONAL DEL LITORAL, RINTOUL, GERARDO

Application No.: WO2012ES70336 (PCT/ES2012/70336)   Filing Date: 11/May/2012

Abstract:

The invention relates to a controlled-release injectable microparticle comprising a polyvinyl alcohol polymer and one or more hormones, in particular progesterone. Said microparticle induces estrus in female mammals after a single application. The invention also relates to a method for obtaining the microparticle.

Priority: AR2011P101665 Applic. Date: 2011-05-13

Inventor: RINTOUL IGNACIO [AR]; BADANO JUAN MANUEL [AR]; GRAU RICARDO [AR]


Publication No.: WO2012156599A1  Published: 22/Nov/2012

Title: THE USE OF SECNIDAZOLE IN TREATING DENTAL INFECTIONS

Applicant/Assignee: MADECA

Application No.: WO2012FR00192 (PCT/FR2012/00192)   Filing Date: 14/May/2012

Abstract:

The invention relates to the combination of secnidazole with an antibiotic of the macrolide family, preferably azithromycin 11, for oral treatment of dental infections, which enables a considerable reduction in the length of treatment and the doses administered in comparison with the conventional treatment.

Priority: FR20110001478 Applic. Date: 2011-05-16

Inventor: DEFRANCE PIERRE-MARIE [FR]


Publication No.: WO2012156820A1  Published: 22/Nov/2012

Title: INTRANASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS AND USE THEREOF FOR TREATING MALE HYPOGONADISM

Applicant/Assignee: TRIMEL PHARMACEUTICALS CORP

Application No.: WO2012IB01112 (PCT/IB2012/01112)   Filing Date: 15/May/2012

Abstract:

The present invention relates to pernasal testosterone bio-adhesive gel formulations for intranasal administration and testosterone replacement treatment methods for using the pernasal testosterone bio-adhesive gel formulations for providing sustained intranasal delivery of testosterone to testosterone deficient males to treat, for example, male subjects diagnosed with hypogonadism.

Priority: US201161486324P Applic. Date: 2011-05-15; US201161486634P Applic. Date: 2011-05-16

Inventor: KREPPNER WAYNE [CA]; FOGARTY SIOBHAN [IE]; OBEREGGER WERNER [CA]; MAES PAUL JOSE PIERRE MARIE [BE]


Publication No.: WO2012156821A1  Published: 22/Nov/2012

Title: INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER

Applicant/Assignee: TRIMEL PHARMACEUTICALS CORP

Application No.: WO2012IB01113 (PCT/IB2012/01113)   Filing Date: 14/May/2012

Abstract:

The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.

Priority: US201161518903P Applic. Date: 2011-05-13; US201161486254P Applic. Date: 2011-05-14; US201161486266P Applic. Date: 2011-05-14; US201161486252P Applic. Date: 2011-05-14; US201161486251P Applic. Date: 2011-05-14; US201161513499P Applic. Date: 2011-07-29; US201161513495P Applic. Date: 2011-07-29; US201161513497P Applic. Date: 2011-07-29; US201261598335P Applic. Date: 2012-02-13; US201261598336P Applic. Date: 2012-02-13; US201261598333P Applic. Date: 2012-02-13; US201261598329P Applic. Date: 2012-02-13; US201161518916P Applic. Date: 2011-05-13; US201161518913P Applic. Date: 2011-05-13; US201161518921P Applic. Date: 2011-05-13

Inventor: KREPPNER WAYNE [CA]; FOGARTY SIOBHAN [IE]; OBEREGGER WERNER [CA]; MAES PAUL JOSE PIERRE MARIE [BE]


Publication No.: WO2012156822A1  Published: 22/Nov/2012

Title: CONTROLLED RELEASE NASAL TESTOSTERONE GELS, METHODS AND PRE-FILLED MULTI-DOSE APPLICATOR SYSTEMS FOR PERNASAL ADMINISTRATION

Applicant/Assignee: TRIMEL PHARMACEUTICALS CORP

Application No.: WO2012IB01127 (PCT/IB2012/01127)   Filing Date: 15/May/2012

Abstract:

The present invention relates to intranasal testosterone gels for the controlled release of testosterone into the systemic circulation of males and females for providing constant effective testosterone blood levels, without inducing undesired testosterone spike in blood levels, following pernasal administration. The intranasal testosterone gels of the present invention are safe, convenient to use, well tolerated, stable and easily and reproducibly manufactured on scale up. Moreover, because supra- normal and sub-normal testosterone blood levels are believed to be essentially kept to a minimum or avoided and the testosterone serum levels are believed to remain essentially constant during dose life, i.e., the intranasal testosterone gels of the present invention mimic or restore testosterone blood levels to normal physiologic daily rhythmic testosterone levels, the novel intranasal testosterone gels of the present invention are uniquely suited for testosterone replacement or supplemental therapy and effective for treating males diagnosed with, for example, male testosterone deficiency, such as, low sexual libido, low sexual drive, low sexual activity, low fertility, low spermatogenesis, aspermatogenesis, depression and/or hypogonadism, and females who are diagnosed with, for example, female sexual dysfunction, such as, low sexual libido, low sexual drive, low sexual activity, low amygdala reactivity, low sexual stimulation, hypoactive sexual desire disease ("HSDD"), female sexual arousal disorder and/or anorgasmia. The present invention also relates to methods and pre- filled multi-dose airless applicator systems for pernasal administration of the nasal testosterone gels of the present invention.

Priority: US201161486324P Applic. Date: 2011-05-15; US201161486634P Applic. Date: 2011-05-16

Inventor: KREPPNER WAYNE [CA]; FOGARTY SIOBHAN [IE]; OBEREGGER WERNER [CA]; MAES PAUL JOSE PIERRE MARIE [BE]


Publication No.: WO2012156999A1  Published: 22/Nov/2012

Title: READY TO USE DOCETAXEL FORMULATION

Applicant/Assignee:

Application No.: WO2012IN00358 (PCT/IN2012/00358)   Filing Date: 21/May/2012

Abstract:

A single vial stabilized liquid formulation of taxane derivative, adapted to be used directly to a perfusion/infusion solution for administration into a subject in need is provided. The formulation includes an effective amount of : docetaxel or a pharmaceutically acceptable salt thereof

one ore more surfactant

one or more co-surfactant

water for injection

and one or more organic acid. The particle size of the formulation is in a range of 20 nm to 100nm and the pH of the formulation is in a range of about 3.5 to 4.

Priority: IN2011DE01437 Applic. Date: 2011-05-19

Inventor: CHAUDHARY MANU [IN]


Publication No.: WO2012158030A2  Published: 22/Nov/2012

Title: DRUG DELIVERY SYSTEM

Applicant/Assignee: EMOTIONAL BRAIN B.V

Application No.: WO2012NL50336 (PCT/NL2012/50336)   Filing Date: 14/May/2012

Abstract:

The invention relates to a time controlled, immediate release drug delivery system for oral administration of a first active ingredient to a subject in need thereof. The invention additionally relates to a dual drug delivery device, comprising the time controlled, immediate release drug delivery system according to the invention, further comprising a second coating comprising a second active ingredient.

Priority: EP20110166091 Applic. Date: 2011-05-13; EP20110181165 Applic. Date: 2011-09-13; EP20110183732 Applic. Date: 2011-10-03

Inventor: BLOEMERS JOHANNES MARTINUS MARIA [NL]; EISSENS ANKO CORNELUS [NL]; FRIJLINK HENDERIK WILLEM [NL]; DE LEEDE LEONARDUS GERARDUS JOZEF [NL]


Publication No.: WO2012158127A2  Published: 22/Nov/2012

Title: WATER-SOLUBLE FORMULATIONS COMPRISING DEXKETOPROFEN

Applicant/Assignee:

Application No.: WO2012TR00085 (PCT/TR2012/00085)   Filing Date: 08/May/2012

Abstract:

The present invention relates to water-soluble formulations comprising the active agent dexketoprofen and to a process for production of said formulations.

Priority: TR20110004864 Applic. Date: 2011-05-18

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2012158510A1  Published: 22/Nov/2012

Title: CONTAINER CLOSURE SYSTEM WITH INTEGRAL ANTIMICROBIAL ADDITIVES

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US37500 (PCT/US2012/37500)   Filing Date: 11/May/2012

Abstract:

A container-closure system includes a sterile vessel configured to store a preservative-free therapeutic agent. A polymeric applicator is fluidly coupled to the vessel through which the therapeutic agent is dispensed. Surfaces of the applicator that are susceptible to contamination during dispensing of the therapeutic agent comprise one or more antimicrobial additives which provide antimicrobial efficacy at the applicator surfaces.

Priority: US201161486056P Applic. Date: 2011-05-13

Inventor: HASEGAWA AYAKO [US]; SHANKAR SAI [US]; JARIWALA KUNAL [US]; GULMEZIAN MELISSA [US]; SRIKUMAR RAMAKRISHNAN [US]


Publication No.: WO2012159064A1  Published: 22/Nov/2012

Title: HIGH CONCENTRATION OLOPATADINE OPHTHALMIC COMPOSITION

Applicant/Assignee: ALCON RESEARCH, LTD

Application No.: WO2012US38663 (PCT/US2012/38663)   Filing Date: 18/May/2012

Abstract:

The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.

Priority: US201161487789P Applic. Date: 2011-05-19; US201161548957P Applic. Date: 2011-10-19

Inventor: GAMACHE DANIEL A [US]; ALANI LAMAN [US]; GHOSH MALAY [US]; GALAN FRANCISCO JAVIER [ES]; PERDIGUER NURIA [ES]; SINGH ONKAR [US]


Publication No.: WO2012159945A1  Published: 29/Nov/2012

Title: IFN-BETA COMPOSITIONS, PREPARATION METHODS AND USES THEREOF

Applicant/Assignee: ARES TRADING S.A, FLAMEL TECHNOLOGIES SA

Application No.: WO2012EP59086 (PCT/EP2012/59086)   Filing Date: 16/May/2012

Abstract:

The present invention pertains to interferon-beta (IFN-beta) compositions comprising interferon-beta and a grafted poly(glutamic acid) polymer having an average molecular weight between 26 000 and 40 000 g/mol, grafted with alpha-tocopherol substituants, the average molar grafting ratio being 4.5 - 5.5 moles %, the weight/weight ratio between said grafted poly(glutamic acid) polymer and IFN-beta being between 24 and 125. The present invention also pertains to the preparation methods of such compositions and their application to obtain therapeutic compositions in dosage unit form delivering IFN-beta over an extended period of time.

Priority: EP20110305617 Applic. Date: 2011-05-20; US201161488544P Applic. Date: 2011-05-20

Inventor: LEBLANC DANIEL [CH]; LAMME EVERT NICOLAAS [CH]; BALDASCINI HELEN GABRIELA [IT]; RICHARD JOEL [FR]; CHECOT FREDERIC [FR]; CHAN YOU-PING [FR]; KRAVTZOFF ROGER [FR]; POULIQUEN GAUTHIER [FR]


Publication No.: WO2012160125A1  Published: 29/Nov/2012

Title: COMPOSITIONS FOR PERCUTANEOUS ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE AGENTS

Applicant/Assignee: NOVARTIS AG

Application No.: WO2012EP59670 (PCT/EP2012/59670)   Filing Date: 24/May/2012

Abstract:

Compositions intended for the percutaneous administration of physiologically active agents, e.g. drugs or a veterinary agents, are disclosed. Said compositions are characterized forming a non-sticky, very flexible film that 'has excellent long term efficacy.

Priority: EP20110167614 Applic. Date: 2011-05-26

Inventor: MEYER STEPHAN [CH]; LANG AURELIE [CH]


Publication No.: WO2012160179A2  Published: 29/Nov/2012

Title: TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORINATED ALKANES

Applicant/Assignee: NOVALIQ GMBH

Application No.: WO2012EP59787 (PCT/EP2012/59787)   Filing Date: 24/May/2012

Abstract:

The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.

Priority: EP20110167552 Applic. Date: 2011-05-25; EP20110167732 Applic. Date: 2011-05-26

Inventor: GUENTHER BERNHARD [DE]; THEISINGER BASTIAN [DE]; THEISINGER SONJA [DE]; SCHERER DIETER [CH]


Publication No.: WO2012160203A1  Published: 29/Nov/2012

Title: MUCOSAL DELIVERY OF DRUGS

Applicant/Assignee: ARISGEN SA

Application No.: WO2012EP59890 (PCT/EP2012/59890)   Filing Date: 25/May/2012

Abstract:

The present invention provides a composition comprising or consisting of components (a) (i) at least one mono-alkanoyl glycerol ester, wherein alkanoyl is selected from C4 to C21 alkanoyl, preferably from octanoyl and decanoyl

and (b) (i) at least one compound selected from cholesterol, phosphatidyl cholines and phosphatidyl glycerols, wherein the acyl moieties of the phosphatidyl moieties are independently selected from C6 to C21 alkanoyi and C6 to C21 alkenoyl.

Priority: EP20110004319 Applic. Date: 2011-05-25

Inventor: BOTTI PAOLO [CH]; TCHERTCHIAN SYLVIE [FR]


Publication No.: WO2012160213A1  Published: 29/Nov/2012

Title: CONTROLLED RELEASE PEPTIDE FORMULATIONS

Applicant/Assignee: CAMURUS AB

Application No.: WO2012EP59917 (PCT/EP2012/59917)   Filing Date: 25/May/2012

Abstract:

The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt.% of at least one diacyl glycerol and/or a tocopherol

b) 20-80 wt.% of at least one phosphatidyl choline (PC)

c) 5-20 wt.% of at least one biocompatible, organic mono-alcoholic solvent

d) up to 20 wt.% polar solvent e) at least one peptide active agent

f) optionally at least one antioxidant

wherein the ratio of components a:b is in the range 40:60 to 54:46

wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.

Priority: US201161489886P Applic. Date: 2011-05-25

Inventor: TIBERG FREDRIK [SE]; NISTOR CATALIN [SE]; JOHNSSON MARKUS [SE]


Publication No.: WO2012160485A1  Published: 29/Nov/2012

Title: COMPOSITION COMPRISING INTERFERON ALPHA

Applicant/Assignee: FLAMEL TECHNOLOGIES

Application No.: WO2012IB52459 (PCT/IB2012/52459)   Filing Date: 16/May/2012

Abstract:

The present invention relates to a novel solid composition, useful for treating hepatitis, in particular hepatitis C, comprising at least one interferon alpha and at least one grafted poly(glutamic acid) having an average molar mass ranging from 26,000 to 40,000g/mol, preferably approximately 33,000g/mol and carrying grafts of alpha- tocopherol at an average molar grafting rate ranging from 4.5 to 5.5%, preferably approximately 5%, the interferon alpha and said grafted poly(glutamic acid) being present in a grafted poly(glutamic acid)/interferon alpha weight ratio ranging from 21 to 125. It also relates to the use of such a solid composition for the preparation of a liquid composition by the addition of an aqueous liquid.

Priority: FR20110054416 Applic. Date: 2011-05-20

Inventor: POULIQUEN GAUTHIER [FR]; CHAN YOU-PING [FR]; MEYRUEIX REMI [FR]; CHOGNOT DAVID [FR]; KRAVTZOFF ROGER [FR]


Publication No.: WO2012162287A1  Published: 29/Nov/2012

Title: SYSTEMS AND METHODS OF STIMULATION AND ACTIVATION OF FLUIDS FOR USE WITH INSTILLATION THERAPY

Applicant/Assignee: KCI LICENSING, INC

Application No.: WO2012US38932 (PCT/US2012/38932)   Filing Date: 22/May/2012

Abstract:

Systems and methods of stimulating or activating fluids for use in wound treatment systems.

Priority: US201161490150P Applic. Date: 2011-05-26

Inventor: ROBINSON TIMOTHY [GB]; LOCKE CHRISTOPHER B [GB]; COULTHARD RICHARD [GB]


Publication No.: WO2012162789A1  Published: 06/Dec/2012

Title: POLYMERS FOR REVERSING HEPARIN-BASED ANTICOAGULATION

Applicant/Assignee: UNIVERSITY OF BRITISH COLUMBIA

Application No.: WO2011CA50603 (PCT/CA2011/50603)   Filing Date: 27/Sep/2011

Abstract:

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

Priority: US201161492299P Applic. Date: 2011-06-01

Inventor: KIZHAKKEDATHU JAYACHANDRAN N [CA]; SHENOI RAJESH A [CA]; CARTER CEDRIC J [CA]; BROOKS DONALD E [CA]


Publication No.: WO2012162945A1  Published: 06/Dec/2012

Title: MANGIFERIN AGLYCONE CRYSTAL FORM I AND PREPARATION METHOD THEREOF

Applicant/Assignee: KUNMING PHARMACEUTICAL GROUP CO., LTD

Application No.: WO2011CN78360 (PCT/CN2011/78360)   Filing Date: 12/Aug/2011

Abstract:

The invention discloses mangiferin aglycone crystal form I. X-ray powder diffraction analysis, DSC analysis, TG-DTA analysis, IR analysis and HPLC analysis show that mangiferin aglycone crystal form I is a new crystal form. Mangiferin aglycone crystal form I in comparison with existing mangiferin aglycone has high purity, high stability in light, humidity and heat, high bioavailability. The invention also provides preparation method, pharmaceutical composition and pharmaceutically acceptable carrier of mangiferin aglycone crystal form I.

Priority: CN20111143291 Applic. Date: 2011-05-30

Inventor: ZHANG WEI [CN]; LI PENGHUI [CN]; GONG YUNQI [CN]; GAO XIAOHUI [CN]


Publication No.: WO2012163501A1  Published: 06/Dec/2012

Title: NASAL PHARMACEUTICAL FORMULATION

Applicant/Assignee: MEDA PHARMA GMBH & CO. KG

Application No.: WO2012EP02222 (PCT/EP2012/02222)   Filing Date: 24/May/2012

Abstract:

The present invention relates to a nasal formulation comprising as its active ingredient an intranasal corticosteroid, and also to a method for prophylaxis or treatment of seasonal or perennial allergic and non-allergic rhinitis and rhinoconjunctivitis.

Priority: DE201110103347 Applic. Date: 2011-05-27

Inventor: HILDEBRAND-CYRENER ANNEGRET [DE]; MAUS JOACHIM [DE]; MUNZEL ULLRICH [DE]; TRITSCHLER HANS [DE]; WEINGART MARIO [DE]


Publication No.: WO2012163704A2  Published: 06/Dec/2012

Title: INHALATOR AND CAPSULE FOR AN INHALATOR

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: WO2012EP59324 (PCT/EP2012/59324)   Filing Date: 21/May/2012

Abstract:

The invention relates to a capsule for receiving a preferably powdery pharmaceutical preparation and to an inhalator in which, for inhalation, the preparation exits the capsule through at least one hole. A capsule according to the invention has as capsule element, a capsule cap, and a capsule body, of which at least one has a prefabricated hole. Systems according to the invention comprise an inhalator and a capsule, wherein the prefabricated hole in the capsule is sealed in the transport state of the system, and open in the usage state. By activating a push or pull mechanism, the hole is opened. Prior to this, the hole is closed by a portion of the capsule itself or by a capsule receptacle that is part of the inhalator. In one embodiment, the capsule can be in two different states, for example, in different inserted positions of the capsule elements. In the first state, the prefabricated hole is closed, and in the second state it is open. A further system according to the invention consists of a capsule body that is open at the top and an inhalator, wherein the capsule which is open at the top in such a way is filled inside the inhalator.

Priority: GB20110009087 Applic. Date: 2011-05-27; EP20120151105 Applic. Date: 2012-01-13

Inventor: DUNNE STEPHEN TERENCE [GB]; BESSELER JENS [DE]; FRENTZEL-BEYME JESSICA [DE]; HOLAKOVSKY HOLGER [DE]; KLADDERS HEINRICH [DE]; ZUMBLICK OLE [DE]


Publication No.: WO2012163937A2  Published: 06/Dec/2012

Title: SOLID SOLUTIONS OF POLYPHENOLS

Applicant/Assignee: 2LUTION GMBH

Application No.: WO2012EP60087 (PCT/EP2012/60087)   Filing Date: 30/May/2012

Abstract:

The invention relates to a process for the production of solid solutions of polyphenols and derivatives thereof in a carrier material.

Priority: DE201110076699 Applic. Date: 2011-05-30; EP20110168164 Applic. Date: 2011-05-31

Inventor: KALBE JOCHEN [DE]; HANSEN OLAF [DE]


Publication No.: WO2012164494A1  Published: 06/Dec/2012

Title: COMPOSITION FOR CONTROLLED RELEASE OF BUPRENORPHINE

Applicant/Assignee: FLAMEL TECHNOLOGIES

Application No.: WO2012IB52689 (PCT/IB2012/52689)   Filing Date: 30/May/2012

Abstract:

The present invention relates to a novel aqueous liquid pharmaceutical composition for controlled release of buprenorphine or of a buprenorphine analogue, comprising at least one low-water-solubility prodrug of said buprenorphine or of a buprenorphine analogue, and at least one polymer which has a linear backbone, chosen from polyglutamates, polyaspartates, poly(meth)acrylates and polysaccharides, onto which one or more hydrophobic groups are grafted.

Priority: FR20110054686 Applic. Date: 2011-05-30; US201161491614P Applic. Date: 2011-05-31

Inventor: CHAN YOU-PING [FR]; MOULIN ALINE [FR]


Publication No.: WO2012166070A1  Published: 06/Dec/2012

Title: DRY POWDER FORMULATION WITH IMPROVED FLOW CHARACTERISTICS

Applicant/Assignee:

Application No.: WO2012TR00091 (PCT/TR2012/00091)   Filing Date: 28/May/2012

Abstract:

The present invention relates to a new dry powder formulation developed in order to be used in respiratory tract diseases such as asthma and COPD.

Priority: TR20110005367 Applic. Date: 2011-06-02

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2012167018A1  Published: 06/Dec/2012

Title: TARGETED DELIVERY OF RETINOID COMPOUNDS TO THE SEBACEOUS GLANDS

Applicant/Assignee: ALLERGAN, INC

Application No.: WO2012US40375 (PCT/US2012/40375)   Filing Date: 01/Jun/2012

Abstract:

Disclosed herein are topical dermal compositions comprising particles, wherein the particles comprise a) a biodegradable polymer, and b) a retinoid selected from the group consisting of: (I) and (II), or a pharmaceutically acceptable salt thereof, wherein the particles have an average diameter between 0.1 [mu]?t? and 10 [mu]?t?, and wherein the variables are as defined in the specification. The compositions are useful for treating a condition associated with excess sebum production.

Priority: US201161493341P Applic. Date: 2011-06-03

Inventor: DONELLO JOHN E [US]; YANG RONG [US]


Publication No.: WO2012167368A1  Published: 13/Dec/2012

Title: METAL CHELATING COMPOSITIONS AND METHODS FOR CONTROLLING THE GROWTH OR ACTIVITIES OF A LIVING CELL OR ORGANISM

Applicant/Assignee: CHELATION PARTNERS INCORPORATED

Application No.: WO2012CA00562 (PCT/CA2012/00562)   Filing Date: 08/Jun/2012

Abstract:

The present invention provides for metal chelating compositions which are soluble in aqueous media. The present invention also provides chelating compositions that possess acceptable iron sequestering strengths and are able to present a physical form that potentially inhibits (e.g. does not permit easy) access of iron sequestered by the compositions to the cells being targeted. Compositions comprising chelating aspects affixed to or incorporated into suitable carrier materials such that the resulting metal chelating composition is soluble in aqueous media are also provided. Disclosed herein are chelating compositions, for chelating one or more essential metals. The chelating compositions being soluble in an aqueous medium and comprising one or more metal binding chemical groups affixed to or incorporated into the structure of a carrier material, such that the resulting chelating composition is able to bind one or more metals, and remains substantially soluble in the aqueous medium with its bound metal or metals.

Priority: US201161494664P Applic. Date: 2011-06-08

Inventor: HOLBEIN BRUCE EDWARD [CA]; FENG MINHUA [US]; HUBER ANN LOUISE [CA]; KIDBY DENIS KEITH [CA]


Publication No.: WO2012167606A1  Published: 13/Dec/2012

Title: PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF

Applicant/Assignee: KBP BIOSCIENCES CO., LTD

Application No.: WO2012CN00761 (PCT/CN2012/00761)   Filing Date: 04/Jun/2012

Abstract:

The present invention relates to pyridonaphthyridine compounds as shown by general formula (I), and pharmaceutically acceptable salts, stereoisomers, and deuterated derivatives thereof, which have PI3K/mTOR dual inhibiting activities, wherein R1, R2, R3, R4, R5, R6, R7 and X are defined as description

The present invention also relates to the preparative process of said compounds, the pharmaceutical composition and pharmaceutical preparation containing said compounds, as well as uses of said compounds in the treatment and/or prophylaxis of proliferative diseases and in the manufacture of medicaments for the treatment and/or prophylaxis of proliferative disease.

Priority: CN20111159903 Applic. Date: 2011-06-04; CN20111365829 Applic. Date: 2011-11-04

Inventor: WU FRANK [CN]; ZHANG YAN [CN]


Publication No.: WO2012167870A1  Published: 13/Dec/2012

Title: TREATMENT OF CANCERS AND METASTASES WITH SUSPENSIONS OF CILENGITIDE IN CARRIER

Applicant/Assignee: MERCK PATENT GMBH

Application No.: WO2012EP02117 (PCT/EP2012/02117)   Filing Date: 16/May/2012

Abstract:

The present invention relates to a pharmaceutical composition of oligopeptides, preferably cyclic oligopeptides, said composition further comprising one or more lipophilic and/or amphiphilic compounds, in the presence or absence of water as the main ingredients, the use of the lipophilic and/or amphiphilic compounds for making pharmaceutical compositions of said oligopeptides, and methods of making said pharmaceutical composition.

Priority: US201161494988P Applic. Date: 2011-06-09

Inventor: GOODMAN SIMON [DE]; AMENDT CHRISTIANE [DE]; EBER MARCUS [DE]


Publication No.: WO2012167878A1  Published: 13/Dec/2012

Title: EDIBLE ORAL STRIP OR WAFER DOSAGE FORM CONTAINING ION EXCHANGE RESIN FOR TASTE MASKING

Applicant/Assignee: LTS LOHMANN THERAPIE-SYSTEME AG

Application No.: WO2012EP02291 (PCT/EP2012/02291)   Filing Date: 30/May/2012

Abstract:

An edible oral film strip dosage form containing an unpalatable acidic active pharmaceutical ingredient, particularly ketoprofen, and an ion exchange resin as a primary taste masking agent, along with an optional alkaline agent and further optionally containing one or more secondary taste masking agents is provided. The edible oral film strip dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). The inventive dosages minimize or completely mask the bitterness, burning sensation and throat irritation associated with many acidic active pharmaceutical ingredients. Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.

Priority: US201161494462P Applic. Date: 2011-06-08

Inventor: LI MICHAEL HSIN CHWEN [US]; KRUMME MARKUS [DE]


Publication No.: WO2012168392A1  Published: 13/Dec/2012

Title: HYDROGELATOR WITH SHAPE-MEMORY PROPERTIES

Applicant/Assignee: TECHNISCHE UNIVERSITEIT EINDHOVEN

Application No.: WO2012EP60841 (PCT/EP2012/60841)   Filing Date: 07/Jun/2012

Abstract:

A newly designed chain-extended UPy (CEUPy) hydrogelator is disclosed that is obtained by adding a nitrogen containing heterocyclic organic compound that is substituted with at least one ureido-group to a poly(alkylene glycol), wherein the ureido-group and the poly(alkylene glycol) are spaced by a hydrophobic spacer. The obtained present CEUPy hydrogelator forms a strong and elastic supramolecular hydrogel in its hydration or swelling state, and shows both thermo and water responsive shape-memory properties in its dehydration state.

Priority: EP20110168974 Applic. Date: 2011-06-07

Inventor: GUO MINGYU [NL]; WYSS HANS MARKUS [NL]; DANKERS PATRICIA YVONNE WILHELMINA [NL]; MEIJER EGBERT WILLEM [NL]


Publication No.: WO2012168891A1  Published: 13/Dec/2012

Title: PROCESS FOR THE PREPARATION OF A METAL COMPLEX IN AN OILY ORGANIC MATRIX

Applicant/Assignee:

Application No.: WO2012IB52871 (PCT/IB2012/52871)   Filing Date: 07/Jun/2012

Abstract:

A process is described for the preparation of a composition comprising a metal complex in an oily organic matrix, the latter being at the same time able to promote the formation of the complex. Said process also envisages that the complex, once formed, is not separated from said oily organic matrix, but the resulting composition is used as such, as having observed that the performances of the complex present therein is thus improved.

Priority: IT2011MI01033 Applic. Date: 2011-06-08

Inventor: LEONARDI GIULIANO [IT]


Publication No.: WO2012170061A1  Published: 13/Dec/2012

Title: FORMULATIONS OF (R)-1-(2,2-DIFLUROBENZO[D][1,3] DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYL PROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE

Applicant/Assignee: VERTEX PHARMACEUTICALS INCORPORATED

Application No.: WO2011US51725 (PCT/US2011/51725)   Filing Date: 15/Sep/2011

Abstract:

The present invention relates to formulations of (R)-l-(2,2- difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2- methylpropan-2-yl)-lH-indol-5-yl)cyclopropanecarboxamide (Compound 1), pharmaceutical packs or kits thereof, and methods of treatment therewith.

Priority: US201113155420 Applic. Date: 2011-06-08

Inventor: ALARGOVA ROSSITZA GUEORGUIEVA [US]; KADIYALA IRINA NIKOLAEVNA [US]; ZAMAN NOREEN TASNEEM [US]


Publication No.: WO2012170655A1  Published: 13/Dec/2012

Title: SILK COMPOSITIONS AND METHODS OF USING SAME

Applicant/Assignee: CORNELL UNIVERSITY

Application No.: WO2012US41288 (PCT/US2012/41288)   Filing Date: 07/Jun/2012

Abstract:

The present invention provides for silk-derived compositions for treating a wide variety of ocular conditions. The composition is produced by processing the silk cocoon into a water-based solution (i.e., a dissolved silk), which is then cast into a film. The film may be transparent to visible light, and curved in shape for easy application to the ocular surface. The silk film may either self-adhere or be sutured to cover the wound. The degradation time of the film may range from 1 minute to 24 hours, or from 2 hours to 20 hours. The present compositions can help regenerate damaged corneal tissue, thus promoting healing.

Priority: US201161495167P Applic. Date: 2011-06-09; US201161494293P Applic. Date: 2011-06-07

Inventor: LAWRENCE BRIAN D [US]; NAVAS ALEJANDRO [MX]; ROSENBLATT MARK I [US]


Publication No.: WO2012170796A1  Published: 13/Dec/2012

Title: GEL COMPOSITIONS

Applicant/Assignee: AMYLIN PHARMACEUTICALS, INC

Application No.: WO2012US41519 (PCT/US2012/41519)   Filing Date: 08/Jun/2012

Abstract:

The present invention is directed to compositions and methods of preparation of phospholipid gels.

Priority: US201161495282P Applic. Date: 2011-06-09; US201161500042P Applic. Date: 2011-06-22

Inventor: CHEN HAILIANG [US]; CHEN ANDREW XIAN [US]


Publication No.: WO2012170866A1  Published: 13/Dec/2012

Title: BENZOYL PEROXIDE MICROPARTICLE PROCESS

Applicant/Assignee: NORAC PHARMA

Application No.: WO2012US41631 (PCT/US2012/41631)   Filing Date: 08/Jun/2012

Abstract:

The present invention relates to the manufacture of microparticle benzoyl peroxide. The process of the invention provides for an aqueous slurry of USP benzoyl peroxide, optionally containing additives, being processed via microfluidization technology. The process comprises forcing a slurry of benzoyl peroxide at high pressure through a narrow channel designed to produce high shear, thereby achieving primary particle size reduction in addition to de-agglomeration.

Priority: US201161495659P Applic. Date: 2011-06-10

Inventor: LEVIN DANIEL [US]; LUCHI JAMES [US]


Publication No.: WO2012170915A1  Published: 13/Dec/2012

Title: PHARMACEUTICAL COMPOSITIONS CONTAINING PEDIOCOCCUS AND METHODS FOR REDUCING THE SYMPTOMS OF GASTROENTEROLOGICAL SYNDROMES

Applicant/Assignee: PROTHERA INC

Application No.: WO2012US41697 (PCT/US2012/41697)   Filing Date: 08/Jun/2012

Abstract:

The invention provides a method and composition for ameliorating or reducing the symptoms, signs, and markers and for the treatment of irritable bowel syndrome, inflammatory bowel disease or gastritis in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition containing at least one probiotic microorganism strain comprising Pediococcus for a time sufficient to ameliorate, reduce or treat at least one symptom, sign, or marker of irritable bowel syndrome, inflammatory bowel disease or gastritis.

Priority: US201113067582 Applic. Date: 2011-06-10

Inventor: OLMSTEAD STEPHEN F [US]


Publication No.: WO2012171335A1  Published: 20/Dec/2012

Title: MULTI-VINYLSULFONE CONTAINING MOLECULE

Applicant/Assignee: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY

Application No.: WO2012CN00827 (PCT/CN2012/00827)   Filing Date: 15/Jun/2012

Abstract:

A multi-vinylsulfone containing molecule is described herein. The multi-vinylsulfone containing molecule can be formed by dissolving a water soluble polymer containing a hydroxyl group in an aqueous solution to form a polymer solution

adding a molecule containing two vinylsulfone groups to the polymer solution

and forming a modified polymer by controlling a number of the vinylsulfone groups that are added to the polymer. A hydrogel is also described herein that can include the multi-vinylsulfone containing molecule and a multi-thiol containing molecule. The hydrogel can be formed from an aqueous solution that includes the multi-vinylsulfone containing molecule and the multi-thiol containing molecule by undergoing gelatation upon delivery to a site in the body. Also described is a drug delivery system that employs the hydrogel.

Priority: US201161457836P Applic. Date: 2011-06-16; US201161457837P Applic. Date: 2011-06-16

Inventor: CHAU YING [CN]; YU YU [CN]


Publication No.: WO2012171561A1  Published: 20/Dec/2012

Title: STABILIZED VORICONAZOLE COMPOSITION

Applicant/Assignee: SYNTHON BV

Application No.: WO2011EP59945 (PCT/EP2011/59945)   Filing Date: 15/Jun/2011

Abstract:

The present invention relates to a process for improving the stability of voriconazole in pharmaceutical compositions comprising voriconazole and a beta-cyclodextrin. In particular, it relates to a use of lactose for such process.

Priority: WO2011EP59945 Applic. Date: 2011-06-15

Inventor: ZALUDEK BOREK [CZ]; ZATLOUKALOVA LIBUSE [CZ]


Publication No.: WO2012172243A1  Published: 20/Dec/2012

Title: DISTRIBUTION DEVICE AND PRODUCTION METHOD THEREOF

Applicant/Assignee: APTAR FRANCE SAS

Application No.: WO2012FR51302 (PCT/FR2012/51302)   Filing Date: 11/Jun/2012

Abstract:

The invention relates to a fluid product distribution device comprising at least one container housing the fluid product to be distributed and distribution means that can be actuated by a user in order to distribute the fluid product through a distribution hole. The distribution device also includes a plurality of assembled constituent parts and at least one of said constituent parts (10, 20, 30, 40, 50, 60, 70, 80) comprises a unique mark (100), such that each individual distribution device can be identified and/or traced using the unique mark.

Priority: FR20110055154 Applic. Date: 2011-06-14

Inventor: BRUNA PASCAL [FR]; DAUGUET FLORENT [FR]; LANGEARD JEROME [FR]; OBLIN NICOLAS [FR]


Publication No.: WO2012172433A2  Published: 20/Dec/2012

Title: A SUSTAINED-RELEASE COMPOSITION CONTAINING PEPTIDES AS ACTIVE INGREDIENT

Applicant/Assignee: IPSEN PHARMA S.A.S

Application No.: WO2012IB01588 (PCT/IB2012/01588)   Filing Date: 13/Jun/2012

Abstract:

The present invention relates to a sustained-release drug composition consisting essentially of microparticies of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium.

Priority: EP20110290270 Applic. Date: 2011-06-14

Inventor: RICHARD JOEL [FR]; LAREDJ FAIZA [FR]; BARONNET MARIE-MADELEINE [FR]; NOURRISSON DIDIER [FR]; HARNETT JEREMIAH [FR]; HACHER BEATRICE [FR]; MONDOLY NATHALIE [FR]; BERTOCCHI LAURENT [FR]


Publication No.: WO2012173933A2  Published: 20/Dec/2012

Title: ACTIVATABLE NANOPROBES FOR INTRACELLULAR DRUG DELIVERY

Applicant/Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC

Application No.: WO2012US41916 (PCT/US2012/41916)   Filing Date: 11/Jun/2012

Abstract:

An activatable nanoprobe is provided having a core component and an active agent associated with the core component via a bond configured to be cleaved upon exposure to an endogenous compound.

Priority: US201161495992P Applic. Date: 2011-06-11

Inventor: SWADESHMUKUL SANTRA [US]; TURKSON JAMES [US]


Publication No.: WO2012174559A1  Published: 20/Dec/2012

Title: INHALABLE PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: BERG PHARMA LLC

Application No.: WO2012US43001 (PCT/US2012/43001)   Filing Date: 18/Jun/2012

Abstract:

Inhalable pharmaceutical compositions can include an aqueous dispersion of particles including a hydrophobic bioactive agent (e.g., CoQIO) suitable for continuous aerosolization. Due to their chemical composition and methods of manufacture, the pharmaceutical compositions exhibit distinctive physicochemical properties that provide advantageous aerosol transmission and output.

Priority: US201161498505P Applic. Date: 2011-06-17

Inventor: NARAIN NIVEN RAJIN [US]; MCCOOK JOHN PATRICK [US]


Publication No.: WO2012175085A1  Published: 27/Dec/2012

Title: TOBACCO CHEWING GUM FORMULATION

Applicant/Assignee: GUMLINK A/S

Application No.: WO2012DK00042 (PCT/DK2012/00042)   Filing Date: 13/Apr/2012

Abstract:

The present invention relates to embodiments of a chewing gum formulation comprising tobacco particles and a gum base, wherein the gum base comprises one or more hydrophobic gum base polymers, and wherein the tobacco particles are made from tobacco leaves, wherein the amount of tobacco particles is between 0.5 and 30% by weight of the chewing gum formulation, wherein nicotine is released from the tobacco particles when chewing the chewing gum formulation.

Priority: US201161499041P Applic. Date: 2011-06-20

Inventor: ANDERSEN CARSTEN [DK]


Publication No.: WO2012175353A1  Published: 27/Dec/2012

Title: DIALYSIS PRECURSOR COMPOSITION

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: WO2012EP60969 (PCT/EP2012/60969)   Filing Date: 11/Jun/2012

Abstract:

The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one calcium salt, and optionally potassium salt, and magnesium salt. According to the invention said glucose and said at least one calcium salt, are present as anhydrous components in said dialysis acid precursor composition.

Priority: SE20110050565 Applic. Date: 2011-06-20; US201161499209P Applic. Date: 2011-06-21

Inventor: JANSSON OLOF [SE]; LINDEN TORBJOERN [SE]; WIESLANDER ANDERS [SE]


Publication No.: WO2012175354A1  Published: 27/Dec/2012

Title: DIALYSIS PRECURSOR COMPOSITION

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: WO2012EP60971 (PCT/EP2012/60971)   Filing Date: 11/Jun/2012

Abstract:

The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising sodium chloride, at least one dry acid and at least one calcium salt, and optionally potassium salt, magnesium salt, and glucose. According to the invention said at least one calcium salt and said optional glucose, are present as anhydrous components in said dialysis acid precursor composition.

Priority: SE20110050566 Applic. Date: 2011-06-20; US201161499207P Applic. Date: 2011-06-21

Inventor: JANSSON OLOF [SE]; LINDEN TORBJOERN [SE]; WIESLANDER ANDERS [SE]


Publication No.: WO2012175434A1  Published: 27/Dec/2012

Title: PHARMACEUTICAL FORMULATIONS COMPRISING VESTIPITANT

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: WO2012EP61550 (PCT/EP2012/61550)   Filing Date: 18/Jun/2012

Abstract:

A pharmaceutical formulation for intravenous (IV) administration comprising 2-(S)-(4-Fluoro-2- methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or a pharmaceutically acceptable salt thereof and a process for its preparation and its use in medical therapy.

Priority: US201161498722P Applic. Date: 2011-06-20

Inventor: BEATO STEFANIA [IT]; BRESCIANI MASSIMO [IT]; CROY SCOTT R [US]; MULLER FRANCIS XAVIER [US]


Publication No.: WO2012175626A1  Published: 27/Dec/2012

Title: COMPOSITION COMPRISING AN ONION EXTRACT AND LIPOSOMES

Applicant/Assignee: MERZ PHARMA GMBH & CO. KGAA, AIR PRODUCTS AND CHEMICALS, INC

Application No.: WO2012EP61997 (PCT/EP2012/61997)   Filing Date: 21/Jun/2012

Abstract:

The present invention relates to a composition comprising a first onion extract (A), and liposomes, wherein at least a portion of the onion extract is encapsulated in the liposomes. Furthermore the present invention relates to a method for preparing a composition comprising a first onion extract (A), and liposomes, wherein at least a portion of the onion extract is encapsulated in the liposomes. Further, the present invention relates to a composition comprising an onion extract (A) (Allium cepa) and liposomes, obtainable by or obtained by said method. Furthermore, the present invention relates to compositions comprising a first onion extract (A), and liposomes, wherein at least a portion of the onion extract is encapsulated in the liposomes, for use in treating and/or preventing scars.

Priority: EP20110171378 Applic. Date: 2011-06-24; US201161571287P Applic. Date: 2011-06-24

Inventor: BODERKE PETER [DE]; HEBERER MARTINA [DE]; SCHEPPLER PETRA [DE]


Publication No.: WO2012175641A1  Published: 27/Dec/2012

Title: FORMULATIONS OF FLUORINATED STILBENE SUITABLE FOR PET IMAGING

Applicant/Assignee: PIRAMAL IMAGING SA

Application No.: WO2012EP62034 (PCT/EP2012/62034)   Filing Date: 21/Jun/2012

Abstract:

The invention is directed to formulations of lipophilic Amyloid beta ligand stilbene and more particularly to formulations which are capable to be administered parenterally e.g. intravenously, wherein the lipophilic Amyloid beta ligand stilbene is a fluorinated stilbene. Further, the invention is directed to a method for sterile filtration of formulations suitable for PET imaging of mammals pursuant to the invention.

Priority: EP20110005047 Applic. Date: 2011-06-21

Inventor: OLBRICH CARSTEN [DE]; KRAUSE MICHAEL [DE]; BURKHARD ANDREAS [DE]; RICHTER ANNETT [DE]; BRAUN RAINER [DE]


Publication No.: WO2012175659A1  Published: 27/Dec/2012

Title: N-ACETYL CYSTEINE AND COMPOSITION THEREOF FOR USE IN THE TREATMENT OF VAGINAL PATHOLOGIES

Applicant/Assignee: LO.LI. PHARMA S.R.L

Application No.: WO2012EP62068 (PCT/EP2012/62068)   Filing Date: 22/Jun/2012

Abstract:

The present invention relates to N-acetyl cysteine and to a composition comprising N-acetyl cysteine for use in the restoration of the vaginal ecosystem and/or in the treatment of vaginal pathologies characterised in that the administration of N-acetyl cysteine or of the composition comprising N-acetyl cysteine takes place by vaginal route.

Priority: IT2011MI01151 Applic. Date: 2011-06-24

Inventor: UNFER VITTORIO [IT]


Publication No.: WO2012175714A1  Published: 27/Dec/2012

Title: PHENYLBUTYRATE IN RECTAL FORM FOR THE TREATMENT OF A MOTOR NEURON DISEASE OR A METABOLIC DISEASE

Applicant/Assignee: GMP-ORPHAN

Application No.: WO2012EP62152 (PCT/EP2012/62152)   Filing Date: 22/Jun/2012

Abstract:

The present invention relates to rectal administration of phenylbutyrate for treating a motor neuron disease, such as, for example, spinal muscular atrophy or a metabolic disease such as, for example, an urea cycle disorder, related methods and compositions.

Priority: US201161499805P Applic. Date: 2011-06-22

Inventor: MARIN FREDERIC [FR]


Publication No.: WO2012175747A1  Published: 27/Dec/2012

Title: PRODUCTION METHOD AND DOSAGE FORM

Applicant/Assignee: HENNIG ARZNEIMITTEL GMBH & CO. KG

Application No.: WO2012EP62266 (PCT/EP2012/62266)   Filing Date: 25/Jun/2012

Abstract:

The invention relates to a production method for dosage forms. The production method makes dosage forms accessible that help even active ingredients that are poorly soluble to be highly bioavailable when taken orally. Another important advantage of the method is that the dosage forms produced in such a manner have good storage stability. The dosage forms produced in such a manner comprise several subunits. The invention further relates to the dosage forms and to uses of the dosage forms. In particular, the invention relates to layered tablets and to capsules that contain powder and coated microtablets. Examples of active ingredients are cinnarizine and dimenhydrinate.

Priority: DE201110051308 Applic. Date: 2011-06-24

Inventor: FRANCAS GERNOT [DE]; PRZYKLENK KARL-HEINZ [DE]


Publication No.: WO2012175775A1  Published: 27/Dec/2012

Title: PHOSPHODIESTERASE INHIBITORS APPLIED VIA THE TRANSVAGINAL ROUTE FOR THE TREATMENT OF INFERTILITY

Applicant/Assignee:

Application No.: WO2012ES70453 (PCT/ES2012/70453)   Filing Date: 20/Jun/2012

Abstract:

The present invention relates to a new application of phosphodiesterase inhibitors for treating couple infertility, which constitutes an effective alternative to invasive assisted-reproduction techniques such as conjugal artificial insemination, and which involves transvaginal administration of a phosphodiesterase inhibitor immediately before and/or after coitus. The present invention also relates to pharmaceutical forms suitable for intravaginal administration of phosphodiesterase inhibitors.

Priority: ES20110031059 Applic. Date: 2011-06-23

Inventor: PARDINA PALLEJA MARIA CARMEN [ES]; VAZ-ROMERO UNA MIGUEL ANGEL [ES]


Publication No.: WO2012175879A1  Published: 27/Dec/2012

Title: FILM-FORMING COMPOSITION, AND USE THEREOF FOR TREATING HERPES

Applicant/Assignee: LABORATOIRES URGO

Application No.: WO2012FR51417 (PCT/FR2012/51417)   Filing Date: 21/Jun/2012

Abstract:

The present invention relates to a topical film-forming composition including, in a pharmaceutically acceptable medium: 5 to 30 wt % of ethyl cellulose

0.1 to 10 wt % of an auxiliary film-forming agent

0.1 to 20 wt % of one or more triacids, at least one of which is boric acid

and 60 to 95 wt % of an organic solvent, the percentages being expressed by weight relative to the total weight of the composition. The invention also relates to the use of such a composition in a method for treating herpes, in particular herpes labialis.

Priority: FR20110055493 Applic. Date: 2011-06-22

Inventor: DERAIN NATHALIE [FR]


Publication No.: WO2012175881A1  Published: 27/Dec/2012

Title: TOPICAL FILM-FORMING COMPOSITION, AND USE THEREOF FOR TREATING MYCOSES

Applicant/Assignee: LABORATOIRES URGO

Application No.: WO2012FR51420 (PCT/FR2012/51420)   Filing Date: 21/Jun/2012

Abstract:

The present invention relates to a topical film-forming composition for the treating dermatophytosis, specifically mycoses of the feet and, in particular, for treating the symptoms associated with dermatophytosis, specifically the symptoms associated with athlete's foot. The composition is particularly suitable for treating cracking, and for promoting the healing of skin lesions caused by said inflammation. The present composition is also suitable for preventing bacterial or fungal proliferation in the damaged skin.

Priority: FR20110055492 Applic. Date: 2011-06-22

Inventor: BOUVIER CLAIRE [FR]; DERAIN NATHALIE [FR]


Publication No.: WO2012175996A2  Published: 27/Dec/2012

Title: DRUG DELIVERY FORMULATIONS

Applicant/Assignee: KING'S COLLEGE LONDON

Application No.: WO2012GB51473 (PCT/GB2012/51473)   Filing Date: 22/Jun/2012

Abstract:

Mixtures of C1-12 compounds comprising at least one -Alk-O- group with thermogenic formulations, such as those comprising supercooled solutions of salts, are capable of substantial enhancement of transdermal drug delivery.

Priority: GB20110010632 Applic. Date: 2011-06-22

Inventor: WOOD DANIEL GUY [GB]; JONES STUART ALLEN [GB]; BROWN MARC BARRY [GB]


Publication No.: WO2012176024A1  Published: 27/Dec/2012

Title: CRYOGELS OF PVA-BORONIC ACID CONTAINING CO-POLYMERS FOR CELL CULTURE

Applicant/Assignee: INDIAN INSTITUTE OF TECHNOLOGY KANPUR

Application No.: WO2011IB53522 (PCT/IB2011/53522)   Filing Date: 08/Aug/2011

Abstract:

A cryogel contains a polyol and a co-polymer of Formula (I).

Priority: IN2011DE01775 Applic. Date: 2011-06-23

Inventor: KUMAR ASHOK [IN]


Publication No.: WO2012176025A1  Published: 27/Dec/2012

Title: PVA-BORONIC ACID CONTAINING COPOLYMER COMPOSITIONS FOR PROTEIN DELIVERY

Applicant/Assignee: INDIAN INSTITUTE OF TECHNOLOGY KANPUR

Application No.: WO2011IB53523 (PCT/IB2011/53523)   Filing Date: 08/Aug/2011

Abstract:

Provided herein are phenylboronate containing co-polymers (PCC), compositions containing PCC and polyvinyl alcohol (PVA), such compositions further including proteins, methods of making these compositions by water in oil polymerization, and methods of using the protein containing compositions for releasing proteins. Such phenylboronate containing co-polymers are of Formula I: where m, n, p, x, R1-R5, L, X1 and X2 are defined in the application.

Priority: IN2011DE01773 Applic. Date: 2011-06-23

Inventor: KUMAR ASHOK [IN]; REDDY RACHAMALLA MAHEEDHAR [IN]


Publication No.: WO2012176215A1  Published: 27/Dec/2012

Title: A PLANT BASED ANTIVIRAL COMPOSITION FOR THE TREATMENT OF HIV AND HIV RELATED ACQUIRED IMMUNO DEFICIENCY SYNDROME

Applicant/Assignee:

Application No.: WO2012IN00410 (PCT/IN2012/00410)   Filing Date: 11/Jun/2012

Abstract:

The present invention relates to a plant based antiviral composition and more particularly to a process for preparing an injectable antiviral composition comprising holy basil for the treatment of HIV disease and HIV related Acquired Immunodeficiency Syndrome (AIDS). The process comprising boiling the holy basil leaves in distilled water, filtering the boiled mixture, adding strong sulfuric acid to precipitate the vegetable matter, siphoning off the clear solution, adding ammonium carbonate for crystallization of the clear solution, adding spirit of ammonia to decolorize the crystals, and dissolving the decolorized crystals in boiling ethyl alcohol for purification to obtain the final composition. The final composition of the present invention destroys surface antigens as well as HIV Genome by invading into the virus and there by killing HIV.

Priority: IN2011CH02080 Applic. Date: 2011-06-20

Inventor: PUNDALEEKAPPA SHINHASAN MANOHAR [IN]

WORLD PATENTS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL ACTIVES PUBLISHED IN 2012
This list includes patent documents published by the World Intellectual Property Organization (WIPO). The list was retrieved by searching the claims section of all patent applications. Salient
search terms included pharmaceutical formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained
drug release; polysaccharides, polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal,
nasal, ocular or buccal administration of medications, etc.
World Patents in Excipients, Delivery and Release of Pharmaceutical
Compositions and Actives Published in 201
2
Clck to enlarge and view details
World  Patents Published  in 2013
 
World  Patents Published  in 2011
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..